var title_f20_50_21280="AF remodeling";
var content_f20_50_21280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    AF remodeling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 471px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mechanisms underlying ATR. Rapid atrial rates increase potentially cytotoxic Ca",
"    <sup>",
"     2+",
"    </sup>",
"    loading. Autoprotective I",
"    <sub>",
"     Ca,L",
"    </sub>",
"    reductions occur via rapidly developing functional changes (I",
"    <sub>",
"     Ca,L",
"    </sub>",
"    inactivation) and more slowly developing changes in gene and protein expression. Decreased I",
"    <sub>",
"     Ca,L",
"    </sub>",
"    reduces Ca",
"    <sup>",
"     2+",
"    </sup>",
"    loading but decreases APD. Diminished APD shortens refractoriness and reduces the wavelength (WL), which allows for smaller and more atrial reentry circuits, thus making AF unlikely to terminate. Atrial tachycardia also increases inward-rectifier currents such as I",
"    <sub>",
"     K1",
"    </sub>",
"    and I",
"    <sub>",
"     K,ACh,c",
"    </sub>",
"    , which further reduces APD and promotes AF.",
"    <div class=\"footnotes\">",
"     RP: refractory period; WL: wavelength.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nattel S, Burstein B, Dobrev D. Atrial Remodeling and Atrial Fibrillation: Mechanisms and Implications. Circ Arrhythm Electrophysiol 2008; 1:62. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21280=[""].join("\n");
var outline_f20_50_21280=null;
var title_f20_50_21281="Gestational sac empty";
var content_f20_50_21281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gestational sac without yolk sac or embryo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse view of the uterus shows an abnormally shaped intrauterine gestational sac with mean sac diameter of 31 mm. At this sac size, a yolk sac and embryo should be seen but were not. Findings represent early pregnancy failure. Arrows indicate the empty amnion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21281=[""].join("\n");
var outline_f20_50_21281=null;
var title_f20_50_21282="Pamabrom: Drug information";
var content_f20_50_21282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pamabrom: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7765726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      diurex&reg; Aquagels&reg; [OTC];",
"     </li>",
"     <li>",
"      diurex&reg; Maximum Relief [OTC];",
"     </li>",
"     <li>",
"      diurex&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7765729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diuretic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7765737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Premenstrual or menstrual symptoms:",
"     </b>",
"     Oral: 50 mg after breakfast and then every 6 hours as needed (maximum: 200 mg/24 hours); should be taken 5-6 days prior to onset of menstrual period and continued until desired relief or end of period",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7765740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     diurex&reg; Maximum Relief: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     diurex&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     diurex&reg; Aquagels&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7765727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7765738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with a full glass of water. Patients should be instructed to drink 6-8 glasses of water/day while taking pamabrom.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7765730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of symptoms associated with premenstrual and menstrual periods (eg, bloating, water-weight gain, swelling, full feeling)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7765731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Patients should drink 6-8 glasses of water daily while taking. Patients should be instructed to contact healthcare provider if new symptoms occur or if symptoms last &gt;10 consecutive days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Urine discoloration: May temporarily cause urine to be golden tinted.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7832028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9508 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21282=[""].join("\n");
var outline_f20_50_21282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765726\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765729\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765737\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765740\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765727\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765738\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765730\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7765731\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299813\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7832028\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_50_21283="Beta-carotene: Drug information";
var content_f20_50_21283=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beta-carotene: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/32/38403?source=see_link\">",
"    see \"Beta-carotene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F140476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      A-Caro-25 [OTC];",
"     </li>",
"     <li>",
"      B-Caro-T&trade; [OTC];",
"     </li>",
"     <li>",
"      Lumitene&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F140492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Fat Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F140477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Erythropoietic protoporphyria (EPP) (Lumitene&trade;):",
"     </b>",
"     Oral: 30-300 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F140486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Erythropoietic protoporphyria (EPP) (Lumitene&trade;):",
"     </b>",
"     Oral: Children &lt;14 years: 30-150 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F140478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F140467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lumitene&trade;: 50,000 units [30 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral: 10,000 units [DSC] [6 mg], 25,000 units [15 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A-Caro-25: 25,000 units [contains soy; 15 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     B-Caro-T&trade;: 25,000 units [contains soybean lecithin, soybean oil; 15 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10,000 units [6 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F140454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9460081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with meals. Lumitene&trade; capsules may be opened and mixed in orange or tomato juice.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13928998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis against photosensitivity reactions in erythropoietic protoporphyria (EPP)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F140490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: DIzziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Carotenodermia (yellowing of palms, hands, or soles of feet, and to a lesser extent the face)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F140470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to beta-carotene or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F140458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sunscreen use: Not proven effective as a sunscreen.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F140462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13928999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal intake of beta carotene influences cord blood concentrations (Scaife,  2006).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13929000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Beta carotene is found in breast milk. Concentrations vary by maternal intake (IOM,  2000).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F140471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Beta Carotene Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit (100): $6.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25000 unit (100): $5.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Lumitene Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (100): $57.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Vitamin A-Beta Carotene Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25000 unit (100): $6.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2613423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic and renal function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      B-Tene (AU);",
"     </li>",
"     <li>",
"      Betacar-15 (TH);",
"     </li>",
"     <li>",
"      Betavin (CO);",
"     </li>",
"     <li>",
"      Carotaben (AT, CH, CZ, DE, NO);",
"     </li>",
"     <li>",
"      Natural Betacarotene (AU);",
"     </li>",
"     <li>",
"      Solvin (EC)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F140457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The exact mechanism of action in erythropoietic protoporphyria has not as yet been elucidated; although patient must become carotenemic before effects are observed, there appears to be more than a simple internal light screen responsible for the drug's action. A protective effect was achieved when beta-carotene was added to blood samples. The concentrations of solutions used were similar to those achieved in treated patients. Topically applied beta-carotene is considerably less effective than systemic therapy.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F140469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Prior to absorption, converted to vitamin A in the wall of the small intestine, then oxidized to retinoic acid and retinol in the presence of fat and bile acids; small amounts are then stored in the liver; retinol (active) is conjugated with glucuronic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. A Report of the Panel on Dietary Antioxidants and Related Compounds Food and Nutrition Board, Institute of Medicine",
"      </i>",
"      ,  Washington, DC: National Academy Press, 2000.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lecha M, Puy H, and Deybach JC, \"Erythropoietic Protoporphyria,\"",
"      <i>",
"       Orphanet J Rare Dis",
"      </i>",
"      , 2009, 4:19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21283/abstract-text/19744342/pubmed\" id=\"19744342\" target=\"_blank\">",
"        19744342",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scaife AR, McNeill G, Campbell DM, et al, \"Maternal Intake of Antioxidant Vitamins in Pregnancy in Relation to Maternal and Fetal Plasma Levels at Delivery,\"",
"      <i>",
"       Br J Nutr",
"      </i>",
"      , 2006,  95(4):771-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21283/abstract-text/16571157/pubmed\" id=\"16571157\" target=\"_blank\">",
"        16571157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9127 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21283=[""].join("\n");
var outline_f20_50_21283=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140476\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140492\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140477\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140486\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140478\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682285\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682286\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140467\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140454\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9460081\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13928998\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140490\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140470\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140458\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298855\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140462\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13928999\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13929000\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140471\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323017\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2613423\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038538\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140457\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F140469\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9127\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9127|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/32/38403?source=related_link\">",
"      Beta-carotene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_50_21284="Development of mammary gland";
var content_f20_50_21284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Development of mammary gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Lothar Hennighausen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21284=[""].join("\n");
var outline_f20_50_21284=null;
var title_f20_50_21285="RAMP position";
var content_f20_50_21285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    RAMP position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 442px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG6ATsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5j0jTZtVuWgt2jVwhf5yQMZA9PetE+Fb4SFBLbFh2DN/hTvA5I1eTAyfJbvjutfR3w0+H/hXVvhvqXirxVLqMRs5blpmhuNgWOMZ4Hrj866oQpqmpzT3MZSk58sT50Hg7UWUkS2pwM/eb/wCJpw8F6kygiW0ORn77f/E19M+EvBfw88beBNV8QeG28Qw/Y1mQxXdyFkSRE3Dcqlhggg9a8bsbhTaR7t3mFBkn3HWt6NKhWvZPQzqTqQ3ZxJ8G6jtz5lrj/fb/AAoXwbqDYxNaZI/vt/8AE13MjghQJG47N0/CkMiEhi54HUVv9SpGft5nDf8ACHahgky2uP8Afb/4mmSeEr9Dgy2x5xwzf4V3jSKU+VixY5/CoSxEsYck5O7A6DFH1KkHt5nG/wDCG6jux5lt/wB9N/8AE05fBWosARNacnHLt/8AE13iybBjzBgngZ71IkmAQH46dRzQsFSF9YqHAt4H1NQSZrPj/bb/AOJpq+CtRZgBNac99zY/9Br0EFnIY7euOvaoptxwqlTgYwDz/wDXp/UqQfWJnBN4L1JULeba8c43tn/0GiPwZqMi5EtqB2yzc/8AjtdyT1DIemafavnCoQNo656e1H1KkP28zhD4L1EAnz7Tg4PzNx/47S/8IRqWQDLaAnpl2/8Aia79pE+YZXcTzg8EetOV0Vwdw2n36kd6f1GiL6xUPPE8F6i5IE1oABkne2B/47T/APhB9SxkT2Z+jt/8TXeRGFZS2cRsMEZ5NSK4VY8uqpn5sjmhYGl/TD6xM85fwhqCSBDLaliM8M3H/jtKvg7UGXImtcc/xt2/4DXcX8qm6jIwY8bRt49+akjkEa4VeSpHHvS+pUh+3mcKngzUXjjdZrTa4JHzt/8AE0jeDdQViPOtDgZ4dv8A4mu70+QtvTqFbdgdaddOrTquRwO3an9SpeYe3nc4AeENQJx5tr0z99uf/Hak/wCEL1LaSJrQjOPvt1/75rtvlxkLjnoOlWZWWbbsJCjpz09qX1GkP28zz5fBmotuxNaHA/vtz/47Sf8ACHajjmS2H/Am/wDia70YK7Tjls5B5PtSeWRnkFh0Gc0fUaQe3mcL/wAIXqPGZrQZ9Xbj/wAdpLnwbqFuFLzWpDdCGb/4mu63HzPmxjuKjv280QKSrMffPSj6lSBV5nEx+DNRkOFmtBxnJdv/AImlHgzUS2DNaD3Lt/8AE13sTBEXHTGD/n0pmQxLY2ggkD0NP6jREq8zhR4M1Ej/AFtoBnHLt/8AE01/B2oIcGW156fO3P8A47Xd+biPaTlR2pm4eXvZsDs3oaPqNIft5nCHwlfhtvm2uf8Aeb/Cmp4VvnYgSW3H+03+FdnLKzEksGzweKWzI8zCjkkY5xz60fUaQe3mcX/wil9/z1tv++j/AIUi+F71iQJbYEdcsf8ACu0jL7nV8Kc9hkAUIAUYYz6kHiksFSD28ziz4VvhnMltwcfePP6UHwte/wDPW2/77P8AhXYFACBKWIYcYNIGB6c44GB1o+pUuwe3mcTe6DdWdpJcSyQFExkKxJ5OPT3rHrvPEgP9h3ZGQPl7f7a1wdefi6UaU+WPY6KM3KN2dF4GUPrEgP8AzxP81r6R8J6c/iX4FS+GbHXNK0z7XrDfbmu7oRuLYOGYIMHLEhcZwCM5NfOPgIE6vPjj/R259PmWupuLaJxK2yMsVHJAz1ranR9rQSXczlPkqH0hovh+DwZqnjS5s/FWl3/h/VtLJMc11EtytyiFQQkaLHtKkjjB6ZB61842S7rWIE4+Rfr06Ckigt3SILHEeByUAJq8sYAXoADxiunDYf2V3e9zKrV59LDRGiYyrMvfmmFkG7I2nvxVgNgFRlf4jmmyKAgP3iORkV1GIi+SVT93wOdo4qAbXldI1I7rzU4jXBJ+8eR24qCIqt0RwD9M/hQA+K1c8KfkY5Iz1NPe1kKsPl3A8+lSQhmReTkcgdKflsgP+WOtPQCp9ml35B4JxUiW7AgEZIHPI4qXYGyQQMc8nmlcZMeeCOhHehAQSiVY3we/RetRW0TYIBIZO2f51POGjU7uvTAP9afbkpIQMHOG4ouMaIdxwhOeuCelJ5BCEHGeeR3FWo4zj5xwRkkHkfWmSJtIIUr2x1P1p2FcjEIT7+ADzx1Ht9aRYVycvtxyMc5qR8lMqD1xgjvUUsSlVIbDDuSTRbsAy5YrGvOcHgsBg/jTnVkiWTnLZZQO4+lJN86shPGwnJ71PbbWsrZkcfKuSD1HvTDoU3YxGVwT8wUZ9cVIjSvCspQsRzwMComR3l2k7UYbhu6mtG3UCMFm/wCAkdfWkl2GUFkk3AGMlsc0b3DH93j2q9KdgQgZGepHaoUxvIOT/dHemwIUkdCh2c56E/1qSS7Zn3CFsn07U1upAUAe/wDjQpKjjp0xS2AjDlztVWDdQcdKjciVlaOMlIhgYPfvUrvtjYNtz6Dmo7M4gbemMyEjnrRfoPzHxyockBlJwPmOMUNc4dRjPOOKZJuaQEqSw468EdqAo4LDaxPH+FO4hzuAD0GDjOah35WRXOOjE44NPlVBglCpY9z0PrURAEaht3J4xyKLgISpyMg+oNT25IEY2gSAnCg02OJCdhPzHkMe1RyF45ISQWIl7DqKV7K47XHMgJ3E4A5+tNYCPa2c5+bn+VWZyjSPuTlugA6fjVPyACQ6HI5JzQ/ICWLDBjzuHU571HG2V+XADfp78U0JvIIUZApjoyY24IHOD7UcwWKvikr/AGFPjOSFwR0PzCuBrtPELH+xpsk4baQD/vCuLryMe71F6HXh1aJ0ngP/AJDE2Bk+Qcc/7S11t5lQ27HzDn1rlPAJA1ifP/Pu3/oS11l3nyRuCryeh6104T+CY1v4gxDjBB6jHB5xV+NVXbgBeOR0IqlArvLwh3dQMdavxu2zcx+c5wTXVExY1oiV4BLY6CpNoKBcHGMHPrSxEldx5BXmkA3E5Y8dgKskiUAMwHO39aghUi7JK8kHnNWnJSPAIJPfNV4GBu14J7HNFhltTtAAPP05pSD1Iz9aJAW5UdeQD2p7bRCM5Zz09KYXBmXCqR16/wCAoc/IrHoOOmKAu11LA4A7d6JRiMnJ2sexp2sIr3TbkyN3OSKS1G6d2TjIxg+tE/8Aqxnn19aLcD7Ucj5TjjPT3+tIfQvLEuwA53EEH3NMkTMYChs47mgnYduA3zeval3hQASSM9/61W5JECdgU43NnHOARUBGF4Oe3XrV9ACz/Lx6moPlIIwpH070NDTKiEsXAwdqtn2p1g//ABL4T8qkDggcn2p1sNjyFjz5R6jnmk0vEtnFkKo5BPXFT1K6BGS18ofjYvBznJ96tMRkEjaT3AzVQMUuwic5XjBq8yqRjgKBx3yapCZG+04BYgg8EjNQygZ4+Vge1SYLsF+UEkGmFlBLbyMdAF70rjGZcjaetOchcljuzggHvSHcvKkEAnBJ61E74AVsb/r1ouBHMAvTGSOp70WQLKrMQQWIz1H6VHKem4YJ6Z/hqW0cJBCu3AZzyD7VKfcfQRyfMypJ5xxSzCRVQqueehpskiJJhSdrdAR3p7SAqpAOecg0wInAYkZG09fT600kbkwcqDyKH+6Tj/d59fWkGR0zvwPelcCXCuCTxjqT3ptz8hgDk5MhJ9qdHwoGSR7io71gHtw394/jQ7JAtx7Mx3GMEds55FROH2crhl655zU0boEfcCrkEcH7v19arlvmbn0znvzRcBokVgPl4UY/Gmg+ZGQfxz6Urkk7VI5bj61HICyEHOFJzU3HYz/Egxo84BB+70H+0K4iuy8Qsf7LuAMAHHH/AAIVxteVjXeovQ66HwnTeARnWZun+oPX/eWusvFwG+XHI56iuS8A/wDIZlycDyG6D/aWuwu87JeWHA+Y9OtdWE/hGFb+IRwq29SX2YPr1FaCuuXALHjjPas1ZXRkyeGGMjkj3q4CzsDvJ3cD0NdUTGRMpG1QGIIPU96VmA3c5OOvYUDnjcu3GOOtPVBk4Jx3B7VZOxAXDEpjJ+lMgT/TspjaBjaRU8qsH+bPJ4xVZRm8LZbAHQdKBo0S4ULtbg98U4q4lZkccj5sjj61CytvAGWXpUuxcY+faflGF607PqLyBcIGDyZ3fNu9KaQE3LkDGDjHGPaj5l2mHLbeDleaaWLDO7gjB3etAWILlPlYE5yOgPSo7Y4nHdevHce9LMwCEBRkjkj6UyyfHyng8AHHSkVYvzAM4DKMtyPUUxGAjZXYEnt/SnMqqU5HAyc881KRGMEIQ3U+n51ViCFmQxq45PpuoJUMVxwR1XtQ6DCom0FeSduOajl+RskKSR1HGaLjsFuEM77W4ERBOOetM0piunKyFjhm4x2qOIeTcR7gOQxwe9Jp/l/ZIwGGWds5NJPUq2gk4b7RCyMFx1GOc5q8JN444PUGqnmEyKz8jdgj+6PWpfkZwQMR5xkHvQmDRNuGdhXLsfmY8/kPWq8ocB95GM+nOPelmAXa2fn/ANk1BNNn5SWYgHr6UgSEl+8AQev1psgG7IGCT09KeSpiViVAxlcHmq+4buHyMYxSGNlxt3HIAIBxzkVctQ2bXrwScAdqrknyz1Kt+tSW8kqOrNwPmxQtAZWYss7DJGT6evap8ny89SB90HpUZDMctj29hSk4jcIcBiCRjuKVx2G9eAc5OfpT1GI1OzHOPr70wEgEcE5z7mnNIVA9ccntzRcLEsR7k7wecVXvR89p94kMT7VMrspA+XgcnHSr+h6LceJPEFtp1jJFGNhleWT/AJZpwMgdzzwKidSMIuT2HGDk7IyZHA3LLgLnOTSi3meEzLbzNADhpBGdo9Oe1fSvhHwPofh63QpZG6uyPnupQrOT7Z+6PpW/qenvq1pJZRsVtZAUdZVBG09eleVUzT3vdjdHdDA6e9Kx8httijYnO3tzwK6Pwp4K17xKoe1g+zWknIubglVI9QvU17JonwK0OzvYrq+1S9v1hfzFt2RVjOOgbqSK9KTRYAuFGAQPyqcRmLtakOjg1/y8Z8q/Ez4YX3hzwhqGqDVrO8tIDGHVUZHOZFUYHTqa8Qr7T/aH082vwe8QNuyAbfAPYfaI6+LK5oVp1VzT3NJ0403aJ0vgMA6vNuAP+jt1/wB5a6+7ZdkwHK8dsciuS+H4J1mbHaAn/wAeWuuvJS08pwMAelexhP4X3nn1vjIIixwTzu/QelaFvhAMEAHkYHSs23IcrvG1gRyP61pRY3Y+bIH5V1QldGU1Zk6kEZI+hAoCElV3YBO7kc1KMqFLYIXp/jQ7t5ZcHAHP/wCqruQQzM6hWDlQTgfSoLZVF6zYwQuRxUsmPlA+5x+NRWIzeTEjGRjBP8qB9C1ncpVST3NGXXgkrk856/hT0ZUJ3KWyOdpp0W1lbduOegJ7U73JGrl9pG3Bxx3FOdcqVJAUHg4pwI34UYz8uQeQO1DsVTYwDDjPvinoBSuQVibkEgZOBUUKgYVSN3XAFT6mCLBplOMj0qqcpMM5xtA6YxxUvQuOpeijBiOFLE8HpzTmDlCVPKnHIx+tSw7REpQcgdSD1pitg/xFcdQOppqzJREctguF988cU2cEABWOw9B1qT5y53ntUTgKkhHOBj5hikxkECNLcwk/MEDNg/59KhsMraHdtbfIwIx+VWYX23Vs5yFO9c+mR6VX0mRY7YjGSHYk4pX1K6Cwti6Ug/KFx059RVsb0kO6JQSMAZ9fUVRgIN6zjBG0Lz0HFXl+ZyCcDPXNCBleVAucnHOaiuI3AGWQsQRnP86vQwzXsxgsonlk/uhMn8fauw8OfDx9QtWudWnligzzFBGdzc+vX8q562Jp0fiZtTozqfCjzhQVZFypcj7nU+wxXVeEPAWteIdQYC3NlZFWZ7i4XaOOwHfNemaXpOmwyJBZeG5dPtFAMl7dkeYR6qoycmukkEPia3uNH0++vtOjtG2kWwA8wA4KZ/LP1FeZPMJS0grHXHCRj8bPNrj4O6jCT5eqQuD/AKsJAXJHvg8U4/B/WgUnutT0u1tdp3tcFg6/8BH+NeoQ2tv4WtDaaNY3U+oCHzDJKGdnXPI3njOe2as6NLN4gspU1vRmEWMMz5UY9D71nHGV+/5ClSpKXJ1+Z5dB8KdLt7Vr/UvEVxdWyZBaxgVAB7liT+lWIvA/gi1htbiQ6ncW033JpJ/k3ejbRwa76HQE0W1vrjRzLf27LmS0+9/u4B/nVDw1FBqejz2GpaLJZwysc4Tapz1+n1qZV60tXL8bFRhCMlG2/k3+JzkvgzwoiyTDQ5ZLRAd8kczuGPsQazoPhvo+vWTXWhvcWzhTiBn3Ant94ZH51e8NaNaeAL67nvvFFpKjNt+wIS2VPKEjrux7V3WnzSXGJrpktbRztitbaMh3zzlmOD+ApKrUT0k/vNZQj1St6Hih+GOuNuVBEkq8hJjgv9CMiul+HOjzeFNeshrtq1s9yWR7gx5Ab+Fd/TafT1r0ez8RadctPawapBp93EWUC8i8okDuFbBI965nX/DWo+JrOdW11L613CRZbaYb1x/dHT3waqpVq1I8s9iIRpwn7qPTntRJEqxAFTz+FSeQYUVgeF5J71neCbuSXTFtNQnSa/s1WKWQY+fjh/xHpW/LAGXHUEdBXIo2N+a+oW0ge3Ujqe/amzuYIiwJaUjAHpTLIulvMhX/AFf8OOgpkIM0TE/6xuMHsKfKK55v+0Wxb4Ja+WBLZt8t2/4+Iq+Ia+6v2lrdY/gZrhQY2m3z/wCBEdfCtawjyqxlUd2dN4BYrq8+04PkHB/4EtdbLIMy7uu0nnvXH+BsnVpgOpgIH/fS1100gd3XGDt5B9a9nCfwjz6/xkUAX5QCVbHJJ4rQiK5I6Kw/h9ay4E3YyW4GRjpWgpw64PQ5z2rogtDOe5dikYIVUnB7d6c3lhD82ec4qsJeeAB3GO1TfeUbgAF545zWqaMxGBeLO3aV7+lVLWYC4nY/KcAZI61eR92QQckHk9DVC3yss4/iDDg0mNbGohXy+wUjABGSabjkhyMjkHv9KYG2ylV2gDv6fT2py4IyCeSMEmmibDvnBU5O7PPAGKUzt5irtUsDyM8fUUx1ZmdTuyvbd1/GmKqs+PMOVPTv9M1jVxNOknzMuNOUthmsOfsMqnBfg56j8KqtlpWKhsYUcnvirHiMmHw1PcW0ZaW3YMyseMEgE/rXEQ+Ir+KSGeXbLHKfnDJgNjsD6iuSOYU56tWOn6rJLQ7uM/uJFXkHAIzQSyrwdydh7Vwep+ILu7uUWBzbW+7AAOG/4Ear3GrXskMKS3TMVyQQxXA98dTTlj4J2SuEcLJ6s9CRztPXcD0NE0hfC7VDqO9cr4Y1tEWS31GbawO6KVumPTNbS6pbXUgEN3FK/tw2K6aWIjOKdzGVNwdizEdr52j5T/OqunkpHsA4JY4P86s2kiSTGNs7mXIx2NM0DTZdTnKW2PLi3eY7nIXngD39qqdSMFzyegRi5PlW5XVglwYs5ZsYUDqfTFdf4f8ACsupXDHUjLaW8WGeNFy7ex/u5/Oup0rStP0G/tlSE3GqyR7sBRuRe7OT92un0+LUJr5Y7K3itNPIzLOy8v649frXkVsxlP3aei79T0IYRQtKevkU/Clg9pLJJbaZ/Z+moo2x7N08xPQk9vWtu2j8RXepyfaGXTdNGPmX77AenvVLUf8AhJrvUra206ObT9NB2yXMgDSyn2H8NWNS165sntrHQoZrqRm2NcSjKlu/XoBXBH3nfqb1ZKEdXp5E+u65q63MY0OylkRACZ5Y+G+pPSga4mnxTJq2qJa3l9jebBADnG3OT6ccjHSq/iXxevhy1QatcJcXTkMlsihSR7449+au+G7jw74tgW9ttNMrBcuzR4CNn7ufXntVxJmm1dde4sFpf3l+Lmz8Ya1LZbQrwjYMsAB1Cgj3q54jv9V03SHFpBeXpPDtO+7Oe/Hb2qXxJBrE2lyWuhtbQM67WB+Vsd9uOnHpWD4H0C/tpZhqV5eW8COAluZSxPfr3B7/AICnZsmUnpBLfquhLptnb6xEt5PZ3+k3ZOWltrl0WRuhU4P6Vdvri08P2BRWmdIxvcTuz5z6nknPt0q7rwS6hfTYdXeymIIRiowG+p6iqHhuXxUsv2PW7ewmhU7Bcg43oO+3uTxT5mnbYpRUo3TuyDRdUs9euFMOkqAykvKUX92B3JIz1AxWN4m8RLa+LtKW3bz7O3UlgpIBbkEdOmB/Wu3vLa3kgns0nS3c/wDPLCnOOMj8f5Vynw30ZLfT7mXU1ku7qG7ch5W3lwOhOfx68VcfiuzKcZcnKnr3L/iCy07xGtrd39oLd5CCjXWAT/dOPy/DqOlV7oa1pdpbxaPokRhjbH3gQR0yccn1zXE/Fi48VXF7DfwpJHp6DYqwNiSB242SJ1A+mVOeprvvDlne6LoEUmvX0om8tfMVuEjwOmB0PPOPSlq9bltJbaFK1uLjSNUg1iXT1sSXNvfIp+WSPs4GeMfnXrlhcx3NsrxsrKwyCO4rxT4gaPfanFFf6TPJPbkfvLeOQHep/uHp71P8HfEOo6bMNC12KRF5NrK3Qj+4T6iiUbq/UlTany2du57NPBlyVJx/Oq1vAYiAx+YN0xV+3kVs7scDOaTA3LIF69cisbm255n+0zKG+CPiEdibbA/7eYq+Eq+6/wBpyIf8KW8QOOubfP8A4ER18KVrHYynudB4MYrqU5ABPkHv0+Za6+QmRfmXDHkZrkvBA/4ms3QgQHOf95a6+dHZmUjgDNezg/4RwV/jIuQDGufLXjr2NTLKNpJX7vApFXagbBwVzkGmwqjjcMhc/nXSjF66k8cwBHyZUgECpBcbW+6x6nbxwKYhTIHO3OM5xUisAwDLlR2Pf6e1UhMYb3Kn5Oe3/wCuomdmLNtxvA5J5AHtV3yPNfaPkHJyRn8BT0hRAuxHLnq3euOvjadK6WrNYUZS8htqsuSxTYCCAxPJz7VY2FHyX8x15IIxTUw4zuxtGMdzTs5VQRuAry54utVdr2XkdSpQjqTwXCooYx7ieuBTJWV8q0aqAN5xxntUcjKuVT2OCOlBHmRjBOf1rD2V9yva9EEqGe0ubc4KywsrAjg5HFeWtLmCGFw21CQEzwD0JHpXqdrKFnUtuIz6/wBa838SWgtNfvI+iF/MXn+FuafKkzWlO6aKDYBOFO3pyearsg8z5SvuM5zUu0nJDDp09KjkTYWwBwP0qkXJERYnJB/AnNJ5jcYYg8EYoVCec9T1q3pun3Oo38dnp9vNdXkpCxpENxznFPREJN7Hf+AIX8UXsMUkv2YRgC4mAyX7BVA6sfSvabXSodKSzttP03zLlOQo4jgHqxHVvzqLwJ4PvPDtha2lhaKtwiE3F06gneRzsHdu2T0FdVNomuPqNtGt1HbWY+Z2HMjH39axqVpV3q9EbRpxox0V2yiNL1m4njFtDFYQOwae9b/WSDvgH+tWdTudXt7q2s9Fs7iWHb89zIpJ+mT+PSq/iLxNf6VqkGkaFpVxfzsdpnuMhWY/3fUV1y3M+n6Y76xcwiQjcwjwoUYHGSamMUtQqJtb2Oa1/wAUXGirEmPtl9LksxGIYgOCoYDG72rY0rVry90kXd/ZRWa7Mt82SOeQQR6e9XdO1PTtRtl+zKGDZCgLwSO+V4/Oq+s6I+tWxtnuVitNu0pFwwP1HtxjFaWtozLmbvOLuui/4JV8jRdVtZrOZYmF8dr7wGEjY4x1G7vwQeKsxWtp4U0SDS9Lt5lG13Vwvcdct03HIwP8KPD+g2fh2BnaQMkALIzD7nHzN/vH9Bx61jWPxGC6teQXGnSLAZfJhXdiUt6ED+fStEleyM5VGoJ1XZsg8N3fiTUpJA83kOSHVJMSKqZ6t3x6cgmu1vYfOhaKOby5pIzsKffUeoFN+0SHSmura3S3ubgfKku0jceELleo78dq8b8d2ni6z8aWlzYzXUmZVjtjEh3xuRkh179DyMqR0xyKb1HTjyK3M36ncW3gu+k8RC8uLppVdQhDg4AxgkEdvQHHNb+qXGjaGLWxluzaq6mOIlzuzj1655rW8NrqK6faf2xJG1/IreYyJgZ7ZA4zXF+J/BM2r6tFPezXTu+2OYRKrRSKDngn5os9T174NU/espGKh7C7orVmV490m9XULGXTruVxghowRs9Rj0z1LUmleKotIuJdPuCiSb/meVGcM3HYdFz35PtW1rmnW+l2f2VLghpXJiDk8sRjCg9AP/181h+BtN0/xTbzS3hVdWt3McvmZYoy8bscZ7HnjIpU2r2ZdanNQbpaNnc6ZcjV1kklsvKa2kUHzVDhmwCGRvx78iuQ+IUGt3FldMMRW4fCypkr5fvjkMe+RjsK2/HniaHwnp9tpumRu9/P8kRZuE/2mY8bj7/Wszwj4p1HW3+z3VkgKFkkuY3AAK9cDowz3GOTTt1RMpQl+5k9Wug7wXoM1nbx3dzMY4XgG6E8eZx99x0X27+vpU3iWwtvEWibtMuk3wybo3jyAJF6bu4I7GneOrLWbnS5YtIuGiVogMKm5g+fvN3247gHB5we3m/w+0TxJpU0+oXd7JZafG5Rw7CRZsH5go/iBJ4P60J63ZrGmox5I7Htfwy12bWY30/UFMOqWq4lRv4gONw9Qa7d2EEm2eMgdd3UV88W3ia4t/HMGq6YXa4tAUe0D482M9Uwep9MdDivcvCvjnSfE8YW0Zo5yATbTjbJ+R6j3FKUFbmaFCopO0XexxP7S8iS/ArxG0bBubbP/gTFXwdX3l+09bRJ8EvEckGY+bbcmOD/AKTFXwbUpJbFN3Oj8CjOryg4/wBSev8AvLXUhnkuHMjc44PauU8EjOqy8E/uT/6EtdPET9oYMeFU5I9vWvVwr/dpeZx1fib8i46t5Sk8txjA61AGPySd+hHrV0ECD/eGcVWZWLhMAkjpt6GuuTSV2c6JHwyld20A8A9auxW+NrTABQMhT2+p/pToIRGQ8rhpOwHOBUksaMTuXKkkkE8k15eIxvN7kNjphRtqx7MqoAGYZ449KjTeASqsWYYFReZiUKuQAMAdKlaZcxjPBGSBxz9a861za9gCPv2lTj16U8Iwb5lIOOPz7mhPnb5lJPTJp+3y2bGBkYPOMVvFPsZSZGwYrkZIJ/MUhLo7cfIV4ycUpl2pyDk9RikdFLAu+GbjAGePWtFcjQgsgd205I69M1zPj6026jaT5G2SPaMDPI5Gfzrp1cRT553f561l+MbcTaO8653QMJPfHQis6kdDajK0jh5F8oKCAG5yf6VCgaaVYoleSVztVEGWJ9ABWjoWlX/iTVo9P0yPzZ5Pmyeir3Zj2FfTnhXwLpXwv8KXmr3xW51CaMQJMyfMzt12eiisXK2nU7dHq9jyf4e/Bu8167A8RTXGmxY3NHFHlyB1BY8A+3NfQfhfwH4S0CQaZoVv/prxkyFJt8gH96Rh7ngcDPanWWqPf+FZp4Y1hikhaG2WTIUDGCze5JNWrCxsPBPhk3izGW9kjIurjeCz/wATY/LA+lZ6u7n0G2tFBaM1NZ1e78Pv9j0fTUvGWEHJbARyf4z2459803Tr2S48J3N1fNuu5vOiyV28liqhfbpg/jXDeCfiPc67rM9vbWFrBarF5252Lu/zqqoecZJaur8TWWo6+ZI7B3XyCPKkUjCyZ5JBPOB0qnpoZu8byWvkVNL8HT2mswavfavLeXCEYD5IVQQdgOeQMACluNS8K+INSaDUriNtQLMioz7ShHHAPf6VJ4R0rU7IyQ30rOBkySuMZGRgfTGazfEfwr0rVr19SXUJ4rpphO0m9SvByFxjgcdc0+vkTTUZU9Y2v0N120/w9oitpMcc0K4kZ8ZMmckKMfnWFot/ofiG6kup9EhjvlDOZA7I2VA+8gOH4PUjjFaF9rFnosUMmpRrJbysULFcqpzxgd8k9a2fDK6JqxNxpzI0scbrhTyAeDkHnt0PpVQ1u2Zyi1KMYNJLocVceIfFn22e50vSba40K2kaICRdjuinGR36dOtdNZafp2qahYanc2bQztz5fB6joT1GeMj2+tc14A1S6vtX1WCZnjtYXaKJWOACD1x244qn43l1jTb1X2eWqOZ7bHIK5AIGP48cj8RUq6aTN5NODklcufEDX9XtNYtFt7OeCC3uNohKEeYCdoZvUHsB0+vTvNGu4tXtLbUFhCXC7kGeWjGcMAfTIqKCY63YRXdxaNBOmEYue5HzAEdPf0J9q5vxJrL+Fbm3msrdlsGlCGJEDAP0EQ9ARk59q2vb3TnStepzaPX0I/H+o6pYpFcQW+4pIBtXLeQMnGQP4j/e6Y4HOa6DwzLfXMUk2oyuF2qwSRgTG/cZ9uOD0ORVrSNV0jxMsZhH75VLhG+WQLnBww6jP5cZrhfj7fvY6Jb6Xp9syQMgM0iL8saEnHvng8+571Tdly21M6dNuo6vNdPoaHxN8Pale2l1e6ddfMhSRoW4YBf4VI6r3x+PNZXhnV9M0lReXyCC7uQJDIB1UdcZ6DPOKl+FEWv3vhiC61C/JslkZI4TH80igYGSffnI+nNUJdIt9X1y/wBIu22XMSiW2l65To315qVpKzNZRajKUN2dzef2B4ojNsxtzc3Me8KyrulC+gPDgdMjke1YmuyReENEh0/So0k1SeJmjxGQAi9Sq+i54HPqa2/DWiWGi2STyxxp9mVmRmO7yQRhm3Y+83tj0Hu231jQ9ZuJbOS6tTPbvzE8g3RMO4YHg89M56iq66bErmcLy0lb7jlPAur6zqAt4Z0T7Id2ZZHJdAB95SeSM4GDXV3GjwXaeW7K00fKuRuAJH8S9COf8KuyxDTLe4uIkzNLIoMjgsOSAC+P4Fzk/jXkOp67fr4knGhOSzSmFMqVkuMH5pmI6bj0UdFAFXZSeiMfaOhTSm3JmtfeGbbQdQk1B8BXU7wkm8ID12A8gnpz0yeteY6x4nvV8URTadJse1YLD5fBVu23PTHvxXr2rapbaDYwLr8rXd3cRlSAF5HoR/npWZdWek3GjQagNJFjcKGZGlTaABzuOOo9KFOTd2bU6VOkmoKxb+LHi5/E/wCznr/9pQG11mIWouIiMB/9JiG9fY/pXxtX0942DXvwC8R3U6kXENzGpzwyg3EWAfrwcfSvmGs5KzNE7m/4MYLqcxJUDyTyf95a6kEC9VgwGV7965LwmC2oygdfKOP++hXXxQvPKixnBzuZj/CAf5130JqFK76HLVjeZcYrKxWM5HoD93jrT40ij4Kl1c4yT/KpVh2oqoMIDkn19zUectwQMcYrnxFd1fJChHlLahRuKBVBPy5OOKVTu81QR8vI96hjBCEO3JOCCKkZdqjYTnp1zXPGmW5kaKxBL4OWwD1JNOWNckMpZx1z0x9abgxsF44Geanjkb5zjA6jP8NWoWIcr6DrfaVYdTu6GncgZxtIPOecc9aiO3d8rjjJOKVJAYiWY7gMbT3NVYRYVQ4cgbegAY9aZJk9VIIPpwOahhcH5WfaAKkUhtyFh/3zxn/GrjqK2pBcsvnBQCdxBJNLcRtewNZ20ZlmuB5aRqMlyajuWaaVYYIneVyERFHLE9BXsfhv4d32mWNjZrKqa1qOJrifZn7PEp+aNW/hPI578+lZVZKKsjalC7uYng7wZP4M8MQadawxS+JNTukWaUEZVU+cpk8ADuO+a7vxpcWkssFvfyRJYWUjZLD5W5DfLnqO2fY1B4g1SLw94x0iKBPMuAH2lvujcMfie1ZvxNsP+Em1bQra+lFujxR3FzwcMT1RfTp3rlV+W/dnYnGVRq+y2JrHS7vxJYW1tpQ+zWEY81ixLb2zkDqM4PNbOmQwxsy+ILnzoYWcgkH5tqqDkj+vrXISeKtW0u8vrawSNLaBdwiVWyQMDgj7uB611eo6FNq3gbSY2MatKkk0z7sMd4B9Oe2R7VdnbyMbxc5zh8S0NDw7daTfwXl1pNpAoDKWkVFwASQApH+7XPWnjq/tr4aebdpGadE3J2Rhksq7OgBznNdLoukQeFND8p52kgSFWkVY/TJ4Azk/NTrXVdHXUYdPtbciV9sYGF2jPtu4p8tnoEpScY80uV/1oa8xnn8My7B/pdzaliE/iYrniuTm0HWzqs09xfibT3L+VbeSR94fLnOOmc/hWx448TS+FNKGoC0S6gjGZVZypC5VRjjHVhWH8PfGuoeOtZaOSzW0sreNmBUbt7ZH8X0NK3RFTpxm1KXQ39QXQbpZNP1Z7ZxbYykgIwSB0PQ8elT+EtJ0zStbj/sghYLhWbYMnJIHc/SqXijwdBr+u/6XcNFaRxq5jjOMMAV5PfIwar3WiT+G9JEtlO0rW5VEKgjEe0ryc9fmHPtT2EnKU3eKt0fU53XdJl0vxRc6dpblrq6bzT5bhPL3H9MY/Wr+maB4hRGi1a4+0wSqNxZlPkkHOR3OegHvXADSvEHh/XHn1m+EMupowjublmZyidiByOoFeleBdTa68PXFvI5W5JYFiT8jFQMr7ZGabpvluT7Wm6ygr3Sv5HVWkjal4dktrAxW92uI5E+7gZ+baexIzg44JrzUeGvE9jrN7Z37DU9Av8jYy7JIdo+Uqv8As+oOO9TXz634P1iKe5t5DYZEcV5ExkcqOqv6k9eeK9Tm1KbTtEW71TyzdbQHWInbuIyQPYDkn0BNCXMr9TTn1fbzOS+G1vaaH4cn814luCwEjg8kfwKM8k/zJqwPEena1cQ2V3HCxmzDsB8xQT0UkdCfy96z21DStTuRd2cpS3nPluAN6K4Bz06Agn0IqLSPDS+HN+oytuUEeTucMGY9ACO3OM+9aKzvc5pOalD2KXJ3NfWLw2Kx6VptmCUgZo4t2zzAo/1aH+93PfHTmvOtBubq98QWuo6zAtopZtjJ+7XgdB6KO+OPWuq0fxfY3V5rlndyy3cZm8kTrF+75HKoR1UEHDdeM1T8cfYLLRdMtbUtPdXs6mK4mIJbJwpyevPYDjqcU5e7FXQRTqVFOMtF0Om1OwXxR4Zlt7S6lt3yTE6kqN2CBuA5xz/WuE8A/CYafqrz6wXmSAgIhQKGPU9D83uen64v/D6w15Lu4tmuriKSOQNJO2WCrnknPUnsPxr0DXL+zS2nsbrUVtneM9HCuoPTqMDPv2pNW2NKVVzjdqxiap4uttM1BLefDrJkpsk+ZvcAcY+p5+lc7qGu6UL1LuG0Q6m8ZKReWBJj3AOMnt3NRxaHa6p4jZYrlJ5REJJJtvRemRzj+XSpNRl0vwZDL9ljkuL/AASbm4QMVDZ7jueenPFFubRBCUoJyq2X9dyS4tNF0SQ6rqcX23VWG5WnXcQcZ+70GB37YrkbbW7jxZq9xaWz5jnjMDb1whJ6bT1JxnrXS6PajxXbSb5gznEgcqVLKeCOvTkg4qTUfD1p4a0mQCJWjjjJCLkFx0CjHTJ6nrhevNbRio6MxnVbSmn7u7OT+Kekv4d+FPi+z+1S3MF1HZuHkXBEiXEQI9ORznvXyrX0Z8T9cvb74V6hazF1jV48q5LFgJUxjPIA471851nVjyysXQqqrDmRveDYWn1V0Q4PlE59ORzXoEUXkKBEmD3weTj1rg/A8qQ6rMzkAeQwyf8AeWu4S/A+SKFnfHDY/nUNTa02Q5WuSAbSAzkd+OKrMAsh246/jUxa8dQx2wAkAfKKnis52iMskkjhWIIEY5Hr0o+Hdkct9kMiKlD8pL9sjrSn5SwBxntjtUf9qWq53afqashwxNufnA7/AEqzFqGjXTAC5ERxwsoZM+3SmpPogdPuQliEZSPp9KSPGx93ynsa0EtYySy7nU/xBuKS4t4kkbaZM8HKkH2q02Q0Uol3kfN8uOrcCpRtDEqcHoQRgfWpDEqAM5lwPTAxSeSqHJbCNnkkDBp2vuLQS5cuRxkD1qMSOcAEBfp6UpMKxGQkttIBy4BPtUdxc2VokYvp47bfkqrnkj6VSSQIv6Hfy6Zr1pfRPGssDhgXXK/j7V2V18U/EGt6lcNH5VhaIyi7liDNHszjqMsBwTxzXm8F5Z3iTNazpO8I3EIC3GcDj616Z4P8M6pqGi3OiKZNGivYkvNWu5YfLm4YiGCHqctySe3T64VEm7s6qLaVj1i/Xw3p6aZqd7fQXF9qJWCC7WTdHGCpYYxn5Tj8Sa5HWLLVdevE1adYrbTY5BBaRqG3Sc48w5GAMdB1rDvbZ/BOp6dZ6HbRgxxblSYO8czsTtVh13E5yRXf+H/Ep8R+KZtJ1MQ6fd2yuLbT2ckSuB8xBIGcZHGAcZrNxaNE1O93b0MoXejaRoupJOVuLqfdyqtJgtgd+B2qt8atev8Aw9YWNvpyqyiOGLDKSCSC2cDqflHBq7cfD6TUNb8xWmikdRvilC7E4wehJIHOMYrqfFmn6at/bm8klklAUiNHYNhf4sLyRn+tDWiIp1Jybc427GT4QMs/guOWOLzNQuEeRo2UL+9YZIxgBfm7VR0jwXJb6qNVZrpLx7gSET7AoG7JwFJz3HauiOpW1loVxc6XYy+VZgKIXRoyc4JbByT1znqa5Lw940vNf1mKxEX2V7kr5T4GzaSQcjk5x0OevtVryM6ipuUVPfpudT4kutJnlSHUJVOwHchIKhTjIcHjsDg9wK3PDd9Yz2M0en2/kR24XkBQCpHDAr1HB/Kua8WeCV1FjDAtyiCRZg0IQ7227WzuI9AadaQSaNZTaVGknkQ2gM04YO+wMzMMDjODgd+aLJRv1CM6sqri17nf+v8AI4nxJqWvatrt62m/apraCfZbywhdrndwCD2C8ZA5Ir0aDZP8PHVjIoNvKfm6ghmx+WK1NN13R5Y47QZXjHkyxZ/A4yOKzvHGvweHdPnmnt/Ms1hbzdv/ACzG5VGABzyw/Ck48seVlUbOTmpXT/A5vwB4lsvE8sUniGCN7mxshHiaLgkn5mC8+g5rd8Vadbx6Jc3nhhbeF4omcBY8AnrnGOTjIBrgLVLLxteaWvh2eR7eKOSKQiMxhGB3bWzx05r0zwfot/p9rPp135r2ghIErsrB2LdsHPQnsO1Xo0zOMqsanJJXXf8A4B5x8J/Ees+OI75dRECWlplVSPLFzgABtx57nPHpXY32jy+IbP7B9ua3ubGN4ZI1PLLIBtY+hwCOexNYWhxW3gnxDPZQhAggeTZkA4BOMgfWm3HiO31vXtLvbKaWy1LaYS4iIjlQHLZAJztwfzrO13dG9WpBLkn1LfgzwhcWXiC5a+AwVTzAqFVdE+7nHyli2D1PCn1pfGl3Z6TKNJab/iXTSqVZl8wQz5zsYf3MdRx1rq9c8U2WiRQz3jobNwrNOH+RA5wuD3JPYdgScCotWsNE8RxSQNsjnuozJHKoH73AGHXs+BjkZ4xVN3dyIw9lDkpr7znPB+iWWgavr9q1tHCkkKSrslLIOOdobleg4yayNasV8Q/DCzeAEXNrd748MA0TeZgoT2xx+VaekaXfReJpbfWLuWQR242TxMctzgHJzkjrg561JoulWWlaBPFLeBpbudkG5uMhyFIA6HPc+w9KuWsbhBckuWKsjoNES/j0vZbtHJc7VDO42jdxub+ZA9a8w8TaBq0+rST6i7Sr5m2JC3zuxOAGxxjpk+2OKv6fc+I7PxBIoMqyYxLcLxkdBwcjHoMd+KpTatfal8SdP0C0uhctEN91cofmUg5IwBjPahq1rEQlGu5Jp+6z0KxgsPDeiypM6q0ePOfaA0shGSAP5DsK4m21PQvE1jf297ei1lMhVEk/udQ2cf8A6q7XxLbaRqKvb6k8SOwIz5mw46Zz0HpXKaV4Ki0/VHuL1Gu7JSNjuwBSIA/LnoQTjJ9PrVR5eugVFUbSik097mtb6VZaNoYOmA3t1sCxNG2dynBJHPIxzmvNPCfhnxLc+NQNSN5a+czSzkSnDKx5BB6AD168CvX/AO14GPl+HNPi1CaJRvCShUjBOAN3Tt0qLxF41PhrSY9S1nRb1oJD5a/YysgDHPDHt0oT1vuaL3VyRVkedftBWgtfh5r0MYVUhW2CFh8zRecgHPfB/nXyNX1L8Xr678a/CDV/E1zaf2dDZywwRW+8szK0sfJPAOcg9Owr5aqJqzGj0T4GeGZPFfjZrBHCRJavNM55KoGQHHvlgPxr6vvfhN4SudK+yw2Vxpt0Ewl/DMzNn1ZSdp+hH5V86/soC6PxF1AWc0cB/suTzJpOkaedDk/yr6ku/FtutrFJo7jWl8xo5XL/AGUqAOWRmXa/P4e9c9S99zRWtqjzK/8AgXq0AaW18SabNCo+9NC8J+pKswH5VkW3wN8U3k8hnurCS2B+Wc3crbh/sqoHFe0aRrmmXyRyXUd7BIWIEE4jHI91JBrWieDWNQkhW1vWaOISAyPshOTgDcnXp0oi5vqJqC6HhD/A7WwVC63EsoOBGJJNv4cZqKf4HeJFVwNRTd1VA7kN9Tt4r3yzXWPtUqa1psCxL/qLiwkJI/2WU9frWwsrQKoaSZsnGXiIH50m6n8w7Q7HyPrPw18faZFui0EXidP9Ev1Yj/gLKDXH60vizRrZm1Pwtq1pAnBmaM7Qf94Livua8vLeCPfNdwQH++/QfjXPSeNPCtrdCyk123uJ5yI1giDSM7NwAAuetV7SquqFyUux8PafP4n16QnQdF1G9weTBbvN+B2ith/hh8UNVVZT4a1NQOQGKxHn2Zga+2NC1l729ubK30qbTba2UCM3DLH5ozj5UGSAMdTitaW6khfEjWoXuXnx/Src5slRgtj4Mn+DPxNjQSSeG9QYD+7NG5/IMTXM+JPDWt+HWj/4SLSNUs5CMbrqFlB+jHg/ga/RlXup1DwfZWQnqJGHH/fNRzjz1e0u4gyOMFLmMSROPTP9DS5prdFWifNH7Meh+HPEnw716K+h3anaX/ms6sVZVaMeUc+gKvx7VoHxTrXh3S49Q1+zzqPlxx2rORsuE3H5ie3HXHOcGvaPD3gXRvC2q6lqGh6TFaNqKqLqK2ciNtpJBEfRT8x6V5544aN7uaBLWS6WwK3EdtdR48yInDxjIx7hvXA9KnVvmWg3PljrqhsGvab4y8OQapa2s0N5YTLci0lOZCqsMmNv4lJ4z61y/iG1EmreGfEFpbBml1GaSYLknG4HGR0OD+lddrdpbyeCotV8IW/nG3TzrbAAYIPvREDoAMjb6+9ZOo3Hn/DnUtU0o5MEkeppGoyUSTAcY/2WDZrSUru/YlJL0NW58XSweOUgv9Xa2spriJLRvNEYIDrkSccqRuGSa3/ippeqa3cW1jpJWOUguC0wi34YA8nrgMD/AErzHxNYWni/wvZMgH2l4w6sF3lGA6EDrnOfzrufhTq2o6D4QmttXM2q29gAtsWUeegx/qxuPIHbJz+gDt96M5wjUg1fRljTJoV0i60mXUbMX1nDEZpIyZYy+4qFyOGPygEDp3xWz4Mg8O6TPIljbWsN1KzPJcRoSoYfeQMxJGM9DXA2rWEnhWTWLzXZJltpGt7e2lSNJbSNywCNGn3nLkEv1OPrXeeHPCUfhbwobqyTz9RmEckjztuyWYZPHHQmlzN3bWpKg6bjBfClu9zN8T6x4m1zU7nTvBhW1tEiBa+eElt3dUzxntziuo0TQ30zwo9lHEz388X75p5dzux+9ufucZ5rH0fxoupXS2NrbI9x5isyudgK7wrNuHBIznGOcVe+IPiW90C1jmsow5COz/ICeGVV69stz3quRxfvbiWJpTg6kH7qOYm8G3+nXl1qNpLN5pWRlj8sE/MDgBgxHf2rofFXhf8A4SXw6LKSQxmWMxuQ+DyyNkHBGRsxg8c9qzfDXiu88R6kdOuIHt5YmV5kMYG0bcjBVjkZx1qTxP4hn8N+ILlBLNMkjArErqFiHlrwMgjk5P41TvN2ZjTdDC0vaQfuv/hjh/DKzfDC4uNLuCb68Lm+wkYVli247nGeOxP0r2vwtqg1WyW7QhopNrxNgAlGUMMgd+cfhXneiwaL4u1K91zXjbiVCsESThNyIB3zxnOe1ejaRYWtjbN9mcNG5DLjaqhdoAChQABgCl6m8XOT5r+69tDyH4gWF2PF6XUUcn2HLxXLY+XzN/y5J6kgrx6V3OleE9Hn0qC6sAlvd+S0fnoi5QsNrcDjOCRzWn4s0/TLnSb69keJWKl/OM/yKwXG4c4BwMZFc58EbyS58MFbjGYJTFnaAGAPX3pPXQcYJfFrq36EXxG8GQ+INKS0VJFjik81TayANE23aGKHhwAOhxwTg1J8J/BR8L6KRcv9ouXd8NkhcE8lQfug4HGKzviNpXiyDXxq3hWK5PmuySRwlSpHyhWKnqMCtjwN4hvH0byfEVobTULf/WRqyuSu4jdtBJAqVorG711Od8aaqr+I1tLaeJLkqJLMtkYIOMkjna2D+QPNcdptpr+oxmYXbSRvevIWSdUtxhsSJIMZ39wPTBArqfiVpFnb+ItJ1a2ZBanckgjIAC98egzVGGS78Ntqer6TYreWzXEb3cWCxMbrkOAOQc9/zqoOxjVpucXzPr07He3mpRnTIGmjSK5cFElZQpY9AwB6Z64NcY1vo3w/mbV7m3S41q7jMEENomJZ2JyxbkgduelddLJZ2tquo6mkM1+V/co8gWMKwyVXd2AzkkZrlvEWrafrGq6VJbImLfdMXkUDy+2A3+elWou92NVFflJ57eynsjqfi+SVJJTuS0gYkRDGBFx98/4mlv4PC2p6SsEcgSN0+SKFiCD7x9Mj6ZrJ1fQrjXDJPb6nvhkTasaNjbx0VhwMn1qx4T8E21jbrdaksi+UNyCU5Zcd2x+g/nWttNWY/b0jvuzT8IMfD+iXqWemRrI7DLB8IQOFyTz3yfrWHbeMLxPEcsV7AJrASlp4tnfpnaemfTvXSaNrum6pqNxplu1uIVfymJOQ5/ut/dJ7dj9citK50LT9Lae7kjMszcQB/mIbsFz1PueRUpxvqOcJ+7yOyXQ4n9oaWytvgvqtrYRNHGzwKEVThD56Md35V8ZV9cfHSPUk+FGul5Qlq5t2kj2jk+cmAp67R6nqfavkespbmyPZv2VrZrr4g6iiSeXjS5GPGdw86HivrJtOuTahI7uFXzkO0e7j029K+W/2PgG+JupAjI/siXP/AH+hr7EVFxk4zj061k4Rbu0VzSWiZyx0i6kjEc729yOhHlhM/wCfwqO10G7tJi1kxsVYAP5M5Xd+VdgqqVJIHpjFPECdCAc4NHs4dg55HA67p3iyZVTTr6yQBtwNyrSnjp3Fb+h32otbbNeie2vI8BpLVmkgl+gPK/T9a6RY0LZ2jAqbyY8D5QP8afs4i5pGYb6GQBVdXP8A00UbT+fNVbgWVw6JNp9tcW/VnW1PykdwfX3FbYs4xIW2g/WpJoVbGCR7A01BdQuzEgGi296t1BHP9o27NwWTkD1B6/Wmar4s07TY3le1vp3X+GC0Z3P0wK34oQvKsefepioIwfm+tOwjx3UvjTMxMOk+EtVWc8B9UAtkX0JA3E/TiqWpap8T49H/AOEhnmSONBvOl2tgsiuvpy2/GPx9q9ra1gZgzwxsRyCVBxTbv7iADLM4A/z9M0hmB4P1y18U+G7PWbGaZIZV/eR5PyMvDLgjqCCKs6tp8Woxr5EytfW/72CYjc0ZPTPqjYwf/rU66MOhymWEQwxXL4Ic7IzKfU/wk+vc/hXNeLfh/aeKZFuINW13Qb9NzILS5KKrnq23kZ/3SM0N3BHlXiDWrvw9r98Id+k3cU5lmtpFPlMrLncgBO4EjGQK2NHDaZrZ/tSA2+l6rB5N1br9y2aYZMbDs3Rsdg2K1PjbNY6Paabe6uq3V3ZSfIynbL9mwBIWbv03Y6ZwO9Q2F/4c8SaM1rpCwzG5hErQwy7WdW6SLuOA2R0PIpxd1qS4tS5r79DnZvD8vhK3u9NnnYNZgNbSLhUkhLZDZ7sCcGsS98Q3lhqX2GffCGuxIU3fKAQME4+/n36elX9W1xdZtn8La/dQwX1mp+x3d0piulYfdDKflbI4JB5HI5FczYtPqTpHqbRC6CECQYlxtIAx2B44z2P0q/h957GUm5r2dPRo6LSvD8E/jXRtUSRAhugpY/MySnLKfTqAOvXtXpGm+JnPiTXfDOoSmG1WNLmOaQZ8gswyh6fIT37Z/Ly9b4WehTDTC1xPblHUsxILB8lwf4tp9OK6nxVMuu6bpXivSwnm3sA0+8A6Aswxkemf5ikpXj5GrhFSt1Z3p+HdpFKtxpSrb3BKkvJO8igBwxwpHt6jrXQ+KvDFv4jih+0yMhjDKRtBDq2CVI69QOhHSsTwfa3+maZpAfVLye2jdop0uWQqibWxg7d3Dbcc8CqXxk1aXSdMS4W5khiC7GAdxklhg4U5PSm7tq7OeSpUKcmo6dUupe8K+EbTw/rt5dWrqge3CsoUqEySTnLHsKf4jtdGui22QXF5P+82Rybt3Rd2B0HA54rI+Hl7ea34BvLlzvfUDLHExcuQdu3J3cgD0/Crdvpz6TDM8t59qvLqESTSbdoiVFx8q5JUe1KV07GtNQlBWjo+hwtr4f1SdvtGkyBI55Gk8tZxGyEHbgqxBzgV6r4JjKaBbQSPmaKSVHyM87znn8ar6T4p0q8gtYLd98zKqqspRGJ9ME5z7VrTX6jSDfwxPLHsDBQNrdcHPpjv9KqUvdUbGNKhCNSVWMrt+h4J8QNM8SnVJI/DiXjaRPAAyWqKiRTAmOQFTyCcZ991egfDSGW28MXGmX2LWa2jM8jSrsCZGSzE/Tk1pyeNEXVHs/KjSZX8tt7N9/OMcL/nNec/tM3rr4H+0R3MlvBq0dsDGh5mKklkY+mCCfpUTbjFNo6aNSFZ8sHc8v8Aib8fvE+p6ndWHhfVhYaND+6jntoQktxgYL7iSV5zjaRxiuY8Fa7Fq1zFBqc0kOoR/PHeLgtJ3JkJIyffNcJJAASFUkDn8KEsC+A2VU/rWfMtzoVNvQ+ifGfxBsntrePVTA7vF5ImsrlWCqBjLI2Tnj1q14K+I2k6Wbub+14ZreeJIhFKDHKoReOxBzk9+1fPdpp0Ubfd3H6VoiBSgIHA6ZHao9ry7G8cK5Kz2PcbzVNN8WQqD4gsre6dsRwySBVVc5wCenvUVxpd7ZW7WdkYriYReZmGZHJBPYjjP+z16V4W8Abgpk+h7VKInjUqkskbYx8rkZrSOJa0sZTy+MnzX1Ppz4b6TrH255ZUuILdWVf3ygPt7rIMfePYdRnOfXtvEumy6no1xbabeC1uGV1jfPAOPXsc18l6d4v8WaTb7LHxFqkETHOPPLAnGOhzWppnxU8a6aGjg1cPHnfia3R8H8R+f51UsSpkUsA6S5Uz1j4X+DpdHla91gus8rNHJaxqWPytkDPQkkZPsBzya9anKzTQPeOEywMURI+9j17nGa+arX46eL7aMI8Gjzhh1ktsH/x1hUFz8avE9xewXEttpzpGSTGIjtYemc5XHtg5qfbJ7lPDyPTP2kUuE+GGrsAXtSYF3K33W85M7v0xXxvXt/j/AOL2p+J/Aeo6LqGkWMX2gx5uYnbcNsit06E/KBXiFVzKWqMpQcHZnun7Hoz8TdSGcf8AEol/9HQ19iZPCjIyM/Wvjf8AZEfZ8TL9v+oVL/6Nhr6+88OyY5B79MUiS5/CB8ox0xUkWduR1xVFblchmJz6Yqws+xtpHyt3pgXEwAAVA+gqZTluoPPaqgkwwB5PbFPSQGRvUGmIt5IJOcZ9TSfeIDevSoUYMfm4HtUwkXb8p9qBj1YKeg/Cnr3wc81XDALnvnvVhTQA6qd3MEMrk4EYAz7sauVzesXhXw9c3KfN5s67SOw3AD9BSA1Nct7S50e9g1GCOezeJvNikGVZcd65S00W50m3X+yLm7tbRFHlQCUyIq4zgB8/piuo1pTe+Hr5YTlprZwuPUqcVjeHzK3g20kmkZpXtQzM3UMRiufENpaGlNa3PLPEPw9PifV3vtaubi7uZrcPL5zfIoJ+RFUcAAAnGOtcxf8Aw5l0K5in0qKRo0beiruXy3ByG45r6LSFFknO1Mgqv1AUf41M1rE4xsH0Nc0JTi+aLNpqE48s1oeDw+Gn8bJHqHiyJ7+28lYkvLNQksThjxuxltvfA9Kj8ReDLez0u6k03UoLy7sxvBjQAOgHSZV5VyB9/ueoHWvV7/TZNENzcaajLbzq3nQxj7rY/wBYo9R6V4Hba74qtvGd5f6DE1/ah9pCxjbJGQMg9C2Pp2r0o1faK2xxKh7N+7r59TntFlEGuQ6pZOsum3KGKeMv/qz/AHceuegFes/DrTLRrHVdDlkH2a7jLW67du1sk8nklh2rHuvCUOs3r6vpU0XhvWrhA7abNEUtrhxwTk42k8duPeuXl1i8i1tESN9P1vS5Q8trId5OPvYxwcjoR2pRi07Gk5xceZ7o9N8VSakPDsdxaxR3ckeIJ4pU80xPGDu2KeCzL8wOD0PtVPTrm/8AFOkWmlSahqOk6xaXUZsLy4izLNEUfhkJGCBuwx68cGuk0+/sbqO01cR79H1BQl3GSVNvKDwx6EFTx9DmuL+Mdxfaats/hZbpLazE0cs1grDB+UgsV9OeT7mtb3XIznjS/e+1T0tt0Oi8W2c+gxQ2nh63uJXtGWIoyvMX3oWMjDoWJzk1ueDtLkvbe1mv7U22qXFrKjkReWpVHwNy8c/OP1qx4U8Q21lpHhweLL8DWNTgMYuS3lh9h+USEEDPzHB7nNdppQ097i7e0lglutwE7RvvZeOATn9Km/LHlsHspOs63Np2PG9P8D3smpGdZ4bV0uUuVjW2lM0bAjcoOACuQSOe9em2qXA0u8gMTWpeSbyBKedrEkMQOnJPGegrBvviFaQXUkV7aLbzRvsUM7M45xztXA/M100s0154YmnUCC7MbhSvzYIJwRkc+oqm5cqb2M6CoxnJUnr1OXl8HJcar/aSB/NMqyusUocFgQTgMF/nWJ8ddGj1P4SXhuY3t2slE8ayYYxlW6HHqDjisa1+KV1p3iCfRhpt9dyNcmCIfaMyq24gZGzk9OOnFZX7TvxBgstMPg3T5Umv7tll1CRG4gQYwmB/ExGSOw+tZV5Nwt9x1YTDwpVLwVr7nz7Z2cbBpQBkDjNTxWm8ADapz1x1qG2u0MBQeg+arllcGQYIA7DivPk5H0UIwdkhy2aoVIGR7VNJblhzyB6D9KsRkNxtyc44q0kfzcjBJHyisXNnVGmrGRLZq/zcKT/OomtiHHRuMH1rfSHedgXIB7inRxxvGN2ACxJ+lHtbA6KZzb2Zw27aF9CelRCyHz9QQOldRJaq6nauMHPSqptmDMojGSfXNNVWRLDo5qa0+QYzuxyKabfftViRzzxxXRC1JDYUjHGD2piwYb5AAWPJ7CrVUz+ro5LWoimm3AOcLtI/76FcpXoXiiCOHw/dbfvEr0OR94V57XZQlzRueRj4clRLy/zPZf2VpDF8QtQcAnGlyZx/11ir63jnY2rnkBRux3FfBPgHxbq3g3V59Q0JIZLmW3a3YSxlxsLKx4BHOVFd/D8evHMTKy2um/L2No2P/Qq3UW+hwtpH1vDOJwrKdw/vZ70/z2IXJDbTXyKPj344BGLTSwOeBZt3/wCBUo+Pnjr5cWum/L0H2N//AIqnyvsK67n2as5KglQOgxUkLkyN6fpXxqv7Qnj4cC00zp/z5v8A/FVKn7RPxBXO2z0vn/pyf/4qnyy7Cuu59mwyk54AGcVIJFxnnPrivjNf2jPiNyBY6Yf+3F//AIqnH9oz4jAHdYaZg+tg/wD8VRyS7D5l3PssMCVFXIulfFH/AA0d8RvvfYdL9c/YX/8Aiqcn7SfxHI+Wy0tv+3F//i6OSXYOZdz7L1u5Nrpk8g+/t2r7k8Clt7NF0qK0kUFRGFIPNfFl7+0P8Q7xVWWy03CsGwLJ+x/3qs/8NJ/Ej/nx0v8A8AZP/i6Xs5dg549z65tJXsr9tPkfd5oMkBb+8Oqf1/OnSyxDTSURo0K/cxyuT0xXxU3xw8eNfXF49tZtcTSpLva0c+Xs6KnzcL6jvmr037Q3xAljKtZaYAW3EiyfrnP96s6tGckkkXCpFPVn2HHMTeXigHYJcZI/2RVlZCWG88g8cV8aD9ob4giR5PsOmEuSxzZPj/0KnL+0X8QTkCz0o/Syf/4qsPq1TsaqtCx9mNMGVlGcjoa868RPc+EEk1HSNOa40ySQyXEFtGPMiY9WAHJU9favnaT9oj4gNt3WelgA9PsTgH/x6kX9oPx+DuXTtKB9RYP/APFVrGjVTvYmVWDR7/Jq+i+PPDNwbB4Jrsldwcjcoz83HJBxxnHHWvKoF1CBJZ/EPhW4k0wgRrMoIltWToUc4Y49OQa83m+KniN7mW5h8OaFbXMmd81tprRuc9eQ1Jonxd8a6PfPeWkcLyuNp863eQAe2TxXRGMl9k5Zrma94+gPBPiTw/a6ethNdwzRXDlbhRGwcMc/vZAeQezduldV4KaFI9T0vVRE98SsUU20lZ7cjKuGHGMZ78Yr5J8T/EnxH4juYrq60vToLyM5+02lk0UjexIPNPtPih4xswBGiYELwKGhf5VYYJHPXmlySeti3Loj6+tbHTdZ1EQxwRS6XaOAu5fkQKOOT19c+9eA/Cn42X3gbxHqWj+KY57zRHu5FMnLT2ZDHpn7yf7PUdR6HlNG+NnjbSNFbS7KzsFt2UKWNo+/jvnd1rgNf1XVdd1y+1a+ts3d5KZpdkJC7j1wKl053ui4zjsz7c1HwvH4nki1fRLmO4sblS0VzDMpjm3NkHoTxkg/Su80fThZaQNLWV5GUMDKfm2kntn0zXwX8O/iX4v+H7XK6ExNtOPmtbmN3hVsj51TIAbjGfSun1L4/wDxA1DTLqyeGyhW4Uq0sFq6SLkYyrbuDWj53Hlsc8KNKnNzju9zrPjD4k07R9ZutN8HT2U2qPcSTahq1vCUlikY8xRvuIHfcR649a8MktyJnDMxdySzHkk/1qql5qUQOLZuepaJiTR9u1HcW+zncT18o1z+xqXvY9FVqKja5f8AKdMFnbaB/wDqrW03cNgLHA/Sudk1HU5UVTbcL6RHn60sOpapb8i2/wC+ojUSoVGtjani6UJbno1syRhQcYYZ5POe1Oa7AZt3D9Mg4rzxtZ1diM2/T/pk1JJrOrP963x/2yNc/wBRqdUdn9q0lsegPPuf5GOeuV4Jp8c0mSCuQw7jpXnia9q0fSIDH/TM1MnijWI8lYkA9PKOP50PB1Ow1mlHqeixO+ChDLuGM9qaxeNwQhZ8ZJx3rgV8Xa2wIEMTY5/1J4/WkHinWyOIE57+S3+NT9Sq9iv7UoHoQMxjDFcE9s1A0bBHDD15HFcSni3XcYFtEeMZ8hjn9aR/FeuOF3WkXHQ+Q3+NH1Kt2D+1KHc2/F21fDNwoGPuf+hivNa6DVdb1S9sZYbq3RIHxuYREYwQRya5+uujSlSjaR5mMrwrzUobWN7wcCdTlx/zxJ/8eWvZPCvw4uPEHhOTxHc+ItE0XTEuGty+oMYwCCByxIHJPSvIfAmP7XmJHSBiP++lr6Gt9Nv9X/ZjvbbSbO8vLk62HEVpA0smBMhJCqCTgc9K9JVJQoJxfU8txjKq0+xl23wZmv8AR7/UdF8YeGtVt7JGklNjIZgCqltpKk4JAryy2l8wI2FUOM19PeENP1C2134nXwg1S40jUdPSQapq1kbO5nmSEqUEZSP5FBPIjXnuetfMECERW5xj5QDn6Vtg6spt8zIrwjFKyLKHPcA+4qSNyDz1HXHWowpY4/lQoJ4ycY9MZrui2crSLqyOMlW+bt61YivZQCrIkgPas9GKsMNnjnIqRRztI4I4NXGT2IcUaMu1490Q4YZ9DUVgdocMgpbWR2hf1HX1NPtVO5sZ2knp2HpWilqQ46AcCMEAH39aUxvIwJOMD0xUjIu1wAcAdCKWJckiQ9sg+ntVXsybELfJ0XJI79KrwpyVOAB69zVm5RSwXcm0c8HtURZEVgxQge/P1qXK40gTJYEhP9WcfnVOxkEdzcZUenIxVmOSIKELHcRgNjj1qgwxI8jk/cHT1/rUyky1FE9yreUvA+V1xx15NXoiFUB8YOccdKouxmt9/Gflz+FSLLscqTuTqOCapO2onG5o7lRsDBHcAVUdMPuKgLjIAFNS4w4PO3ryKJrlJFyG289AKfN1Eo2GIeTgcdRxVmcAW0eACe5A/Sq6yANlQxJ56dKd9oQxlGV+BxxUqRTiFuFCgsB35xTYlKhsAcyZ5FNWRV/vnJzwKkLmJAzKVQnG7HencLFRuZfu8DGOOtSBiCSo4PtUYH707mbbz2oUEKwwef0qLyKsi1ONypwMH17ioiMEbFDHvkVNBHPPCuI9yjjLEAUJvVym1VPTG7jFVd9RWHIu2FztBPAyOwqG/I+yRAjjzAenNSBnU48vI+v60TI0ixxEDaG3deMelDd9ENK2o1vlIbgnqap3DkszDjHtV+aV2iKMqAg4yo5rOlPlkKV+tS7jSIZwehUHJ6YqnLgKcDP4VPLIzleBx71BJgqMHjPT2rM1Ra0ziG4baM8Dp2rUt02Q5wuSOmOlZung5MRxiQbvrjtWmXfG0IuPY1pBXRnPcjtUBDHAwSe3SpSpYDAAx39aj3GNSDG556A9KUSEnIjYCrRm0Zfircvh65VsD7uB/wADFed16F4rkLaHeAxsudnJHT5hXnteNmP8Ven+Z6GE+B+p0ngRN+rzDcVxATx/vLXqGja74g0W2a10fxDqFjatI0nlQyALuPU9OpxXmXw/ONam/wCvdv8A0Ja75scsSQR27CujCU4zo2kjGvNxqaGxP4x8W3UM1vP4q1d4ZFKMplByCMEHjuDXMSWxiSOPeSqjA9qvfKMhTgY4zUjIMHg5KngciuqFGMX7qsYSqSe7Mm1jLo/70qw56daV4pUjY+ZkkcjHNOtOWJXAwSCBVsbQPmBKkcgnkVSQNmeDIQdzAnt8tCtMHxvC8YGR1qysY8sFQMk4z6VHNE4AzjPagLiRTTIuN20E54HelikkVjiVueRg4pSvzcj6Af1ogH70AfxdqpIRZFtM5DmRxxkDfyalTTncjMrrnqSeKkV2h24+dByRVlLlZPvLgdq0SRm2ysbCNSqtIxwM09rCNSHIBzgjirAGXycnHOKkP7wjABPTI9PYU7InmZiXygTQogyOQykd6rtho5gFAHykexrR1YILm2IPByOlUcgBwgJXZ1rORrF6XIYn2q0XBO0EZ6jkVevWZZVABwVGc96riNfNhOR8y4Iz+tWrwl2AxgD8aLaA2VQ+QQ3LGnx4Y7QOnb+tMIOQF49s1YAEbjb97Hr0p2fULjRvXjqW5BzQUbJz+FEZBkO7jB5qeJlAOVLsPugDpTSuLYlgtlBUMpH161X1pm8pU8tlHB5xV9UbcXlZQzDJANZurswt0IPORj2ptWQou8iBGPHHNTxwsSCeehIp1jErKGfoMcZ61bgPll/MUH+4ff3qUimxskhAKp16YqC3i8yYORz0Heh/9a2eMnJI5q5aRgEZxnk5xVdBbEU4CsRgE44qpDn7UCo4wOtWbpi0h3EAccjv61Hbri6Un5lBHfHGaQ0VrpsMwHWsy5LFSQTu6CtC9O2ZiRyWIxVKRh0BPHXPSs2aRKwQFC5GD6Zx+VRIp5BBxnpnrUgLI7EEcfjmlRtxy2SSOnc1JZasIt19CDgkIxxitHGVGRyOOvFVLDJ1DGDxH0xV9gFT5wc9ABWsdjKW4x3YyMB+PNMXDAgZ/pTgCSxb6fSgr+8H8qqyIMrxZz4fuyc7sIOe/wA4rzivR/FZz4dvB2+T/wBDWvOK8bMf4q9P8z0MJ8D9Tqfh2ca3Mc4xbt/6Etegsp3EAgjGa89+Hv8AyGpuCf8AR24/4Etegx/KOASrceldmAX7k5cVpUKzHMg2cH0H9Kss25ck8BSMY6VXaNkkPHHrT5nwjHI4GcYrsMClZJuExHrnpUtw5VFycFuKbaMVEpAGWbjtmluWDP245P8A+uoLHxcI6Z68596XZvQE5OOlNiZVi55Ocg+tTB1KnPBI5+lWSVXX5ec5Pb2pLTJnHBHUDHFW1VQcsdw9fQ1WhiMV2VYg9wfapsO5ZRlDkvkZB/E08OAxwThhwSKRWU/fbIIzg0xHGCoUkc8Y5xV7akWLLN5YwCCeo4qS3eV1zu2hjxn1x2qCMB3Ac4PQVMWUDAO7pxnpVaMnVFPWGXZAclSGOc1RhBzLhQRtXnNaGpoWtOF5VhwTxiqtqDuY5yh2gZ4xUddC1sRQI7uQSeCR681emDYyAMY9arp+7v54wcrJ8ykDIJH/ANapmcEHgkDoc9KpWsN3uV1PzcDJzwam2nJXqTyTjt7U0OhYIzrn0HNO3psyTk9KWnUNSMqCfm6dakjkJO1QOSOvFMyoUlj1Hpmn5G4FRyfbpTAsRh8FlK49j71W1eNmtc5y28ADr1qe1lUKzOMgnGAPvGq2oHzUG3K7nUkCm9UJbl7TgEh+bDDA61KxLE55wemO1QWhdQ3ynaOQCcVPhjICwAyM8MKa1E9Ci2d5xkbjxWhbvw24j39RUEqgTbs4C/KT1/KmCeOMv84LHjIOaegtR12duQwyvY96rpt3oQR6/TBpzOpUgOCD05yaitvll2uThWzu9qkpaIoXE26chRg5OfzqCV1APPy9KS5fNxKc/wARyfUVXbOAmep6+orBm6VhSOT+mOlSRbVII+XH61ET1XJz3HapEcZGMEDk0kM0NLA+1zupIwoUYNX5WzsjI5UY+pqrZeWlkxJAkLZGR0FPiK4DPLgd+9bR2MZbkoGS6g5yepprHL/N1zTg8W75nAB5wKBLC6nMiKeo+tUSY/ivB8OXp7jZ1/3xXm9ejeK8Dw9dYZSfl6f7615zXiZk71V6f5no4T4H6nS+A5RDq8zHPMDDg/7S13JvsAFVbI6VxXw8XdrU/wAu7Fux+nzLXoUiuWyI1PPHArrwH8I5sU17QpC7lc4ER9OmaYJHcEyqR2A2nFXzJKFV8MBjBokZ8FRu3Y43H2rqMEzOgMYB35HXBHQ0sZj3ElOckDByMUAbrdWbO3eVI96ttGqIhwoBGKaVwbKZ3EYWJgvXk9KXOW4jAHr6VcgVG49PvcZqbyFjXhQx7e1PlDmRnYdiSIRx1wf6VDJGQ2fL2hjgAngH2reFsoZtyk5GSBWdeKqM+XO4FSD6U2gjIqGK5/hi6jHJqQW90UYIh9B1yK1rcxtCpB28ZIAxipiNiEt8oYYGeOKaiS5mILK7YAkfTmpBaXaIWcIpJ+9WsECQu2NpGDjPXmpjEJIwH+fcM5yOlPlsLnMGSC48tmeWHaRkjOc+1VQgdCwk44XaT1OOtbd4sSxu6oN4B6+lZ+nRIs9wpwBsBBqbFp6FcgpJHIDhU+XjqTin2x+0ySAMV2DPIJLU+6VIogFBDMOc9smrWj2i7JHkDcdgeaa3G3ZXK627ghkyVB6lQKHSbYBggZzwBW8kNv5QVIl3DtjNROiNKx24x7Cq5bGakYsXnqNwUEc9ccU8+eAm3ys+3Bq+0AIyE4PX6UzyxsVmwCvbtStYq9ygpuAgX5QRyMf1qFM3LsD1jxg/Wrz/ACKQCBuP5VQt1KLdMTggAgfjRe2jGu5a8mQBVLHaPSmi2G/ncT7d60ZYcvlx95Qw47EUp2xpnJ3e9MlvQzvIUM2YnIz69KXy41cgKVFSu4P8XDcnJqo7EqDk5z1zii9hj9gCEpjcPbrUd85jtHdco4UcemamiIIDEZx0FQaqAbaVm3FsqAfxqXew1uZWDvPOe5z6VEQTJ1HHap3KqAFGfXmouuScYzxWRuNycnBGAeT6CkQfNtAHPFK5QswAAz6d6fbcyxgcDeO/SgDbso2ZJSpG1W6EZq0ygJyih+Og4qCxOxJGViFdmJGevNSgKGIPHzDJrdbHOyXaiSZ8ncwGOemKYNhZhIgA/i+Xp+NPkIYncSrA9emRUTliucAqeB0piuYPjGKNNCumRQM7ccf7YrzivSPGBzoN2MdAhz/wNa83rw8y/ir0/wAz0sH8D9TrPhtj+3pc/wDPu3/oS16RtLSk7VCqOhrzT4d5/tubGP8Aj3br/vLXoZfGwZIHqB1rrwH8I5cX/EJJQUKnBVQSM9hUExCtkZ2EcelTsf3eScZ6gVVvyGhAU4O7J7V1mCK1mc2zjBDiUHjr061ccnyUYKOBkZFVtMCiBwWyTJ2HrVmQs4KqpV85OewpxQ5bj7IdWzuUcdP51Op+dWXhTyBVa2ZNuwZDf1qZ0IIxjryKtXM5Folo8t0B5GRwRWLfk+ZNk5LEHpitYsWTDEgZ6dhWRfD94464HUfWlJjhuXLfIiGG9sGrLklTlSQOh6GqdqSqfNw3UMe1TqSHIyWJHOapbCe5O7AojBMg8dcnFIJdrA/dyMD86iDM0eELbc5NLAXZ9uCPQ/1pokZqBxbTMe6kD16VStC4vVRSF3QA8jPerep/PbkY6q3OepqKNSNVtwSUzbnnp+tS/d1ZpF3VkMv4wIZJHcFiwVQP5mtS1ykKqmdpAzkck1Xu7bzIg0Kb5AOAPXPWplu0s7VprosqqhZz/dA64rN4mlT1lJF+ynLRIsKGjy2CRjqRnFQbPlYscqDgGqmieIrTWH8mNJYZ2XciOOXHqKnur+wimFv9rhWZsbY2YDn0z61UMTTmlJPRkyozi+VrUkPyMvU5469ahuG2w5zyDzjrT3DBMkBWGcjqRVKSYlBktgnJ+tW5CSKr52HH8PQ1HFgx3pB4Cj88inSvklckj3HektTmK+ZRyFHXtzUJ66mltDYkceXGQP8AlmOp71VmcMNpB3cGn3EiokRO37g4qAyHacH5u9acy6GajqV5GIOGGB9OtMHzEnadvb3odycD06ZqFc7gMEZ568Vm33LsW4gxX2zUOqBfsBGRkOueelSwjK4JHBzgd+ai1Q4tvlwT5i8/nQ37oJaoyyOoGD7CmyYAwnBHUU9m2yZHIHp/WmMQxz3J5x0NZXNSIKDydv8AKpLFS99HjjnNDkMvAxnjipdPUCXnAIVjnOB0prVjexvabs+xpnHJLZ7DmpDE25dp+Y5OPUe9VrYJHboON20D61ZkYYBzzjHFbGD3I5sAHcR+HWmxOCmSmc9z2pQFaQ5wAB17VJG8WchSPShCe5heMxjQ7n3RMHPX51rzWvTPGxQ+HZXQEBto/wDHx/hXmdeLmTvVXp/mejg/gfqdX8OMnW5wAD/o7df95a9FZQRnozdK83+HrbdamIB/49yPp8y16MJ1KF2B46jFdWB/hHNi/wCIKgwQCfkqjqfzMOQCQcetWTN8rYQsQeMVHJtuCSNqtjGGODXY2c8SppOWjl2hfkYVoS5wDlSTxnPPtVPRxhbrgFgwDc8VZmBLIRjIGe4pJuw3uCLtBX+9yvNXkVgAQuOB+dQDypJFLOOmAfSnOWRFBKkdNzn+VWiGTuAxK7QPr2rGnZnkbbnjPbrWk2BtCyJ05OOtZ92Cs64wWY8nGOKBx8yxZj9wr7snnK4/zxU2RnOenHHamQmMwAMqkAcDsD6VYt7XzXUnChT06A+1cWIxkaXurVnRToOer0RVYlgQoyRzx6emKkCzOFYcDtgdavRW6huYyuCcj/69SSYSMgDII+76mvLli6095fcdsaFOPQpNbMU2sDxz1qwkC+Wu0dOoI6elSKp2KCNuSN3tV8xk5YgbO+D0+tZXlLcq8Y7FeH5E5JBA5GO471yvxDnxoHlIr+bd3Cxhf9lRuP64rt2QGPBUdCd3tXEeNGD6tBbISpt4SxHX5m7flWVWTitTow8FVnZHGXcgaGw8iOe3uI1PmS7+D2G3HtxVQRRZcE/Iep6475rcvrZo0JckBRkg1iSZEikDI759KxhK60O+tT5JalrU7kx3xnspmcRhSkhJySAOD611FrqtpeRRbbhPOZcmM/KQ1cQy7flxsU8jFVjkqwAySPXpXdhcVKgrLVHnYmhGs7vRnpCgktnnHUd6khTbbXf95l4wPfvWV4bvJLzS0aYfPEdhbuR2/StKB90FyXZsBflA6E19BTkpxUo9Tx5pxbi+hau8BohxwgGDVfcxO1VIx3xT7lnkYEqvAHBPambnGAgXYOSx4qmyUiEphyGU/QnipUQdtpI456U1WcncxTB/ixzTSSQAGGRzjbSGTry+doAJzVbU2/0VMqAplHPrxUwd9ud6pjAxiodVVBDGCxx5mB+VDeg4rUob127to5NQOwywCgEntT26AbsjPPFNL7mI4BP6Vne5oAOFOD901Zss5lyMsYyAR15qowVRjgZ64q7p4U28jZIPA4781UdwexoIAYxlwrKoXbikTbuHmHbjue4qWSRmYKByRzVcvufDICF6EmtLmKLxW36CUc9w1KYiwysq8DAqgVjJ3MGXPUkcYqRVVWBhkx1688VSfQloy/GBxoN0hBRlKfLjg/MK84r0Xxe7voVyZGDkbBuA/wBoV51XiZj/ABV6f5no4T4H6nUfD4Odbl8vGfIbr6blr0FmkIw0q7emNlee/D8D+2Zs/wDPA/8AoS138hzKFGcZ9ea68Cv3Wpz4r+IPG0NgvI/0XFQXIAlJcEHpz/SrCqEfJIbHI59aiujmNFIGM9OldbOdEGnOEEylyAx/Wr8BIR1LkFOp7GqNljbcgLlVwcn/AAq3bfMoyoxj0pxaSHLcsK6nbuIIz2OMU/Ee9GxuyMkg80xoyDknAJqTed4baQMcYHAoIEwpUn593bjmqskBnZFAICnJz1P+FWWkKABm3s5GMHpVsKIokUZZ2zlq48XiOVckXqb0abb5mRR2qXDpEo2xKOTjrWqoXymUJ8gAA9KWyiEUYACZPPHGPapCilmVgN5xkH+VeRbqdnN0KoGF6MOTmmGBxywDA9Of0Bq75Sg7BkEj5h1zSrEqQkYUeqtzj8aSgx+0IYIXIbeAD7DpUxjYkbEyuc+uacg27lzliRkVPb8uxZSNorVRMnIHjGMSLwgLnI+73NeUzCa+1G4vGOBPIWB54XoMfgK73xjqX9m6TOWciS5/cxgnBI/i/IdfqK4P7aTH+56D5fYivPxU25WR7OWQjFOciO7tZo4GaQ78e9ZNzbHKyrkHHHHFdNb3Imt8SEZ/ujpWJqcyRyMqhSWPNYU5O9j068IuPM2YF6uPvdec4qmxY9CQD61buCWcs2COlVmG0jocniuyOx49Tc6rwnNG2lzQgYljfc3PUHpW3bLmGVSDkIWGe9cp4QR31SWNEdt8ZyEGa7GO3ukVvMt5VXYRllxXu4SrF0lzPY8ivTam7D7yRgIscZQHjvxVX5ioAbAHPbmrU8MjRJsjckIMkKeKfHpt5JGoW1ky7bRkYx710upFbsx5G+hRKDYAN2AfWkVcZxkf1NbCaJdbzGzwo/XbksT+VTr4Zu2YbWjd/wC6FOTWLxdJfaNVh6j+yYoBAGDkn1Peq+qFmjhJGPn/AKV08HhPUmnVCscZYnHmHaCfx61oXHw61q4gQo0CojZLA7gePap+uUtrjWHqX2POnBUHgZycc0ipuUZUBgeua7WH4da1d3n2aGS3kbODtyAv1yKval8MrjTmCXOq27Tg8CFdw/nn8Kl4ukupaoT7HnLFju7r9avWC/u2BORuXjv1rel8C6q1yI7VoZ0JwHbdEGPp83GaqS6PqOmEJqFhcW+2T5mePK9PUcVtTrQlszOcJJaogLcsw47EelMGZJCAAARQwLNkNuGeMUkKuE3KMcmtjAeNxJPGPapVAC4I+U8DPSoc5OW6DrzRvzHv7D1OKq4mZXivA0K47HK8Af7Qrz6u88WH/iTSHJO7b9PvCuDrx8w/iL0/zPQwvwHT/D9S2sTgdfs7f+hLXeSKynJ5YkZOK4P4ftt1ifgnNuw4/wB5a70DMQzgfj3rqwX8I58T8Y3dhgRnJ79KSWXdFtIJKnqOcVXuHwe/HHWnWR+ZlJ4I/Ouvqc4+xJEc4BG3KjryfatSEqI8PjIH5+1Y1mChmGcLvHNaRAWNWJCjPA69qcQkXQFA+9jjIz3pzKpOWfI25PPpVYuC33ueOopY83TbRzBHy5PGSO1TWqRpRuKEXNhp9u0zmYqwGNqKeMAVqwopJ6bBwOKhhQuQMDk9M8AVfih2YVegx714km5s9BLlQ45AjywIJ596NzKSOSBng9qR7lIGxIq8NjC9qZ9o8wMVIK5yM45pRiJss72H3+5pzAsuTkHHbmoPtSJIqOGKtxkDP502SeJiVQgSFuFBPTPNWkQyUPsDySfMD05wT7CpbbMVoZZpArNkuScBVHJqJLdmmjAHmANu2n1rzv4j+Kpby/bRtOlX7Oh2XLpzvbP3Ae4H+NROajsaQpubMnxfqsut6y1zGoFlGTFb+655Y+5NRWkiiMh24PQDoaz71b0iI/ZwIkfyNy8p2OMinIktvdqt0hWEsyoo5+Yf/Xrgl7yPapWpuyRoy5jjCB2+927VnyKzyO2Ogz/9ennUzOTiJd/Q+g+tTpBJcukUIknuJeFihUszH0UDmpScdzWUlPSJkyRFeXPvzXVeCfhh4o8awrd6TaJFpxk8s310/lxE99vdsewr0X4VfDPQ7vUrk+MbyNNR09PtEmkSgqojAyTIf4iOMqPxr6B0bTfOh+1+dLJaoPLgh2LFFGnGNijgCto3ZxVHGLseT+B/gzovha5S+1PUBqupRKwZBN5MIyOwHzH8a29V8GCdYprCwhtRHuJM1ySMD68flXWrofha716K5jjU6sj88sTkD+LBx0HepdfutL1jU49FmkDyAFmiBOAewJ/pV8rMedNXieWXXh3UrlEuI7ZnJGGkiACgdsEVUj0iFZSl3JLa7f8AYJMjHtnsK9dksI7LQzpVj5aTBCE+cjk/xE9h04rndG0nVhvh8Rw2JRVKsYmJE3oSOgP0xSs1szTmulpqc5ZadBpxFtPJbiCUD97GCsmf7u7kVtaekAV7PTjdWtyePMmg3k++atXMkSQTWmm6dBJOASLSfKFwO654NQRf2rLZJ5UBsioyY7g5P0DA9KaJeuqNGeGW2twJFGp3KKSyELkH+dUJI4tTtFn1BL7Tjb/MyibYOO1UXsNJ0i5+33ltM91JnEoaRlz6/r9K1hLeXtxHNb3FrPYEZaORCOMe4poT0egtrey3EBbQDaXUSEBw8h39OpJ5qvrlzpuiwm/1HT3xKcO8URYR575/rTodT0bT7x7S2uLOHUJmySwIHTBx6VYtra/kgmTUdRtZrFjkAEbWHYUArpq+pVs7O4njk+1XVpe6TMqyRtu27AOmPSr+nx6bNHcf2NIL5T9+MTiVR+HpUb36TyWqaPdWZEUqrJbEYO3ocevatSLQ9J0jUJL610+NJJGJZ4eQG6kH0/GnuhKyZ5j4k8Bx6rBLeaFZPYXyE77ZhhJf909B9K8svLaezna2u4zBcISGRuCK+lX1GPxJazW1hdyWl0uRyvBI9f8AP4Vy+v8AhCTVNMEmqRQSXlupCyI2GZR7+tdlDFypaT1X4nNUoRq6w3/A8NyeEfv69qdGgaJkYDnPXtV7X9Kl0WUyTuotGAaKYjhx6fWsX+1rA3IjhuGZAu4yOmzB7ivRWLpXir7/ANfI5Hhqlm7bFHxVt/sKTnkFR+TCuCrvPE9zb3miXMltNGwUrkbsHlh0B5NcHXnY6cZ1E4u+h1YaLjCzOl8BkDV5yf8An3bH/fS127yKVYbMnHX0rh/AaF9XmAz/AKg9P95a7qSAjaAzcfnXZglekc2J/iFYxGZi5xgDO3qKfAzJMxUbc9T7VLFGHcqpL+rAmleHy492eV64rrtYwuQk+U8pfIydw54NWIZEdTvI2g4+9zVVcMULEnnJ9xWhbiARPIyfdJz7+lDfKrvYLakqSB48W6j3PWtC2Ty0ICgYX8+eBUOnQbkTeAT1zjAHtWhbKWGZOFB+UdzXkV6rqyuddOHKia2jZYWlcEsuc49fYU55/KjJYA4xyD1NMeRS7BCQ5bn0qneT7IyrkEZx6YrNWQ73C7ZXYu2ML1A600XASIhCOB9c1nRAyFpMsEzgEdDTYIZJztiEgA43E8U9gtc0RcneBy2RgIDwDWhGxghje6GGblEA+ZvQCqjm10SGSS5IULHvklJGB7AV5r4l8bXWoyyJpu+GFlKGQ/fKk9B6fzqJTsXGFzqfG3jJbK0m0zR3/wCJg4K3EyNlYR3VT/e7ZHSvN9Hlt4r2FrmFpokctIobBZfSs5Gx0ye9KWBOejfSsJLm3Oqm+Rpo7+TUhpl3M2lRskF3EUkt5081RxjcrDjNc/eytEIQW3FP9UpbLg981jQ3Dhdhyyf7xpVkVXDrwQaxjRUTsqYt1FY2rK1ELb7ltgPUeprr/h78SrvwH4kOo6Zp1rewtF5E0Mx2krnPyP8Awnj0P0rz4XbljI8hZscDHb8aAS3IPuBiny63ZDqrl5YnqXj34x33iTT9V0/R9CsdEtdTA+2TqxluZsYJUycYU46Y6d69t+BHxDsNZ+G9pompXkNvrWlKLaRZ3274QfklGeoxhT7j3FfK3h3Rb/WdTt9P0i0mvb+c/u4Y8ZOO/oBXqHhj4IePbnWIpWtrbSTA+17i5nVgBjkbVJLcdv5VSlZ2IdJON2z6cNppWl2T39vKvljLySxgHfkdSfxyKxPD1npt/IdVtHDTqcSSyLhsde3HQD8qmuLPSdC0Wz0vUGmvm+SGG3ViqOxIXP0BOTnOBVq0bRrTTLoW19b2cCTNbM0jAIXXrs9R2z659Ku+pzpW0VrIz9X0i11i4jubfU9rQPjZHIFBOejY5pdYsL2PRxDpckcc6Ff30rdvr35qh4c8DaTpmuPq9hqM8z/M+1mDj5jndnA9+ua1fEXh6DXrcPDd5mXo2d36enen2VxtRinKCu3+JjWMmrTXhi1+e2cQjMLRLzk98gdeuar/ANqaHfrd2eqSSwXCMUWMZ3soOM/WukvU1VPDzRWWxtRjUiPAAGRnGf0/OuJ8LPqesvd23i3T4UvVbyxLt8t24JPTqox1460luXa8dPxNVzB4c0+XD3t4I1DeUF8wgE96qfbX8Q2IuPD+pGKVCN0Uke3aOOKg8R3Om3OrRadeRujyKY45gzKc+vH6e1b1rANJ0C0sbGCF75YyVUvtMozyfftRfqJW1iiK4ksovJk16Wx+0BsKzLgjI5FVmfVk1ONpLS1l0txkFThNvbHepLWJPEVjImrac0BRsDA6EcH5u1S38V7Z2CxaBDDMkWAFL5Ix147UxXuuZPRfec/O2kDWxaaNFBHrDEOsb5Ax3APQfhWnpFrquqzzEXlxo2pW0gD+RhknXGOQePxxSf2da65PDqup2zxXFiSVcfKHwPz4NS2F3fvaXF9oOycCQg+ZncB7A9+9C7FNJLmRpzahFpQIuPIF27FGmaHyyx/Dj8RVCaSPWraS3QtZ6kJPvKcpKPVW6HAPTrWhYx6jqmnq2sW0DJknLDDZ7cdPX6VR1C6Wz8R2lk8JtUu1Kxy8FPMA6fj70N8olH2i12Z4T8aLgpd2ejmTNxbM7zbeEY9FYe5H8q83hsmM6MT7EGu6+KLSN44u0uUIljUI+7npxXNqNpZlGxSOPeuSVRnpUqMWk2YeswCKxmJUbuOe/UVzVdXr7g2M4A4+XB/EVylb0neJyYqKjOyOo+H0nl6zO2M/6O3/AKEtdzPkN154wOp5rz/wQ+zVJvRoCD/30td2krnaI1DEdyele5gn+6PFxK98twIYYSWBz1J96qXMzSLgAAYwfanTPMIgWZTzjAH9arSliFUAnJwfeuxnOtyIY4GSfmwf/rVr2MZkkVc/L296zYISs0a43Zbt71utGISmwkGvOxlVpch0UY394vQxgqiJknp9BV5tkcflkYOOCPaorKIxxbuWycktwaS8m8mB3QhWPT0riXdm700RUvblYAFUbpWOFVRyxpseniYRPfDdJIceSX+VR/U1Fp26T7Re3DDdny0LHART1NZtpd3mo3s27d9h5WJnIXp0K/Xmm2JI3IyvltEvylCOPQfSmX19HpyG61F1ito+fck+3c1nKklrbzvvuLgKDKzzNhVA9B6V5RrWr3mrXJlvJSyg/JH/AAqPYf1rOUrs1hDqXfFXiSfXbpgoaOzDfJF3wOmawcMegNTCGVYRO0UggJ2iTadpPpmrem6Lqeqq76bZXNyiYUmNPWs20tWbqLeiRmlSO31p+1lXkA56V32m/CHxpqMhWLSGiRSP3kzhE59zXVWf7PXiR2Bm1XSbcdzvZiPyFR7SPcr2cux4uiNISqrlvSgqwcgnBHFe9n9nG/MRx4isvOOMBo2C/jSj9m3WEj3SazayHrmJOP1OaPaRH7NngpGDk5yO1dd4C8Iah4x1VrbTnhigtkElzcu2FjUnHTux7CuwvPgH4rhLbpbQqATy4z/OvZvg1bw6d4Kt9KvtKtbLU9PuCLmeGPb9pxna5OPmIBIOeMihSUtEFnDVk3hLwL4f+HlzDqiXt2spAiCO/wA91KeAOnyryeBzXdeJI9RuYkexdo1C7dgBx16D3rEvI9P1bxXaXV26uYZPLs7cOMIuBulPbd7+lXNT8RXL+MYNF08L9m4QHIzkjJbkdK2jGyOWtONVcre+mg/xFpGo6p4Xiis54odQt2WX7Q6Bgrr0UD39a0BplprOiWi+J7a1ivFXbKkfyxs/UsvcDjPWsqbVrlPFH9mQFmsIXOXz1f0B9un41S+IU90NQ0+xhWR45SEYqH2xMWHz/L3APftStffqHtIcrXRaM6aws7bTdPe0tp4xFJ8sLDlV446/e71zem+GNW0/UoLhbhPLZ2MwTPIJBzzwMY7Cur8UabNeaBHbWcaJKqAbwMKhAGMeg96zvCi3kVpOuo3BeSFQCC+4Kee/0o1s2L3VUjDldls+hX8Uz6nZzpPpdsZBtAbk9MnP9Kh1K/kHhmfUJI1SeNTnYAzN6gH8DWdonjS/1TxNdaDFYsJInINywO0oCATggc+mDW94h1e30RlW6SJrdx93+LNCV+hcrU25ylp+Rz9n/ZviSGOVkcXduBvZeCrYGefxqr420ebVra3On3hg1OxfdFg4Dt6EmuqsIrCOzbULaEQRSx72HYDPPSs3VfD0F/cwakl2xZJBJmJ+HU/w4HWl1NFJqN1q/uF1C9e38PW0WqXcdpdyKAC3ygMO59a5xo72w0C9vRqC3pQAr5cfzkseuRya6U29jfX32HXbeOScEeWCdxIx271sDw7a2uk3cGnqkA2DyiT8qsMsvX3NJp2uxqcXLR7Hnljqc/i3RLkaPPLBd2ZUyRMBmUgfyNa3w9tpktLrUDMscMspeWE/wnHp2571X8ES2UN1Ja6RYtc3t1L5s906bEjJPIXvU3iuN9N8QGCOBp9IuRtuFRcFCwwTkU3FoPaQb0exvJqFl4itpodJ1aPzEJRljI3fUD09xXPw6UN15FqN0bkWko8kvztO0E4xzzmtTwb4S0nQEm1AOZJzIQjSYGxB0A9T9a5Dx34qsLDw1f3jP5LTXrxxRqeZmUDIHtxyfelKy32Ha8rrVnMa18Orzxt46vLpL4Wen4UPMIjK7kdlHA/EmruofAp2t2Gj+JYprkceVe2/lAn/AHlJx+VeZ/8ACceKxeNc2uu31lvAAitpNqKvpitzRPjF4y0m5ie/uYNZtY2G6G7jUOwz/wA9FAOfrn6VxvlbPSSqxV0cF8QfD2qeGTcWGvWctpdjG3cPkkG4cq3Rh9K4CvqP4l+L7P4hfBHxDqLx25nsLqBoIW/19pulRSD6ggkBhwa+XK6aSajqcWIlzSuzc8IkjUZiOvknHH+0tdokjRE7TnPauN8Hf8hOXp/qT1/3lrrTuZj84J6DivawbtTPKxHxmkXLxYC8jkjNQ20byuDknBwAP1pljBLNc+WzlY1G44Gc1rwzJFEwtkC47nqKqviHD3Y7mVOmnuS28MVs3n3JAVeFBPXip7W6F9KVjGIwec96zHt5JSGaQSFjzz0FbWmxfZ4kVVHytyf615kndnVFWLU7zcwjaqgcZ61XaBNgEjFkB3ZPU1bn3PcZYfMenbI96guWkmDBQMEFScjgdBWl0iNWZOtQNdiwtUBKEtM4B+96L71Zu4YbZ0csqRIAxBIG3HQD3J4qK0u1n8Rm387ZEkQTzj935euT2ya7Lw1odvK0OqXUId5M/ZophwVHWUj0z0rGpUUUa06blY4a88JeMPGkZFrYLp2mf89blthcHkDHXFafhb4MLpupQy6/dx3LoA32eJN4LenPp717fpdreXwQOhlQttiYthX9Tnv+Aro9O0LcTuVJ8dY4m2qD79z+dcjc5HalGB59D4P0uYQRX9rAYoiCkMrbkU+46fhXY2VmyW6W+j2BmjXgeTDsjX8TgV10NmbZcQ2UUK9ljRc/yNPktrlN815PEsA/hmJAUenX+lSqRTqtnOf2JqcnzXU9vbJ3zIDj8BVmDQYmiQ3Gs3jc/wDLFAo/UVt2UC3WJLZI1iHRthwfzrRNlJIwBlESAcCNRk+5zVKn2Jczmn0O1KbU1e5H/XSJW/kBULeH7+CZNlyr2p++/wAyED9a6/yPL+eWcsF5+ZQAB9BSG6Q2sj2qLIcEqm7buP17U/ZrqLnZzTaJarCw/swz99yXDMx98+tczcaTYWP9rlpLqztkjVnE2WKlzjnHbPGa7nTIL64v7htRtre2g2gRRxcsfctx/KotbsbZLlvPiQW1xCYZT0yvoe9aQVncyqrni4vqecXUGkafpmn3MUga5lb7JHMh3DJOcntnjHPTNdBoL2UusvJEv+kWys0p+bIJHTn6Uy40G0k8KahaWUkZCuGjEqjEbqchvb68VBodqU8SanqFu7GJ1QPGo+VX28nOfU9q3buc1ODppWir9bGlpF7perXCfYxbyuu6ZnQo2DnHJBOD9aamrWVzq4tZIgZXGwA7cnB796w/APhJvB+paqUneaC5VZF3gblOTkcdetaEGgKniA6mjOZhjb8+VGTzxjrUq19TWpKat7NX119DX8TeJItFn09JJFiN3IIQWGUJ9OvXitDVb9bDSop79IonZAZUOSF45/pXP+NfDMPimwgt7me4gjSXzEeAgSBxnGMgjHNa2rWVvN4cafWi92LW2IuAAd8gUA5478ZPal6jmpWfLuRaTcWdwZbmGJVCrvEqHKsDnp7/AIVA0elaoDl4592AQw3c9sg9Kisp7fTLG8s1EcMcPli3YS+aJVcbid2BjGcfl61Bovhexiv3vLe7mkYFmIHyqVbnDetPToQnKyjNJvqS6veWOladHZyzIjn5VBHHXPPpVHwn4Y0jw7DLPYzXErEkyTXDnGSew6flWjrOjWOvwlchjGdwX7pHbg+h/KrV1atd6W+noTbB12FgA232HrRpa/UqLmpNW93oZmp6ZZXGrpd27q90hyD5mQfwFL4/0+PWfCdxZyXLW6eWZdycMSoyP1xVTwj4Uk0HVpHuZjNbpERG2Mc56n3qLxfob6rDd3d1eT20LDy4kiGcJ64+vpSlta4U/dXNy2b3OU8K6nqA8E2tzpTxQX1qBCUlXq3075966DSfEV3daNcyeKtIOn3dqy75yAscp/hIB5/LIrL03w5fQwxTC5hcW8oaO4g6yEDH3Tnp/Ssrxr4rv/C+lC51yym1BJJSbF3UbS+P+WjD07DGeTzS59Ls25Umox3Z0U3j3w/aaFtv7p0mkZjIfJYbFPUgMPmz2GOtfMfivUU1nXri6gWVLJHYWsMjZ8tCf5nqabr2tXmu3099qD+ZNIckZOF9hntWbG5JznLE1yzqOXoehRoKD5nuWUBGFAPJ5ANNCgqOSD+lJG/zZwST15zj2pWcNkAAEj161idqasU9T3waPqH2d2RJo0jmAOA6iRWAP/AgD+FcfXd69Fs8OXLHljtA9hvH/wBauErqoO8TysWkqmhu+D8f2lLuOB5J5/4EtdYgbzMKO9cn4P51OQesJ/mK7iMhFZTjfjqRjFe5g/4Z4+IdpmrpUIkSccAquSff/ClniLR4e3VsdcHBP/1qx1ubhDtgYLzjDfxD0NXLK6WeJhKSsmSBF1I9x6iufEQlGTl0YU3dWLtha+VNuCqq45G6tiYsNu0gZIxntVWyhaOMFVLMeQRV64gEiBlOxh1BrlWr1NdtAllKj98GAXncnJqGS6QxuIoWYqN27bj9fSlmaOCMvLMCcj5QePxNZGtX093FMluDHHwOBjcfb29zTk0kEVdm/wCDNAS7P2+9jDIz52kcMT0B9u9eqaHZJq/jORZ1xYafbeZIgGAQOij2J/lWXokMI8PaSwRkSRjJtyeCAM5/EVteHS6aL4ov8HzLiSO0ikBwSSckfqK41q7ne9FZHceG3bUpzqckUbrKWhtkAwscS9SPYkfkBW6b4NbGWBHmiB5aP5FAzyfUiuO0HWLez1O58P3by2/2a1it0mC8FtgLEEe5rp01K1lZ9N06MSpEoSWUcIpI6D1NUpIzaLNpqJnU/ZFwMkcx4z78/wBatWtkGAe6PnSDnc3r9KdYQhdw28DAFXgMDAq0r7iZW1B/JspCuFxgD86rfaRFD5jsCzDAXGTijXmzarEM5kYdOwqEKEjjZV3yZ+XI4Uep96l3uNFeaa4km2SsqQ4zsOPmPofapkaJUG5drZ4HvVuKwULI0x3vIc5YdKi+yRSBowxVwcjB4P4VPKyrmmq/xH7xGCap61BJcabOtt5f2hVLRGRcgMPp+VXADnkn8aztc1mx0LTbq+1CYpDbxtK6opdyoGThRya12RmcPFps1nLqMsHzWeqwBcnqk2MAnPtwfce9cvBb65oWgtKHcXEB23cZUkTKW4ZcelaP/CR6h4l0FdX060ktrW5lYrbynMkYBwNwHAJ4bA6Z68VF4g1vXtOvdOMGltqFhP8ALdQhSZV9QO23FaJ21OaSU5umrpr9TStpLz+3WeQSpYvCMbuR6YP5gg/WszRtT1WPxPcafdmeS0Qu6SlCMqD69Dwf0q34l1q48L6TDIdPfUdJj+cP/wAtIkzym3HJUc+4FSvq+nXF1BbSRJIt0qy20oOUlUgEH/OaL32K5OS15df6RX8Q3OpQeIbZLRZJLSR1RuCRHk8jg8HFaXjeO4m8NxC3ecTxujb4SQ3HXJB6HHfiqPiDxLpOk6pBYa0IommBKNIThse4Bx6da3r7ULfTLI7w8SSxER7VyAABx+tK+iQ/ZcvNJy3/AAKs6p4g8K2z3UX9nPgI8YYcHgjaehyMcVc0O0l0/SlWK4heEDardiMnqfqe1UfiJr1v4f8ACEUt0krWs+xH8sYce3PTNbkhefwskcMBimaNdiNjKnqMnp170PyH7OMX7Rq7scJL8PdVn8Q3WqnWZ7e0mdD9kgkKq6hQCCc9DjPSug8QLqCvbvpce6O3OQc43HpxVvws2pPDPDqayRzRI+xSR8wGOTj3rL03xRcyXcVgYEcSlkjZSDyOmR/Wmo2empnKtGpBJ3jzffcl8T311P4UvXiJik8po8j7zSFeFXHv3rjtG8G6te+Hdt94nvBPKobKvuSI/wB1c9fQnIrrtUuWS/v4528rTLSFYw543SHlyvfPIGenWrOmX+n3tuba3ULGqqoiwVK56H6Gotc6FUStFvUh8F6BaeGooYE1GW8MxIJlI6nngdqd47i0jXNGvNA1mNlhuBgHaS0Tg/LIMdMHn6VVuNMvbbVor2KX/Q4SG8rknHpgDFdLqGlWOqBru9mMMUKEzNnaNoHJJ9MU5JWtIzVSo1zQVpJ9T4r8aeF9R8I69NpepqNy/PFMv3ZYz91h7H9KwipUZxx711fxE1w+JPFt9eRSv9hRvJtNxPywrwo56Z6/jXLbTGfb0xXAme+k7JvcWAHk/d5z09qtRRsJcsBj0xUMSZxt6jr6itKAeXAZCcnGSOtRJlLY3LnQXufhP4t1uT/j3sxb28II6u1xFuP4A4/GvF6+sfG3hp9C/Zavzc5W5mW3uXXPTfcRkA/gRXydXdTjyxSPIrz55tm/4MONUkPpCef+BLXX+aznDALkn8a5TwMqvq8qucAwNz+K110nkhjtAHP4fSvYwn8I8vEfGRbgGJ3HaO4NSxhXmiRAdzEYYdV+hpVZXJ8tMMTgk1atY8zyOGKnbgEH3wcVrWdoMzjrJI6EXCQ4WaZQ4GAqje36cD8ahlvZXb91CUQjAaQ7j7kDpTIVGwpGcDtx3pzuGAQAgg5ry7HTe5XaMCTzZC0rkZ3Sc4+g7VHGQ9zbhv8AlpMiHPoTVmU5Q8nNQ6daxXWp2y3L7IYs3BGcDK/d/Ws6jsjSnrJHr1mGhs4ApkmMZMSIExknqFA/Ku/0vTo7STTtJkUvBZE3l6QvBlb7qn6f+y1m+CdPkFna3zIsuryRboYnGVt93/LQ+pI6Cuq0OKGW2uTFIHtInb7ROTkzSA/MCfY9fyrnjojrkxNE0cTzz3F3l/PZpA7nGcnoAOw4rZ02wWIu0S4i3Hav9aj0ab7dDBdSZ2MzbBjHy9q1LI4jXAwrAkA/WnCCRDkyaMEA5AFSCmj2p1akmNq+57yFFBLdh65ojvIYpZLWI7nhTdJIfuAn1P8ASi8kkGpSLGACI87yPuD1HvVO4s/+JbJNtCBG3qPU9OfXA/WuarNxXumkEnuXbRprpfMlmbY3RRxVlreHZtYke65B/Ss2C8EUaW0atPcRjLxo2BHxnMjHhfp1rGk165vNSS0htnniAyY7NmBY+pk4wo/Ws1olzbsp76Gvc6dMzhkuri4gx/qmlKkfQj+tVbyCKLR72OBFUvA6klfn6dz1pzXz2c8i6pPp9vCyjEAkZ5l+rd61rM/arbfC6XFtIuAx649DVK+wmupyfhyZtPtJpry8e7Dok7ykc5KAdP602y8R2mvaibexWSORULJM3Q+w9ag0uR5r+e0u4Y4lltEaDyyCskakrng/SpND8LWlpciWKSRJFDBPmJ2A9lHAH612RWmpyVJVOZezta+o4XcOu/2hoOsxPA5ACsvAPdWVuxFedR6de+Db5LXxCftGj2Um6DUNozbhuhYD+DOR6An6V6V4r1ew8PBb7VIWMG5UWVULlW7ZxUutFtZ8PC90eSG4PlmRUwHWZSOUPqCKNi1FpNS1OQ8Y+GrLxnBYuLvAiGUlhIO/OD34I4ra1zTpdZ0JLEkLKFGSH5GB+vT2ryuS/PhNIoNNufIs55w0drOTvtJScFQT1Q/mK7LV9U1KDRLC6tH8u/jlMNymC5GRnoP8807CqSXK1NXVjqPG2hN4g8Ex6fcOyMIw2/owI5Bxz+Vb1gLiKKxIbG3hwBwy46H+dcrrup3b+ArLUrcssxg3OqnGcjB/I1cvJLm68KQ3FtIgvFjBAbJUvtxg9KXcrmS0XTU7G1a3kSW5jhETLlXbaN2Bz171zV9e6Bp0P9pKY0W2LS4AILMc4UD1JNUvAOpXdxaX9hfJcRzNJ+685QMZXJAwTxn19azfCkKTalLG0FxdNDOftLShY0tGA4XHO89Oaq2tjGVWT5Wlo+/fpodDo4XV9Lia6tlWe4Vpt0keduezD/Oafe2mnaNaRyKIovs7gkIPXj5u56964zW/jFa6Frd7pl94d1SC7t5NjtuRwy9VYcjII5rUu9e8KeONHlg03VoTf3CAraynypS2M42tjJHtnpWcakJOyZ0zoVoQU+W77mj4x8VNoNtbtLbNPBcEqrRkAdMjJPc8dq86+NHjyOfwPYaVpxaK+1SFJL5A3MUQ42H/AHj+gPrXq2uW+m6f4ZGo6zb/AGm2020E3ksgYFlXjGe56fjXyBrl/PrWr3eo3ZQTXD7yqKAqDsoA6ADisMTUUVyLdnbgKHtJc72X5mE6FThs4PWo44xvHfjOTVi4ILEANnqMjrU9rEqxl35xzmuTmsj1Gk2RwwKowRgEZzV/Q7H+0tTsbHBIubmOIheuCwzUD5dPlGBj6V2Xwjs4n8X6ddTEBUnRIgxxucnJP4AVdFOc0c+JlyQbPaP2l1WP4H+II1UKqC1UAdgLiKvhOvu39po5+CXiLOOttj/wJir4Sr0DxTU8PX8OnXrTXCyMhjKjywCc5Hqfat1/EtiTxFc47fKv+NcdRW0MROmrIzlSjJ3Z2sfimwVMGG53DphV/wDiqsQ+MLCKUSCK7LDsVXH/AKFXBUVbxdRqzI+rw3PTh480gMcW17swAPkTP/oVNfx5pRcMtveA+uxP/iq8zorDmZfs4npDeONLbrDfZzk/Iv8A8VS2fjnS4Lh3MN6oYBcrGhIGeerV5tRUvXcqMVF3R9Z/8NI+ErHRpLXSdN15bpkCiaWGEEHGN3Ep/AVmaL8f/CmmeGRo0dlr/kLuVT5UROGOWJ/eckkn86+X6KnkRdz7Gg/ae8FW9gsMWleIQ6JtT/R4cZx3/e1Yh/al8FRQxINL8R4RQD/o8HP/AJGr4xoqrCufan/DVXgj/oFeJP8AwHg/+PUv/DVfgf8A6BXiT/wHg/8Aj1fFVFAH2Sf2n/BJv2nbTPEZRlAx9ngzkf8AbapL39qbwXJZyJBpPiEybfkDwQhd3bJEp4zXxlRUuKaaHc+mNA/aJsE8OQ2WuxanLeFmaZ7a1iCMWYkn/WAk898dK6mx/aX8DabZGGx0rxEZCPmlkt4Nzn1OJf8A9VfH1FJU0tRuTZ9g2X7S3ge1tvLTS/EQkclpZRbQFmJ68+bVB/2kPCqmWO2sfEENq7ZZRDFucehPm8Z9q+TaKfKhXPq6H9oPwFaTKdO0LW7WIrtdY4IRz6j97VPXP2itDnnjfS4NcjQMCySwRdvQiQ18u0VadjOcOdWbPq/Vf2hPA2u6GNP1nS/ELhgPMMcEPJBz182pdG/aD+Hui2ot9M0XxDBEONohhxj/AL/V8l0Ui1orH0d4u+NXg7xDqkMk2l6w1nx5qtDEC2PYSdc98jiobX44aBY6zdfZ7HVbnRp0JENxHGJI2xjbkOQy+hPIr53ooHc+qB+0J4PfSGspdI1nYxJ2eTEV56jmWrcf7R3gy1shHZ6RrYcHgPBDt/8ARtfJlFArn1dZftIeF1aVrnStYV3/AI4oYiT9cyDik0j9pfQYdSU32maqbFFbAihh3sx6MRvAzj3NfKVFO4WPdvih8WvDfirW7fUNLs9ViZY9kguIYwW9Dw5zjmuZ034iafpurWWowWdw8tpOs6JIi7WIPQ/NXl9Fc7w8HPn6nVTxlSnT9mtj6Y8dftDaP4h8EvpFnp2q211cyqbgybGQIDkqrb8nkDqBxXkT+LdNbJ8m73H/AGF/+KrhKKc6EZy5mFHF1KMeWGx2B8S2RblLkj12rn+dWP8AhLLDywoiufclV6en3q4eil9XgN42q+p2p8VWIi2pFc5zkZVf8a7/AEL4l+CNIl0OSGx1wvYqTKxhi/eSHksB5n+eK8LorSFOMNUY1K0qmkj6S+L3x08M+M/h3qeg6ZZa1DeXPk7HuIYlj+SVHOSJCeinoOuK+baKKsyP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) In the supine patient, access to the airway is obstructed. B) With the patient propped on linens in the RAMP position, access to the airway is improved. In this position, an imaginary horizontal line can be drawn from the external auditory meatus to the sternal notch.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wiser SH, Zane RD. The Morbidly Obese Patient. In: Manual of Emergency Airway Management, 3rd ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21285=[""].join("\n");
var outline_f20_50_21285=null;
var title_f20_50_21286="Methimazole: Pediatric drug information";
var content_f20_50_21286=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methimazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"    see \"Methimazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/53/16213?source=see_link\">",
"    see \"Methimazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tapazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dom-Methimazole;",
"     </li>",
"     <li>",
"      PHL-Methimazole;",
"     </li>",
"     <li>",
"      Tapazole&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antithyroid Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13766154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Congenital Hyperthyroidism:",
"     </b>",
"     Oral: Initial: 0.25-1 mg/kg/day in 2-3 divided doses; once patient euthyroid, reduce dose (usually by &ge;50%) to maintain euthyroid state",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=see_link\">",
"      see \"Methimazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hyperthyroidism",
"     </b>",
"     : Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's labeling: Initial: 0.4 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses (approximately every 8 hours); maintenance: 0.2 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Alternate dosing: Initial: 0.25-1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in 1-3 divided doses; consider doses on low-end of range for younger children; once patient euthyroid, reduce dose (usually by &ge;50%) to maintain euthyroid state",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Graves' disease",
"     </b>",
"     (Bahn, 2011): Oral:",
"     <b>",
"      Note",
"     </b>",
"     : In severe cases, higher doses may be required (50% to 100% higher); once patient euthyroid, reduce dose by &ge;50% to maintain euthyroid; duration of therapy usually 1-2 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-based dosing: Initial: 0.2-0.5 mg/kg/dose once daily (range: 0.1-1 mg/kg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fixed dosing (using",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     ,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     , or whole tablets):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants: 1.25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 1-5 years: 2.5-5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 5-10 years: 5-10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 10-18 years: 10-20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hyperthyroidism:",
"     </b>",
"     Oral: Initial: 15 mg/day in 3 divided doses (approximately every 8 hours) for mild hyperthyroidism; 30-40 mg/day in moderately severe hyperthyroidism; 60 mg/day in severe hyperthyroidism; maintenance: 5-15 mg/day (may be given as a single daily dose in many cases)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adjust dosage as required to achieve and maintain serum T",
"     <sub>",
"      3",
"     </sub>",
"     , T",
"     <sub>",
"      4",
"     </sub>",
"     , and TSH levels in the normal range. An elevated T",
"     <sub>",
"      3",
"     </sub>",
"     may be the sole indicator of inadequate treatment. An elevated TSH indicates excessive antithyroid treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Graves' disease:",
"     </b>",
"     Oral: Initial: 10-20 mg once daily to restore euthyroidism; maintenance: 5-10 mg once daily for a total of 12-18 months, then tapered or discontinued if TSH is normal at that time (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Iodine-induced thyrotoxicosis:",
"     </b>",
"     Oral: 20-40 mg/day given either once or twice daily (Bahn, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Thyrotoxic crisis:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Recommendations vary; use in combination with other specific agents. Dosages of 20-25 mg every 6 hours have been used; once stable, dosing frequency may be reduced to once or twice daily (Nayak, 2006). The American Thyroid Association and the American Association of Clinical Endocrinologists recommend 60-80 mg/day (Bahn, 2011). Rectal administration has also been described (Nabil, 1982).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Thyrotoxicosis (type I amiodarone-induced):",
"     </b>",
"     Oral: 40 mg once daily to restore euthyroidism (generally 3-6 months).",
"     <b>",
"      Note:",
"     </b>",
"     If high doses continue to be required, dividing the dose may be more effective (Bahn, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No adjustment necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F194291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tapazole&reg;: 5 mg, 10 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F194276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer consistently in relation to meals every day",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F5648496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursion permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hyperthyroidism, including amelioration of hyperthyroid symptoms, prior to thyroidectomy or radioactive iodine therapy [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F194356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Methimazole may be confused with metolazone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F194354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: ANCA-positive vasculitis, edema, leukocytoclastic vasculitis, periarteritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, fever, headache, neuritis, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, exfoliative dermatitis, pruritus, skin pigmentation, skin rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Goiter, hypoglycemic coma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, epigastric distress, loss of taste perception, nausea, salivary gland swelling, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, granulocytopenia, hypoprothrombinemia, leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic necrosis, hepatitis, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Insulin autoimmune syndrome, lymphadenopathy, SLE-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methimazole or any component, breast-feeding (per manufacturer); however, expert analysis reports methimazole may be used with caution in nursing mothers (Mandel, 2002)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13766144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antithyroid agents have been associated with rare but severe dermatologic reactions; rash and urticaria are more common and may not require discontinuation in all cases; discontinue in the presence of exfoliative dermatitis. Discontinue in the presence of unexplained fever. Antithyroid agents have been associated with a variety of autoimmune reactions, including a lupus-like syndrome; discontinuation may be warranted. Antithyroid agents have been associated (rarely) with the development of ANCA-positive vasculitis or leukocytoclastic vasculitis; prompt discontinuation is warranted in patients who develop vasculitis during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5648495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause significant bone marrow depression; the most severe manifestation is agranulocytosis. Aplastic anemia, thrombocytopenia, and leukopenia may also occur; use with caution in patients &gt;40 years of age or with doses &ge;40 mg/day and with extreme caution in patients receiving other drugs known to cause myelosuppression, particularly agranulocytosis. Discontinue if significant bone marrow suppression occurs, particularly agranulocytosis or aplastic anemia. The lowest effective dose should be used; monitor thyroid function tests closely. Rare, severe hepatic reactions (fulminant hepatitis, hepatic necrosis, encephalopathy) may occur; possibly fatal. Symptoms suggestive of hepatic dysfunction (eg, anorexia, pruritus, right upper quadrant pain) should be promptly evaluated; discontinue if evidence of liver abnormality develops including transaminase &gt;3 times ULN. May cause hypoprothrombinemia and bleeding; monitor PT.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F194344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F194285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antithyroid Agents may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Iodide I131: Antithyroid Agents may diminish the therapeutic effect of Sodium Iodide I131.  Management: Discontinue antithyroid therapy 3-4 days prior to sodium iodide I-131 administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Antithyroid Agents may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antithyroid Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F194287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F194299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Methimazole has been found to readily cross the placenta. Congenital anomalies, including esophageal atresia, choanal atresia, aplasia cutis, and iridic and retinal coloboma, have been observed in neonates born to mothers taking methimazole during pregnancy. Nonteratogenic adverse events, including fetal and neonatal hypothyroidism, have been observed following maternal methimazole use. The transfer of thyroid-stimulating immunoglobulins can stimulate the fetal thyroid",
"     <i>",
"      in utero",
"     </i>",
"     and transiently after delivery and may increase the risk of fetal or neonatal hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Uncontrolled maternal hyperthyroidism may result in adverse neonatal outcomes (eg, prematurity, low birth weight, infants born small for gestational age) and adverse maternal outcomes (eg, pre-eclampsia, congestive heart failure). To prevent adverse fetal and maternal events, normal maternal thyroid function should be maintained prior to conception and throughout pregnancy. Antithyroid treatment is recommended for the control of hyperthyroidism during pregnancy. Due to an increased risk of congenital anomalies with methimazole, propylthiouracil is considered first-line therapy, especially during the first trimester of pregnancy. The use of methimazole is an option during the second and third trimesters of pregnancy. If drug therapy is changed, maternal thyroid function should be monitored after 2 weeks and then every 2-4 weeks.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The severity of hyperthyroidism may fluctuate throughout pregnancy and may result in decreased dose requirements or discontinuation of methimazole 2-3 weeks prior to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1060270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of hyper- or hypothyroidism, CBC with differential, liver function (baseline and as needed); serum thyroxine, free thyroxine index, prothrombin time",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the synthesis of thyroid hormones by blocking the oxidation of iodine in the thyroid gland, blocking iodine's ability to combine with tyrosine to form thyroxine (T",
"     <sub>",
"      4",
"     </sub>",
"     ) and triiodothyronine (T",
"     <sub>",
"      3",
"     </sub>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1060276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 12-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 36-72 hours (Clark, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Almost complete (Clark, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Concentrated in thyroid gland",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~93% (Clark, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 4-6 hours (Clark, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 1-2 hours (Clark, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/53/16213?source=see_link\">",
"      see \"Methimazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take at the same time each day, around-the-clock (eg, every 8 hours); will need to be taken for an extended period of time to achieve appropriate results. May cause nausea, vomiting, abdominal pain, abnormal taste, dizziness, drowsiness, or unusual CNS stimulation. Report rash, fever, unusual bleeding or bruising, unresolved headache, yellowing of eyes or skin, changes in color of urine or feces, or unresolved malaise.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10263662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppositories can be made from methimazole tablets; dissolve 1200 mg methimazole in 12 mL of water and add to 52 mL cocoa butter containing 2 drops of Span 80. Stir the resulting mixture to form a water-oil emulsion and pour into 2.6 mL suppository molds to cool.",
"    </p>",
"    <div class=\"reference\">",
"     Nabil N, Miner DJ, and Amatruda JM, \"Methimazole: An Alternative Route of Administration,\"",
"     <i>",
"      J Clin Endo Metab",
"     </i>",
"     , 1982, 54(1):180-1.",
"     <span class=\"pubmed-id\">",
"      7054215",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, \"ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 37, August 2002. (Replaces Practice Bulletin Number 32, November 2001). Thyroid Disease in Pregnancy,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2002, 100(2):387-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/12166417/pubmed\" id=\"12166417\" target=\"_blank\">",
"        12166417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bahn RS (Chair), Burch HB, Cooper DS, et al, \"Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists,\"",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(6):593-646.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/21510801/pubmed\" id=\"21510801\" target=\"_blank\">",
"        21510801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark SM, Saade GR, Snodgrass WR, et al, \"Pharmacokinetics and Pharmacotherapy of Thionamides in Pregnancy,\"",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2006, 28(4):477-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/16885714/pubmed\" id=\"16885714\" target=\"_blank\">",
"        16885714",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper DS, \"Antithyroid Drugs,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(9):905-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/15745981/pubmed\" id=\"15745981\" target=\"_blank\">",
"        15745981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Diav-Citrin O and Ornoy A, \"Teratogen Update: Antithyroid Drugs-Methimazole, Carbimazole, and Propylthiouracil,\"",
"      <i>",
"       Teratology",
"      </i>",
"      , 2002, 65(1):38-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/11835230/pubmed\" id=\"11835230\" target=\"_blank\">",
"        11835230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johansen K, Andersen AN, Kampmann JP, et al, \"Excretion of Methimazole in Human Milk,\"",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1982, 23(4):339-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/6897386/pubmed\" id=\"6897386\" target=\"_blank\">",
"        6897386",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koren G and Soldin O, \"Therapeutic Drug Monitoring of Antithyroid Drugs in Pregnancy: The Knowledge Gaps,\"",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 2006, 28(1):12-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/16418686/pubmed\" id=\"16418686\" target=\"_blank\">",
"        16418686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mandel SJ and Cooper DS, \"The Use of Antithyroid Drugs in Pregnancy and Lactation,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2001, 86(6):2354-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/11397822/pubmed\" id=\"11397822\" target=\"_blank\">",
"        11397822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nabil N, Miner DJ, and Amatruda JM, \"Methimazole: An Alternative Route of Administration,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1982, 54(1):180-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/7054215/pubmed\" id=\"7054215\" target=\"_blank\">",
"        7054215",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nayak B and Burman K, \"Thyrotoxicosis and Thyroid Storm,\"",
"      <i>",
"       Endocrinol Metab Clin North Am",
"      </i>",
"      , 2006, 35(4):663-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/17127140/pubmed\" id=\"17127140\" target=\"_blank\">",
"        17127140",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raby C, Lagorce JF, Jambut-Absil AC, et al, \"The Mechanism of Action of Synthetic Antithyroid Drugs: Iodine Complexation During Oxidation of Iodide,\"",
"      <i>",
"       Endocrinology",
"      </i>",
"      , 1990, 126(3):1683-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/1689656/pubmed\" id=\"1689656\" target=\"_blank\">",
"        1689656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stagnaro-Green A, Abalovich M, Alexander E, et al, \"Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum,\"",
"      <i>",
"       Thyroid",
"      </i>",
"      , 2011, 21(10):1081-125.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?20/50/21286/abstract-text/21787128/pubmed\" id=\"21787128\" target=\"_blank\">",
"        21787128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12592 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21286=[""].join("\n");
var outline_f20_50_21286=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194314\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194315\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060271\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13766154\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060265\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194291\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194276\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060274\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5648496\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060273\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194356\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194354\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060278\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13766144\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5648495\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194344\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194285\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194287\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194299\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060270\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060263\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060276\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060277\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060269\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10263662\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12592|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?18/39/19062?source=related_link\">",
"      Methimazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/53/16213?source=related_link\">",
"      Methimazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_50_21287="EEG Small sharp spikes or BETS";
var content_f20_50_21287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62862&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Small sharp spikes also known as benign epileptiform transients of sleep (BETS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 403px; background-image: url(data:image/gif;base64,R0lGODlhIAKTAfcAALm5uYCRfG2QaP8WFq6urrW2tZycnNjY2AMDBNXV1YKCgvD27qKioklIRbGxscbGxtHR0cnJyf7Y2Kmpqf6YmG9qXZGo/WuJ+6Wlpf67u/6oqL+/v7rZtj8/P97t2/z8/H1+fcTQ/LrI/pmZmY2NjZvIlpKSkr6+vl9fX5aWloaGhv5tbe/v74mJifr6+uvm2q+mk9/f325ubv6Cgvj4+P708/b29oW1ffT09PLy8fDw8Mvixc/Pz7y8vOTk5P7v7v7Pz8Tevevr6+rq6v7AwHNzc+fn5+Dg4OLi4v6xsdzc3Ojo6P7g4MLCwtTnzszMzC8vL/9FRv6Li9fMtIV9bqKaiFNxTndza/XAuqzRqqS3/mVlZdXe/sa8ppmrlVZ4+/75+crXx5qSgZmxlKi2pLnJtl1vsHl6earDpc7kyGV8YOTBsuPq/sbgv4KbfcvBqv///721n6XAntXKsipSI36Y/UFqOIKkfMLdu7DIq9GLdf78/JKoje/07eCvn/H0/rS8somZ0dfMs3J/b8/FrcSniMHSvLqrndfLs1ZVVJSdktzRuPC2ruvw/tnNttTZ0tDdzP729uzt5HVvYv7+/qCsncLMwOHo38DZub67taurq/n7/qi025nCktPIsNLHr3d3d46Hd4y/hvz8/q+3rdff1bi9toqSiJihlrm2sGRfVMjgwjtj/l9vXE9PTsPcvP7//v7//////v/+/wAz///+/v7+//7+/f6Rkf63t/77+/X3/v3+/eXl5eHh4cbHzP7Jybu7u7y8u+Xn7cvLy8PDw+Li4fPz85W7ktra2tvb2+GRgJ+fn+ickOPj43x8fP39/Zees8rFueLXv5eelbS0tNDXzaSoo8jIyMfHx1BcTnyHeoSEhP6fn56oy39/f729vbvDur69vr6+vY+ajJSUlLe4t/n5+YeIh8HBwe3u7e3t7R8fH8BuTaioqNaBbPX19f6Hh/7m5v7q6o+Pj4uLi+bm5oODg7/Wujk5NMbawPLLxPf39/7Fxenp6bjQsiH5BAAAAAAALAAAAAAgApMBAAj/AOEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rckNKL7JnUu3rt27dR/i3ctXbsS4fQPj7SARsODDcwlDNIy4MWIUFeE6nkwZr9uxGzaA/KZ3I2eInz2G7ryQxYYYcHhobjia9UYeFVtDzIySBWqJsi9zpS2wg+8OMuAw+90BNg9XvqEwU5gbYWtXBxULX36wecLPw38vZwYFSvCC0plR/y9o/TrBb8kJCIzB7hsBGa6+MyxfPTVx+Qc3hCZAbz10ivQpxFsMUHSgnEDcebcRCrDhpttSspzzgiQvVGhhKqlYqKGFmqxGCQLkjcZegyyMZ1AsV2yoooZXDMQMOyAW9OFAfh2U4oo4vnCGQSgshwALcEDRoEAzClQjeTnmuKOR/7HAjmZ+FenQN0muuKSLkCV0TIxwuKIeHPSMF8NqpxHEA2ymASnLGVUm2eF6QKoT449BDklQmWMSlGZqdkIhkGlDjgnkehsMimKbiCaq6KKMNurooxrmcFIOjkwjBgM55JBJKKpUMAUiU4QqaqhVjDMQArecN5oM/TlUAaijCv8yhSCwilpBQagalCscfv2GwAkCvSqqrKEKYuystV4Ri5ns2Gdkq6emyitnvgL7zaizhlqrtqIqKxA7Q9IDGTvsAIcAcFNui62oiMDq7Z/s3GbkZwhQ0mU1srDApZ+8QoGCK/9+g4AzcPgmAxTfxNcsHFcgQmy2xUK87hSlFkRAB7LwoNg30AqEgCvftPcvZBuwE593B1PHTH88tOdKf8N9I6RwCM8Mh7AT56zzzjz37PPPQAct9M8vyEKSLLJQmooJIBBjzxngdDAJFarAIKvDxiJSxWq3nGswr+X6prFmpm1gZ0GjeDpHFYjAUAEVk1QwB7a3DtS1QV3/1t5A4gr/lPaojlThCAyExF1FBVV0C95yG2w8Wt6+7S1Q37xiK8ghnsTx6RSfgBrHIYK0CIeUcDQ+LRx36wXqHFSwnbW2ccRBCAxTiG5kljRyljozkDGQJQ9ZRhmjAtRqZnrBG6A4RwUVfAIDrLKK4cjmDrdL69YEHaze8UeiHqPwpSvWgfGKuYLaN9+x4KRABLiy5aBA/j30/PTXb//9+L8wqSDSbDCBAwlABzhkUIFFXMERn6MCFd4Qiipgz2PSmhdBOqCeGHwDBdI5iNwIcQVBiOETi5jE3IY1hbpFS1fSqtEGoDCom41wVlcgBBW6IAZCVOENjnCErN5VuoVxrzW7UiEL/41kuVC0ToYwcEUcWte6d+0KDhc7HRyeOB+HOTAOnggFDKqwwFAcwhUwCMUbtmA0OOiLYKqCoBlB5CWBMEiCU0xVr8jXG81cYQpziKERvRjGt8VODHEIxSeoALoHEiReP8SVHOl1i+ONL3xwiMF/YtABk6nGa8A5HkHkhr9OevKToBSa/o6WNEe8oBrKoIQq6YEOT02CYmKYxCIqkIgGPDB1uSMIM/4DSYSkDREcnIMYQhEHMMaqhATBpd245BcnDUl+2ppEKBLRBVUMkwqjsl3BqLM+OKDgSwLBZTPBRSPLVUEMVBDDNCZxBXXGsgKik4UrxoOC/vhFmVVExCLEMP9MVajCFSEMRSg68IkKTHMg98BdLnHpinvsa6HfK14vx4ciYE6iC/l4Qyyv0KlpVAAGDWhgBSahCq2thiBQKNTCvpnMiHpvonQMk54SBoGFCaRlaPNUKHfK0552cpQlyYEgXhADFqiSEjxopSM81cCQGrF1J0XAODIDmwtmplAFc0VmMKiQDTp1EQakFQlNOCapykuNp/NOZgbFyW4tIhQ0pJjE3lWyCdKDAOxoIVr9olasXmtUWnMEFcJ4hdYJVAzwXFZq2MEM/QyxRlRcyDfatUQxwIAKoZAlPKl22VCI7owGWeEGZLArZiAAFOyDFmQXiTyYMmwKhcMoDSeBToP/GtEVVGhnKMSwttXQ4xuO7c1d86pIKaLKkXSUzm/hEpx/bYAZwckkcIP1Qp9a97rYXRdQRYI0Sr0AFEXQARzcARxPEaJwn1BFFwTxBhuuRhZ0YRxdbsMDuZz0IGmjVRe6QIhZ9feYJtSPfQkC34HQZr5wgGaoCCGIT8yhc51L1kAIcF8W/PascCiwQA48l/OtyxNT8AQi+PsJT3ThE5/goJ6Y8Y3x0EbD6WpXe6fwhhQj4hM1TvF5RQcBBiCExRYkiAJuYz4Da0bDtGEGamKgshigiFaEmMMbbnze9nbBE4S48humcGKT/onFzIDfhQuC5CNzhskIWjIzgDeQErV4/8Icuw2Lv6Tg7Nr5zjvd7kiEGgcCkMAGlNCEORKh0zn09xPa8vJHOPm6icnKhBhpa7YeNjEecuSvgG1Xuz51tU9Z2jO1ehioNK3p2imWIizIIEXuCKtNk5DT7CLVfUMig1lHRNJ4zrWu66fnkCRtCsiBQgNcAQVXsANnDgOsITlSZ27FShCQtkizeabNS68r2ew6lqc3U6tRk5DS1V4Jipz9qepBDHrVWzZOpr3rdrs7Z0M9iTKYV4FO1Zve+M53BVyBgH77+98AD7jAAZ4PfRucefkYuMIXXvCDHxxGC494xB3ucIhL/OIBp7jBLY7xjnscAcfWuMP5/fGSm1zgDf8XucpXzvKWu/zlMI8581JhElnoIB0bSAfO09GEnev850APutCHTvSfN8ENZCi60pfOdKYLoOlQjzrTAeEGqVv96jpvgimejvWuQ90LXg+70jfAh0qI/exD5wPa1w50sLMd7U3gg9uD7ousZMEDsKiJKOxFkwWUgBd5n4nfbbIDvsuEEhxwAi80Qgku1KEOFnj849kQeRFoQfIWiLwFDC+QIFAi8DFRZRsiGHo8pIHzXLm7TURxapn4vYyCLwHoZbKD2cMkFomfhUZo0YjKcyHyWvjD5UXw+zpoofhfQH0QWi+TNuh+JrIwfVhUr3fmw+T1NfG77WFSe5rg3gnPxwj/LY4KDWjUohZIKz/SZEGJ9ctCC9AoyPJt4nyaRD8N0/fA6q3/Euz3XfY10X0z8X3hdxGbh3oLwQvjJ3/89xL1B33SBxbURxOsl30lAHuuB4A0IYAyQYAa8QefBxGwsIAEMX818YAycX/5t38WiIExoX0BuH0u4YEZMX4IqBDQcAHK14AugYIxoYISqH/V14IWKIMuwYExQYPiF4IPQQlasIP0V4AwAYRfMYEzUYH/54LXp4EzgYS3l3sacYAQQQkkOBAmSBM+OIURWIVCSIE8yBL+F3tG2BJe+BJKeBFscH5jWIad94YskYYvQYVeYYUywXqqRCSpdIMmEYcZOIcs/1GHMwiGNXiID2ELOsiAUWh/a5gTqqFXHkGIMbF3zIABlCAEPdAEPWAAkqKIIsGITRgSMLiBjqgSd2gR42cLTVgLWjAKmHiCUhiIm5gRsvAAmAQBIWMg3PRIBnGMvuFNcUFOIAGKMCEKMcAAEHAGJpAAqqQD7tAER6ASrugQlOgRsdiFs5gStVgRYiiO0MCHcHCGMwGILiGIGqFJp+NMGoMAxVAdozEo3dMR0tgSqiQKDOAMlGAPH3BUqmQPLcADrPgRflcLB6GQREIkqnQOxQANh/iQEVGOJjGOBwGJLXGHIAkRbKCRo4OA9qKQLFAOtLAB4wiPzfeLFqkS9JgRTf+QQTWSUnXEjwXBAheDYRwRkCxBCdBwB+5QkgOBBMyglLBYAjeoSgywkaqkBPRACQQQDBOQkEelER5ZEl2JECLJEkoYlhJhgymJegnAADGgSr1AAkJwAQxQDIYnkzEhjylpk8GYERuAAA2ALlYlMwOhjBb0ZsxIHRbkCmdTkQrJkQhBlGNYkaMjmTKykhuZksGgBgswmQahSvcAD3l5ERQZlke1AHSgDrzAA21JCR/QC5RwACrgAKqUCBqpAsmwBeZACQBgAuhAm5ZJCT6gHl1JlVEJB363kmk5joZHnJPJdyrZnCtZD7JJiRtZeMTZmNg5mtTJmRRJEMuJnCuZeJT/EAGq5AAwaZbYCZ1HZYOqRAB0qZAj8FyjIwM5AAsWcA4mIASH2AZO6Z2cOZED8ZvXiRDDSQn8eZ0P0AJDQJ0CqkpPwJWd6Zyo951EYnqzkJ4WUQwdcGro0WItpIxlU1W50T4RWg3gQAw50J8LAZlN6Av8IKFOSQmueVQzGmjhsHcJoUouIAMQihGUkAAnAA85oAnrQCQIWQDkgAEHYA4MoACawA0t4AAp4AIEoAwRkFQYAAEf4JCqpA4uoAMtkA7FEAy+gA3m0ATE4AAmoAmUkAwQ0J2V2Qd3UKMT8ADdeZDQcADEcA+gAAE1mgPEgAM0AJoyEgPFYA4EgA7nwAMA/8AAB0AJLLCgPOADKWqdQ6CNCeALH3AA8FCVxPABo/MEJGAA7rAOlGAEjyqjowMBAGAO4PAESsB5OJANAJANKmAAkAoKmMoDiZcDDPIE1aAJRwCpDiAQyeAOdAkNBnCe5ZCbtZAA13ABxbAB5jABJhABr3qR5gANzJAOmpAAcNCOlMAP9cACs5ANagACJPAErGgDyaADlJCiBXEAw5qcD6CNlBCocOqdQjABT6ADOcAHCoAOG1AMxOADDmAAALAO7hAMxLABD6AC5gAAlKAOxSAEcPAEZ5CRCZCU3okOW8ClG9kL9qBKyWAECml6T+AP5UkDjrkQ9viPrbWM/YggvP8UoF3qDgrAABNwAPqpopJ5d/ual9mZiIe4AVopXnBQDOmAASOgSusArpRQDDFgAhhAApTgAMHAAL5QDbmJowSqSspQDaRICalEEUelAP7AAOkAAQoADz5QDsHQBNbwd8HwpmlZDJKSGsGQp+CEs68ZAxAAD+CQlJRQALH6ADIADjxgjeUwnUJgVEhAlwywdSZAAipwrcHQAj2gAtZICSMAAIdaAE9gA+YQDOlQDSrADQVgABjwXEjQlk1AlwWQDPaiBE0Qq5TwAOkADqdYAASgABhADtXaA+aQAhNAABgAACeQsADgDuBQDAwALJSAA+DAACYwAimAAcFAAOZQADT/AAdCUABJaQAOQJfugA3QYA7rAKwG0AvS6Q5KwAcBgAE5gIouAAdzuab+sA7lAAcq8AGnQYq+cKXpoAIE8AHe8AhLUAvYoErjSwAE8ATsarYFQCQ2WI1XmwezsATVgLLLubSgqwnMMK0XbLaqZAIb8KYjMJ0A0ANkWwAk7LTpkJyqlA3oYATmsAHcwMGU4AwHALyPOpk2UAD2sAGPag7VQAI8AA4R6wLgUAQOwAPFqpAK8AEpQAwEwAwE0AQFEAzBUAAJoAlXSQn+igdj0AMkMDojAA4vKyA6KSIh0yM0e0gyIAPQSKAf8AEPQALp4A5YO6EwqgRucAoFcA7oSQkx/5AD+rkOOpAA9OAOGLCsDkBhw2oPVpu96/ABQzABIzABzBC6SnACOgANNrABgBYDJ6AOAoGFOapKwaAA1VAOJTsRbAoNMEkD2vgB6EACXPl6KlqgYWvDAcqVMcADHxABzGAClcwME6AEG7AOfoeQe3yRR+ACHwCkL3qnqlTNH6CROfAEqqEEB0ACygC4NnxUe7wKSKCRrFl+7jwExqwE5WeRvoDI1ezOlukCG6ADvWACoGBUCkkArgkNupt4+qxK0KAMLMAPzKAJJ2CUbEkJNGAARaDOtyALtKCH3gkNRlC2ZFYHfGfQLLB87QkA9HAbB5AC7vANKMsDsQoACeC9E/+QDApACU/ADNWADTFQDbZrlEb5zclsAswADsxQDiSAAclwDCsJDW1QmROpkO4MxN2sSgWgm8xQBCDgApQAxcdwDPaQAg9MCUPAA85QDODAlOWQB1ZACTzt0w8QARehAxBAEEdwVmVjNgYRAxjGGwtxmflKDwbwAfygDIisBNjQAz0gwaN4B2GgzAxgp23qAzBsAOVQDgbwDQzAAOJ1mTUJBwmgDobnD/yAAw4AqjLyn3DgyjlakT5gAGPIlYkAAMpQ18jpA20pEOH4yn9NoAbhC0UKB75AicepkhgaoKrNmM6Z2owpI9bJnYKM3LxNmdCtiIjnBNbtD8SQnNU9EOP/J4PLTRD2uXgBatICkQ3V0KQKIAMaia+WudlwcACucAACMdz80AIggMhEm5LqUHdwsA5MXRCwgJcRGqOjQwARUA1wkAMmoBDI+c/c8AEQsA2asAdLgAEMcA45wAC2JhRHFbFhqgBHgA4PnJK1MApCq0oToAAg0AIE0JjvCbR//bKs3RCUgA7xZ+PGSAzO0AQGoAIPudsu8ZXcd44okY4UsY4OIa69+NmsyJzK/cYIQeASoUrC+9kzrkq8gAanN5pLAZ7J0AL4WpN3h4GkqZwlUeMM8Zra6ODHwLLu8AT08ABDQJ4LIeQtQeQvMZbiJokYEQK2IOUC4Y52Sd3MLeMU/0HlVZ4N9D0R7Wd6sEChTjG0AsGiK6HmM37T1l0N7lAOPHDRB3APZokQeA6HXEh7Rn4SSD4RaNmEm9fk8UiTFoHoCXGTUDHqBGHpKoHpDGECptqZQoANVw0NJwDClnnnF1iEMeh9fn4RtyiCr16CfrgSil7lgk5me7kVup4SvL4QOIC1nWkOgAadEFHqK6HnR5jqJrHqEqHkNk7o064S1Y4Stq4V244S3b4Q9dCpCwnBT2sR5g6Opx4TfE6LzW4RIRAL6g4HIwiFvqiJ+BeELFjl7pANYos+ivvrFRHwKYHudLjwJMHuEdHqDjEKIuDwaCjrLFHvdteGV+iHw4mzGP+gAArADHvskBjB8Sjh8Y8I8iMh8hBB8g5hAZsA6zMJ8Ss4hA7+AVPpnQp93Buf7P/n8yNR8Oh48OpI6wPRjrZX6A6o8ivB8lhx7yfhyqoED/WgCdDgAhgwAT0QAwRwBB9wDK2b4+Qo9XK47AOI9RSR8BIpjmSI8rGO9BLvoxxhiEc1BECeDBOAATEQq6MDDhMwqgUw1nevha3NedfeEDy/ElbfEQ8J9A8h9AtxCwfwhJzneTSRd/w5EsjZEPdH9Q8BAcTBAwRQIDajJwdjIPZUIB3giUPp8hWh9Q1hiOvgA5RQD3znA6xMoA6QCKjNEdhXoFGZnXcv+yHx+YwHtKL/7xCkrxA+kAiBsAkxSfwkIXq4KBKqZJDEbBD3t/mzkUENEkUFATJflhoCIQMBIt2tDRBwBMLJ4gEOpYEJE1JiKBDhQIQfMEBs+FDhQ4sMKemAIwqhOxMAwGG0qPAgHHUjTK5k2XJBCVkHJyCE5uDcMSEnHY4IRumcAiMIKy5EiMNFS4gDX2oUWjIpSZZOHSadunIHLKckoTqUSpEiQn89hFIVaIuDk1pNG5IdOnaghbVTszIs8IsWpSaaoMGBhyYFBo06kQ6O25Xo2lr2MEHIUbgqUowrGxIwAAEODXQ9HzvEo+/JYNCDN3RYKeObwhgIWLLosOHi4YOBW1akVDBu/9TYsmO7G+GLKaUlPH7/FrKBgMYECj7c+AAugb8RtwmfkB4a6YJO/IScKAKBkiZ3BdClEIqD0jESCiiZ86UADg5u6zYS+PCbXoGSlMxvhbNUI4/jhmPqgwMOwOYed/QjgJ/cDqOklwOgMee4D1jITaOrmLowBx2I026t4VioTy1K7GnhOCHuMUE2jTgIAIDhCICHISGIo8QIA2oMLARobIFoRgEZKoYSWiYoIAFNcGAmgFnMOQGDETXKoReGjqlus98m6irIEUYYhAFu7lGCnwN8G0K+K7lqyiSGCCBPPWL8aUE/Z5bAAAmm8HBDBmgoYQE/w6xTSJYHEOigAxkGOv+UBzhi2GCDGIohzSQeOnDFwoQA6OEkZyKI7YQEHgPRgb3gsAEZDyJI8yQCTFgiBwZK4qeFYzDIAQITjoBGAQYAYCZBSiJAggBNMCChBQdScIGSciAgRQ0TCLBBQ0E3CFVQyARawA4SRihACE2QUA+AbIh5oBoGNqCEmSOKASdWFVxg4BxmKHHHAe8AOO6JatSbqgB3ltBohBgc0kEARikJJh0HVFVmHVUp2cAEEwwoYIIJzIGDYgYgcICBZJWh7YERHCBgAgzAgcCcBFIogAEeHsAAGxXSoKQHE0aoJrYYlNGEgWyUIM+ZFFpQwYQTBIqYBgieSIGEmRjixx5KHPD/pQkevpF4Aggi7gUDZ1xE5yAeYMSmGneG+PgBhpLBwIECCOChmg0wKPUui7AZQdWIDYiYAAxkESEBhsxhxp8gGNqgCXDsIUBVGpghIIECUjjiNoQIsIw2AgooQBNN1mwqBrpT8IcHEwhvgxLCzXFgAsq+IcCIHAiPiochCTAnPx88ZyiFJUawIZlswNHEhGRWpERzPNQAYPcRSJjxWmxbGm2lGNiBY4NvvnkUipaYQUEheEbggQV33DmhhyeIgZ2hB3w5SIgmAMPh5REYwGAQagxIIAf5SWYDxVAHA+5xBHcUowfmAAcz2MaDHriDB8wohw3OsQEc+GICPYhgAg7A/w9oJAAaLEDHzAQiCnXUp3oOiUG9TJIDZ1SPITw4gBVc4IJzwOED7mCQQD5QDwjAQ4Gx0kEKZsIMBmCDddXoiTvMAYAEVEMTH/CFJgCmghgQ4BwGcEY16GEPjJmjByMYQxMO8IAJHMQcHzABMyLIAGWoQx3HWAg/1GEDgcDjAzoAh1h8UYwcFMMGHzgIP5a1AVAIpBcA2MABbLUNZmBDHTmQmzmC4Q760EATLTACPUjwgRy4QB0FKEYLwEGPCZQDHMdhwQGOc4AUmCAC2dChCvajAxKowDIEUIYDyEGKSNnASWXDywQc8AFNHABC/MBINtLBD2YUABS0SMATjFAMc/+4wwUNNMEBJtALuFXjANMSQS0cgscgxMIhzKjHAU6gAnQwsxpPQMIEGGCOA1BEARiIQTJGoERiPEEoPYCAC+iBDoacgAH0WJsNRgAAdSCkDbN4IT/g4Q6LMZIBDOgQ64JVADHGAFBNYUCp4EAvwFBiBENaluYooQBuWOIUOqAHJbjxAAA8IGkrZEkTJqUQdahGIQgomEAwJRAC/JQrJGAA4SjhggTg6QEJwAALerABBrjDBv5QgAx2hhBbFCQW6BgBM1TAkBwpTgGamYoNXPCBo2jEHKFTghJIAo1zDCU2cHABM08Yi1URhosgooQK1MOiqDCEAQc4wxjSBKIe9Cn/WByhBA3kchBoEDIwxOiQC5hxkA8wI0qUgKskSkCJbKDpPA3AE0NooNeLiO6dzCgfdTLCEBWe5CE7yMgB4EqiwDBlkEHSoQLSQQkITKBUd4XGPSKAn2SchRL0uAcEoNGDERmAIdBQwTdGVJWnCiQQJphAEfQo2RASoAlrOshduAKHdF72qXHVSH0+kAIjOMQEKUTiB+5Bif9iJAEkOMcDFKAAIAV3LRNlU2ze+gEa1McAB8ZXNRiyrBwobwL3iIF2E7Ks4cBBGRjY7wZAwLb//tcADFACT1lyvYGggBkbcIUMYpIQBrBjxt9wBRw6QAACQIEAbNJQYISgAKdCSiiZ/41LQW6BWRccuBeaMAcJYBQookgWy4MRhTpdLBAlHFhL64mAemLAkBicObEMOHMfThsaEG0GzizSjbZOm58N2GLLkPmAlqt3FaJ8mcgNYskSdseQs8yCyToZC2n7NJgQ8AIaJoXIFnankFi4NyHxFRRqizEBBWiiXkzJgQIi6iDJDobB1tkuQ/CFkXMg1ATVwMY3RAZnFUjvCHaABCyq6wBKnFLQJjnCZwcSA3rIjiXIlp2FsvYNRjX4NReiVp0L8hoBsVowLu7ysDXiADrmoKa+MAAz0mEEFcjgtZJJF0JeAgtt73XPC3nvthPin0DPezZ7/TO8vTJsr9Q5tkJJtP/o+E3oluDN3surjgicwuk5w4EBFnaLggc+71WzmjZJYQYGDkCJEAYWIk0oAiVmIQebEQMElzsAMQD+cpgL6toxh3m3Ab484zwBUD6ghAFSMAQeOIMSACBkQtKhLnfDhOYvf/fSAQ5op385FomG+V38PXA2ceHGA4F4p6OekIwDnB8OsDdoKAGPy8kCD2mAgzO20BiRf13u1pn53Fdo85tr7gzB5YoJ4NECdXEFHXm189btLqimHx5bUFd8aKbuBIq+3OGG6UotNM11L3da318Ou7fjLhmBqN1mxwABext/+sHUHfVczvzLBe4QBrTAsxjBQDIs8hLDr54lidd9Sxj/33uTPD7yAA+BnrEFi8sLpOvAN0nnmR/6tR/8+cxX/fQHgneYU74HsUrBEyBgDzhMYFpKUbr1712Cq5sfDr+3vvCr/vmB8MLhClm++Z3/fNFLX/2or775sT93SogB4UiALSCAb2CBACG/3LM+3lM/9ps+93s5hes0Nni41lO/+2O+/Ns/6jMIDuyIC5Q7t5gWZygCJFAI3PvABjS/B3y+CBy2WJi840s++ApB68tA4NvAD9S9/rO+/zs9alFAFUS/D2xB5nvBYQuBskMKW6DB+rvB4TM/HdxB/vNADvzBaeM7gds8sii8IUw/FgRDCKQ6CYS/0NMCC9xBHOy9KaTC/8brwenDQoeAhmfAgQ8ggA3QhF6ggQ0ggY9LiKIbthTkwBW0PiMEPiQUtAlkNTYwp02zwelbQ91rQzc8PDiMus+Tw4PwGAzIKrRCh3SABwYoOoYggZwQxDuLAYExP96Lu8Iww9A4RJ56PWpriUTUPI2wBYcDw98wCWjAG0r4wyCQhZigRd2TxBWSCmMclOg7PB6AlIF4xqMaDGmcu0t0Ot8KDU2kBBNggSC5ERJwCGcggHIAuAUQABN4AmaYE1YkQoEYgj2zHYcYglOEOVnkKXlUCHHzDqS4RUFJhhRQIS4YhbkAhxxYCeRjCAx4hqMYxpgYEwyMwpdzhwCCCB84SP/QoMSlgwAoQIFv6IDxQQGPZIdoS4gOgIKTZBSR/AaSFLTf8KwNM4BjsI1lVBNllI7KsgF4gAcXaJX6eAAGCAYhOC4aYQiPCC4HuIePwwGym40NUBVoIAAaUIHckiF3owP0eRR1UYdn8A0iCzHp04r8oLPYeIm0QKtyCDFK8B0feIYmWIcR2QAHwAZw0KO5oIR18AEdKAK4o4QUKgmocwF4xAglcIfRqi9vHI4D4AbfuK3aO44c0A5/GJKEeLwtPLu/mJYpCZZgEBgMyAanugtHhIgNKALqGQh+cIZAYAAfIIElMABYAAQH2ACDGoEZuY+NiKhgYSacHI4RSAF4oIH/miqyg+xFrlidImOKJVAVNZkNG6iHiUiIqJwAe3CBeogYCBALSujLtYOfWKEEZQiGmIMC1xAIRsGU7jGJ1oADHlAN9DyNL4uAB4CHAxiCHmgtJeAGVIkBePBKpMCBlZEOaIgVhSCAFjjQFDAZHkgHNxGCYggJ4YAAUBCCA2COygKMBBAODGCYGZkNE7mHeyCcEcivWbQQdSgHWFCHM1OPb0ACtloIIaiGxtAB+TiIXlAIPDoInMoPCs0hvzxFSrgEAQAUJWCAJ0C6HBiB4vyGYriHergZE3AHIbABdSmAJmgBEpCKW0EHA0iEn6CEFNkCgUoIqDMAGYCHg2BKAziA/wLAiQNorQ8oB3r4gHXghhGwPUqIFRRgTq6olw2gB3pogSJQAEaqzLNAk9hiBiRIAGY4AHooKwIoBnp4AmBr1BFYRIEIngIgBqfoAQMYBh0wAGYChycQAH5whwRIhuS4B2IwgU5SgSGgARkAtpZRCAAQnou6B2YIhpZhhmoANmdghpaqBxAtBp67rVVgCCOohuOQD00ggAPoFSHwgQOwPciYACXYmYRggZrShGIohhHIp6cBhQhogcb8h3+YhZ4DhQ4ZAfB7OQjQHpNAwA4oKpN0jRwQKnq1V4GgJKagDEp4gjHVCE2AAGcYAWXgBq0RCiHwgiKgmAcA18/IjQdQl/+yioEjUIEmKAcG6IVeMKgEQAdwiI1deQgXUIIZ6QV1oIgYIAHyIIBkEAAn3QJscABjowQZ+M5OM50gvBKm6AUQGIFEeDOGGAFxGToCAAV0OLMWEChmiAHAMIBn6BMSCJ0DUAHCQQeSwQZ22Z0CkE8S6By2SYAz+IZlIQF3GNIOwYbdWZH8tAdmSAFQQJMeggMdcAAVyKeBQALt1AglKAIMEopviAAGEAhNYFoSoIdVWKwRaAIlEIsPYLFlWQIG4CU0ogQScIYcOBFKEKYRoAf56bkRIIb7egZovQxMgQAYcY+ARTQvYAbCgYAnxdyl/U4jEJkSySsXMIAZsQElwIH/QEgArIgNB3CAxlAPITiO6AGMy7MBB8CE5QlIiIiA/8KB9MiBFBgBFXi12EAHR2IGb/QBQuKHaZlLc8gBEjiDkhIIH9iA6NAIAriH1kgBcxgCJWiBolEHIVAGf6CkDVACGaANpnAAe6ABwHCHBPsAFGiMhVIsExALeFiRAqgHB3ADNRAYBUCPeyhJgIMx1OAxRuEe7/ExeqCxRGkUEL4IYoCRbGCAaHIATYkARw2Gv2AKeIA7h8gCSPgA83iAJdiAIRiCtHEADEiADVgCEPuABxCCIyjhDWAbHMiYHsCAHW3O/DiIdLAro4QGG6gRACiq7Ry/TntOSsCAetCtI8kI/4eAgONarCWIAaVjiCbYAvOIAaIDpyZIhm9wm+8gHRxwhyMAAB1oAfA1FnOgznRoKXOIgAHCgYMAAEbOARywFnPADiFQAk1Ah9fKge3rEDgYAu/QDYYwj4Ug3IRyhwegLIc4ho7FLR6wXxzQgQAgnSXoE5xyF6ZwAclSBpVRMODw5Kf6YQAYgicwzINjCAhIgWCoBrsqA3JgASqLIkqoBxxoOarx5SAJgUxwKntAVY1AshFoGSM4BitJPkpInAQYWYg4hgRzZErwh2ruGIbYr6G7nORcFyrZiHXTiOUMnZ67hX8gAB3Rj3PIq0ZDiGNA1SCunBMIhhZAEgCYkQcQC//GIYHB/ADe7LllyY10gAAO0AcISDM4ECEuHIx4bQkC6DFHgUaQVLaESOmVSI8USAD7cghQqlukgENSBg1luNkPmBZmgE+e0sRZHIEJSA5KYBv05YZeVMiLiQ5ZGEQd0lsc8y5RrI+O8w4DWFgLIi0dOAqIOIeNRooP+AD/UALLwKyqXKEHMCvLWiHeUggX0BrJoATezL4PAIDMUoAmCABrgAMUUAY4yIYtGDVskYVbuIsnCJMRqFtKgB2wjj+4oD9IRIp1+AZ0uAdguzlzUIF7oIFaQEaIIBiFoAGcPgh0QFXT3jyNpDl2KE/2hANMYYYeU4j1HIjZrm2FOEyxDA3/OPw8LQS5QLy7ynYxHVAiF+iBA6BgHyiHc0CCWMEGA7AH5wXPGumP8kM4H9rohqAiAba4r9gyhvCPOINFhYCGZFhrQYlr2PjKkoaMioAGYuADJ+AFFeLi76oevFGh4OoFnruIR3vEZHSBfb65HPg4hhDtf6O33RYotwiN1o65ePVIkIQDdpABGWhJ24ZtC8dwDY+6awQ+or45oXiCJSiHb4AGeoCAanAXFMxu9SvE6btH1IsFXiBDgJPBTnPC4gY+BW+8CKe5ahSIR2GJ81GIIrdGK9y/ESfxEmEGvR4BwMBep5DqGHfH/aPxGsfxYWuEtMAWIknDD/xxxQvySnS6/xDvvSbPPhM4M3egkt2D8XYUwxmn8yPkckWExVm4ADHnQDI/PDM/c5pLc91bc9erSexewOmT8efT8tPzR56yOjDfhT7fvz+3u0AXdJgj9NUz9NOz8jkvQjtHRDz/ModT9NngcTWUyOnLdE0HOE5HPU9v7y78MlBnQCx3wFHvPUhfoT+ghF1nE1Ufc1bHv2Z8dSXfwVmHCCGgGodggRR4a0G79UXP9TDkwF7Xb/Pmc8pedQ50dWT/slg/vWV3CG5Qju38DnMQbFREdeZjdOZz9MbLdmzBVLNrhNx7QsVLk0ufO3APd54a98YrdziY7nPQH2ZQgAeAhrFp9y8UdWwvdf+e0kVYDPNu171iQCiW6He5+3eAH7SBi3Xz5rYet2LMrWMCLUUrmXY5B3Pd4kJabMWRh619GwwjRHQZAg16X8aG2IUeYZNvQchhbzyNWB//VAhkxPlk5MeBED14M4I//HhBCXCIgLDaWHLCeKvDW/MWEgoXOKtjtqn3Pj93Nztl0OLhDo1zSHs7uzrSmkXS2jOJUW8ypXPcGvmoGGtblPgPY/vYSAcPu4sLJC0UCB2T2PNKPzzFSeTCXQlkdAEZyEfXqwYSwIaEED2G8Oyx13SGcAcH14i4qQdzkAMP4IULaYngSRAHIbJ0gLsI0CzjDIwfxAstFoLdrQZz8BwDwGH/RkOuAniA00c8mKgdqicMoeAG7eKBLFXLwEiGPkkAO6U2SiBvOFCChWUIBP9Gpqgbc7Cw1U8o9XCHM3MK9iaKJkiB1tIrsIStihgCBUjjjRuIbEe2zc5+hjg6FgtzqXAAHgAIBZQGUoJjkBIXXgQLBiEYo5oLggbhEMwGbeHBhUsGHumlkcVAOEowUDTgLOREOG1mpUw50Ag2eg9IJEDZcmHBlnB6mYuBc0QMApR41KSUhwyvIxBGGDFnLpnOqFJbbvj2jR4LODxQdECRVecGrihipKQ39WxKbE0wKBvoYMQBSrwOCPBASV0KoTl1+mMGr5jPiQOfcPsq2EGKYBEw/3Bzd3EgPAIG+FFMYFBULJ29RmAYCEqGDzjHjLQ9SwlmUZtoDS4oIesAinN7TVOkxExdtgkGGPg0wSxFAb0jmFES4k4TpR7w7hG0R7DPDXMESfRKMeLBEQYKACykgW7ggZoRFBw4Z2PCbI5PavdQkM4BPdVwdsw+uPQcASQEGSCvTSlBf/7tNZQCGBigjg4FJOCPEHDUlFIsHDjBklSUMECJOyl88MwTSqjwDCUj2HAMMwdoQUlmLjkQg0AsnLCXLLTgBEdDA6nAg1AJWAbHESqYA8E9RTknICUOmIAjCCPwYA4xEKRgwnfZnEEZJTrEp9NKFfrADDMRUSJQfQdZRv9JYC4R4Ew1xRFwkUATPMAMc7W4YQUl5dggBDoJjLYan3B8g8IG9EDBAgE8wEGPKzoRAAVZG7DTKAoIhHlTTjjlYAA38OTQgg8MJGCEYNRQ04I5/iRgQA4uKRNBNQSAekwK2jnADyVPpJDDCAVQQqsQ0LRACQQRKOPgBgbQU2ACPRRxzwTu+GDPDQr9p05B1QhBAjzOGFAURXwOREI135xjmmqtyQIACULYVClBOVDyAT0+cfPBf3DgMMEGCfjiT3jV/DjBASmc8wA9EFASzAb1OOAOPbqloIYDT4yAjXRDGEFMC+NW44AB1YxAQAQTaFIMwQx066AMaQ7EjDn0oMr/DDo5YIPOEM4wAAIPlNAghA5j4ACeAhAQc082lKlTDwHVFHBEOjkVQ081vjAwhD0sTEDAB+c84YwC5VCiDEgDPXACOAU8kGlOETqR0zH+4FRMMHAIQcwW/oCTjgvBBMOdaMWQ8GJIA61jABya4OCOAwQooEAysNDSAgAAGAAAHPjsdsATlEh2lT02kOCLOSPk8IABEyC88ghQE2APNgl4FEEBEGQzEAQFEOPuQcS5JAQmBOEgnbsOcKPJOoEL5NIxtB5gwggMQB04JfAQ92s1D1STAHo6yMBCCksk44Yb9KQQeJ99WmVQBxtMxAwKOkFBwEQyyABHDOMgwKc7BVGS/4MDx1AyL9sMgAOdZKEMOAFHSmgwAXPkTH86UAIcqpGCB/yKEprQRDUMgI1EJCACGBkKTkBIiVkYYARWAIALpOYOeCjBAZTo1AO4M6mpEIQHNCAcDXVAr4m0hhJpEgq14BCBERSEBeoSggJigD0DmGN2gqnGBqB3gmeo4wAGcOFCjvEMHyyEF31wA4bSIQOUkDFnvTACJY5BAiU0xyWUAMA6HqCJCcRAHSw4AwCYQa+FqMOFv6GHF0hgAAgQhwC6YlcD30gWJVwvigSwDlYSwA10FEB3UalUDC5kkAil4QiUkFoL4EEmHBTgkBnRHyWkg0pakIABEYHDOpRQsDdqgv+NhoIDAG7xBc0VgxLpeEIAfGgCHVDECDz4wAhaEMX/SIQfLjxABRN5yhAO6D8InIiTBsGCISghBRtwxzMeYAKMGIQHcZlIDu4RDEqkAI0xINQO76KJmvTgBAb4UjAyR4nHoGMEaEiDfmZYPqmcjwUIcAb6GKUTSU1kAx2YCAJuoZMXugAJOTgAOiaQjQgAYAPFIAAx0hOmLHigFpUCh+kKMAEA2CAj/jEIBIKxEYqwgBj+AEAsTHDJSrm0NqLARg8Y4IwlZIMBvRxKEyQyUMGkIDU3OQcGcHQMOECjAJ1QxoUwCAChBIMbVXxkN33Qg3s+ARyvPMjJBGMwIp1Mf7X/aY203HqTS6bVJf7QGwBmKpi9UgQCmmgLJeiDBAJ4kq/1sRkEmlYhN050NhGAAASwUYAxkOIaJ5hABHzhjhNg4AEPoFRbWyIjJWjiGAlwAEkoggM2pkQJ7gjELSQKhyU4QA6UgEWZ0lPXgaSjqPUZUF2jwg9zZO4BwXgAJfDQA3NgwH8n4ME6L0kcStgNpAk4QZoOEgFz6GgC5egPJZpAA2Bhg6eU2IAD8JAGWAh0qTpRADs6AAWTTYQAD2VGBzrAjFvcr6EPhQN/L0kMFRiLBEOAnlLRQtKWfMABB+CifNwo0hm5VxQD8Qg1IzxQSjjjDBgw2ICyAQrpAMCF/jBB/xEY8DOCpCAb1XgxES2U4fbWZqmtgYV7V4NKDUs4Jztgb4IrFMIc73SEQ7DD2hYyBKcO9ESUUAKUyBhkSsSomkGIBY+F3ITgujd698CACvbYhhlfUmn08NqQa5MMAhDgQRKBHqXUS2TzfUMqDE0JFNRnEPlBVLZzVrAH/izoqWBm0Ks5Bz/S4TYyceMZKUgJM1pwjwV0ghc4TgkL6AUBFxjaxiW4dKcN/eNQG9oWEqLQoC+C4w+c9Sy1kFFLrkzqHFPCBvzYoUpQreM0fmDWKZGFnH09kfNNJF5++m9KFtWoRxkkwMKeyIKfPedCSzsj0HBHOo7ADF98oNcTgQY/XP/QGj9Pk8vVZs2nz+3eUau7fJQ4dadlxK7VQOMC9ZF1u4VMziz1iZzCBnYaqs2lZLuiA9uLSli6QhY44De/zJB2tPPdJ2rnm5BYlIq5JN6nG2ucT+zu+FTUpus/y3vDFpBFrFME8rPwe+VRAbjLYy6ViMu8JRRv90B0INCM17wlHO95Sj4OdJF32gJZlgqsU4JvoE+k5UCHOdNlTnOm3xzoPI/6z6Mu9J4T3dB/uAWNW/LqWqQ86k0fec2hbvaVTx3oVe/51ZmedaZvveZdH3TJy1fve6s86k7vudrX3vG29/ztNY+71dNt9rrL/O6Cznu/LQCNsq/972kPtuAHH+j/tRte5oiHu+K1Duqhw9vQRg97ShzHd8FbXuaBz3y+CV/zzsf884cPPd1Hz/XSD7oRFxmoLZI+kaX7He2uxzzsY795s9Pe5bb3PO6BzviYO57kVAa+vSlv9tbH/PXJP7fsZd78lT+/9tHv+fRdXv05y8gWJke50vvOdO673Pvfh/jyoz5+kJff+eevefqt3PoR2ekNVJVpX/GZnf3dn7CFX8ztX8f1H/n9n8wFIMgNYI5xgSyg3kQE3+pVnvF1H/IxIP4JHgRqnATyHwXGnAV2HAa6F+T1SfbFH+uFYP2NIAk2YP5RnfyBHvxh3Qq6XAtq3AsuVQzyiQXoHvHNnw2u/9wC5mCoOaDLnaDEpWAEBuHKDaHEFeFAGR3ZlQ8vCJ9BLCHQ0Z8T4iAUkpoUrhwV5psVoiAWgpwW5hsXlk8IwMEX9psY0kgP9pwZgtwTpuGgrSHItWG7vWEVxmHHzWG71WGfHCFaQEMdfOD2NSEgoqEgGhohdpwhqhsiuqEiahwjqpsj8omM5CGfwIIFbAICMqECYmImCtomalwnntsnHmIoStwonlsprkYB6t0ekqEfWmLHBWIsEtksSlwtVtstemIu5tsuVlsvokUIQIP7lY8HtmIZEqPGGeMxulcy5htmSNnR2aJrrN3cSZ/u2R3vPV45toQtGJ02DuMrBtw3Rv/hDrpdLJzD5GlOAfSS+f2g3D1ju0WjtE3jWdAC2L3fPNbcHxYjLN4jOOZj4VGCCiDHEzgANBBANjjHO85aM5rjOgLgSFJfO/7ZL/bJAdIgCNbjysXABhhGz4Vju4mCEjAABBBAOvRSDkhOL+BaIgpk4pUkCxKlAJ7knIWALRjlRAVjHzokN0qcNy6VLDwAAuRXB0DAN8QXFDwcomwl/LTEVmKlmCCAnumg2Q2EKGwbJUzAxcHBpQDAigVljTWWYDSYuwRZp6Uj+jGlCyIlkUHiWUCDCFBiAkbdVC6VQ6VEQbEDD3yFfekEsU0EC7ADFBRDCUadzggAARzDLQwBiGX/RDqMEwcaWsZpTn08QTa4xBCoAElAgDt4G6nxJUmaHUJOhWBOBSxowSg0pMw9ZDdGJJE1AbL5SZ3BQZ6tT6KI5XEaBAt0AA+kD7mUZkvQ5LMNBC/Qgx1MgGmAwwCRkbCFRGu4HzvlD5kcmAGoAEF4UAI0QZqQAAH4xAfoU+CcBHVSRA8JxqSkGa3xZ9D5JRECZr8VhCzcggW0ALf0WEtgAC0kKI1QAirSFQ3Jx0dSCiWMGaWgA32iBTFM3ob5m0EAnAqslV661wYgQAMYnJ8AyjdAAWU6Jv1YxcONpX7BgSvAj3TuVDH4Ak8NFEk95VLJlUvQUFtBQz0cwA0sXIV8/wADdMZAoEd4IgEcLIAaSEIspMA6EAAE3BBy3cMT/JBASAcz+ECalIOvyFBe/McIzI9+DulEmYMaqENt6IdLVUoxcBFy7ViFUsIDYABymFdBjFqPMhZaoVJwzZuh7udEwIKEXKObtilODEHGDMQJmIEkuMNCvtmmfFZDKQMt8AA9pIpBYEIEROhErcehYkBntMQTgBeNDQQBuIMnGYKjTkQK8INWBlS3ABccEIB6ohVdLYQ75OlewYJ6EcB31Ep0/VkxdIDKfUMHfAMzfAULdKVzbsAGGMpkbgAUWAU7jIWFPgA6mEyJAtp9XpIOuA1o6SclJMM9xMdCMACt7B8lgP/DFlCCARTBufJJMdwDL5DCGKinO/ADNGxAmD0BBiiBEaQJOAAAEtzTBxSBUCjBvEAAN9yDP7jDBuhRAcxO7GTYXp0XKbhBFMGBD2yBeuIEBjCACoADNwjBFkDAEIAA9BzDW/LFPZzDBrgA9lDYfADZQmzA7MwINcFBAyiAfc4YhekpQUgIsKhM0WKDAiQVJThpEdiACtzCPRSDjDhANRQDCuDEE2CDCbhQE8CkLBTmB6gARdhCGXxDSNEQAXwDG30ZRUDF/4CJ+BSExsoQM8DrfiYAAbgAA3CDGnzD+FBCMXDDFvTAQNBAOTgACowAAOlpOpzAFpzDclob0QyEk/r/Qh6FUMKqlzkwB4YAAAT92WIOW3PCQbU+XFRMJgtgK7dixUQlgBJ8AMwSgD98h45NRB7IgBHgmKLORgIcgEHEwDrwgAu0gAFsRE4oAQSYCjwsAQSAgwMwQznkwFJUwz0cCGmO33qCQDL4AxGFWk5sxwMMQgkwgC9QLT10xgbIQEtpQuaew28MBPTu00B8wGPEwGNkwz1AAHcUAACMEwCkwAAdhDr0ADi0hgNsgPNAAwMEAzNswD0IATNwExsJQTHYgAKQwDzxADiUAzFogjlgw1xRwgEUADRggLpQ1wGbQAHcwz0QwAb8GDioAAhEALbGwAM4gBAwwAhoiPKOQDlo/+wE9IAK0MA60MOXOUABYAA9MAAzAIAK9AAJpMAJBAslrAM4+AIcPMEEYMABpAMD/MMgdNMBBHE5mEAMDAEGENExTMAHnMAHMEMCYAA4sNERmMA63IJCvlAy6AABWHE1RECyPsA9QNlAnJwF5akazEIToAM81GXywgMJ6AADMAA0hGoPtNOXpMMGCAE43ANFnEAOxMdtnEoDGRZ6DAQ0tMFcGIASTAA07BFB9AJgxAA3KEAP5EAMXHAq0RIGhCUSHBgD3OTDKgEznIMDfAAA1EQxOABFKIAJ5IEbPEEE+AQArLKgra5BTKaNdis5j3PrTkSOVgg0IEEEpIC/vOoSBP8DPLSCNaADBBDJB9gaNDxBMhCEMujGARwyAzgACDhAMACGPXyAJqgAYmhCPXxMNafWbGWOOzDDWp0gJQTUCFyyocmy4LIAPWxDCSyBCazTJ02ElJpsMUyeDAxLlzEM1kCAAjxAMbiD3gSDCphAMeRA1g3EnVLXCJylYGBDFCEOBqzDIdVDAtDKQTyAAlzIb61DAnwWsKQDOYwAOESAOhSAC5VTOfyzJHVyMUwVJdgDYLRWSBVEDhyBM3xAMcCDDTDAi2FzMTDAAdTDnmmpGhjCM3hzW3wAN7hvNRBDCqiLL9yDu2AVZUzEKDjZRPjCEbizOXh0SxygD9nDCIBR9Bj/AA1Aw3hFBDicARlXyUV0bAF4jjscgA5sQAE8wRMcwAdIhwnYQ7IiAU5Tggu4gA3sEQt8tUGsBCUsQRHIqWmoAzMUQHwcMhexQCJYEI+qAD18gEAw9D0dAwYIhDqYwBAzB8AkAPgQgy9AABL00mv/mQ7k80QcgZJqBe0SdfK290Q85nQSBGLoHHjqz01yAwmQVCpZMQBQBg9wQz0MTww4bwEogF7k6ZulQOkYQNMg2JSREwTixAHEBXXyKjQAgGxsgE/0QDiUALBgOJzVZYVaaNEKyJSGHsii+AcVxBOAgFm7ABZFmFwNhBzwANj525AhqoKC7ELYwDeod9NOiNKq/4BepPhEhMAoAJfPLmrStSWNSAszKEELoIM5tMDGwEEsL4TL/AcoUMQGMMX/tMDPOIMrPAZFKI4KBEM9WLEzxExKCHe5StgZYDiDI9cBgAMl3AM2VEOyxmvKwowPgaq73IEabASB/wwcIJREUsIQlG0U1QQA+FUPCK59+rc/xAASYAMGOECX64UPeJBALYQHTRuQCtnxfKj+nMABIIEIv9FbnaPZ0aag2QMobIAmLPNSGWSnnfpEvCCZvGMsyAiATkTaUiIKiBI2zOcMSRkchMVAJIuhSlh5xcAR3FNLACehSgUGFAM4GMGqukQKqFIM5IwyYEAowcGcTLvjSiSlbP9ABFw0A2zACSRADADOQCwYu+zzrvqni/+ZIX7LApNPoRLTQiTrBkgQALDAkuj1QIQkMxKkt8BDBOjIuh37dbYEF35kbkpFLYTAyOGbhD/7vOGAlCpV8fbUnEdlm04FEUPvRI0I9JxDCnDDQJDBKeyBLdQ5vFNENQQRAVHk7KX6VKTAgam4YBCACznzQCSCwQhEMRSBQUQMD9E6EGo8NGo9KQqoe2nBQrqbU9bgrDGDO9hAaX6xB+2BIYTBvv58SljnudUiKYcEOigAOlALQSiAB2HQBPhDucOBQBwDKgPrigsl6HG9uvm6sN2mVNxhho99S5KaDxCDuS1WbajX28P/vUHIfbXVom2YQBsjhzPoSgxsgQ7g/f84wwg8wRKkgAv8KafphMRLm60XpW16vRGeOBwku2/GHLe7258lJufPHNGLn9FP6AiQwH5QQgQ4AIElgDuMkzqtA29E+KTU/rPdvhAqvjTq/kB9fFTAAhd46PAlP8gFv/ATGfEX/9CbIPqz8+8xHCXoihJchDk4BwE89ygDBByBAwkuKCGLYEKFCxk2dFiwBKyHEylWHLhDokWNGwfG4uBkFkeGWihR0kiJlkmCQWKJdGmxTciXMxnKwpOGZk6dOrN42PkTjqiWDksWTVgSjsoDCVQUNUrJli1KTVQyNIgQaE6DGbPOxNh1/6ZHkDu5yKpKsVbKhCzB0ozZ1qVNnEmRwrWbs+ddkUIfUqLBrO5AeGc/QBlyluNVvRu3Ltb41TFFsTJpxkqJ+OEoEYjZRq741vNDuQIpnTsROHRqgnlVO+Q70CldbBhOKCvJo4ADAs8gHMXM+GDrho2FL4RcnODknZdPsuG1dijyhKBFmkQ9MUaC33BGJx1RzsZ26XZZjx/4mm56SupMUMJRr2T7dQk+KOiq2LxA4vmPj1euczPxFkqLs+jyo66664gyp4XtuoNjhDN0yOqIbyz8JoaBCNhgIQJc6QAFDgeiJ8O2ystPKL98oOQDEhwgjZkjTEqmBwb8oYuSAgQUSf8xp4aAoCqkjLprv8WGZKg/mmJTqCQdBPwvJy6g2ZEgSgikRAccSspDB66yWpKiktqw5SVKANiASpUoqaZBStKJYUi5JjCpHnScBGoDKDbYkwWBGEDgG4W+cSXDDWQgbQsERATrRPNSxGALFrmpJkNKWiCNEgiEqHID7YDqsSgFSOAHNqeo1CoizygxYtOGklRSwaQiaNAhKGeyhTmKZDEilQu+oYQbc3hJYBAFamkLzIl8waGNUxmihARwdnyKgHTOgWOLHuw5RyWbMFEBAEruOWBOPDtIiIcOilAAK4FYQEAdhZhBoYNifAvT1FJLysIJJGKtskkBg3RgMNKMyKH/pA80nUBLk3yAQBRKiHmCgXOKwYEGdHJMAJoqq4wBMIGEQOzf4UoQwpdjyjHnhA3SyWYde+EwIoWSSDiMEn8+oFIdjgGuS0hK9jumKHXCdcoICJhJKoadKclBGWeAZBLHkgpQgMXDqqZkh3wxzTe2s4oyAB0XcEC4JHvMjMAcJ3NQAjOPytBEa7o+cMceJg8YDOxcS00BZyWmNIeBdXAgQAUhHtAEA0x8MMCeJ1wAO+BnA6NEiA2e6GUCEphUc9WcfQABAyseQOIJyZ/2GrbWReU2b4DtMYIScwgwyYQmztnTBBCkLQkWPNxoAr574LDvgZ82YMfCpWOAggULE9rg/9yEPISjg0VFBoAifymZ4IiEWHgAliwUaaHPvpRGJ9yGKEmfhiKysa6AERxAAgIACCjHHsAoUcEAILiDpfhxMQeUhBlIoIrAJmCOYhTDBLETCA0SUTKFxGIBnTAAM0jgCyEcjQAMMMDIVEAPOKijHu2BBwYYMBFogeJGsGFABOAhEGx8IClIMAhByoEBX1CCAWfgBg9yoA4MTIAeEGDAEhlgEgdgwAAEkEEMCSKEYmDgii0wgn0AgI4NMCAG0EhAE2Swg3MQgAYY6M1AhEACBRwtKQxQQgL4oYSExKAYBIgBAJnRxByA4gnBoEQEmKEAApyhFwvhgBrgMQKTOIkSzP8IxosS4oIRyNEBS+gFNyBgjF6YwQjHqlIwQFEMf6BDBdxggBCGcAtaHANIlDiAEIJwjhQYQAEQyAEEiuEDJaTgAJQ4Bjqe8JsIPKFKI3hANUYghBHkQCFbcIdAErAFfqQgBREYxSuCwYxqVEMTlEgBkJRRjfAMBAlJgQMLckQMBmzABPXwzTcM8AECtIAflDABD44AgAeU5B4lycEI8KAGdQTUPvZJh/L0tAEeYO+h0mNGBzrADOrdsQN9yt5RJuCkXjCgKU2iR0lcEa4RRIAe5SjJAxhwjxwooBWk+EAiFGAAU5WkFydoAgqKsTMCKOAZVPkhAL7hD0qUwwCCUwH/NFKggHvI4HYuAIASfkeJYnyjGOCAAy8EkAg4QUMG/kvABJo4EWgcgB/8SADcfLCFD6QDkdMaGzesIIlYRKckT7jHEBRwAAX0oBgG6IUDeNApdNCAEuDIRlJMoB0GcEMBKHgCNAhwDHvc44sxSMEDHKCAdajgHgooQAOsYIJZUMIdB3DBBlb4AWg8oI80cC2LdlYMBSjAjkn5AD3u4T9ZusMGH+CHC/LJDwUgQR2Ss2gCbGCDVtDjHCjoxR43YANXuGNKPmBGC7hxjxjIgAQmYAAO3HECBYCjCTboGBw+8IFzKMAVH5AWHKDBjPZ+oBonSARdmuCLMpCiFnpVwDeU/6CCnYEDsqI1yVJz8AB+0OOAyQjGBkKgAB7coijQ2AAzoGFIhPFjvigp0EAeMIJk4MAcBn4CAFLwgZYqwB2mUoH/AEAMaEGTNCNQAjfYSUAFJGMLKYAGCXQkENBQohd9ZcY90kGDcqQAHQfgRjAwQAkDfKOHWuLHB45mKgWcIxgsjcET1Hbe9R4gxhswwB20wYt7gJESCijGCZRXPYFQtAPsYMfSBqIOBKRPIOmiKAKg8FDYQMAcAGjBEZTAAB5oIokRqAYOYkBYSkBDCFF8QgxicAto9OTSVgVHMFRwAm19rxgbmJJTsmFeZvRQB9XgQTCcYQAeLPDSq75pSdwxUv+TiIIXRdkAnEoiawuqkzTcyAE9OoyBHJhjR77YWaMH0YrnKCQBIxsyPDqs0hxMoMrFSMYQMLCBNKojBSZQdahLAkVo8OCA4uRBSaAxJVuQogQOOEE1glkaWpUkAtahHOhK4gwTKKEHCjDC1oJ26XQgpWtOUUI6tqBrSiCBH/V2CjEAcICHPxxo9NY1jpICj2+Awx1OPgEzWmENkVMCA/HONSWyEQydPqUot3DlHiaQAHAw4AQO6MEDxBjw2NTCAiNWZ1H+WRKQF+UAVEmAAxLADAdsQAktYEAyDFClA3B4AuA4wWlcgIFkWNwkR3aKrp+QAAME3AEmxlw1nIIDElD/wgbuIFoTXHDFYj9hCcebLxzWoVIAxCAA5BBXjCI55zovRHoJkQGh4GAogtSLSQXYgjo/4AAcJCWQpzqRL/xlxRGkQBkamQBVikHJvRhISS2IwAG/HGf39AIzJAXSBnLwCGR4yX3M0A4lNjAnfT6D5uhYgnti6RKD8MM2XbmfSF7lGWcIc8aUsFVDnOGLh9DiFv7AwLwR1pfrdEYjmmCAJr77eRZgoBf8YACpFiJLOD0EQS70F5P40aAnPMPGCACHSKMaTIBbFGCkSMM+5kQNIIEXiAEEZAQATGBCdgICDkVe+CwhmOFDZEB7ZMDQjqLfSI4EH+JEbiqRLOKmXgI9/3IikphBHSgBHWxKAYasPZhEE5jCTYSmBE4F55yi31bQ+XrQWTbi2JAE+ELjprbPch4iQFjnWdRiJWDPhVwAbn7wSHzj2PKPKLKQNI4HiIClw4LEjVYK96wDHIRAAWDhH9KAEnyhCPxlAzYvPxyjUcajBV3wdmSFEpRpAkbABo6BGa6lKJqJezgEP/KjSMaj+oSDCV2iEWqhCLlDCgcC/Q6EMnLCHTZARwqgGqCNIDYo9zSrCeSCEpYABZLCCNKpDhfjDqUjD2FF4NakCCgB8FRgtUoCSOiuB2xgoRLRPBZROhqxNR5RJFKCTCxiFJIOOloRDrjwJdbBFa4wC72wav9GQ5/Swxn14hWRIxaBQhcxxwHc4a2eBgXWhBIeQN3gABjHQxiRgxhVwxg5wm8owhbYYL0skQqlAxpdggZsahITwhSPcBt/ohuL4xt/wlTQAdqqbB2KQAWmSQm2gM7aUTresTjiMTXmUSM0gyBhoxIF4hLNox8T5CMXojsCsiBf4iCFIyHBYo5sDx18YQsMrQBcgB2Dow4xUjg0MjQ4UiP+YBQmcRZCEg5GcjxKUjUeZCVd0Sda8SW/JFRQCw6SAXRysl2CMVXq0Cc9Aygtoh4p4gKUrg6VMjWYsinvoiVbIyrBwsosbSEsEjl4sjW6MjK+siLCsi/YQJT00RnNMjT/0DIt4WItVaMt+8IIT6hmrEInFXEr+SMJiwMvKYIkJhEWjBIp+TETpUMwB5NRnrIOD3MhzqEFtARg8MVkstIdH9M87NIxJnMiZMEsTgIz9xE5ANMzOtMzs6IwUyMWxcM6ykEIQHEgCmAd8GU7esQxI9MIncUaCcI1lUQbGQI2MWUhUoI5GQIaxvIsMvM2N9MFgXMWUYMSbqIk+KH8VHI3HaI3QyMPFcRUWKCJSAAnB6IetIomDOI5W4MukRM5SyY6ZyJZLugjwNP8rpMSVJMokIATbgEO3A6HvLM4cPMkBEQIEon4QmYgZMEQKiHYmEEGaihnPBM4Sc4kkIBbFqIw/41CCIjhhwgORt1jHYJkPMsvKWJQFGBBSJLiBA7FKZyhGgwAA9CBGSaHBVrABpJCCQDAwCjBHmb0KSpCP0/gaHggAvLpKj0G2ZBN4FpHbHY0MPbjnAQiB0okbEyl1oyNPOEgB25kPeihPT5gQlADMi5n146NEo5gZ7bmHAAAA/gmWcTiTGHjbRpmHfgBApwtr3wADmyhMo/ihIakJJDAHWjBHZ6AAG4GDvKgKHTAaRpuFj/HOqqmBOliHWLwc9pAEnf0Z9ZjPwciHSjJKWIATfqwiYCoTTAlGFwhn1SAAbwvArSHJnRABqCgA6DAhNzFFUJwIGSAolAA0FhgWe+FSf+OYQJi7BmQgAGaYATmR0VBkyGWwF8IwBwISwWUgQcmRyA4azxdgABcrw87hhL4AbOS1UyqYQMEgBeCTUgKwABWJEciQJCW5BQdYLMYQAdGYPlG4Btc4FdyQBOSQUpFIQXcQRO4ZQJ4wPi+plSs0ynGihKuT0nLCp3MoRpG5kgMoiVWhQD20B1UIGIFIgLmpyRYIAWwtFaf4InERhmeyAC4FRocoBeqwQEcYAISok59IwGMLmQDzn14AAM0AbFMxQCeYAgYIAXMoQmCgXuS4yOkIlPKZSAO4IkAQBNSoBr86XB0AAKKllE17ih44BkYdQiwKQKawMZoIQeMbgQSoAj/qOG0iqCqds0BpoRJGEA7NuCAxuoceqFmxOYJqgFrUtWqHCAb+EZfhgDcwmkiGMAdALUkHKAFhsAf/PUDkIAZnsAdjsABms4LAiACbCGgdERhf8IVAmWdNBAK2EFYsYdDmAEKBmJ3hVUIYuxrWMAdksoZuKEX6mFqAMABuEUZWMwIXAANnKAI7KGp3MH4igIAmEEFYmBynsYAiIEAcuCjEiAbGIAEMGBSUEsInKEFHMAARmAIzGH1HMAI3AECtKMHNAEW+EENRgaXdsYGSMAZ0ARkCmDkQMcFhICOKKHR0GsESKAJDsAcEuDuRFVN+sAOhOADbIAA3MHG1i+EIMAE/27LHXoBitAEAAxgAgDAHQhgBE4gHZCgHgigAHYYG+yhGlLHHXKgBYSABjThCNBhh6fEASxBAG7HTB4AAiYAYhMgBwxgchQAGxSAGcpLCILBBI6BQ0yCBtKBeyjBKqciBz6gx1jkDCAAGmjgAHSkqSYgD84BU9cFktaDGUyWATbHHDYAHDirAJ7AE5FCHWxKGUaAHvBGCWSgBQIPDmxACHASGjDAU4qCA/QBBObHAaoBbUyCBD4vkjfFOnLAaF1gCEigUoNGchVAE8whedxBCIQglmxhLAdiCYoBE/yBAJIhAQ5gswoAjLYL+ehBCcyhAO6hYIqt0lYpBqqBx+qBHv8y7RhcgNh0AxpwoH5iSaAUgBxUAK0SAANagASCwQdUt5MJAB7OIQGGryj8IY+tChsajRKwoQDc4QFSrgDScAjcIQ3hAAcegAbqAR5m4Q5WgQBQJ7Hi7CeOAAEWAgUmqnc3Cg4QwCQimqJhA41UohgYgB4OQEYoR4nQAQOyIdMwoBUmoBjoYfkOIBia4I9FxR2SYQRxZB3oYYRK4gByQDsIoBp8iwfOsA+1qii24AEwYGRu4Q6oAeaKF+bgRkcYgHZcqCie4e5kSQfcoWZMQF2rZAkwIHxYJBhQYb1kqSS++nucWJZGIJgIoNxKIhus8gnKYTAIYLEw5Qi+yQAYgGb/n4AZgIQBICAbzFYNsAH3sKYPt6DHEkATtiAInYIHTACZBiIHOCgBLikFBrZVk8KusUGWAkAFqgEClgIAnMHFTABtJO0cpyIYIEDSsuEJnMoeHKDf5ucARmAL7GHeFkKESSAbMIAq/qEVso4FekCDBTuF/+lZIKBWKSEBmEOYZC7OsM5jRaBdSiIIKOFsiWYdRgAaeiBSiM/W3rkHVMIeHCkYUHYDyGkI4ED+mAgeyLEoqiGGUVYBnqAN+BXg/OEBDIDf+CmfkkKlnJsSgiEFTuN/7MGI/4cF7g6DS4K3TCKKdnSmKeEO0mAECsA2MniadqIY7GwgpGejaHXYfBcO/77hXERcWCmBB6oBAwrABDQBbr6wS+kCRQciGWIgD6hBIqxDCU4AG6jibUgw5DDjkDuWYzEFHKZkX29ABWTAKhkAGgKKEugBG1akIqzDHIKJNB6AaADPHfwHHm7Hkh2JEggA38QGUmncFgeX4CBVTYjhC5eOa1nAII4BA0jAaeFgxkEvjIKENPr8C2PAs5RgCHJLS0mjn+S1a5DNBAzgBO4vybvUOj4gGHb7NN0HDo6h4yJ3G0gByahOglcM0H4jSGRhD5KuKDDAxgbCBA4oIS6TRlnCCOyIZAAaAGgANsDBAUzgHr5B16nGOrABTVj3ks+zBwxAE8ABbmIi96I0Kf+IoRoIIBgIYE4w4AN0dsKS4gGKAGUHIgGUuxoNAAncIA3gwRVwBwDMgaHQpaGQlQU2wEI45Fg7QAZYgAfenR4AjTSeQAkAclTdhzx7Aq92TS8CQxZydLaC4Rw05n2a7yTuxR649k3qi+7oDgCgQQkwQD+b8yQz/V54kGC/9DpqvFXxdEj6Y0Cp+uP1RYLVwAl01OA14hbyhxgE1qYObWqqpDb380isZh0M1/ygcOmcgkLp4gDUpiiKIdm9R51sg0af000UQA5wQkgaIBl3AgHCx11i4ELYAQVKZCAy2ustBOzFHs63VCMaJeAFlAWrQge4IeRckDS+QR0oiwSO4QD/QAFNxsq4DaIvVVDtd6Ik+nM7BGYSq6L6AlI9mQQWPkIStVE9acEYkkEZWLFjEWM7R0xg1jzLvyb3YEMWjp7GMcWS53zwK6IWbkIb+V0nGIAd3mlQLm+ie9fETQRcHaXgG18FcxAazqgomJsHFXQuWZMRs1MeC3Q5Pp4StAD4JFQ4SL/+eF8hdBMofIEevoEA+J0Z0F4gun8hwB/3nVE0PUMui6M/UyNA76I6HSLpAt+FavMvDVQ4rH89eSL38dA2heP8AQKOwIEECxo8iDDhghKwEjp8CPHhjoYRK1pMGIuDk1kXHTaSVeuiLVqUCgaJ1TGlyjYcVbqEKAtPmpc0/2vaPJjFw82dA0Wh5HlzoSygQRkStTnxKM2MG3eSDGnR1oWSBE8qrcnyqsuYM7V6JZrzq0qfYjsKLXtxIUW0EZOyhci0pU2SaytaGGXy51uIWfc65Oo3MMSwghOSLXzwLGKDahcbdOtYYNydFihRrQiNZN7IBftyBswZMeHQcA6HVnzaKGnIkSffZENJb0RYmqvK5uzZoeWyoEkHHh3aNGfUw1WHZu3Y9VxKdSFCm7rZd+6DlneL7e17L3DOwhGWvDwQPE/iKsXbbLzTvErki5VX/C6epHjr1O9G3/sd4XSDlp8Mya8VJTKpl91X20XWHX+UKKEAAzhYRkMLCcBh3f8HHwhEn1klDEVThucZ91J1BHbEHmLuRQQNDR5WNl91B2UmnlV+UcKPhwLtVxAlvZjAADw2umTZCOAJmMaINm3wzTf0sEAQARsctAEKHaAQg0AEuNIBPUSBF5aRFLpIIYZUmSfikC1+KcqIu+GAASUx1IMECybY4I4zNABgBBwAaAINJTQU8KOR5CWUH3znpGAdfWDmCN+XAqHnaHhmZkiJEEpsYKakYc5HUIlhhpejmApqKtA6GH5K0InUEfSACg9kyAUlHIZHAwlGUKJOjbvNQhINcKyTAyVBDHkqql4y6h0lObgihHiwzNKGLTaOyYASlChwLEGchpcAOk3A4UL/sJRYEo4si/L0DQob0AMFk3AwgMA3BhEARZUbsFMlMzGw0AEzKZUJJiVLQGBZTpb50yaZlvVCjwmWJeBCdREYwOkRJlgLsGUQ6EoJLxCokYyC1ZkDwoWWueNAxJRAkEICEaSQQjDF+MPMN4H+CIdQSnAjInWW9aAxEpRM8DLAPdzas6S+qANwziXIFnDA2Dj8JSXY9MADBsRgM6aIwVRHwhZD04MoeJ7CV10wDoiZdNO7WWZOAQq02YsPBICnqqTpPEGwCfTw8IEKlqXQi2VP5VgNCQlQwowBEUMAwS0XKDACMwU4IKwOJFByAAriZnxusgT7TAkApZujKCVthF41/yWalETAEupV58zbb/tycaIFbNAmPdycwwsf2ljGQDGWLbHETkkK1MGTPHRQhAKzCgQFAQPJIANBy2t7Kn3FGKCJEcnw8EQwIzxBSQLZpOMkAwAg48GCG1zKg5gQMGCAEko4oEMCCZhDgAmU5ADmsFiwzGEA9LlDE+uoxv+SgTICBGMDD9BEApTAAAYE4wB3YAAvLAMoCjWhAE2wxwiY5qiuVUcITHuCA+ChjiZkqhioU6FlFkIJc6RjcU940tCCBQdmPOADwShAAarxAAeAgweUUJsSvlcMBxSAGR9gRgQA1R97PIEADqDY/wjgA3tQYgF3MMAxLOOAajksGRNDX/9JkFCABDzpBCN4AKYo8YETuKM6cqREE7KBDW7QowfKUEIc1QGBESzuS2ngxZee8CVfGKAHD1CCPZKBtWr44BgGMAEAADACMS7IgUo4QEk+QAITRABrlomBA05AgAT0AGOW0Yi0SuLG6kygB9jYADg2oA6mUUIZ5TDBEOZHALpsihIRYMYxSFCAIfjiAAzYwAYgUIdb3OII0IgBD/hAjyZoYgMN9AE9mPEEJUyAARHAADN60IMI+KN1FHKGPyxjAAK86gn1g4cBmoANCd6RABEIjz3E4QUDbKAaBvBRfwAgBGZM4D8UYkbSvpQOBtQjlT56QAL5wYx1bOAJxagdHND/QQMHOKAYDzDdHQIAARZMgATHMIK+lCevYyAgBjFo1/bCgwCCbKADBGHHk7TlIss8oB4qAIcJR9AnGpyDcSw4AwAwBwdbnMMOkDiBReEAjQJgaAItsGRSP2CAHCjjHg9Ax8G+wYMJ2KMa2UhBxD7AgGykCEKts0wOPiAKBtROExF4XQwYwIITlIMfHXnbA3L5NgU4gGCuawEo0nHDEjBuswZwQC8cMALUZa0ALVAGJXTAgp5R4ozwsEfZEsCNM07gBCS4BwgwUICpHqAcE6gGJ9GZAwEYAQXNwlal0FEEGlyyBREggAwidoR7+ONQpsRQAu5RDnocwAHoSIZfj1GN/zKBiwHZLUcLBgGKNqnUeCZghj0+QAkMQDVY/EgBCeyhAxzkgAYjKAIlCIA0t5KAG0awQTWY2CgK4bWCPvCBRtLBtBFoAglFKwYE4BspDC1BB5axBQvMkKgH3KMAZ3xGeC+jTVrcYiC34AUgzrgOy5wjrSwAAcBykIP6UtYELSCAM/DXgnvsUcLVqAYBnmEPAJgAWLuBBs++hIEDBMEeOGBBNehRjnqYQAH+QMETVPSdUIqIB0fwI9BskANwnMAIofwGCR5EiXMA4B4fSMcJKGGDsinAGW6QQxMA4AwckGAEvlIeOzoABQbAoQP1Wx4zOtAvOCBgxQIZ6kBQkL0c9f/AlMMshwFwgOEPnKN16tgAnMckh0ocQAcYYsATntADAoD5MgADgCgpwQIHTBUaKWgW29A2pi/BQhT8IIES4cAnApgsW8iiBDxSgMQEKAACRtiaEQCAAQcEgx/rMEGwDCCAy8KBHgQ4wQfQAYActGkC8LVBoiIFbG194AC1s4GPKASNBGAYXBggRSdmwQ8MkEBoEDqjZWwAgRgAMWAE+YAvmEwJFywzqd/hdg7WYQN98OIJDLAoAWP8HVFXDVTVYYE5lPAlI0xgcUkVVZg+kIAjFAMcY1ADBjZgDh644AEQEII5EtCnYklKRLYIQTmaRQkc3JkqSjhChimhYkkFARb/bxMVsKtDA1mnwwc2OMIDXAAPxlpGCEigkC8K94FZDwQJIzhH3JxRC5Z8Rx0x8AHGTwvft/kjGAlggDlyXg13fENlAmFAC2QHD3eLyAXMIIHKqkNCN6SBBIJbbdBxShBId4Ad7PDXQGQBhaPCAXsCQQEKvEOCCQDgGRhLySxyohc8GhEc2aJU18YSiyPIcJjoEH1NIv6EdGDWAPXA4gleRZUNnIAfICiBM3y0jgIIAQ5ppEQxQIDVsmQWbZGZyPGYbRGcIWQW63ADJMD/F1r8D5rmoKhDeFGHGN0GIpbxAbbF/x4IAMB4N5JLRKzGAEgDB8rAaZKSDThzLpSwAUWQ/wdpkAAxgH4W8VPaIy8FQS/2gi9wYHoO8QF9EnQRKBCwRyqo8hDbgn+GgRJNZjMgKDKbAg0XMnECAQ0bEAx9oFkJRgnQQCHn0Ccs+C9jpBo+eBTel2E8EYGUoBFCWBDyETFFeBC1YAGbcB/v0TQhInRwgCOEAircQ3IEclGUgAQHMCBawQyeVxBlCCVSQiXMo3mZphQH4himIV74gSSDshiQwhmeIhh5oxIschG8UBsDISOkkYUzYhkyUSB+AYeLkSAkiBa4lgB2iBh42H3N0R4a4X80wQXQYAsXUQuBKBCDGBqFiB9wgB2JWBaLiBiNOIkb4huU6Bh6GBh82BEjcf+CORJ/U4gbmbgYp4iKBqITvsGKhSGJxAgilUgatNgR8nERlGAftpEdpOgXvviLWqGKhTGMglGM2niMsWiJJoKJlHGLBAEjuhgZ0rgX1FiNbxiMpJGNgbGN8NiNiyGLfqGMFxECnOiJoAgHoriLpKGO6wgW7Rgc83eHrkgasEiP31gY91gRsXA4FhELWiB/0ciLiBGQAskT1ygY7+gX8fiR84gY9bgXDlkRymQRtaAFeAGN0nGRhZGRGnkTHBkYHrkXIHmTIlkYJPkWJhkRfmgR5diShPiSghGTMlkTNOkXNvkWONmUOikYPMkWPgkR+ViUB0EbFemSAImISHkVSrn/F0zJFk45llAZGFKJFlT5EMxoEaNAkeboGOj4FkfplS4Blm8hlmhBlnppln6BlmWhlg4RkRUhCysJl4shl2xBl3WZEnfJFnlZFnsZmX25F38pFoGJEG45jgNhi4eJGImJFovJmBfhmGgBmWIhmahJmW9hmV+BmQgRApuAflCnlUTJlV0xmhtJkNxhkK04PZGhkCPJkHsYjjYBkcxxEbIgArU5ilc5jV2ZmztRmmVxml+Rmta5mmzRml7xmgfBlg+pBVAhiL35mc6ZjtAZnTYxnWJRnV5xne6ZnWixnVrRnQUxkZspEFnpmYUBmryBnulJE+v5Fe2pFe9ZoPFZFvN5/xX1WRD52IkWoZ9D2Zy3CaAzuZsIQp7c+JuOEZw7OZyzWJzLgX7KyZz/GBqiWaEJIaBeQaBXYaAuiqBioaBKwaAE8Z2zIQI6KKEm+hn/maKNeaFxmKHyuKEH+aFneaQlGaI1QZHo15k7eo7mOZc++qOkGaSMOKQhWaStmKSV2aVTuaQ0kY9Zqi386I9RSqFVapdXuopkip818aJK0aFR+aVpGaYvcaMwsZz7KRj9eR1UqqYRsaJaYZOsI6cImRp1Kp+Kepl36hJ5+hCywAXiGYpkuhd++hUoGqgDMahX4ROl43TdUx1PwAwpIErYuaXGyKgyuqrc6agpMQrLqSZtE/+IJTEsAIKmJwqom+oQnaoUnzoCnkUhyVBHCkgAPcACQ+AOBuALb6ohqcqNreoVM3oUNToQXCCbhFImEWAOtQoBfCBRzuoVmOoVmhoRR5AkSXIESKIk7gIHBFAlBsGuy5OuEziQ2ZEm5BNEeMQAlOAACiAETfgd3JUDyHcUZAk6bEOCzjqnSNqMjhh+VZgqr0oqhmqL8RYeBKACU4UBSuACIIZy1hcM+DA0ITOhQGKojGI7FPIqBGGuELEBoWdNOpAu69IuMSADCFAMB1Gz1gQH1rQBBBBUX8mmhXEHyUACwRIDCqACeecdtRIMJgCDQBGPlyEEG3CA67Nv6cMD2DD/agMRYyXoA1PbsKGiFJeBlurQcUNQHitDCb6wAelwRvYZourRrBjCA8eAEIejMZgSHgYQA+AQA3dDCc4wN8FAAMwADSfxAW1ysuXhA77mHRjiC2FSZpbRAiPgsrv6EpY2ENvTPCxQDKHHsxVYEAqgAPQ3h4JatBELJOEBDeFgBe5AWUilJnDgDgdwsK5YdRQCgf+lDDGgBN+QABCAAQyADgWwZQpgAvKFDtpmAuBwAApAAjKgLP+hWsXQcRiDQ6urKZUyAj0gENYycRmzBA+CDez2BLT3HQCgAPmjDnCwAxeFIfxQONVhQUMwAYXTV24jIjnwDGEjUhNQO2XCAWkA/6+W4V9lAgEgsLOck0FJ97syKKsUogPkxADJECw+IEO+IDaUMBKd6AwwGASd6AAsp4S2q600Yjwi0gb+UAApwAxcYxkfUGb92zokADTiVR0Y9F8pQHsH8Azw9QDFwAz3Zoqc6xL3kiT+sjwsgADOwDy+97kdkCSiFwMIoLcJcQ724CPOIATuZhG+CgfwgHIp8QEQCAf+oAnmAA6iQHUsSAkmsLtD4QJ5dw44UAzP0AQJMALHiwEspwwqkg31AwfCxEwPoA7FgAHrgAOyRALMcA5CoAkEgAQQ0FIu4AwOYA/uQA0CgAEfRMm6WxDzdgwAUDw9wAyJOwIfMAT08AQ4gP8Dd4VnB+ACDkAC39BxRzRzNvCvFuUDGLBlasAAPCDLUwsHH6BSAGAACXAALawEkxRxuqJbAAAxhrIy6KADrdxK7rR7/PABHLANxYAomsAAr8IP9cADPsAAvmBBSqACOdAL6JBBG/C1H8AFHwQHLMAATBMDKgAAcBBKosIr8kcjE6AA/GcTeFQjhPIBOcAMOccPstwLfJAC8nQE5sAMCqAJjQMBEUADNcIPpuRwTUsAMOMC/DABKsMDYKYAy+oO8NAmBWQAE5ACnGRaAvGyDxGz1gQBcPANh5ZoA9E8AvE8HZA9PRuvGpi6CgIO3TJTCpC4LQBZD6GUGVM18JC89/v/AeYQTAYnXjngAjSgeg6gDglDCWkCsf93AotUyqajEjik0pgDDypAAq+yDiSQ090jdIFCIRCAAxorOPvDA4tUEgQMCAGwATGgDoKDDunwgu52BNxQDJszcv9VfRtAArWlAGeQAPVQDCpgPTkCACkwOmIyCxORAJtdNpRwZaYkBMqADQ+gLfmDASpgABCgAglNCU/gODZgDtUgAzZAAtVlEJqgVirADFnAB3O8DpgVz99gD53EalZzAlb3BCDgAgagAvJBzmWCLQ6wxZ9SGZuxGxakDiwADRHgDupgA+ogcakzEDkAZ3CAAdzQAgoA11toAwaADkzUVps9AYagWpvC/wAxgA7PS9n/41kjcDdX1AAnUA+Vcg93owS0PRD3cAT0QAkPQHBwcGKHWCQQwg3uhswp4bkCYa+LRsUqbroCkcXjjVT6mzEPYA9xtNQIcdVSBQ1LwAI6sAQnQAMHgDU5AAAxQAzE0AQmYAITsAEjwAMRcAz2kAPu8DcAcDc8YAKXR6CU4AMabhDMUA9+axY3YAIEoARYTse/lsKgo1rVsRC8wAwm8Ls5cMIpoASYxTr/5QNVRwn2QLiBkn0F4X1KZQ/K9wQRcHWSMgJH0GCBbhn2AAHgEAFPoAzW/CP+EAMn4AvOMAjWAA08wAxf4wPuoOg5EEJOaBnEAAFjSwvuBf8OnxIkPkDmAwEL2Sqh1mcC5QBHB+BJJEAP0kdrlJAOEJAAGEAAh85zaTMh4WFNPXC/ALM6yVId1VBmBPUzd3QCEFgPOHBNvZYCOsqyNdQz7tUEIP0KfOBGMYM56UATKQ7ULz7FpVsQKNDU/8ID9NACBhBjLhAx/A4PB/AxYZAMH8AP06eylJAC6DACKeA3IxABCuBWrUZ7jBLABqAlD9GicOADQXYPxABfEPA6pgN+lDALl0AHKby70qoVrPHn4roTsJCElIBFNLGc3zgBGu0sZmqpFFIPUlwdGPAABUC4cHAAMhQeE/AAU9ULBoAND0GuCKEOLdCvlIACg+4QMVD/BNnwBNVgDg9gXNjCAAfQ4hcBAW4YRGYIB0eN1GGu9vziro31JQnQ0SAADhhgDt/ADMGbBZUwARiADgYg7gLxBP6w2aajeNXBDw1NTwl/LBtvHU9gDhGg6JQwBA7DbJQADqDgBdlRtl5quyrvEkzhvSkxqeoBD4mQAw86EMfJpwUBD01QDq7tQD14e5KCBPRQBCPwIFAvpRXxARtwwxyW+ZbxDXeQBr7ADAewR8XgCjbAqzIXtAlwDFMFBwaTADxgDi3wAC2gAiZQDUWgCRBQ/Y/Z8/TXAikQHkPQAusQDDKAdItSHbygApIQo9jJ8ldBrURhrQABBw4tSpQEHhRI/8kEwoOU6hhEGCQWQ4oUKQ1REKEexIoWP/DryLDNrJAlTZ4smQBZGhwkGMSg5GIdSpo1bd5kWFAnnJ1ZPCSkxC8Bv3PqEtjAxrMgTqZwRE1sWpEGPIM6c2xIZiMFJR8PliZ8YI6BkQUlOEZFW7EsrLRtKe5g61ZuLA5OSLoleLah3oSb9ErEuZNvycEVR8qVWytIGjgjRkD7iljyZIY+Kbd9erkipQnODJDIAdTHN2xC4JSVpTnqWtVN4bbGSdeuXBGRUVIiyBAwbJyHedeUhYcxvNC/jeO0fJxm5t+UNtD7oAQDJSGUmDn4ABG1cpSsuZt8/T2k7Ltt/0C2CSt3RP+o4kP6dk8xeBrb8e0nt0+ROW9KOdQVNCCBEaqphqHt8jOwhLgQPCg8BuEgTy6CFkRJlod0a+9BOOBjcD4N7/vpQ6cyhK0qSpRIxJYCEkgwtQ+909BBBiPEixIXaapFlhsF2u1DDhH0UETx8NNwv70KQ6w+gQ7UEMYHZUSQxrZqq8Um3P4ikcEf8wtSSO6IfNDIhHxhAUm3lDythB0ZdJJBKPOTMq0/ajGTIvWwFHJL+7r08jgwGRQTDgjMcaBOzZh8sE0E37QvTrTyuukCPEXUMz4++/ztT6bQbOopnSg5IIFqKCEgAgiUScg4RNlUUERG43M0KoLWNIkSLtbsUcP/St27VDMZOgBWBh6ADRYhYomF4xsogGVBNU0DswcxTwtKYAICdCKGAAaw6YXTyVZFUNESzXzVvVib0sJbi2RZ76BcH9xVvF4v62CDiphBgaJvvjmIB4Fk4BehyAztyKBnN+NJqVQ3MGGIwT79FCiOChKlIAJSYMY0E3kqwJwUnElVM0rKGsEcSrySuCGlII7Yto0JXrJVmiAycaeEN6PEn2TgKGa6lyHaQTCBbQZK5fqqyokSYigpJoYJiIawrqWQzknhvRjSsUqrP3UgGYiUcADShILg5wm+ILa61oRpprlqtm1pQ4kTv6Ia5oKpNrptOOalrF6KWGAnBn0DPogF/78RIoHuie2m5OChp47sHHRY0CTic5BgOfO9eAlAAQVycOGDkChJxoCn1W2qIFgWsMIHBzTpAQUANYFAhsybyFmBHtBGmuWaYPRF9NEpKcBzBUBwToFrj6YEAgVScKeHDYLx2fegI16ZeZsHhjqhCdwppgcGRlCAGIboWiUCtB//VBnsBRI7c0rQuRaOWx645QvP71Hgg1nKaMGo9EKJBBShIF4bjDPkthdNGK8Y2WNfQWzBDQWogQEKwIArluADBSgBBIm7WfduQwlzVMcfBoAYBP4jEL5NpgPL6oC/BPKNfMFhAzecIeHgMCxXNAshOXBHMAjAg2CcIBgxWEIwEv9ANwgWZB3qOIAbLpEOGshvasQ4gQnAQT4D9CAYTwBA5UCQjQSAgxhK4IYDSOC5CZzgBA64jgkYAI4geo0YG6iGHXiBuoQloBjHgEetzjI1gQjhCBBTxwnoYY5WwEII5oCDLwgAACQkgABCYMY3znFBcJDAHCRAIQYIcI8T2KsXJ+iWEk6gjBNowmQ5CEZ2hLBAnfAAPQu4Qx9sQQkdmEABgvlUMDRhgqUVhAcbgAABPUeAlX1AHdWoXjHkRoACMEMBoAjGBhjgRTT0AAMKIAE4nvAEFzBgAyQYwQH8AQ7IPGEDBmiBV2Jwgk8pAR0AiIDEmIbK/vEEHiM4gRGoo47/dfxjGwCAgDMwsBWaPaAFCgBAMC6IQc8xw4uQuZJOIMCMe2zgAN8YggHs8UtKBKMHshCBOiAgC0qogBkC2EMCWnACcLhAHUpQwgEcAAEHgEMTmvgiy8qhiXWAKh1MWyIloMEACDTGBNk4QjCUEQxwuJEZD7igC6DRhlEkBJS+YAAlwAGAA2ADAl9kxvYKogR1rCx71owACXqBgWRMkhiaIIEmUMgTWAjnfYKTzOEOcgwEAHZfAdsXRfCVtCdEwAEPYMEDNAGCJ6SjW+ZIhhDcRzpKsMAEJGBGAVowhkHkdQksO0Yv1GEABRSjIM7QSVeqR4kWBINpGICtTnAwE0RS/yIC30gBAz5ghIrVpCATAAEKkcQ9nRhACKBdygVNoIMPgMILE0MCbIHSC1BAwBc5KIgyMNfZgthjBCqgwQjugQFf+CwBJ2DABCCASQcUIAcQQMcIHMA/ZmhCACQgAA2q8QS66sQIT1gCax8A3qtBLhkKaAHpDGCCyg1wvPB4QHYS8IAAEOC0lDhGNQoACh/oxB0pKMY9yoG7ggTDAdWAAD0K4AAFVBgACjiATiPsjvo4gx8kWGgRSKAGQxDPucXABgEUYAIjjIAS8HBAPYS33QdgoAATsIBOYkCPgsQAYwkAwDkiwI0iJJUWFNrDK2BBCSTQwB70YAAGAGA70lUnB/8PqIYJyqSTbyRAE/7QxAYUsMSGnGDJlHjCVTGwYJ1sIBsQ+dGn3NGCDRAAz74AADrRUYACqGACS64wBujBA7EqgMcXMYDJTlaNHMTACNkAgHUAYAg1qAAm7lDABo7pQnshhIYdSSxDCNCBpGWvs0qAAz/SsQFi9KwJG3hdD8DBghzkgAdL8IksIFBKcyQAAhuQXjpOALK2CW0pQ2irW9XdMjgYgRihoURxZ0aJcySAGCOwx9l862SD4GAEAOCHAZwBjgSkAwBwMIcv1lYKs7APKE/AKOSKZg8dMHEpBxgCHB4AjhywgBg9eMA5ovXaa5RAUAAoFGcGZY4NAGDcG9P/59CQEIxi5Ps/D1vfDmaxPbPVrCDEOMbUeCC4HBDDXzZrQhN4MCgj3ExlyVA4JewhtaXgABxHgAMLTkAVdV/tAMQAwC+CUYAepKNZOnlAx3TS8yvtJQgTw0HFm25sgShBEyJ2wMvfi4O0rc3ng/zKlj6V70/9sRfnIAYxXACBXsDhAADYgDN04ABqArOJlFCHCW6YjUGEwQUYwIDZvFkcxAgWDoQF7OAO0gECEAAKzDSu7/zRveQUBNApFyFvAnUbIdRvaM4gH9o3oATHTs0HBshGi0TUJmhogut9HyEfK1Iu8ZzrJgWhBQAK4DCGQKMIaWWILSSFIZzYwxk+QCBl/+J1fZpxQ/rQSAA6PgCNPNBnHc84R+7TwozU75ABIcEhgeCBfZEhKxmgwcAPl5G+ydi92wAAVQMKGkAHRHMAIdCmgkiBo4I55XsRmbGIkGE/16CQKKmL8kCLjNqMRPAaihCBrmKPwICN9YuKBZyavkqDNXM6THGWEPmQBryNDSA0OFCHRUs5CCCADWgZMwGX/BAX+6C+77C+mxiFdHmY0+m+duGRLEEQGVSOFtJBynAc9/DBk6A3FfgAEyiASjuDKhoa6FMLNVk+D3ySEYSTEpSLTUCPmogFLISDd9ESEwQS4fhC4whD8RhDlDgAFWABALiWoEOLJbSPJoyPJ+SOKP+8CYLQGpoQv0nxEUDkEkEcRN4oxO84RDLMm0eEww6kw/ygROWwRJsQG01MF/KjFE/cE1AMxdYYRe4oRe6AxPiQRPdoxeN4xZrIMruBED70wy20RUvBxVzUjF1UjjFUqwVsil90j2AUj2E0jmKkCTZgqfRQRi3MDy48Di+ExraQxuPwwYLAAchxAWvECWwUD238Dm78DW9EiVhECWgYvxesxQ9Bx3REi3U0jjF0gUQYgioKhntQAWScx1RsEjl0k1WEFTusEYssGAuABlrsRIF8RoKUDIP8jTEcMOC6hwKghBjYAoi0CXr8DnvkDnzkDX08iWO0knHMk2bklZCkDAj/OJYOkAE4cAUogIKhNJagTBZ2KJYk+RSSnEHN0Y8MoYQPILWCcLIyaYhkAAeXrBUkXAABUIc9YobcYkIPxAYuYxt9OqQj2cCoYJT1GZ6rwRl1sUmL2AlwPMAzQBWLyAvOyI5lPJOoMEfjGEi5ECwZgoJe8zXCCbYZtIjGcwYTeAKfsAU3DBm9McW14YFEyI4jMIBjYJHFEYXLpBkScIAWWIcW8AUFbAHc+cCmyIZvsAd1sIJyAIARuECCYZyb8I75KQAQggMDSgj1SQcQCEJKcAYHoIFyWDAynJi3iIsB4gGV1MybYSakYYZAEhieMAf1WRyEuMu94IEWgIxaoAUg/xwkACgzirAFfywICnu0t2OpmunONiy2g/gGeEub6DSM8ghPojGUwnCZHKQEG8zEHAwsxhSIGGAHH2pM/USBDYDQwNgeJUiBCTCHdYAANXACDEgAJMRLnWABZvAZhsiBRLCB7iMGXDsA11GHM1CAYBgCcAjOZ1CCHCgHH4gAKyAFZojHHFABGzgHX5gABshDhuCHsTgLGsC6phCxamAGRYCGvIMGesiBD0CBYhqdJciOqqSnuhykklgAUXCGnWsJSjAAIygGACOBB3AHcygG5fmAFEgAyDgA/iOqBOAxwtgrntAB6RQIeGCRgwifGHAAYjAAGchDXqIE3cyGAzCmFv9IquyJABHTgSfIgWRwhwI4H4wcnoLwgWNQKYNIASFwhxalBSMcmALwB3SwiASog3RQALNJnHB4MRv4hnrwBw7Kt06rIgZAUh74JYQ4hgPgCSSYvSEwh3LIgVhbSQWoB9eypVHdgNkTibuwihwYAS7zBR7rFv07iMoRmA8gADnlARNQNRYwAk/6BmdIAR0Qjm4RAiSqpALhNYRgBigImBvqtcfMJBlgBwaFAyX4sKLBHkrgAXQ4ggjgByXogdkrCF7IAxnABgzYgCfozkQkAF9IBxNQgnQ4LR8QnILYlgmgAYSwMq9hBhU4qt35FBbgBwVwgCcYAVO4AyMkAXoQJ53/YACzxMtYS5VqUIB4VJuEsYccJQE4mIUwMIsnKJQmAAdlgADXmgmKUILZw5iq3IIawhw4QIKKowSUgwjJe7F14E44yIaOPA01MIHTwgaTgYd6IIECwAElCAZkNREcGKUiONVPSYDkoxkhQFYkEIgRwAA4cIFgOIOMg4MEqLjwYIBnOILWXAdmAK8nKIAPOAAGKJT04tndAQBcSwECgAYZoIcmaE0loAd/SKsEkAFQIIBnqKYlyB6pSRjDvRl/SAAMqA5KUABmYAYCmIAmGBVsKABlyDIMwNYuK5RiRQgWOIP0rIoNaIIAOAdNOABl2DIDgIZ7UIJq6LZjwIB12IIT/wBRpAGHZyiThTIHA6ABHiCBbLgHOQIx0CqCdyKBd7JdgZgFWGiDWjiHJmiBq6OHe2geA3iGHnAHdDCBlhxTmvGgE2iID3iJ+YmwCGjJCQCFQ2KBEfAHelCDALggUGCADL2Hq11QikABZkiWYHvMgxg2hgiGb2CBZICGYmgAaICGJqCHZEqIe/iAExCCFKCHMzgLn+CFW6AEWqUW/jGHY2iCHqAlbvheA8CAGJAcsVIBh1UqBNano2kBvY23WACVHB6Y4WmBlOUJaMCAETgtQXIiS3sMg0ANpYKDIzgBBP4pDJCB5SmIs5oAf8COqvqAImYAAnAya2qAA3CHF1sCBf/4BiD9KK9oAhPIu3T4BhBQEHo4hnvAKHPollDl4ZzIBtsqCGhwB2INBgU4gQcjodBBYkr4hta6HhOwJXBghk1K0oL4AK/YAsjQqk/BKGj4gHPINRXws47UifkzZgKoYVTmAD74htMygaf5AM8xB3QwlW/qH4w65iTlglG40qCryocEXoiBBgPoBVq4hYOABmaQA2iYAFeQGBpAZwL4Bqr4gJbcq4JgBmjYAGYosXhUZ52whyXKP51AYJ9thXsggfw7hxP4gC/9Uq0yZgbYrIgDXs/JhnXQhJXZANfKGSD+ABUgKYnBgx2AjC81ZnohWDgAGNUTNnvOCRQgny0AB8//yVgHSAHIYAYWC0+B8AkTodUaA6avWAcFgAcFAsJH4wxzUIE8ncD+PMCVyQyhAUG8hIP/Ix4FqI6GrppUOQCvIICk0g41+QoGIOkUYAF/GJVcgwb3cx5k3YKwIp5CieQNsAUXQGcak9RPKZ4NeIaWWq+yKAhQgiDC6J6CAADIsAEQECidkD9+2ABu4Ak/QwdlmIUeUANuSITWTGVYLVAUGU3NMRGBFtCNWYdvkOID+IAyIAVKKAcF+M5qKogIsF0rshpbyAvNLYiuBJCT3k8KcgZoyDK3s6Llxid6+wD3iwGzTMK/+xQhMIGCUIAYaAPq5p2C+AZ0MB4SqAcFuIdD/9IJAYoBBSBthTEIFMAGxaEEv/I5mBaIDZhQZggcmoaDFnY92GOfihMYHHjA1jQJInmfWomBpsqeBLg5pujFgokBBnDOhDAA4kjZmDCAekgmSqABJTjZ9+bArRZAGRACFWBnt7xqYztAYJLJm0ACdEgBFWCwoYEARySgL6WEHXDBEboMnQAzPnCCPaqKBHhSnPjLI5jdQuEJAvDdk5kaC9jxLAyMx9sAcPjStIiBESiAMilMljECgxYYIxjeCsM5+fBJzeA/Gf4Geui/gwhAONiybyjA+3yfuilwHkwZ6IRvicOJBxfTr4AAA6CHb/gAB5gAIfAsAvoGAogW6GMSNP/h8wOnc61WmRxscStZ7O6EnE+5HpgR19TRCV7A3eu8iWP0z/447aWABp00wKQ+wbUBYJ7kaklPFR4YFZw4TJFEDjwPE3KMSlouh99tnmpwAIktDJj0RYpcFI2sPlBNixCAA2b3S07UFVkHda/MdV23CaiEDT+PvXW4Sp2YAA3kFGRXjks3DpqEjfEMiQmxiVFIboD8yB5nimzXdprg9tbw9hP89DShlbOU9nsMeFd09keRR1iwgE3wyGoHSca4d8TId9XY918/CXM/DnT/DXVvDXbvCJysCV5g9Xl/EHt/+DsXkomHDYtXFWVnxYEnxoKPCmhHxraTd4bXEJIv+ZD/iHjNQPkIcguV/w2M5w2NVw2Orwh+PAlbmMWaPw5vKczfwPmcr4idv4yeR/Gfl8hEYXkndPluhPmmQHqTQPgo70NfV425eQ9r546ol/rK4HVAMftQPS4GOAEgTgug5w2hhw2i1wyjhyCPj80rpPbj8IW0Goyn5w0PofW2PwmqpwyULwgMEAtf8IUEEK62wPuU3/pJ7Pp8/PoR6gFJhYMQsIUEPYhzMICKuJOFPw7WKgzEhw3FpwGTYfxZ1wkmO63aU9AR9XTFQQkjWXygaIKu8QFA3l7MN4sPsPsQlD7foQgn2XTKmJrrnr7Ov3ZD8XscqAd+Q/rj2ogBqg3WZ+zF/9lz7lkZc8CGesi//2RsdjUbyegeGxQCHDAAEDCNY6j9g1CGapg9gMihyZyDES0eZPEABw4LShs2LIwocWFDShMvLqQE75xFODqgYbwoKpZEShVDwvkQA90DSi47DiGAcubEBSUoJUDRkCZGlzt5enQJL8Y5jDZhRTSZ8RiPjkCfUspWDQIJcC4n7kD6dOtFl0JifKAZi4OTWVwnmsDh7oARWpS0JqWUokDTibG06JgYhCRUEvzipkugUTClHAc6QlOHoYALShF6fKDRxKnENmZRHrNnYsQZIWdpDqZMCdOYcuYIUCKAIcWBz09ZPHwYMsaGGK5Rutxw5EwwdMVUhP91oSCPk3MH6CkwAW7iVZcEiqjD8dLiS89JTRCgMQQCvQlDvJpLneMlHEojp1PqAMFGT0oYGGTreQ/997NHa6OmJIR6UsLT13GTQAwkVOMUThu8xEA6lPCTyBKUgMOAVaItIAoNL0XwzRIQjKCCA/GVR11zLx0DgRAH+EBZeToYQYk6QjygQApC0PNTRFllNJ07RaQYklfoTZeMVeUlY04KLShxVUhjlcXcdOoYAMCDQBa4RD0o1KFkSQr0gkFHV0FDSz2U7YUec+dAkOQQKDxDXgHYuJMAATK4NAIG0FCyhAIyEKAEA744sNAHKajoUhsqJqXECCPY4JICWpbkpY//xIyAHg71qIAePJpUmpQPS1Rz20QydAAFAg10wMMG7HzT6kUsdIDCNx3IEFEMCIgKR4rBUEKDEs5QwtGKagxCggMvqTCREQ9EoAkGSnyAwTc2+KLJAwuBcw86EtnQgw4pTJANJeYAgIQJKkxgQhEnOIfOE+cNgY4LxcDjzLZdpUYecy3AMyc09HyDKE02UVLgo9iA0gslB+RQHj3suocCnszQsAUB0AAAQVIbEBMBJQ5AgKA7NAQMACXoQPoBCVaAYksMTzhwTDUT2MDCB8nCEQEGcNgAyscbeFyMAUhokoA7hZYjgxDPPPOBDoIppiKOcAxBpzPc5ECDDAkU0BMz/0U4UMwESLjUgi+UyPCECS20AMGxlDAjcERMXpaUx44xKoQCH5RDyTqJqIBNfpTcEogBt8hSUgwMpIbDQtjBAQsta0lUJtpDdGWAM0+486gDEZBgAjpnQHMOAwYQAAEl3OhwjyYFvtREE/xQl/pEzDRAhi0hpYOBPdM9KnAT9HR6EQ0YZNOUCUf3AAEB6NCDjnRbqJGGgZDmulAxHewOxwYdoCRrRB0wAwczHeDaVV45diW0Jh6jlAUpH1HHgglXHVBNNd8k0NpCNDBAASMAxwkccLRiPIMBOuABNz7Qq7CUhxkAUMcHEmODexjAAAmABykEQIlnmMABwdCES56Agf8IOEMGD9AEKHwwgWTIrVf1KMcBNOiPCQlMRCECxCAcMAE4JGMg5/BSOUCwDkoogHFKYMYSCCCEYzUKJ1ECgAlYA40UGIAeTUwAoVaYJAIEIwLp0IFhGHCJTiiDGS2oR2MMdAQSNEEBwegBADBQhAJsoACaMFlElGACslHCHixogWk0sR4DRYAbMKRELYoxBmzEwAcYSAA9SOiSB5iAAcqgxAPuMRkGEWADwdDgNwDAAHOQ4B77UYcNaGerLThDBydwRgwUsB9fMOMIHNCHflSwgQTkYAQF8KGxFmKDBgghi9RSgOrgIItb0IIlF8KBDigBjRG05nioFEIKEsAMCwz/QYLqWEgQchODFqCjCOioBxKa8IQnlOcAhHJBCk6gjnNE8QAVrAYAAgUBnKHEBSizyBKcYSoE+IdXvehFE4oXEQOMJ0SUeAIJ0MEAFxgBAyl6yQMYcICjTSAdPYhABBgHDRrEwAEA0EQxMJGG7PHkexFZ1TfKdxEEOCMizHBFRBCAqAScwR8ZQcJFgjmd+HlASx8YgTnAcQYDEKlQXjmiS45BEGYgyEwjGhE2fEIHajxgTPt5iQ3McY90PAMaQjhDeGIIJErU4zA5xEA1jQmCEhwJPSQwxwYcwIxeZNAXBjjMe1r0pYj4Y5GU8McTKIEEA0yJrN8wAAYI8A138IBg/wq4EKReooxkCMEcLLigiLTkEmsF8BnpOIZEr5eDAiXABAe4Bg8YoLS3riMHDOCGARyCA02oQGHTOUdT3nq9LK6DAe7AgWxRkw5TbMMezEiAPQhAAhj6owfk0erdFiILWiTAANU4hzm+YYJv7Kw8z0BHpfT2BBHoAha3CA8cDCEDXsQNA0hYhwHMwYANkOBLRzXuW3GDxKto4hsIWPATUFMABhSBHgaIW1cCVR4kBOMZLgCtReyBgSH0QgXnVcIWqLNIcyjWJTF4gC3w8FKYzkSmC4lBKF3B0w20CiLpW4iMb7FjicQAsDlQAgZPUA1/bAYaBYAHUBLSFWzQ60Gu4f/BOG8TAGE0qicxcIoSIrqVPLmjRU46QIcOsGUcbKME9shyRBxQDumkAATHgFtxCzAmGB+DPTHYDxyOAuOJ6KAHSlBCXWdCiQKAQxPjnBpubLaQB3zjAS35c3ncYYBZiIMOZGiBAtiTPS24pBjoeMY61CE3OMSAF7S4BY8pYQs1QIAZDIgUpQ18NEqk1BnoQ0AsOLTZAkQAN/SoZgywapuJ2GACLTiGOpRw7KfIwsW1xoiMJ+JT2tQGDghg7UJ22lNWO6kA6PgkHA5AQiHcw388cbKT9PUZ7HFFFO4uSWfP4hIdTMAecYEDD1RHiRFkshwE6+zbKJGk7c5bVEq6ip//p71V0ByV0QYuDxw+eep3T8cNZYH3Z0IADVuYycBuWcgEDhCMO8ziAaFKyrRxA4Fgeyk9C24txyMCM3NUKuFa5Uq0X9zymYKPIjNmx0XEtxDyLcTHPlJK9tj9c1GN5OklWYcKitAS9xRAJhexSeKk7pqGe/0sEg87UOj2Z7dc/CKyEIGImrCBf/CF7CFxQTVGgCA47BouQKFEOrDh6Zb3POzVpkcHvsEOm0oEVrKiFY8VDAKI4AumTpf7U6Ie9uYU6KMU33oJuk55oID98zQZu+gxYnYYu0XvPIkFF2rR2r2U3kkAaBjeZ/7lo/488F7XgcZstQEWoIQ2z8Z2tp8+//nYh8TylF+CCTCgbs57HvlGKYHqpS8R0lsfDqeHKahdv5VajLxycc/++BZc/ezrnvzqP7764aB8uSOxBafmevslEvr2Y9/6289eCEDOFUqEX0TAXv3V3o+1X/oRIPKxn/q9H9lRwsttHvQlYJ9R3wTmn/TtX66gHVfwAtvpxfipX94lIAJOoOgtIPk14OUlnP113gTen/pdIPJloKhs4FbIAhdEHxwMYP3t2gSSYAlS3glmXwqSH/0l4AuSXwzG3gy6hi2w3fmhBPipyA62nwgS4A8CIdkJofURYfYZIQEiYfYpYekxoWuEQAQCheRMIQiSXw+OoLRloQkqxAR2of/1fWH9haH1jaHoleFnuIX3PcUoeKD4JaAV1h8WxqHUbaH01aH03WH75aH07eHn9eFZ1OBTwEIjjMIHFqLtXSEcJqLcLSLyNSLyPaL6RSLyTSLlVSJXsF3aTYQUcuJt8IArQB5OpM83QAEUPNuo8MBC8ECtHJ35vaHPhWLYjWLslWLsnWIRVmACrqLcteJW4CAslkQAkhMbbsX5QB4L7CJD3JgwdhuqbQAPoMBCoMAvDqMBqh8iHuO0JWPpLWPpNaMXPiMBRiPZTeNTXCJQyAKozeJtfAPkpQr44NjRSYRBfgPeIWT5IQAUSp87viOlxaPozaPo1aMd3mP95WPY7SP/UPQjT1DCLqxhrgwkHNADFBgeVi0kQ46P9ywkPRAAAdBDQnriIYLiRBrfHCbgRX5eRjriRuIfRMogWdRN9rwiz2GjDmrjVpwktkEBD7AATwWjREABHFgWqtlYLxriAeakTrZcRX6eT1IeUJqiUMIgUS6hUf4ZG+CJUpbkbcgAO0AB4gWdLvKiRKBABxTeQtjYRLjhJxojWMIjTxIgWcqdWTIjWiahWpIhW6JezYUENFhAXPIgMQomYe5kCSIm2SkmPTKmGDomH0ImTIUkaDRCDlJhCN6kVw6mZv6ZWFJeZ4bdZ2JkaOrhaFJiaSLlW/zfUq5mG2ImTr4mbEqeYdYf/216nW3+JG5Kom6yIm/mSiPUgjUmBXA2pfQFJnEaZ2FyZnYGZQ6ionOqInRKo3TSoGSa3gVYZhUOp2t2Z63Jptwpp9QxZ1mSZ+x1pNd9JE/84f+RZEC6JzuSn0TG51nMJ9nV59PdZ2LmZ+ntp9T150wIonp2BXZ24kMW44HGJnK2Xwpa6HK24BE+qOhF6NNN6Ew0wltyBYYS4HbCJ4ce53caCBJMAJMthDL0CBoy6IiCYYl+3on+XIqyj0ScJk2wp4CypoZmpow2nYcyYCyMy/0I1gEAwAR8TAHw1UswgwPYyLQ1qGcCKeUJacsRaWtFxJGixCykppIKJ4Gi31fCGP8E8CVfxhpfusIvEgAUlIo6SsT51ClW8mlUKiKUoqBLGEAxHEDwwIE6KABhbIACbEARqM5eWad9+Gj2HFZGfN2Y+ginwlSZTlsr5hBhLIQTwlvNxYKLIh9/OKR5KlyI0ISBuka1wYGr8AA7xIA6ettEuEpPsRYB8NRm0uHJnIMO0MPCIVwMRBQlkMCO1lqYtkcJXer0qaVkDli1hoSoQoWFVuK8MQgzFIAAXcUu8IJUoYAv9ASrTpyhUcIEqGt5YAAfLZ27wejTGVdIkGCI0oSt/moHQB5WBp1E/OpCsENNMsM5Ll2uiKWr4gaoshynOmxHiEIBNBbuZStl2EMBOIX/A2nr9CWODkkUxW0qyZYHDxiACYjXBAAAM3BbSeRIvRGMrEKs3wALf1BCBVkEMRQBDkDDBuAoyxUKvTXHDoxIxNasyaKhaZUHR7DAA2xZSiCt9pFFqpbHMaBDOkTEBxQAM/iDS7iDLzgQLSiDC5CsSzTB1mBPLCQppwYBR5SsRHwAEngsSviDAwQYJWiCPGEOzSbFBxxGRNjCrrkqLIiILEADP4hnRsjCW9iCVsiC55kFJfRCC4THOhQNJcgCLACiM7mYsMCBJhBK9mzAqTCeq5Tuy3aATMBGOd4qO/Bl+azKLvZiu4lKPLoEBHSVu8ZsabWWqlBHE3wAAQhAMdzC/8fCgQoUBRzAAwkEbvZwXahFlmDkACCJyFAsTAJAwxJwjFaRALssSMwOgbe4xAE4AJ5QwsAhXA8UQAywAAZoQjpc7HcwgAMgmgPEAD0AQDrwirJu1yf5wMGhh9HyAA+cRgIMwQcUgw8QwCzhBPq6BA9MxXQ4zwkQAO28BARgjQkYAQEsQQJUw91QxljsAATYCHooqjs4EEFIWURoQgE0AS3410sg8KH5w6MIV0TUAhdcjyFgwBMggTnwgwOAQxOYQwLYrz1YlEzCznQcAAKPwBIwQEOYjN6aQzDAUIjMJE2aQG28xK7VaRiHcT7Arhib8RmbMRSQcal0QBmfsRr8w/89bJISAEAPJIAS5Mr2xJ3hxUrvwQEKKGwMtEr5FCwLsAPwEd5E/I4RfEAC3AMINAcNKG27uURC+IDHwtt4wE02hBkGi4jN8MMxNBYNXJMmPKszFMARUAIDJMAHuAMGOADZgIP9QsANOCxXCEHfQIMJrIMKEy2mLsw9TMAJ9NXy3IPdMcNYwcx7wPIDTADKjGxSxIDFagI/2EAOPME9mAAPjBABFEMMZJAmEO8J4MADZPM9cMMP+wMJFMHXUkIxOEAKkEABmIg/HIN0vMQTcAp12AAD1MM9zDM3PEEKCBM94IALMEMMEIP+qAE6HAAP2APXoIPF/hIPFAAJPAA9QID/yTgAAThDNnADPRQAPWRDAtDAAZTDOZ9BBCgBa/DMCeyMO9zDc0xJDpwDBwzCBkhKRwgBA5RDE1hFaBkAMdyyS/xjVBRACjwAAYCDAvQWCBgECSRJiGygS/BDAFCCMqQDAGzBE8yZP2TDEfjDBuDxESTAE9QDP8ArA9xDC4gbauSAjFDVECxBPzeGCzhAAuj12RxDCkQLAeTDggn2YBN2YRv2YSN2Yi8YO2xDBBwEAOgAqDiOqPhrS0YEIIdEwW7AVS6ET0kEnciAOWBpLxxzMGBAm+BeScDDCMw0HwzC1hwAPPDZRFSWaMMBDowAOrgOJeA2BihA1bXABNxDOWgC/1ErQwZFADNogglMwFAfxjcQQIEshCjwAngampf0QqUog5/67VbYRDEwTgQX13SYQAJoggM0RQ35rqEdAAq0AAkQynoHEgTYBOiYw8p9wKz5LSWMN24kAACQgCO3gH/kc4tcyhkcgbg2RRocZWq/BA+IkKT17sIhcQSndo5ogg7wyQTQAzNwAB9AAzMcHBxAwzfYcz3QnoWOQuO6BACM97jI1RYkQDEQgCbQQtGgwwncgwzwwbl2t49swBYwQArgMc0l3DHcAzEUAL1mRDL0wATwADqQMTNkUJVb+ZVnEAg0QD60AArIQAbJigGkAK1kUBGUAwpgeZpvgQEkwggYwP82WMEemAAJeBnpDuytWjYcyAAUxMZFFCwcqOQGeLmToCk8LMGJ3AMG2EIilNYDslejrAMyeMC/NME3OMDFhsgDJIA6xIAkS5S4YQA/sMCc2cOtrUMT54ipwcHXroipUax1szcB5NyBvYTKoMAiiSQFAsdWNfoE6dze5cD65JBFDNzmKWvviuSxTvXCoalG6JDRwmy9uYQNOIDZyqpo8Pqwn9Q6VFMP3MPVgUMipIM8N+ulop0ONQenKsEEsMA6XECzQYMRQAM0lBNS8Gs0NzuiuAQSQGuO+MI6wAHIrcKlNq4t2EItnMMx7A4jzYIsHLRLMINDzQSRTcAt8MIrWA//C1AYjCW4RMiGTrXKn/NYwDIEM0C3vS0MCDjAAyzQCLiDynGWRTiZS3DEuJpAMjxBAeRcSJyDqY7sCgJFfbpEAixHeaSDO9CDWTEDPPCDCchAlRkYJZSCACRA9/Cug8Iq2a3ihU/bObgBgwtFAfiDz7covzbHGbqp+llGy3F91GuuiwF9fJJHLveAA+RAiZjJzBt7amhX3EMszd77RAh9BA6YRPmCXy9dDmBAOaSAAIwm8t5GKuondIZcy/FC1eLsjwMFqFnjVahh2pPf2rP9LRtaeege5L+jY0RtSJxg4E/bgn6ZBPvIEZxAMqyDTRwlJHqq1mc9f6LnbZCkeX4+/yFOoOhzp5OCxkwkaNjBPlcAwGxPhy9oXfqWQOfqfu97HbdS2plihJpOZtsKIKzHnvEDBW14Ha0iv/Ib6hCK/59VV0KXRxN4DDp4OgUurj1iv9Rp/59xP0DAETiQFiVKAxEmRFhLi6yEQWIplDiRYkWLA9vMujiQGbtvG0FKlIUnTUiTJ1GmvJjFg0qXG0VFfHnSILMPDnig26DgoMAFJRzOFJrwJ6yhRwXuMIpUaCwOTjQOtWDQpKyCD2UyFZrR5IaPCGV06MCDWQcoPODIgHK2Kkmtb+FKZBn3ZUy6Eg1CIKCJEo0eVH0CvZuy6GCUSg2bdAr16CbAICldRQgx8f9JriG9JmQLp8MGAq5ioBDIom3JyqdTzkUNMyvqM2gPPv4ZdHXFwrUrIsY9cXFUoQV7grR1IbhAyrspXgaZGaFXKBs8fmPG/ORI08ixI1SdPaHd1QaLI5zNnWiJpeSTniff+2jBWoq1jMKKHqHyizHooUA7UIZXeh2mowcOKAhgZj+QrKMPu+3o8w4v8MK7azwFb6NPN/TYk+qxjXiRbKDjFLTPIq+kQ4iAElmg5xu0YpCOtJASFGhDBQ1jED0HFTLoBBtQm5C+CtG7cL2nfJtpl1oirCiy8ECkT8TsYqRkiHXiCkssGeD4Zi1XXhRIrC87GIgFVw58y0byYoLQoGT/6DHIHHN6wCDJtyj5KTiDipmxR/NQAy839bjL8Dc9EeoJvOEgNI4+CNuYMy41/RzIOvBGqIbQmTobiAcoBJJBwIS++WogKNjZgK4zs6MkTXQOoOQDBTCA4AFKDDBoAwYSq7MEaKDpiYECsnHUMCAHM6gBW/6sLFKKBJ0JOCVlVEIBBcyIhRhzMPgAjiDoy2ZaBdTYY7VeRIOjABOKsy4dg+4xQQdhVcpUIGcQMBUFZhQKFaF75R0otkRVYom2iSDsZQIf/AS40IRl9JcSJc4xiBgAHLDDHhnUMeEDAnwd4RwZN5C1BQXQRYoqSrIZpBMF0gmGkpAp4elfSA2KodVl/2t6Qs2FaTZogRuUAG+DZBKGUAh3JpjgYfCEUIeSBHCI0KAmHHDnmyHumVlNpfQ0yBkjej7Z0IeDhhQAEtwRW6FaOEBjhBQAAFvsf+HYWaGp3lv4gWOcYcYdAO6BAI5YaDGHAR8gMACAQcDpemyFRxNC67o3gnAEeCiZRQ4FGHBmabspouSICJIMu5omzhGinAMYwFygkbwAgJ5eDHCXEnW0MksstBRYK0w4NgheIH2H/6hfgZgBAJoPDsCghYNcoOGD2ASaPkeBsiBDh+VdOLluSpxpQQgSRujhgAJIwL1uG4KZlXKBjtHEHQLgwGECElKwIQceSCBBE0sdUIxs+P9CANxgASV8wQxmhOdfxCgG5h6Qgu4JhRLMGIGrTPAIAfiDEhAwB1/goAkeMOCC/KAHAzbwBHfQowe9IMAJUuAAZmgCfSRIGgRAYUMeEMBSA3EBARwwvQgwIwExwAAD0CEAA7BAHazbwAmMID8SGIAsDADAARJQDAycYATq4AcDCECPDUyAgwk5xwQeAIEDZAMaJ3iTAzBAAHOoAwOaYMAroOEAf/CDH2OLADh6MIJgFCAF5jCBAS5nkAS44HsvPEH/wLGBKJpDZzH4FQmYYYJzQONjcPhADvJwDXsMIRvuYMAEXQAB8ByjBdNjgAlOEDF+qEMdLrBBCGhwC8rFpgn/mtAEAXKwxl7BARbPAl82/vEAZpwAGgOxAQ1yUAwcwCEGDtAEIJXwvbppghmMLIA7OGnHhvkrITlgBhBnBQtZtAEaMQAHtlzAjCb0TxnTxEH3qAcedDDAeuCBRzNpJacEoGMdlBjBEcABANLFwB0fMwgeWpEDdDDjCEY4qKmY0q8NhIkFKPhIqL5CvE0FDwr06BIchCCEERQhATnIwT0sWI4iIGEICiBBNRRQjhEUADxDIAEBIDAIAoyAAUUwB3icoYkYUMIEOSDdzAjQggTgrxcJKEIvDnACSkDjGwYJRjkccEBKYMAcRDOIEbihSkrIQhQ5kFEvcgAvGRnhqC4B/88EDsCxHiTARzKCRhFPoIkJ9ModEcBcOjhmkLg+oQACgcfNKMECogEgBSSwaRGOkTGyUKIA5cjBMX5CA2xgIwF1c4bOwAPZ750VG+hIAIRwqoKe9IIZfXwQHIyAjbhSghwjGIIDGMAAEtxjAiNAR54M0gvwqOOZI+AHARJQjhSYQAHJ0KYzTnsnCJmzCCMwAQSYUYA7OMFQxygH+QyAAXSYgB7VMEIKFJCDD/jAAJwbbTkwQAsVlK0YG0jA/ODQvvAg6iEG8cEWhFAMBmDAHQo4AgFMsEBK+MAHTUCtQeILjmKk0ZAsmKom4LZaNaFDcsW5DCXgkQI1bjUBBDAAN//6p4AzUKIH6EBkDIDqGYPwQAWzosQ3DOACd6gjGAlolQIaJxAayJYS6QgAIChBrogpQBOlzShGs4Ql4P0OIcRrUajYgYIYFAoO6gha3aCxAUq4wB/q5QcONAGPIdijB8GoRjrOkIBqEGAMHoDGAWJAySaowB0JYIYCbvY+8NiABK81iDJGgIEmuMMAkqubEEQ8OYSI4nFy/Z4BqASead6JzIVSJTNyAA57qLmvIqZBS3uW6U6L2BlxxYEvDOICTUQMQnYKG6Rk9GuDRMAcOYAGBpbqKO9RYhWhNkjUDrCEPhbNT8HgoUGGUGIRvy/YfiqAMiixDk0cgxJPGRsc4OH/Dxu4YJa7HUKs4XALWtiDADEoBjjSoYlEz4gSFpDPZJaLDnAsdQMlVsZuweOAahgAHfRAAiWKoQIemUBOKE6AEB4wrRQkwBkpuEc1SKBWE0cl1nBFArkjoIBi0KAX9jBICxSeAHgoDR3nKMYSlqCCgjKgGO9GxwVllI4h7FkOabiFC5RLCU2g4y39igE7pkOgfIlqIMe7COQEwgNKuFwgsVDNjheoEsBcijV2fZ4QDtiCJdDAAG0a+pqQe+YcgAAcDqDEEyZgqlZzh1hDoYQhv6GzkwgpJFhvCpGOMhVKTAAbZB8INDxknNZUDkJa1+Zq8XICZhDD8HB4Ek1yrYIJ/wQtAfcoQnFIAApgU0KlbXKLvwpQjLcwY8wDwc+KJCK8hNDeJN5LiMK2M7OUjN3TE8ERTTRPAAIU4J08cEAvC6CJJaiOADrYgAp6AYd0FAADpIMDCg4Ah71np+8U3LZJCA+ZZR2lWS/hQq/WTxGrMGnylE8U8Uu37CR9vvfg4QFPQQcOdMBScEbpuuf1uo1GEgNVsuP4es8F3kVG6oEAaODv0uEYTIkfPgAFjkpOgG4gXGf8sKP8sCP9sKP9XIIWbqH4BAIa6oD+FJD/diNGFHA1GBA7HLD/DOUc9g2BUMsHOKgXzOHMHEb8BINC+ERBTBA5UFAlniUkYMECNmE+aP9EBnGDBmvwNG4QOXJwBI/wR5LQQgAlO5owJSxAFlgQDiAPBquwSLgDC7NwAVuCRroQOUTQDsMwSMbwBBFvKEKA2zaimNgwRNwQShAwDuVQAetwN+6QEfOQPJZwN8oQJZ4QJKBhKqiQEBUEDhHxLrZwNxYRNxpRFB+ROyIRNybxJCqxcqQwE52kELGDEzsxLj4RN0KxNkYRF0sxO06xNlLRJBTPJNbQFdHDCmtDFmfRTOZQQUIR3uIiF1eDBJGjF1fjF0MiBGwhDWsh8ral/rjDGFcDGZORKWqxNprRGd8CGvdkD0uQHSWxDwclDWVBCwbxFTfxEMcRLsqxTzjtelb/ixiojBIYIAUC8Ch8JP500R13gxpNxvGskZwoYhVlrWgsAP4QhhKCwPFwAxwfZf1oMA1D4ghAKlTwZTSoLktG8it4AAXG4lSWkTyQ4An6sVDUAV+GLQWgwR1aYAMigKeM4OHS8QvrJvu8UCFxgyGPghISjTfg8eocgAgTIhgXJumUwdEiAAPugRbKwR+YIYJyICONsjY4Ei7+7nkQggYR5i2sbwNKagP2gwU6AAGKI3hQAAWEhy3H7KQuL0cg5eEIhQHD5gjsjm5KJ9OQoAnUJAEAqiYJwA6+ByjNxQQeDgdIwCCEANxQxhwMgBnUKtg8kzCAAkIwwAAWix++R5XW/4Ee3GEJQGduEJJutMlnSgBCIhDzEsVphG8dmiACnqAC+RI8IKDiKGEJCPB7IpHahEXYKAEbSKCgEJI9DIIgtQYHgkggNYEeXC48QgAakKVQsgEEHm4ENIFzyioyCEAFPiY1W4Ev1o/43gXXfk9tjIAAtGUvHUZhDKJRzoEAzMogjuAiqaIaGKA4EDJHhABzEAg36UH1xgYP8sCrygG54OJ47gUBJIJ44MAV6EciFOAJHgT+eiUYGCARXksuXrJQpscHkmEnpoUAhIAASMBlDsIcvsEffg+R3m2sAOAcVAAaRmBaVK0m1oobeGHxQOBjGC0BHgAaIGAwE2Z6KOEElv9KIOihoJxBAbDsJHytV46gm0CgHNzBAZZgWg5gWuzhA0BuWhhgC5qpbj7gA66UARRgSRnIAJRml9DsJ1ZwwpjhHgQiAb4Fc1gUAxSABz4A/jYAA1xACHoBBBhoebYKGnoga54gBSbAAV6LV6DhFJ+AYw51WoygInYCACE1HaDhmwRSzbYqPKDTBBwA3GQEAhQgBTIOSw2iGkoGISTyHBigxQwgO6FUFkRgVSknCHAAA+CAHZZgYQZiA5hBBYIBWRHiAc4MUkeAtlpQanoFSgcCFigBE2zqA1JuWpTgG2SrV8Z0Rae02+CFs8rBaRgga5QAA4YgBT5gXQwCALYAYSj/agL4wRdwJXewzFPgAAF0CVREBQFcwSyyFA5ygAGEABrWjRJygNKSIQWwagNagBucAQ6IgRhcIGLgQBnyhCVs4F4fyAVU9gHu4R54AAPUzF+eAB7mlQHcYQN0YLCyIQGmxwYwwB5oFQkAEBzuIVTrhgTMIQZs8ga4oQfMAQm0CgCCxQTuYQQgEk8BFgNs4AA8g3ZeZgNsgOzuT1dgoRhgCl+TQWfSAV/vBALwNQY+oAkSIBgiwAS4oVaOgBKCIe9soMrAwQUMAAnyygZQp1cxgBnMIQAYoFcwQBmaYANIAF/t4QDQ4QQQwgG4wRwOQAli9tIAEDw+IAVSgAAYIBje/1QB3KEAtA4DwCG4AIAP0OEJIsAdbOIDbMAdIMAIYiAdJuAeggEOVtQE7IGg0kEZyia6KCECkgEcTgAd4KQHAIAqNiAdDgAcGi/XKpADBqEF7MEGRu8AziEYlIAF7O73BGIIeuABcOAApseYmgxmDeIZyrdQtOA9giMjD6Ac1oEEWOADNsAFzCGNngAJkqyCAPQDFkwJDoAbFAAJVAAOlCAGlCAYYkAH0IEAbYAfNmCBe0BnziF6mEENZuFkemFomiAYfACMeKpumOHhIOAJiOEejooqbBdKaawYzIF0DIAni4F9Hq4AuMHO6uYO0IABsuGBscFwjqDpMIoAROMWLP+UM8SieAQCirOOHeKzHBigHu7BAEhACVgzbMxBBRy1Zh2gFVCBi7OJBABABVTAUowgaqTGIPzyaUzAM5YIHcCjACRsbJfzHpCAmDjNx4LBBZ6nIMlszepB68DUIKBBBRLBegimGOKrbmbBA6zAAT4XHSfSq1SJXSm2HvKqHrhBaUJ5t9JGV4TgG+yByX5tnCZMBeBTRjRhBJLHIPQt08B4bGuBDChBjiiBGKqBGdBBCRwgNrerVsoBHT6AUNFhMG0TYCAEAKalAFQAHbihFSCBVkT5e4rBHvA0Rw73jLiBAMwAMHCAbZ+mRAuFGzMSQqi2GB7JIArgHqbpeyzFpUj/gNyCgclIU2y2oKsigNhawMco1gQAAB3c2BcahWcgBAKOQUZiIBhiCFcpgQSGgAUgAB004RmYIWyVoBjo9lZrBQ4aIHohhB50IAbcIA1ojErgIBHAYUIxqizEAgE6YGBQciAQIKILVmrGDBs69uo6iADU7AOeIAvK4DyS167WAdx8wARcwjs6qKTtyvvgh2OI4S+ozR34QQEEAgJIYAyuoTbJoygMqvaGohd8ARusyRwGTz3MYahpggY+GSWaum6ewiWEYF0EIgI4YQJswZgNwBcuQhCJcSOKgZDS6yCwwQcqomzOhZEQggWu1xdqYSwHAhtY019MwAQoUJVo1IHb//T3bAGrZWR+iq5QjqA7BTYhrHjqBqIIsIQeXIEvP9MiwAMJ4A8WWEK7XoJhVIKqC7TwHoMSmoCFTkAIIEBw6gYCcoBjjhkOWsDXQFJCZrO4h88g/MEB1BokhEQjCUa7lcRQmhL00IwWnuAeMOCANkJY61H9xra8DU9NNDu3O3kdEmFd43NDwOMQxVslZKBMvESn4UCBuqwDZEAvyfFE0cQbG9JpaIAZMAAb7MgAIuApmyyLYkAdT0MaFzIsUeMhN6IgRNxfsDGxvxEWZ8IgsrM68DEftWIfUeMWg/tfIiBPUuDdVmsI6oHVhPKsd7EdFYTEL4Ie8wYy3BnCseO+jf87wM8yxmUcKWj8NGw8MYrICA2c/IZ8Gk+8MozcIv5wyyliG+ObPJx8MMRxymeiyivjyg2jJzy8MkD8KL88McK8IiTSIuBbxbMjze9izdncJdw8MeCczoOc77o8xIv8vFMQyl8nBM58xe/xOgadyh2cOw49Meac0xfdzhudMYaCHtNwSfy8yVl8BqX80l+i0A1j04cl0bn8zhMDKcHc0VXiD7VxyWMw1a9w1Vk9YDK9AZncEYOCBa/bJOq8Nmwdz3E9JfZc/m7BDOjnfot9N8Yy2VFC0IPdJFx9MGB9MBagExgJi0p7vCEdNGndMJrdMPI8IiH9ZaIhHcahPrux13X/2wWKoVUMg9u7PXTe59tv3FHC3TO1XSJgoQ/soLQ+21DuMzaiu/P6mwWXnSluJ9nsEw7afTDePZEpYVhZkDILIgEmAB4kDzdoaY4bWkkeAACewdICHdj/XbflGA4EPriZJ0kKHqXuAbWHYgHogBlgwQG+AjlRKwJQgJ7TRrdzwGlCouKTkhJaYAvCNv42/i46ftuOYMxDwhwSADgSoK6aRFlkld+YrV0PuasO/r1lvhPnhPhk5Knqhhi+wRkeIKk9IDZ8nqjrhu0MHvNiU71Uj13hgNPmBhBBuW6e4QNk1UP7Gy92SU14QQhOgR6OwByaQKug4fQM6maegXSi77WY/+Eb8AnxaZknHn4ifK1ufCBYipCc8ik27Pq4DyIZcHOpTsAFVICLEwGyg0M3tMvhi3BnYj90wOMIOOgxoJP2tWbsjjYd3MEEor1hAOME5hE83EFb3lm4E3CcmNV8fw0bqiEtEYIXZCAfGCj2AVBmwP81Hd41AWNSuG3tN4IFNuC7ESIG7h8heAAgNsAZSBCOD0oFCVICkQBaDgARIlRLdIBfhAPf+DELVk2NBx7pCBRg1iuhyYGUUiY4QgmdMgc0KB2EI5OSkA1CaFKKwWAnA4MqewGwAqEXQp0pEx6hxwzAExsAWuBISQPdUZo5Zp6kBAFJygk94BzIQWlduWobE/9oaqkJghAFPXtl40ZJhTMDlArQ2ACtScOt3BSk9KHiA5wEEWycXFAiZUoM35LqLEgJ3FrHlHScGEFCMlIA5ZgZ4ObuAKVj8Cidw3AVzg5YKI9i9iwzgj9K/o5gSGc6ZTEFBda11umDxUUZDpYoEXI0Fgcns1D2Rjo75YMUCCEUoBfhHC3PJik5SCZTUw9Kf2QNZOZLhyIAXRmo4NcaM9KECIc7LpaNEpIWdMHRiwE2FDNcAdi4YQp+lDhTwBJCgEMMQvwYmJA9PRWzhT+UNSHQAeRJRgkLEBCA3UCy4IHPE0kdlcNJMMYIhwwd5INABx3wAMc3HXxDgEksdIACjzL/DIQCCjKwE0NCIxjRImYmoPNMAfCYYw4xyYBTjDspPOAYL6eQQoAz+YEzG0oo6YAEHAR8A8AGyrRASTkR9PINMb6kUwQDzBzAjA/cMGCCOridoYABzEBgwAjF3JACN87w4Es1xThwzGwOOIYOM/AokxQ0CQAAj2KUVAMCaww+UY05lPQygQoJnLEBLyN0MmNKCnygAn8MxCAYOucoYBY/BMRAACUmuKBCE/nNJkQ52QCAQ58mOKAJPSzOxgsL2jAQ0wGlyZAfdvl55c5LTyjAjHjrwPEEMTTRxAADORQABw4GAgDNk9hYmNIOjikxgU4RxWDAOfmpo4k5zGzJzAPK/0wASko9UcIAoZS48GKBghYwgToHTMBAOb1R8pxjALjDAAS+wHEOXjIxcEQMJJiDjTk4VOOYLIE4UItjsek0AjMfCJbSdzopQMAY4o2w07E6CVEMMfMSyoOcSDWhTrwoFWBYm8XQcxgBQshwzgcmyIYQPby8gkExRqCUQxPMnJMCCRPQR5MJkw1EQDImMLAO3zoVY8AGClTTAj/HZErTBC0c0cQJPsRACSbbPGMPJUZEQEkxOsooekIbdEBQ6TEOSVAHzMDBwkAyfJNQDvTogJA6GzCQTjoJ8A5113KClwcqsKG0gZeU9E4AMRv0sAE47myQDgMf7LSBLykxM4ESG/84gJMSUxUAzgdLOsYcJUdsgLEosPiwwQkbPAFODxMk34MDB/Q0ED+b43eAOQ6Agw7oEYMNHIFBzHAGPSgxgiXQQ3A4GUQJfkYxAzCLACZgwQmKoQIXMAMDLErABobAFQccAQBrOyDuGHCCHBCLACRUBw9S4o5jgIN7SqCEMhSBjAQU4AAY8JQyGCC9E5wAYblLB0vUQol0eA8l2KiGL3qgBAdwb0ky8ocDmpCO5o0hGAmwGDPglw4IRKAYvVhVShxgO36Aw0mOGcLuypeDDdhxXnYEhwvscz4MdC8G/4BED5rAg7DEAAI9IAAG4AcODCRDek9wIQPcwSyCcGEDwrD/QQkdkI4T9EAIBLAHCzaQQzjUAml7Y0AQbrEEy+UlGEqwnAOqkY1DGqCKYMQMKJjhSpo8YQQASAcPlAAOzyWvedUzwOZOY0QWteEc4IBeBPi0gZREIAGToYQmwuiDLjIgjE9ggQsuw5VjOQYCDuhTOoKRDp1RAh7zIoASSGEJG5BgmhhQggFGx0+CpMN0RvrGN+jxuoQgAItwYIYrCoICsSXEH06jxAmO4Iz7DIcGS0DTQGKRBQ9EhyAfYIYCElcWTXyjGC9qFn7gYAPmoIk2GlUpSkRhi6ClBAAEYEAxjrAFw/DTBOuIgDngQIPgzUYwCUiB03rRExYYQAETdJE7/xngtBg4QAEuQ8cxYjqQBxyhAMQogERZ4BWaQKg+ookBBliAgQkQoBSNMYI7wBGvGOBgIMfgDgYUIpk1FYQH6CjGWsEDI0owjBK+KIYXiqEJBZDJF9hTKTZGYAAdKIRr9nnpBnwghNTcxyQ58AUzBECOFthgAk2YDMvgsITQXYUS/GDNUWRBi1v4QwbNaw8c1lGMcigDs3CAhhauogMdBAEW6kFJORjwDQOwyjEP+AkcZNaZ0uTgBEdxxjfOgUERcY0mg0tJsZyxrzbMAiFGIMFlT8KCYFCiM0YohmEcowlspGSBsoFDMnIChwdo9BjnyME9rJCG5OnITlvrJz9RN/8QIW2AHuyAwwYEKhAEFITBcOABOwpKGTpBYEIKNklHw5NNbPggxCg+iShiwaAmNgRoo6MEM5BgAtu1xAbMyNQD6GEO1nygBSRsEQvgmtzYyEST73UlYUGaDgPQIB0tEIjoVBNkleSAMbBZ8kBw8IB98dMGwhmOjDK7g33BmEH2SC2KM8tPHeSBDEvgxZljfObv4MaYfD0JLDYxnCCwWCFk6YVRKHOUPI3kHtVjrDneZLlj2C5GKVEBJQ4AgauYN2hjtpgMvBSedViwGmFGcQ7GUOAWPTrFMcJwB6S86gJuYEkI4LBCB6Lh0IWnAMlCNUFGvBVd+7ogKyaxmPspA7z/DIQFW1hHC3LgNGxwOl6eYUyRL5ufvg2bMnCwB/Zi3DeaYHnKv0Y1wD670l9fG0bOcUItzE0QEVBCFuc2CSxQSRA/r3TJr6WE5zDNbxkVgMatubSC450SHYzA15TAQxrCPToMx24gSkoICu6xutbVurBsRjWvGc5xggS74wMRAlnywxwamGDkopM2yPkabxl9e+UMfw3Mw53ujzKcDT8L8bz7/Oc1ZzzFQ3AACzwjcJBruZ8pWvjMLwxQ13VABq5AAZCERKSBIMAVAm1deFrOz40vXdcfXzlM1+vyEkz76yh+OdpTLPO1o7jmHbezzuvAc3bbPeA2dzvSFe52HUCA/3QINUkBEdoED23A1jP3ut77GfbF81Plju+n2iMvurZTXkZw5/h3tFAHEcCB854H/ec7P3otnN3elx9d0VN/kqSz/vUyUjzsgd3z2RcE8ra/fQmKl3uCWL73mQ+3cLnAigtYwAJ1+MIF2HABVohAC1+owwU4z4ov1L33BVl97l2P/dnLPveN7z3usT/53v8+98EXPjTUEwtebGIU0IAGHGAxilHYwhay4AUvZAENXiQE9d0HB9pne9wXgDNHCbBACTUFI99ne+GXe+OXYgjIdSFWfrl3fraXfmt3dP9Xe9g3gLNXgAa4crCwB17GgB4wgg9oexGIYrVwgh1ngbaHgf+zp4FoRwm6wE8A2H0gCHsiOIIglwH9cG4NGGK1UAMaQIH8FH5zdnkt2E+wEAsUQARKKHm7x1frtnYSwIE0CHs2+HWUMAMcOBA76HPzMIYppn2wAA3dgIbhRgn9sIUF8YNAyHC1kAEaIH8oyHH9gAse6Gvhl4AUsHa8txhmp2sJGAVEcAsrp3a5AA1ZuHQJKIbn1oX8hFwJCHKZBwuwcF5guAISoIcxUoYhlhJ+WIX8pH0pQYkbmAQZIIpwQId1aG4ZEA9EmIIMtwK4gIoywoTysAIbiIAw8oQKpoh5x3BqFwW6UIgwF4VRIIwwYokxFgtAwIuY9xzRcQsSUI3W2E//urACSTA6pDhwlPCM3RgjqqgLM9CGaxcLSbCLc8h3MMcMAlWP9niP+JiP+riP9hh4lBAPjxgjRRhiMxAPkRhuTJgEK1ADB7lykSAFzEgQxNhPitiQ4fZtCBgFe/CHIGcLlJAEFACLCSGNUwYEMyCSvwZ3lIALKxAL5xhj8ZAEFtmBvuaRUTCEK5eOBfmS/PSPSdAashhuVMePRFmURckOUoYiM5ABsYeL4TYDMwBygaiQcrh0GRAFC2gSE8lPK0ABPKmVV0gJYLACSeh2RBCVMUKSYxYPYqiJ2GhKFLACbuhrMSmOHNlPLBYFTJmTxygLYDADUnB2MzcDuZAQQflr/6s2e4lJELKwlE3JcVAplR74kTMgARHJcLEAC1d5l1spI+cFlV+ZEBgJDLUYmjEyC7VwlnfpGpfZT/+oAXvgltAxfyCZiV8Xk4JJk7rmkoqYlRw3gOoYD7m5coRpmPK4cov5eskZi44pkE75a5HZceFXC0lQmcP5awnYDSswk3DQmTEShRTQliD3csCQC2j5dWt4lq3Jmr4WC92QAaa5UW8JB0SQAfCGdnUpOuPomhSQC/DJlwkBC38ZmG5XnPGodMgpZT9ABAxKBExAnwThoAPBBLiwjj9gEkDAoA8KI0AQBVGwbssZhv+5h7/2M1B5jIDoge44A0AgibCwjhIwjP+HiGoemQEzwJ26Rp7muXY1ep4noZaQxqDrmWJwJwv1WQur+YYxyYgysp89iQsZkAtDmobHaAtMkAtSgKMc96K5AJTHCXKLSQQDAJUzQASRMACxSAFR8AO1oKZJQAS4gKYFoQtRsAIzUKcwMgBAcKFwsJw/gAtU6JxvCAZsGZ/hZwvvKAHX2Z6xQJgtaoiLOjo2qqUppqM++nU2KiNAGiNCKpsfVZ+R+msU0A/s2KRJKjq1AKV7CXKqaKYE+nW1wATdUKoo8qUdF6ZRIAu1kIUDUAPdEAVMoAtMMAA/AAbrxqcFEQW5AAY/MACRAAcdGgUyKabrCKJJSZ8M6psJMZD/PVkDUgAEMcpxTJgLRAAEKDl/CdiEoxMLjZoEjwqWoSojNhqfAzGaO7p2spCpaTmlMmKkRMCvCgZ3sACqaEcB8jADp+qk/KSqlIpiA+iq9HoSGQAM4lmrCAqmUkatUEkENTAAwDAA8zAQLCkjYKCIcPCxcCABwPoDiggEA1CuDXatDXqd3MpPNYALTPCuCOmBsPCIXboVKVGsvMiuM+CuMhqvMTKvjRiW5XmpVum0BbGpMNKpHQd3e0CwX2ewMxCpCouqqgpzDxuGEZsQd0ix03aYvoar/umgszAAA/ChAxGdHqqRvxoF3VALUfC2egoHuFCndzoDe9CrH7WcDdqU/wArI97KBBKAonBwXuqqYh44C12aC0xKEOkKBlJQoWBwC1W4ikYLqboGb3h4rgORrlWIkd3ABDPQmi6ZEg2rEOkai5Rgo5eZgABjm6ITuyjBoOc2gXMJdxKgAfZZWMUzlyahtbkJCz9TC0FgvOEhBURAuejmvANhXvaRmmFYu7OhrQomhFt7oBtlukIpZbkQBQQxCx0rASsAjHDwq6a0Bx37vnsgC3twk83aouvLoBnABPG7OjLLoDTrAV/5kDmLcY9rEg+YC7VQmAwCDEnwA3sABEPYudCgAZ8Lr74GBEAwokDrvBh5kgiLcdxIjklRC+BasZQBCwAzl66rEOTau/8/h25vGbzDuxXu2Q1niGrIq2cICATNe44vCg0oTBCty4vWCzS24JVQqxNMEMP95L1nK4+m+5W4CgYF0avzMADdMBADoAG8WgN5p5fQCrJiyqctKrgNdghMsIBEAAxEsHW2IA960Awa0MTKy3LVMQ8MmgtnSAkErLM68QNAoAGzqgE1sC9Z5hi1AG+UIAo1MA/uymKxoMCU6xjysMEa4JWOwQRJUAOywMiOwYkpAQt9bAvQQATuWrmxwRjBu4XMWB2UwAReRglSAAZEIJKU8DNAUMhM4JL9ZkopIQ/7IAe3wLliuLoMAguymgHdIAEUNMqgPBsS0A3AgBC1EA9/mW//jpEByzCrwLAHCFHEUwwLNdCfkbBulECuG4rHzNwND1wdcOCRmCEPceAEsEHDNaDNlDAPqcsEGvAD0MB78lzClCAPkZwSD/y9KUwJwNANRKAHGTAPRRzKsEzOkYAQjRmGWYkZNZAEhXzOjiHPCZiAA90GP8DMSRCbtXDMlNG6He3R3fDP9TEbCRi8GmCuKbG/Cj0QtaBwKdHQlXmqo7OYufC2HtoN/TsPdpuyKzC37EsQdPrGe6CmP6ABRt3Jctq4HXAIZUmfsUAEZ5cS/ZALHTW78cAEvFcdwEChUvADP1DOlBALGVADBUxodawLKeGe1ZwfwNCHuIALFAAM7RDT/5HQDVb8kNDQpSkhBUkgDz9gH5RwC2DQDX8tBYAJlVKgC7iQC7v8k5RwymDwswXxM1jQDhJwtVWJx3A4A/0gBTFaC1IQCWCNH8CwAvKQEtDAzGqTENAgDzH5Au3w2C8KB07L0FIAnzgoAfFAhbFAobiQud0ADUnQ3N/6A/2wl9gcwrERCxowAzWwwvIgBQ860N3g2u8oBRRgy14Zi+T6xgWRrm2dEkg4A3udFETQhrcgD5v9DmuAEMFbnq/1p4x9FHsQ0/qMENKdBJFAocAADUO407GhwbkcBFX92I4BDLiQoX3c24A5q7DRmMRNaHCY3imhCxRg4Z+N4WwpBfnsGP+FYMiU4K1wIA9KTGjNPQNNHNmnfBW10A8r0MfVPNmxAA3+HNfwCeGwgAeE8NynvQe5gAvygJhJuQdgoAt7sG5gYMVwkOUDoQtVDgaxSbaRyOUDEQlWTOZ9ugE07pJUGKimKwXxkAGw0FE/owvdYJvdwJZsSZjdILS57KCU0A3NDQRFrAFsKcu5bAuwEAm5QMhwngu54NY/MA+5cAOoGctEEAsPmc7QMA/eHdfpilxw4JKyEAluHQnknNPx8APAkIcI+9lUKKWEJgGMUAJ7wLlnTRASIAW8Hg+WDZ+xIA95GIZXa2YIDZA/kJmbjM1MAOdkSqaGDQsL0AkaoH+ri5b/mLHZ56zs0KALRODrff4Dpq66JtkNIE0JmpzdmDEPbBmKsfAaCOirQ9gPh46Ee4rqKaEBoZjOvIsZFMCWFx2FP+Pkvk6mDurrJ64LmPAObd0PQADgjiEBuCDutrmGhLySvV6Qyx0P5uqRiZrpq1sdSeDZstC8YPDvzh7pb1qhbEkBml7QLi+2lOgY4anAvgsGuODObJkB4h7jzg6VfnDRNSoFK3DkoBze64jvjkEE/aABuAAN01wDvg6QgAkGsfAzqtsPtzzzKOEHy+DWig4LuvAD4apry5l6q2YLf1q0cl0DpiTshgzOcMBrYsnMGRDRF33RTQgNDgwMcUyFNqoB//IABmcWCx4pD/Ng5iFNE7UgCrIh8StA+BpABIJPvY5B+HkNrhV8oQxMxAzKGOgMBqR590AQCaYPBpEg93BwC+3s8nLOz4TJBHqPH2AwsWb+ybg/0rHAGIa+Av8alXdIAcKbz1uB+qovC5wL2bF891sohrBPBJiPEG035BKQARIQ/Wfmx/4ZDzXAu2Dg0Tyv96+M+inByKhP+HDAAWlQA/TO0F1KoaOK/iZhC/Mw16YPzll+/U+iC8cNEJRmwKL0o9uMGRqY3ILTMEgsWGDARIpEyeJFSmAuwoEFLYOUFfME1vrRr1sSIBYbrrQ4jwkYWbNYUtpjcVYQSg0pQaNYc/8GJSAaZuSqWHOlTgnyamQAUsMiRYsac16UIAFoEmC5EOKKkybn0VhHxY4lC6fDhrJp1a4texZWLYvQoCXJQIQCBQmwZlGqBSeLh4ZwCTaERbBwrVhhj1KyVYugrRlJNFwkKPPoXls5Z8myCYcSLFGKP8O6dUsgkVifFbOdeVGWrFgzcHXbAyeXxVtCZxChtKCELM+UVmfmm9mxzs+MYc3rtkJeYeF9xfKl/Nq6YTi+ecFKLDDDDGDyKmYmC8sWxNWI3zKGU8sxY4szmDOBqBoWnB33gxO0CNH4asMsqoUIIoCJB4juZikMOLAseosz/lTjwAn3LMoqiW5+sKWx1Y7/gk46/t5zjyOLJLgtFwpkY8JBvlZ6SEHD+JORoFqA40y8xGCJDJcM5LmFRrGgU4lBODi7yJY2pPuMxNM0kKDG0TqEg7j3BGxMxpxSY3GeKLDqSxY80tBvJelYawstM9NU8yyxaskgCozE+ktNtQSKRyU6xQqNrFhWSALPPMeSa6NcwJBnBqdU8o3IQCmJZIDUAiXLtzEFqqg/SdcSiAJ5vhIrv0wbIvCnDUOFI5YJLYOjnxkyANRU5Cy8zSJbyHoo0FjOgwOa3RwcM9M2VD2qlhrg9BRWsuZZAU8w00BWrA4QkHZaaqu19lpss532hLEk+CG1446aE1aLBhDp10D3/xyLkhU0GBHZAC0SigKM7ls0VFvAiCJSZClliYifWnx2OiJW4PdTdPNklTdGJUXVCVWBWcGqMuG1ZS95wADSVinN5JeSeIhA7NlgyZrlBwpiEXbglWDRRZevmmW5IetqtvlmnHPWGefyjpUTMHJjwUXgUNVtUwqfBxZuBXp9vjdT4VJLWFJ/dYIGmKRZdpS3rEENFQznss7zYVV1uXPm6cR2sWM6oZGHCZZLHos4tNmSuW688x4373TZ5nulFUQe6+m/1ay6cJZ4SstrqOWpOFSyEVfzVsnTlLvyte7GfHMz9+Y8LaM3/2nS3z5X63DJNyqLcUlfNTVy08uiPHayLtqnfSXNb7/dc90bCh3zGqAhvWHdUe+ddd1h790hv2m3Xffcl/+c995/r9z1hghf3njdkb9d+eVnl/7526OXfnPqdbf+du175/5272kHv3fxlyefdvPPr/wv4m8XpdbzvY92Aoxd/GL3sMfp7iH9c97Kyhcm/UVQghOkYAUteEEMZlCDG+RgBz34QRCGUIQjJGEJTXhCFKZQhStkYQtd+EIYxlCGM6RhDW14QxzmUIc75GEPffhDIAZRiEMkYhGNeEQkJlGJS2RiE534RChGUYpTpGIVrXhFLC4vIAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small sharp spikes (also known as benign epileptiform transients of sleep, or BETS; see boxed area). This is a normal variant.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drs. Lawrence Hirsch and Hiba Arif.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21287=[""].join("\n");
var outline_f20_50_21287=null;
var title_f20_50_21288="Stroke caused by varicella zoster virus";
var content_f20_50_21288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stroke caused by varicella zoster virus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21288/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21288/contributors\">",
"     Maria A Nagel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21288/contributors\">",
"     Donald H Gilden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21288/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21288/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21288/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/50/21288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella zoster virus (VZV) infection of cerebral arteries produces a vasculopathy, manifesting most often as ischemic stroke and less often as hemorrhagic stroke. Vasculopathy can occur after either primary infection with VZV (ie, varicella; chickenpox) or after viral reactivation (ie, herpes zoster; shingles) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, epidemiology, risk factors for, clinical features, diagnosis, and treatment of VZV vasculopathy. The major clinical manifestations and complications of chickenpox and herpes zoster are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22278?source=see_link\">",
"     \"Epidemiology of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=see_link\">",
"     \"Treatment of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV vasculopathy has previously been called granulomatous angiitis, VZV vasculitis, or post-varicella arteriopathy; a subset of patients have specific ocular and motor findings known as herpes zoster ophthalmicus with delayed contralateral hemiparesis.",
"   </p>",
"   <p>",
"    Early reports described ischemic large vessel strokes, although it is now appreciated that both large and small arteries are commonly involved. An expanded spectrum of stroke caused by VZV infection has been increasingly recognized including aneurysm, subarachnoid and intracerebral hemorrhage, arterial ectasia, and possibly dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV is a ubiquitous human DNA virus of the herpesvirus family. Primary infection occurs via respiratory aerosols or contact with vesicles from an infected individual and results in the characteristic, disseminated rash of varicella (ie, chickenpox).",
"   </p>",
"   <p>",
"    After primary infection, VZV becomes latent within neurons in cranial nerve, dorsal root, and autonomic ganglia along the entire neuraxis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/5\">",
"     5",
"    </a>",
"    ]. A decline in virus-specific cell-mediated immunity to VZV in elderly and immunocompromised individuals results in virus reactivation in one or more ganglia. VZV reactivation most commonly manifests as herpes zoster (ie, shingles), which may be complicated by postherpetic neuralgia.",
"   </p>",
"   <p>",
"    Less often, VZV reactivation leads to other neurologic and ocular complications, such as retinal necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/6\">",
"     6",
"    </a>",
"    ], myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/7\">",
"     7",
"    </a>",
"    ], and VZV vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. Any of these complications of VZV infection can occur without the characteristic rash of zoster. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=see_link\">",
"     \"Clinical manifestations of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Direct infection of blood vessels by VZV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likely mechanism by which VZV causes stroke is by direct infection of cerebral arteries, which leads to a spectrum of both inflammatory and noninflammatory pathological changes including thrombosis, necrosis, dissection, and aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/9\">",
"     9",
"    </a>",
"    ]. Various animal studies have identified afferent fibers from trigeminal and dorsal root ganglia to both intracranial and extracranial blood vessels, thus providing an anatomic pathway for transaxonal spread of virus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In autopsy studies of patients who died of VZV vasculopathy, pathological and virological analyses have revealed herpes virions [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], VZV DNA, VZV antigen, and multinucleated giant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/15-21\">",
"     15-21",
"    </a>",
"    ] within the walls of cerebral arteries (",
"    <a class=\"graphic graphic_picture graphicRef74568 \" href=\"UTD.htm?23/7/23672\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential role for autoantibodies to phospholipids and coagulation proteins during or after varicella has been suggested, although the contribution of these transient autoantibodies in the occlusion of cerebral arteries is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. One report described an adult with varicella who developed a stroke and multiple peripheral thrombotic events associated with a transient protein S deficiency and transient anticardiolipin and anti-beta 2 glycoprotein antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/24\">",
"     24",
"    </a>",
"    ]. The presence of lupus anticoagulant [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/25\">",
"     25",
"    </a>",
"    ], protein S deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], and anti-protein S antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/26\">",
"     26",
"    </a>",
"    ] in association with varicella infection has also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varicella is an important risk factor for childhood arterial ischemic stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/27\">",
"     27",
"    </a>",
"    ]. Approximately 1 in 15,000 cases of varicella infection is associated with subsequent stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/27\">",
"     27",
"    </a>",
"    ]; most of these events occur within 12 months of prior varicella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/28\">",
"     28",
"    </a>",
"    ]. Furthermore, varicella infection precedes the onset of stroke in 44 percent of cases of transient cerebral arteriopathy of childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/29\">",
"     29",
"    </a>",
"    ]. Within a large international study of immunocompetent children presenting with stroke, 277 (53 percent) had an arteriopathy, including 19 children (7 percent) with a history of varicella-associated stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Risk factors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link\">",
"     \"Ischemic stroke in children and young adults: Etiology and clinical features\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, VZV vasculopathy is reported more commonly in immunocompromised than in immunocompetent individuals. Prior to the introduction of potent antiretroviral therapy, CNS infection caused by VZV was detected in 1.5 to 4.4 percent of autopsy cases among HIV-infected patients with documented vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/16,17,30\">",
"     16,17,30",
"    </a>",
"    ] and leukoencephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/17,30-32\">",
"     17,30-32",
"    </a>",
"    ]; most of these cases occurred in patients with severe CD4 T-cell depletion. VZV vasculopathy has also been rarely reported among renal transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Varicella infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for stroke caused by VZV include a history of varicella within the past 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Using a health care database in Taiwan, a study was performed to evaluate the risk of stroke within one year following an episode of herpes zoster among 7760 cases compared with 23,280 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/34\">",
"     34",
"    </a>",
"    ]. After adjusting for other cardiovascular risk factors, the adjusted hazards ratio of risk of stroke among persons 45 years or older with a history of herpes zoster was 1.31 (95% CI, 1.06-1.63) compared with controls. The incidence of stroke following herpes zoster ophthalmicus was higher than among those patients with a history of herpes zoster at other cutaneous locations (1.7 versus 5.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV-associated stroke has been described in patients with advanced HIV infection, sometimes accompanied by acute retinal necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Cases have also occurred in immunocompromised patients with leukemia, lymphoma, and among those taking immunosuppressive therapies for systemic lupus erythematosus and rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic clinical presentation of VZV vasculopathy in adults is ophthalmic distribution zoster followed by acute contralateral hemiplegia; or in children, varicella followed by onset of acute hemiplegia. However, since VZV may affect both large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    small arteries resulting in cerebral ischemia or hemorrhage, clinical presentations vary widely and include headache, mental status changes, aphasia, ataxia, hemisensory loss, and both hemianopia or monocular visual loss [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Some patients may also present with symptoms and signs consistent with encephalitis (eg, mental status changes) followed by a focal deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less frequently, patients with VZV vasculopathy present with a transient ischemic attack, aneurysm, subarachnoid or cerebral hemorrhage, carotid dissection, and, rarely, peripheral arterial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately two-thirds of patients have a history of zoster or varicella rash [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. The average time from rash to neurologic symptoms and signs is 4.1 months among those who have a history of zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]; on occasion the patient can present with rash and stroke simultaneously. Since both zoster and stroke occur mostly in people over age 60, clinicians might not consider VZV vasculopathy as a cause of transient ischemic attacks or stroke months after presenting with herpes zoster.",
"   </p>",
"   <p>",
"    It is important for clinicians to be aware that approximately one-third of patients have no history of rash; thus, the absence of rash should not dissuade clinicians from pursuing a diagnostic workup for VZV in the appropriate clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV vasculopathy may also coexist with other neurologic complications such as VZV meningitis, radiculitis, cranial nerve disease, and myelitis or spinal cord infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients presenting with a stroke should have imaging studies. The relative advantages of the various imaging modalities are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=see_link\">",
"     \"Neuroimaging of acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=see_link\">",
"     \"Ischemic stroke in children: Evaluation, initial management, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Brain imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV vasculopathy involves both large and small arteries. Brain imaging shows ischemic or hemorrhagic infarction in virtually all cases of virologically confirmed VZV vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. MRI typically demonstrates both superficial and deep-seated lesions, in both gray and white matter, and particularly at gray-white matter junctions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51689 \" href=\"UTD.htm?25/1/25618\">",
"     image 1",
"    </a>",
"    ), a clue to the cause of disease. Most lesions are bland, but hemorrhagic lesions also occur; some lesions enhance. Whereas multifocal lesions are common and thus give a clue to diagnosis, VZV vasculopathy also produces single lesions; in early reports, a single large infarct seen in the same location as the cutaneous rash was referred to as \"herpes zoster ophthalmicus with contralateral hemiparesis\".",
"   </p>",
"   <p>",
"    Although gray-white matter lesions are often seen in patients with other disorders, such as metastatic carcinoma and embolic disease, VZV vasculopathy should be included in the differential diagnosis of patients with gray-white matter junction lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Angiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic or hemorrhagic infarction at gray-white matter junctions should prompt consideration of vascular studies, such as magnetic resonance arteriogram, CT angiography or conventional contrast dye angiography in conjunction with virological testing. Typical angiographic changes produced by VZV include segmental constriction, often with poststenotic dilatation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51689 \" href=\"UTD.htm?25/1/25618\">",
"     image 1",
"    </a>",
"    ). These features can also be seen in patients with other CNS vasculitides. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=see_link\">",
"     \"Primary angiitis of the central nervous system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to arterial occlusion, aneurysm and hemorrhage are also seen. In the largest series of 30 patients with virologically verified VZV vasculopathy, 23 patients underwent vascular studies (conventional angiography or MRA) and 16 (70 percent) had vascular abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. Brain imaging and vascular studies demonstrated mixed large and small artery involvement in 15, pure small artery involvement in 11, and pure large artery disease in 4 patients. In one report of 25 patients with a variety of infectious vasculopathies, MRI showed enhancement of the arterial wall in two patients with VZV-related disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the presence of stenosis or occlusion is helpful in diagnosing VZV vasculopathy, a negative angiogram does not exclude the diagnosis, most likely because disease in small arteries is not detected as readily as in large arteries. Overall, mixed large and small artery disease is seen more often than pure small artery disease, whereas pure large artery disease occurs least often.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CEREBROSPINAL FLUID TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrospinal fluid (CSF) abnormalities are common in patients with VZV vasculopathy. A modest pleocytosis, usually fewer than 100",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    predominantly mononuclear cells, is seen in approximately two-thirds of patients with VZV vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. Many patients also have red blood cells in their CSF. CSF protein is usually elevated while glucose is normal. Oligoclonal bands are frequently present [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSF analysis should also include testing for VZV antibodies and VZV DNA. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV vasculopathy should be suspected in a patient with a recent history of herpes zoster or varicella who presents with a transient ischemic attack, stroke, or altered mental status. VZV vasculopathy should also be considered in patients with a stroke of unknown origin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/42\">",
"     42",
"    </a>",
"    ], particularly among immunocompromised and HIV-seropositive patients. The absence of a history of rash should not deter the clinician from pursuing a diagnostic evaluation for VZV vasculopathy.",
"   </p>",
"   <p>",
"    Supportive data include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mononuclear pleocytosis in CSF",
"     </li>",
"     <li>",
"      MRI findings consistent with an ischemic or hemorrhagic lesion, particularly at gray-white matter junctions. Suspicion for VZV vasculopathy as the etiology of stroke is increased in the setting of multifocal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bilateral strokes, particularly when they accrue over days to weeks.",
"     </li>",
"     <li>",
"      Focal narrowing and beading in cerebral vessels on angiography.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The confirmatory laboratory diagnosis is made by demonstrating either the intrathecal production of anti-VZV antibodies or the presence of VZV DNA in the CSF. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a clinical diagnosis of VZV vasculopathy is suspected and supported by single or multiple lesions on MRI or CT, further diagnostic testing should be pursued with testing for both anti-VZV IgG and for VZV DNA (by quantitative polymerase chain reaction assay) in CSF. The assay uses primers specific for VZV, sensitive enough to detect approximately 100 copies of viral DNA.",
"   </p>",
"   <p>",
"    Testing for anti-VZV IgG antibody in the CSF generally has a higher yield than testing for VZV DNA; this may be related to late testing in initially unsuspected cases of VZV vasculopathy. For example, in one case report, serial CSF analysis revealed the presence of VZV DNA only during the first two weeks of disease, while anti-VZV IgG antibody subsequently became detectable during the second week after infection [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. The yield of VZV DNA testing may be higher in immunosuppressed hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the largest series of virologically verified VZV vasculopathy from multiple institutions in the United States, Europe and Japan, 28 of 30 (93 percent) patients with VZV vasculopathy had anti-VZV IgG in the CSF compared with only 30 percent with VZV DNA in CSF; in each of the patients with detectable anti-VZV IgG in CSF, a reduced",
"    <span class=\"nowrap\">",
"     serum/CSF",
"    </span>",
"    ratio of VZV IgG confirmed intrathecal synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. Quantification of virus-specific IgG in the CSF is frequently performed by calculation of a virus-specific antibody index [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specificity of the enzyme immunoassay test used for detection of VZV antibody appears robust; this test was performed on more than 1600 CSF samples from control subjects with migraine, epilepsy, and other CNS encephalidites (HSV, EBV, West Nile virus); no patient with an alternative diagnosis had detectable anti-VZV IgG antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a positive PCR for VZV DNA in CSF is diagnostic, a negative PCR does not exclude the diagnosis; only negative results in both VZV PCR and anti-VZV IgG antibody testing in the CSF would exclude the diagnosis of VZV vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV is the only human virus that has been shown to replicate in arteries and produce vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/1\">",
"     1",
"    </a>",
"    ]. However, many of the same symptoms, signs, CSF abnormalities (eg, pleocytosis), imaging, and arteriographic abnormalities that occur in VZV vasculopathy are seen in other CNS disorders, such as primary angiitis of the nervous system and granulomatous angiitides of the CNS (eg, sarcoidosis, neurosyphilis, and tuberculous and fungal infections). Thus, the workup of all patients with granulomatous or other CNS angiitides should include CSF analysis for both VZV DNA and anti-VZV IgG antibody.",
"   </p>",
"   <p>",
"    Hypercoagulable states, multifocal cardiac embolism, and intravascular lymphoma can also produce a pattern of multifocal stroke similar to that seen in vasculitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=see_link&amp;anchor=H12#H12\">",
"     \"Ischemic stroke in children and young adults: Etiology and clinical features\", section on 'Vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;VZV vasculopathy is caused by productive viral infection in arteries, as evidenced by the presence of multinucleated giant cells, herpesvirus particles, VZV DNA, and VZV antigen in cerebral arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/19\">",
"     19",
"    </a>",
"    ]. Prompt treatment in suspected cases of VZV vasculopathy is important to minimize morbidity and mortality.",
"   </p>",
"   <p>",
"    Because VZV vasculopathy is uncommon, there are no controlled treatment trials to assess the optimal treatment strategies. Patients are typically treated with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    intravenously based on the clinical experience of experts, descriptive case series, and recommendations from expert guideline committees.",
"   </p>",
"   <p>",
"    The largest case series consisted of 30 patients who were treated with antiviral therapy, steroids, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. In those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    alone, 66 percent had neurological deficits that improved or stabilized, compared with 75 percent who improved or stabilized when treated with both acyclovir and steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"     8",
"    </a>",
"    ]. Because patients received varying treatment regimens at different institutions in an uncontrolled setting, the determination of the optimal dose, duration of antiviral treatment, and benefit of concurrent steroid therapy awaits prospective studies with larger case numbers.",
"   </p>",
"   <p>",
"    When the diagnosis of VZV vasculopathy is being considered, and the clinician is awaiting CSF studies that detect anti-VZV IgG antibody or VZV DNA in CSF to confirm the diagnosis, it is advisable to begin treatment immediately with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    (10 to 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    three times daily). The duration of treatment will depend on the patient's clinical response. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Duration of treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As of November 2012, there is a shortage of IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    in the United States due to a manufacturing delay [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Clinicians should check the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm\">",
"     US Food and Drug Administration's website",
"    </a>",
"    for information about the availability of IV acyclovir. If IV acyclovir is not available, an alternative regimen can be used. Specific recommendations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"     \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since histologic specimens often demonstrate an inflammatory response in infected cerebral arteries, we give oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily for five days) without a steroid taper [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;During intravenous antiviral therapy, the patient is monitored clinically for stabilization of neurological deficits and observed for the development of any new strokes. Based on our clinical experience, we repeat CSF analysis if:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is not responding clinically within two weeks of intravenous antiviral therapy",
"     </li>",
"     <li>",
"      New lesions appear on MRI",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CSF analysis should also include evaluation for other concomitant infectious agents, such as mycobacteria, fungi, and Treponema pallidum (the causative agent of neurosyphilis), particularly in the patient with advanced AIDS where multiple infections may coexist. Consultation with an expert in HIV treatment and management is also important regarding the role of antiretroviral therapy.",
"   </p>",
"   <p>",
"    If the initial CSF contained more than 50 white blood",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    and the patient has not returned to baseline, we also repeat CSF examination to see if the pleocytosis is resolving with antiviral therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     DURATION OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially, we treat patients for a minimum of 14 days with antiviral therapy. If the patient does not improve clinically, or develops new lesions by MRI, or has a persistent pleocytosis, we often treat for an additional two to four weeks with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    based on our clinical experience.",
"   </p>",
"   <p>",
"    Unlike most acute viral encephalitides, VZV vasculopathy is often chronic and protracted. We have encountered multiple patients with VZV vasculopathy who continue to have new neurologic symptoms such as focal weakness and altered mental status after intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    treatment. Most patients were HIV-seropositive or had AIDS; one patient had diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that the risk of stroke is increased for at least one year after herpes zoster [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/34\">",
"     34",
"    </a>",
"    ]. Thus, it is plausible that widespread use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     zoster vaccine",
"    </a>",
"    may decrease the risk of VZV vasculopathy, since immunization generates an increase in VZV-specific cell-mediated immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/47\">",
"     47",
"    </a>",
"    ]. One retrospective study demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     herpes zoster vaccine",
"    </a>",
"    was effective in reducing herpes zoster disease and VZV-related hospitalizations for complications among persons between 60 and 80 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\", section on 'Adults &ge;60 years of age'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Zoster vaccination is recommended for individuals who are 60 years of age or older. Immunization is contraindicated in HIV-infected patients with a CD4 T-cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Varicella zoster virus (VZV) infection of cerebral arteries produces a vasculopathy, manifesting most often as ischemic stroke and less often as hemorrhagic stroke. Vasculopathy can occur after either varicella or herpes zoster. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The likely mechanism by which VZV causes stroke is by direct infection of cerebral arteries, which leads to a spectrum of both inflammatory and noninflammatory pathological changes including thrombosis, necrosis, dissection, and aneurysm formation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VZV vasculopathy usually manifests as ischemic stroke, but can also produce aneurysm, subarachnoid and cerebral hemorrhage, arterial ectasia, and carotid dissection. Patients may also have a history of recent zoster or varicella. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VZV vasculopathy involves both large and small arteries. Brain imaging typically shows ischemic or hemorrhagic infarctions at gray-white matter junctions. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A modest mononuclear pleocytosis on cerebrospinal fluid analysis is seen in approximately two-thirds of patients with VZV vasculopathy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Cerebrospinal fluid testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      VZV vasculopathy may be clinically suspected in a patient who presents with a stroke and has had a recent history of shingles. Supportive data include a mononuclear pleocytosis on CSF testing and MRI findings consistent with a hemorrhagic or ischemic lesion in gray-white matter junctions. The diagnosis is confirmed by testing for anti-VZV antibodies or VZV DNA in the CSF. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with suspected VZV vasculopathy who are awaiting their CSF laboratory testing results, we suggest empiric IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A reasonable regimen is 10 to 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      three times daily for a minimum of 14 days. We also suggest a short course of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for five days) without a steroid taper (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As of November 2012, there is a shortage of IV",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      in the United States due to a manufacturing delay [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21288/abstract/45,46\">",
"       45,46",
"      </a>",
"      ]. Clinicians should check the",
"      <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm\">",
"       US Food and Drug Administration's website",
"      </a>",
"      for information about the availability of IV acyclovir. If IV acyclovir is not available, an alternative IV regimen can be used. Specific recommendations are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=see_link&amp;anchor=H72507949#H72507949\">",
"       \"Acyclovir: An overview\", section on 'Acyclovir shortage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/1\">",
"      Gilden D, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol 2009; 8:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/2\">",
"      Fukumoto S, Kinjo M, Hokamura K, Tanaka K. Subarachnoid hemorrhage and granulomatous angiitis of the basilar artery: demonstration of the varicella-zoster-virus in the basilar artery lesions. Stroke 1986; 17:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/3\">",
"      Constantinescu CS. Association of varicella-zoster virus with cervical artery dissection in 2 cases. Arch Neurol 2000; 57:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/4\">",
"      Bhayani N, Ranade P, Clark NM, McGuinn M. Varicella-zoster virus and cerebral aneurysm: case report and review of the literature. Clin Infect Dis 2008; 47:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/5\">",
"      Cohrs RJ, Gilden DH. Prevalence and abundance of latently transcribed varicella-zoster virus genes in human ganglia. J Virol 2007; 81:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/6\">",
"      Holland GN. The progressive outer retinal necrosis syndrome. Int Ophthalmol 1994; 18:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/7\">",
"      Gilden DH, Beinlich BR, Rubinstien EM, et al. Varicella-zoster virus myelitis: an expanding spectrum. Neurology 1994; 44:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/8\">",
"      Nagel MA, Cohrs RJ, Mahalingam R, et al. The varicella zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology 2008; 70:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/9\">",
"      Kleinschmidt-DeMasters BK, Gilden DH. Varicella-Zoster virus infections of the nervous system: clinical and pathologic correlates. Arch Pathol Lab Med 2001; 125:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/10\">",
"      Mayberg M, Langer RS, Zervas NT, Moskowitz MA. Perivascular meningeal projections from cat trigeminal ganglia: possible pathway for vascular headaches in man. Science 1981; 213:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/11\">",
"      Mayberg MR, Zervas NT, Moskowitz MA. Trigeminal projections to supratentorial pial and dural blood vessels in cats demonstrated by horseradish peroxidase histochemistry. J Comp Neurol 1984; 223:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/12\">",
"      Saito K, Moskowitz MA. Contributions from the upper cervical dorsal roots and trigeminal ganglia to the feline circle of Willis. Stroke 1989; 20:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/13\">",
"      Linnemann CC Jr, Alvira MM. Pathogenesis of varicella-zoster angiitis in the CNS. Arch Neurol 1980; 37:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/14\">",
"      Doyle PW, Gibson G, Dolman CL. Herpes zoster ophthalmicus with contralateral hemiplegia: identification of cause. Ann Neurol 1983; 14:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/15\">",
"      Eidelberg D, Sotrel A, Horoupian DS, et al. Thrombotic cerebral vasculopathy associated with herpes zoster. Ann Neurol 1986; 19:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/16\">",
"      Morgello S, Block GA, Price RW, Petito CK. Varicella-zoster virus leukoencephalitis and cerebral vasculopathy. Arch Pathol Lab Med 1988; 112:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/17\">",
"      Gray F, B&eacute;lec L, Lescs MC, et al. Varicella-zoster virus infection of the central nervous system in the acquired immune deficiency syndrome. Brain 1994; 117 ( Pt 5):987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/18\">",
"      Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, et al. The vasculopathy of varicella-zoster virus encephalitis. Ann Neurol 1995; 37:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/19\">",
"      Gilden DH, Kleinschmidt-DeMasters BK, Wellish M, et al. Varicella zoster virus, a cause of waxing and waning vasculitis: the New England Journal of Medicine case 5-1995 revisited. Neurology 1996; 47:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/20\">",
"      Melanson M, Chalk C, Georgevich L, et al. Varicella-zoster virus DNA in CSF and arteries in delayed contralateral hemiplegia: evidence for viral invasion of cerebral arteries. Neurology 1996; 47:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/21\">",
"      Kleinschmidt-DeMasters BK, Mahalingam R, Shimek C, et al. Profound cerebrospinal fluid pleocytosis and Froin's Syndrome secondary to widespread necrotizing vasculitis in an HIV-positive patient with varicella zoster virus encephalomyelitis. J Neurol Sci 1998; 159:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/22\">",
"      Manco-Johnson MJ, Nuss R, Key N, et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 1996; 128:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/23\">",
"      Josephson C, Nuss R, Jacobson L, et al. The varicella-autoantibody syndrome. Pediatr Res 2001; 50:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/24\">",
"      Massano J, Ferreira D, Toledo T, et al. Stroke and multiple peripheral thrombotic events in an adult with varicella. Eur J Neurol 2008; 15:e90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/25\">",
"      Kurug&ouml;l Z, Vardar F, Ozkinay F, et al. Lupus anticoagulant and protein S deficiency in a child who developed disseminated intravascular coagulation in association with varicella. Turk J Pediatr 2001; 43:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/26\">",
"      Regnault V, Boehlen F, Ozsahin H, et al. Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation. J Thromb Haemost 2005; 3:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/27\">",
"      Askalan R, Laughlin S, Mayank S, et al. Chickenpox and stroke in childhood: a study of frequency and causation. Stroke 2001; 32:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/28\">",
"      Amlie-Lefond C, Bernard TJ, S&eacute;bire G, et al. Predictors of cerebral arteriopathy in children with arterial ischemic stroke: results of the International Pediatric Stroke Study. Circulation 2009; 119:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/29\">",
"      Braun KP, Bulder MM, Chabrier S, et al. The course and outcome of unilateral intracranial arteriopathy in 79 children with ischaemic stroke. Brain 2009; 132:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/30\">",
"      Gray F, Mohr M, Rozenberg F, et al. Varicella-zoster virus encephalitis in acquired immunodeficiency syndrome: report of four cases. Neuropathol Appl Neurobiol 1992; 18:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/31\">",
"      Petito CK, Cho ES, Lemann W, et al. Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 1986; 45:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/32\">",
"      Ryder JW, Croen K, Kleinschmidt-DeMasters BK, et al. Progressive encephalitis three months after resolution of cutaneous zoster in a patient with AIDS. Ann Neurol 1986; 19:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/33\">",
"      Hovens MM, Vaessen N, Sijpkens YW, de Fijter JW. Unusual presentation of central nervous system manifestations of Varicella zoster virus vasculopathy in renal transplant recipients. Transpl Infect Dis 2007; 9:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/34\">",
"      Kang JH, Ho JD, Chen YH, Lin HC. Increased risk of stroke after a herpes zoster attack: a population-based follow-up study. Stroke 2009; 40:3443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/35\">",
"      Picard O, Brunereau L, Pelosse B, et al. Cerebral infarction associated with vasculitis due to varicella zoster virus in patients infected with the human immunodeficiency virus. Biomed Pharmacother 1997; 51:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/36\">",
"      Berkefeld J, Enzensberger W, Lanfermann H. MRI in human immunodeficiency virus-associated cerebral vasculitis. Neuroradiology 2000; 42:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/37\">",
"      Hall S, Carlin L, Roach ES, McLean WT Jr. Herpes zoster and central retinal artery occlusion. Ann Neurol 1983; 13:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/38\">",
"      Gilden DH, Lipton HL, Wolf JS, et al. Two patients with unusual forms of varicella-zoster virus vasculopathy. N Engl J Med 2002; 347:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/39\">",
"      Persson A, Bergstr&ouml;m T, Lindh M, et al. Varicella-zoster virus CNS disease--viral load, clinical manifestations and sequels. J Clin Virol 2009; 46:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/40\">",
"      Katchanov J, Siebert E, Klingebiel R, Endres M. Infectious vasculopathy of intracranial large- and medium-sized vessels in neurological intensive care unit: a clinico-radiological study. Neurocrit Care 2010; 12:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/41\">",
"      Gregoire SM, van Pesch V, Goffette S, et al. Polymerase chain reaction analysis and oligoclonal antibody in the cerebrospinal fluid from 34 patients with varicella-zoster virus infection of the nervous system. J Neurol Neurosurg Psychiatry 2006; 77:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/42\">",
"      Haug A, Mahalingam R, Cohrs RJ, et al. Recurrent polymorphonuclear pleocytosis with increased red blood cells caused by varicella zoster virus infection of the central nervous system: Case report and review of the literature. J Neurol Sci 2010; 292:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/43\">",
"      Schubert J, Weissbrich B. Detection of virus-specific intrathecally synthesised immunoglobulin G with a fully automated enzyme immunoassay system. BMC Neurol 2007; 7:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/44\">",
"      Nagel MA, Forghani B, Mahalingam R, et al. The value of detecting anti-VZV IgG antibody in CSF to diagnose VZV vasculopathy. Neurology 2007; 68:1069.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Red Book Online News. Shortage of intravenous acyclovir. file://aapredbook.aappublications.org/site/news#76 (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Current Drug Shortages. file://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm314739.htm (Accessed on December 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/47\">",
"      Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21288/abstract/48\">",
"      Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8271 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21288=[""].join("\n");
var outline_f20_50_21288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Direct infection of blood vessels by VZV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Varicella infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Brain imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Angiographic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CEREBROSPINAL FLUID TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PATIENT MONITORING DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      DURATION OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8271\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8271|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/1/25618\" title=\"diagnostic image 1\">",
"      MRI multifocal vasculop",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8271|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/7/23672\" title=\"picture 1\">",
"      Viral findings VZV vasc",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/60/10183?source=related_link\">",
"      Acyclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2378?source=related_link\">",
"      Clinical manifestations of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22278?source=related_link\">",
"      Epidemiology of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/61/23513?source=related_link\">",
"      Ischemic stroke in children and young adults: Etiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43608?source=related_link\">",
"      Ischemic stroke in children: Evaluation, initial management, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17290?source=related_link\">",
"      Neuroimaging of acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/50/25386?source=related_link\">",
"      Primary angiitis of the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23110?source=related_link\">",
"      Treatment of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_50_21289="Rotator cuff tendinopathy";
var content_f20_50_21289=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rotator cuff tendinopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21289/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21289/contributors\">",
"     Stephen M Simons, MD, FACSM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21289/contributors\">",
"     David Kruse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21289/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21289/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21289/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21289/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/50/21289/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shoulder pain is a common complaint in the primary care setting. Prevalence studies indicate that 16 to 34 percent of the general population suffers from shoulder pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients with rotator cuff pathology comprise a sizeable portion of this subpopulation. A thorough understanding of the anatomy and pathophysiology of the shoulder will help the clinician evaluate these patients.",
"   </p>",
"   <p>",
"    The clinical pathophysiology, diagnosis, and management of rotator cuff tendinopathy will be reviewed here. The general evaluation of the patient with shoulder pain, the shoulder examination, other specific shoulder problems, and general treatments for tendinopathy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the pathogenesis of tendon overuse disorders remains incomplete. Histopathological, biochemical, and molecular studies reveal a degenerative process with little evidence of inflammation, although inflammation may play a role initially. The pathophysiology of chronic tendon disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=see_link\">",
"     \"Overview of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term \"tendinitis\" came into common parlance to describe chronic painful tendon injuries before the underlying pathology was better understood. The terms \"tendinosis\" or \"tendinopathy\" may better describe chronic tendon disorders. Despite support for the term \"tendinopathy\" among experts, the term \"tendinitis\" is deeply ingrained in clinical practice and the historical literature. In this review, we use the term \"tendinopathy\" to refer to symptomatic primary rotator cuff tendon disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of shoulder complaints is approximately 11.2 cases per 1000 patients per year [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/3\">",
"     3",
"    </a>",
"    ]. Shoulder pain occurs more often in the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In working populations, the incidence of shoulder-related symptoms may be as high as 14 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rotator cuff disorders are a significant source of morbidity among manual laborers and those whose work involves a great deal of repetitive motion [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. In the general population as well, rotator cuff disease is the most common cause of shoulder pain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/2-5,8,9\">",
"     2-5,8,9",
"    </a>",
"    ]. Any of the rotator cuff tendons may be involved, but the supraspinatus tendon is most frequently injured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repetitive overhead activity, whether in sport or work, is a major risk factor for rotator cuff tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/3\">",
"     3",
"    </a>",
"    ]. Other risk factors include anatomic variants that predispose to rotator cuff impingement, scapular instability or dyskinesis, and older age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. In the working population, problems in one shoulder can place the contralateral shoulder at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/2\">",
"     2",
"    </a>",
"    ]. Increased body-mass index may also be a risk factor for rotator cuff tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Athletes who perform overhead activity, such as swimming, tennis, throwing, golf, weightlifting, volleyball, and gymnastics, are at risk. Weakness or fatigue of the rotator cuff muscles or secondary supporting muscles is common and can lead to poor mechanics and dysfunction of the shoulder. Instability or hypermobility of the glenohumeral joint unrelated to muscle weakness also predisposes to rotator cuff injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5,14\">",
"     5,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RELEVANT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical anatomy of the shoulder is discussed in detail elsewhere (",
"    <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"UTD.htm?35/8/35978\">",
"     figure 1A-C",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H2#H2\">",
"     \"Evaluation of the patient with shoulder complaints\", section on 'Anatomy and biomechanics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BASIC BIOMECHANICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically relevant shoulder motions involving the glenohumeral and scapulothoracic joints are more complex than previously appreciated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5\">",
"     5",
"    </a>",
"    ]. Nevertheless, the function of the rotator cuff is relatively easy to understand and provides the basis for clinical testing.",
"   </p>",
"   <p>",
"    Rotator cuff tears most often involve damage to the supraspinatus tendon. The supraspinatus muscle assists in abduction and external rotation of the shoulder. Researchers have tried to identify accurate clinical methods of assessing supraspinatus function [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5\">",
"     5",
"    </a>",
"    ]. According to one approach, the function of the supraspinatus can be tested in relative isolation with the arm abducted in the scapular plane (approximately 30 degrees of forward flexion) and the shoulder in full internal rotation (the so called \"empty can\" position) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/15\">",
"     15",
"    </a>",
"    ]. Despite these efforts, it appears that supraspinatus function cannot be tested in isolation because of the inextricable role of other shoulder muscles in abduction and external rotation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The infraspinatus muscle assists in external rotation and abduction of the shoulder. It is assisted in these motions by the deltoid, teres minor, and supraspinatus. Although some researchers advocate specific assessment techniques, attempts at isolating infraspinatus function for clinical testing have proved difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. The infraspinatus is commonly tested by having the patient isometrically resist external rotation with the arm at the side and the elbow flexed at 90 degrees in a neutral rotation. This method is thought to limit the assistance of the deltoid and supraspinatus.",
"   </p>",
"   <p>",
"    The teres minor muscle also assists in external rotation and abduction of the shoulder. EMG studies indicate that the teres minor is especially active in external rotation when the arm is abducted to 90 degrees [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/18\">",
"     18",
"    </a>",
"    ]. Biomechanical studies suggest that the teres minor contributes up to 45 percent of the power of external rotation. With hypertrophy the teres minor can exhibit sufficient strength to compensate for tears in the infraspinatus that might otherwise manifest during testing of external rotation against resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The subscapularis muscle's primary function is to internally rotate the shoulder, but it also assists in abduction and adduction. EMG studies show that the pectoralis major, latissimus dorsi, and teres major assist in internal rotation and may confound clinical testing of the subscapularis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The subscapularis tendon helps to stabilize the long head biceps tendon and tears of the subscapularis can be associated with biceps tendon injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25991?source=see_link\">",
"     \"Biceps tendinopathy and tendon rupture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to its motor functions, the rotator cuff compresses the humoral head in the glenoid fossa, thereby stabilizing the glenohumeral joint. By means of this compression, the rotator cuff counterbalances the elevating forces of the deltoid, as well as the forces of other muscles acting on the humerus [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Weakness of the rotator cuff can lead to superior subluxation of the humeral head when the shoulder is abducted beyond 90 degrees, predisposing to impingement syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology and the mechanism of injury for rotator cuff tendinopathy remain unclear, but researchers propose two theories: one emphasizes biomechanical factors and the other vascular factors [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5,10,15,16,21\">",
"     5,10,15,16,21",
"    </a>",
"    ]. Most likely, elements of both explanations play a role. An alternative approach to describing the mechanism of injury involves intrinsic factors, directly related to the tendon, and extrinsic factors, related to surrounding structures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrinsic mechanism &ndash; This mechanism emphasizes injury within the tendon from tendon overload, degeneration, or other insult [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5,10,15,16\">",
"       5,10,15,16",
"      </a>",
"      ]. A compromised microvascular system compounds the problem by creating a \"critical zone\" of avascularity at the site of injury. This proposed mechanism involving interplay between tendon injury and microvascular compromise remains controversial.",
"      <br/>",
"      <br/>",
"      Tensile overload during eccentric contraction (ie, muscle contracts while lengthening) with overhead activity is implicated in this mechanism. This is particularly true for the overhead athlete. As an example, when a pitcher's throwing arm decelerates after release of the ball, the lengthening posterior rotator cuff muscles contract to slow the arm. This eccentric contraction places a large tensile load on the posterior rotator cuff.",
"      <br/>",
"      <br/>",
"      Age and comorbidity can play a role in this mechanism. Aging tendons develop microtears, calcification, and fibrovascular proliferation. Comorbidities (eg, diabetes mellitus, rheumatoid arthritis, Marfan's or Ehlers-Danlos syndromes) can contribute to tendon pathology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=see_link\">",
"       \"Musculoskeletal complications in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extrinsic mechanism &ndash; This mechanism emphasizes the role of compressive forces exerted by surrounding structures in causing rotator cuff injury [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5,10,15\">",
"       5,10,15",
"      </a>",
"      ]. Various structures may impinge the rotator cuff, including: the acromion, the coracoacromial ligaments, the coracoid process, and the acromioclavicular joint with osteoarthritic changes on its undersurface (",
"      <a class=\"graphic graphic_figure graphicRef72709 graphicRef54102 graphicRef69995 \" href=\"UTD.htm?35/8/35978\">",
"       figure 1A-C",
"      </a>",
"      ). Glenohumeral instability can also lead to secondary compressive forces. The mechanics of such impingement is discussed elsewhere. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Basic biomechanics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"       \"Shoulder impingement syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotator cuff tendinopathy may be a manifestation of shoulder impingement, but must be distinguished from other causes of shoulder pain (",
"    <a class=\"graphic graphic_table graphicRef55507 \" href=\"UTD.htm?21/36/22091\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53038 \" href=\"UTD.htm?9/20/9549\">",
"     table 2",
"    </a>",
"    ). A detailed discussion of the differential diagnosis and clinical assessment of shoulder pain is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=see_link\">",
"     \"Shoulder impingement syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In particular, it is important to distinguish rotator cuff tendinopathy from cervical radiculopathy, acromioclavicular osteoarthritis, subacromial bursitis, bicipital tendinopathy, rotator cuff tear, glenoid labrum tear, and adhesive capsulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with rotator cuff tendinopathy complain of shoulder pain with overhead activity. Painful daily activities may include putting on a shirt or brushing hair. Patients may localize the pain to the lateral deltoid and often describe pain at night, especially when lying on the affected shoulder. The history often reveals risk factors. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology and risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Overhead athletes often complain of pain while performing their sport (eg, pitching, freestyle swimming), weakness, or a decline in performance. Reduced performance generally manifests as diminished speed, accuracy, or endurance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performance of the shoulder examination is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link\">",
"     \"Physical examination of the shoulder\"",
"    </a>",
"    .) The portions of this examination of particular relevance to rotator cuff pathology are discussed briefly below.",
"   </p>",
"   <p>",
"    Overall, examination techniques for rotator cuff pathology are moderately sensitive, but one small trial found that a battery of carefully performed physical examination tests for rotator cuff tendinopathy failed to diagnose a number of pathologic conditions identified readily by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Musculoskeletal ultrasound'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Notable examination findings consistent with rotator cuff tendinopathy are described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection &ndash; With long-standing rotator cuff tendinopathy, atrophy of supraspinatus and infraspinatus muscles may be present. A sunken appearance is appreciable in the corresponding scapular fossa.",
"      <br/>",
"      <br/>",
"      Movement of the scapula of the affected shoulder may demonstrate asymmetric motion compared with the unaffected side. Scapular motion asymmetries may be subtle and dynamic in athletes. The inherent strength of many athletes may produce a normal appearing scapular movement with a single abduction. Repetitive abduction with some resistance to near exhaustion may reveal subtle asymmetries of scapulothoracic movement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link&amp;anchor=H1181467#H1181467\">",
"       \"Physical examination of the shoulder\", section on 'Scapulothoracic motion and strength'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neck examination &ndash; Shoulder pain may be referred from the neck. It is important to examine the neck and perform a screening neurologic examination to rule out cervical spine pathology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link\">",
"       \"Evaluation of the patient with neck pain and cervical spine disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Palpation &ndash; Rotator cuff tendinopathy often creates tenderness over the affected musculature (supraspinatus, infraspinatus) or focal subacromial tenderness at the lateral or posterior-lateral border of the acromion. However, the location of the rotator cuff deep to the deltoid makes palpation difficult and unreliable. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link&amp;anchor=H11044346#H11044346\">",
"       \"Physical examination of the shoulder\", section on 'Palpation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Range of motion (ROM) &ndash; Painful ROM above 90 degrees of abduction, or pain with internal rotation suggests rotator cuff tendinopathy (",
"      <a class=\"graphic graphic_picture graphicRef70787 \" href=\"UTD.htm?0/11/177\">",
"       picture 1",
"      </a>",
"      ). Painful arc testing demonstrates greater specificity than sensitivity and is most useful when used in conjunction with the Neer and Hawkins-Kennedy tests. Pain that occurs between 60 and 120 degrees of active abduction marks a positive arc test. Abduction is performed with the arm at 30 degrees of horizontal adduction (ie, in the plane of the scapula). With rotator cuff pathology, passive ROM is usually greater than active ROM. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link&amp;anchor=H11044360#H11044360\">",
"       \"Physical examination of the shoulder\", section on 'Range of motion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Strength testing &ndash; Supraspinatus strength is evaluated by performing the \"empty can\" (or Jobe's strength) test (",
"      <a class=\"graphic graphic_picture graphicRef74738 \" href=\"UTD.htm?1/60/1987\">",
"       picture 2",
"      </a>",
"      ). Internal and external rotation strength of the shoulder can be tested with the patient's arms at their sides and the elbows in 90 degrees of flexion (",
"      <a class=\"graphic graphic_picture graphicRef77117 \" href=\"UTD.htm?28/13/28882\">",
"       picture 3",
"      </a>",
"      ). The push-off (or Gerber's lift off) test can be used to assess internal rotation strength (",
"      <a class=\"graphic graphic_picture graphicRef71635 \" href=\"UTD.htm?42/9/43155\">",
"       picture 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link&amp;anchor=H1180003#H1180003\">",
"       \"Physical examination of the shoulder\", section on 'Examination for rotator cuff pathology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Special tests &ndash; The Neer and Hawkins-Kennedy tests are commonly used to diagnose impingement (",
"      <a class=\"graphic graphic_picture graphicRef76237 \" href=\"UTD.htm?43/7/44149\">",
"       picture 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef60425 \" href=\"UTD.htm?19/27/19891\">",
"       picture 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=see_link&amp;anchor=H5844119#H5844119\">",
"       \"Physical examination of the shoulder\", section on 'Special tests for shoulder impingement'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Clinicians may want to perform an acromioclavicular (AC) compression or crossover test. This test may be positive due to AC joint or rotator cuff pathology, and therefore is most useful for ruling out AC injury when negative. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=see_link&amp;anchor=H5#H5\">",
"       \"Acromioclavicular joint injuries\", section on 'History and examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       Lidocaine",
"      </a>",
"      &nbsp;injection test &ndash; A subacromial injection of lidocaine can be used to alleviate pain and to distinguish between rotator cuff tendinopathy and tear. Examination with adequate analgesia following injection provides a more accurate assessment of muscle strength. Patients with tendinopathy exhibit normal strength with pain relief; those with a large tear have persistent weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to distinguish rotator cuff tendinopathy from rotator cuff tear because management is different. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine plain radiographs of the shoulder do not reveal signs of rotator cuff tendinopathy and are generally not indicated in patients suspected of such injuries. Plain films may be useful in the following clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment when there is no response to conservative therapy and other pathology is suspected (eg, AC joint arthritis, glenohumeral joint arthritis, tendon calcification)",
"     </li>",
"     <li>",
"      Recurrent rotator cuff tendinopathy",
"     </li>",
"     <li>",
"      Anatomical evaluation prior to subacromial or glenohumeral joint injection (not essential prior to injection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Musculoskeletal ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinicians consider musculoskeletal ultrasound (MSK US) to be the gold standard for the initial evaluation of tendon disorders, including rotator cuff disease [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. MSK US enables the trained clinician to evaluate tendons while they are in motion and to compare them with the contralateral shoulder at the bedside. Clinicians can then correlate MSK US and physical examination findings. Other advantages include ease of use, absence of radiation exposure, and relative low cost [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple studies demonstrate ultrasound's high sensitivity in diagnosing rotator cuff disease, particularly complete tendon tears [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. Changes noted on ultrasound diagnostic for rotator cuff pathology include: tendon hypoechogenicity or thickening with or without internal hypo or hyperechoic foci [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/22,30\">",
"     22,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MSK US has limitations. Occasionally it is difficult to visualize the entire rotator cuff. Further research is needed to determine the accuracy and role of MSK US in the diagnosis of shoulder disorders, such as capsular and labral pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is used to rule out rotator cuff tear when conservative therapy fails, to assess for tear suspected on clinical grounds, and to aid in diagnosis when shoulder pathology is unclear. MRI can also be used when diagnostic confirmation is needed to guide the patient's return to sport.",
"   </p>",
"   <p>",
"    MRI findings must be interpreted in clinical context. An observational study of MRI performed in 96 asymptomatic individuals showed rotator cuff tears in 34 percent overall and 54 percent of patients over 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/12\">",
"     12",
"    </a>",
"    ]. Rotator cuff degeneration produces a high-intensity signal on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ORTHOPEDIC REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many options for the medical treatment of rotator cuff tendinopathy exist. Orthopedic surgical referral is obtained if nonoperative therapy fails to provide relief within 6 to 9 months or a diagnosis of rotator cuff tear is made. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with adhesive capsulitis from longstanding rotator cuff disease that is refractory to conservative therapy need surgical referral. The appropriate surgical intervention varies according to the patient's age, comorbidities, and level of activity. Three basic surgical interventions exist: debridement, acromioplasty (ie, shaving of the acromion's undersurface to relieve impingement) with debridement, and rotator cuff repair [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many treatments for rotator cuff tendinopathy exist, but few are supported by strong scientific evidence. Below is a discussion of the general management of rotator cuff tendinopathy. Our suggested approach to the management of suspected rotator cuff injury is described below; a general discussion of treatments for tendinopathy is provided separately. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Approach to management'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Basic management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy for rotator cuff tendinopathy consists of ice, rest, and nonsteroidal anti-inflammatory medication (NSAID) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cryotherapy &ndash; Despite a dearth of scientific research to support its use, cryotherapy is generally believed to decrease acute swelling and inflammation and to provide some analgesia [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/15\">",
"       15",
"      </a>",
"      ]. Ice may be especially effective when tendinopathy is associated with surrounding inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rest &ndash; Rest means avoiding activities that aggravate symptoms, including all overhead activities.",
"     </li>",
"     <li>",
"      NSAIDs &ndash; For acute injuries, we give a short course (ie, 7 to 10 days) of scheduled NSAID therapy. Thereafter, patients may use an NSAID for occasional analgesia if they find the medication effective.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of NSAIDs for tendinopathy remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]. During the period of acute injury, debate continues about whether blocking the inflammatory response inhibits healing. In the treatment of chronic tendinopathy, it is unclear what benefit NSAIDs provide without evidence of an inflammatory process. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathophysiology and mechanism of injury'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A review of 32 studies addressing the benefit of NSAIDs in tendinopathy identified only nine prospective, placebo-controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/15\">",
"     15",
"    </a>",
"    ]. Of these nine studies, five found some analgesic effect from NSAIDs; none looked at tendon healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Adjunct therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No clear evidence exists to support the use of the modalities listed here and we do not routinely use them in the care of our patients. Adjunct therapies may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrical stimulation, phonophoresis, and iontophoresis &ndash; Electrical stimulation, phonophoresis, and iontophoresis are three therapeutic modalities used to aid in pain relief. Phonophoresis uses ultrasound to enhance the transdermal absorption of topically applied analgesics and antiinflammatory agents. Iontophoresis uses electrical charge for the same purpose.",
"     </li>",
"     <li>",
"      Therapeutic ultrasound &ndash; Ultrasound theoretically stimulates tendon healing via collagen production, thereby increasing tensile strength [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5\">",
"       5",
"      </a>",
"      ]. There is little evidence to support its use [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/15,31\">",
"       15,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laser &ndash; A metaanalysis of studies of physiotherapy interventions for shoulder pain showed no benefit from laser therapy in the treatment of rotator cuff tendinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of physical therapy techniques are used to rehabilitate patients with rotator cuff tendinopathy. Although well-performed clinical trials of physical therapy programs are scarce [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/31\">",
"     31",
"    </a>",
"    ], we prescribe the exercises described below. Many good rehabilitation regimens and web sites exist. As an example, the website of the Nicholas Institute of Sports Medicine and Athletic Trauma of Lenox Hill Hospital provides diagrams and a description of many shoulder strengthening exercises (",
"    <a class=\"external\" href=\"file://www.nismat.org/orthocor/programs/upperstr.html\">",
"     www.nismat.org/orthocor/programs/upperstr.html",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Range of motion exercises can help to prevent shoulder stiffness and the complications of adhesive capsulitis. Generally, full range of motion should be achieved prior to strengthening exercises [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stretching and strengthening of the muscles of the rotator cuff are basic components of physical therapy. A systematic review of physiotherapy interventions for shoulder pain found that such exercises are effective for short term recovery and long term function [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/31\">",
"       31",
"      </a>",
"      ]. The combination of mobilization (ie, not keeping the arm in a sling) and exercise showed greater benefit than exercise alone.",
"     </li>",
"     <li>",
"      Rotator cuff rehabilitation that focuses on the restoration of proper muscle activation and appropriate strength balance among individual muscles of the rotator cuff is important [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/32\">",
"       32",
"      </a>",
"      ]. Exercises to strengthen the scapular stabilizers and better integrate their function with the rotator cuff are emphasized. The restoration of range of motion, strength, and coordination (ie, kinetic chain restoration) marks completion of a rehabilitation program.",
"     </li>",
"     <li>",
"      Eccentric exercise is the application of a load (ie, muscular contraction) during the lengthening of a muscle. Several studies suggest that eccentric exercise stimulates healing and provides effective rehabilitation of tendinopathy. Preliminary trials in rotator cuff disease suggest this approach may be beneficial, but further study is needed [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/33\">",
"       33",
"      </a>",
"      ]. Eccentric exercise and other rehabilitation techniques using heavy loads are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of the management of overuse (chronic) tendinopathy\", section on 'Eccentric and heavy load exercise'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aerobic fitness should be maintained by the athlete throughout the rehabilitation process and beyond.",
"     </li>",
"     <li>",
"      Once rehabilitation is complete, the need for ongoing exercises to prevent recurrence and maintain fitness should be emphasized [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/32\">",
"       32",
"      </a>",
"      ]. Many sports place greater demands on the shoulder than activities of daily living. Rehabilitation and maintenance programs should incorporate exercises that simulate the specific demands of the athlete's sport. As examples, a tennis player may perform a service-type motion using a five pound dumbbell, while a pitcher may perform a throwing motion using a three pound dumbbell.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Subacute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no improvement is achieved within two to three months with conservative therapy other treatment options may be considered, including [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although subacromial glucocorticoid injection is a common treatment for rotator cuff disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5\">",
"     5",
"    </a>",
"    ], clear evidence of benefit is lacking. We believe it is reasonable to treat patients whose symptoms do not improve after several weeks of conservative management, including physical therapy, or whose pain prevents them from participating in physical therapy with a",
"    <strong>",
"     single",
"    </strong>",
"    injection of a glucocorticoid combined with an analgesic. The general role of glucocorticoids in the treatment of chronic overuse tendinopathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of the management of overuse (chronic) tendinopathy\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One systematic review found only a small benefit from injection at four weeks compared with placebo, and no benefit over NSAIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/34\">",
"     34",
"    </a>",
"    ]. Another systematic review confirmed these findings and concluded there is little evidence to support the use of steroid injection in rotator cuff tendinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/35\">",
"     35",
"    </a>",
"    ]. Conversely, yet another systematic review found that subacromial injection for rotator cuff tendinitis was more effective than NSAIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/36\">",
"     36",
"    </a>",
"    ]. Authors of all these reviews found the available studies to be small and of variable quality, often lacking clear outcome measures, making it difficult to draw clear conclusions.",
"   </p>",
"   <p>",
"    One double-blinded, randomized trial found no difference in function or symptoms in patients injected with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    and xylocaine compared with those injected with xylocaine alone, suggesting that glucocorticoids provide no additional benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review assessing the value of physical therapy in the treatment of shoulder pain found some evidence to suggest that glucocorticoids may provide greater benefit compared with physiotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/31\">",
"     31",
"    </a>",
"    ]. Steroid injection may reduce pain, thereby enabling earlier participation in range of motion exercises and rehabilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Topical glyceryl trinitrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical nitrate therapy is thought to cause local vasodilation, increasing blood flow to the damaged tendon [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/15\">",
"     15",
"    </a>",
"    ]. One randomized, double-blinded, placebo-controlled study of 53 patients with a clinical or MRI diagnosis of supraspinatus tendinopathy found significant improvement in symptoms and rotator cuff function at 24 weeks in those treated with topical nitrates [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/38\">",
"     38",
"    </a>",
"    ]. The median duration of symptoms at the study's initiation was 14 months. Headache was the most common side effect. Clinicians should counsel patients that headache severity decreases over the course of treatment. Clinicians should exercise caution when considering the use of nitrates in patients with hypotension, pregnancy, migraine headaches, and diuretic therapy. Nitrates are relatively contraindicated in patients with ischemic heart disease, anemia, phosphodiesterase inhibitor therapy (eg, Viagra&reg;), sensitivity to nitrate therapy, and angle-closure glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Experimental treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little evidence exists to support the use of the experimental treatments mentioned below. These treatment options include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Topical NSAIDs &ndash; Topical NSAIDs in the form of gels and patches provide some symptomatic relief in tendinopathy and osteoarthritis, and this method of drug delivery may limit systemic side effects. The use of topical NSAIDs is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of the management of overuse (chronic) tendinopathy\", section on 'Nonsteroidal antiinflammatory drugs (NSAIDs)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=see_link\">",
"       \"Investigational approaches to the pharmacologic therapy of osteoarthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperthermia &ndash; Hyperthermia machines use a microwave power generator at 434 MHz to provide deep-heating of muscles. Hyperthermia treatment is thought to increase local blood flow to damaged tissue. In one small prospective trial of athletes with supraspinatus tendinopathy, patients randomly assigned to treatment with hyperthermia had greater short-term reductions in pain compared with those treated with ultrasound or therapeutic exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/39\">",
"       39",
"      </a>",
"      ]. Further research is needed to confirm these results and to determine the appropriate role for this modality in the treatment of tendinopathy.",
"     </li>",
"     <li>",
"      Extracorporeal shock wave therapy (ESWT) &ndash; Randomized trials show that ESWT provides benefit when treating calcific tendinopathies, including the rotator cuff [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/40\">",
"       40",
"      </a>",
"      ]. However, there is no evidence to support its use in noncalcific tendinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/15,41\">",
"       15,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Platelet rich plasma (PRP) has been proposed as a treatment option for chronic, refractory, tendinopathy. &nbsp;However, evidence supporting its use as a treatment specifically for rotator cuff tendinopathy is lacking. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of the management of overuse (chronic) tendinopathy\", section on 'Dry needling and autologous blood/platelet rich plasma injection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     APPROACH TO MANAGEMENT",
"    </span>",
"   </p>",
"   <p>",
"    The clinical diagnosis of rotator cuff tendinopathy can be difficult, particularly if the clinician is not skilled in musculoskeletal ultrasound (MSK US). We approach patients with suspected rotator cuff pathology in the manner described here, but recognize that alternative approaches may be reasonable. A management algorithm outlining our approach is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef65343 \" href=\"UTD.htm?8/13/8415\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We begin with a focused history and physical examination (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical presentation and examination'",
"    </a>",
"    above). The examination includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete neck examination",
"     </li>",
"     <li>",
"      Inspection for rotator cuff atrophy",
"     </li>",
"     <li>",
"      Evaluation of range of motion (including painful arc testing)",
"     </li>",
"     <li>",
"      Rotator cuff strength testing (including drop arm test and external rotation strength testing for rotator cuff tear)",
"     </li>",
"     <li>",
"      Specialty testing (including the Neer and Hawkins-Kennedy tests)",
"     </li>",
"     <li>",
"      Bedside MSK US, if the technology is available and the examiner proficient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If we suspect a clinically significant rotator cuff tear based on the history and examination (eg, weakness that impairs function), we generally refer the patient to an orthopedic surgeon. We maintain a lower threshold for referral in the case of high-functioning athletes. If we suspect a rotator cuff tear but the patient has minimal weakness and reasonable motion, we generally embark on a course of conservative medical management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"     \"Presentation and diagnosis of rotator cuff tears\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If we suspect rotator cuff tendinopathy, we initiate conservative medical management, which includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cryotherapy (for acute injuries) (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Acute treatment'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Relative rest (avoid aggravating activities)",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatories (NSAID) for 7 to 10 days",
"     </li>",
"     <li>",
"      Physical therapy (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Physical therapy'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration and success of physical therapy depends upon many factors, including the severity of the tendinopathy, compliance with treatment, and the appropriateness of the program prescribed. We believe that whenever possible it is important for patients to begin rehabilitation under the guidance of a knowledgeable professional (eg, athletic trainer or physical therapist with experience managing rotator cuff injury). The timing of follow-up is discussed below. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Follow-up care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If function and symptoms improve over several weeks of physical therapy, we have the patient continue therapy and begin a gradual, stepwise resumption of activities, including sports. Should function fail to improve despite adequate rehabilitation, we obtain imaging studies. MSK US, if not performed previously, is obtained first. We perform a plain radiograph for persistent symptoms to assess for anatomic variants, such as a downsloping acromion or os acromiale, and acromioclavicular or glenohumeral osteoarthritis. We obtain an MRI if the MSK US is nondiagnostic, a rotator cuff tear is suspected, or the diagnosis is unclear. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Radiographic findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Subsequent management depends upon the results of imaging studies. Alternative diagnoses are managed accordingly and clinically significant rotator cuff tears referred to an orthopedic surgeon. For rotator cuff tendinopathy, we continue conservative management. Some clinicians may choose to incorporate adjunct treatments, such as glucocorticoid injection, at this point. Physical therapy may require several months before adequate shoulder function is achieved. We refer the patient to an orthopedic surgeon if, after six to nine months of conservative treatment, patient function and symptoms fail to improve significantly. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Indications for orthopedic referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial assessment of an acute injury, the patient should return to clinic within one to two weeks for reevaluation of symptoms and function. This reevaluation helps to determine further workup, or referral. Once a long-term care program is established, monthly follow-up is appropriate. If a rapid return to sport or work is desired, more frequent reevaluation may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated, long-standing rotator cuff tendinopathy can cause a significant loss of shoulder range of motion. A vicious cycle can ensue, with diminished motion leading to diminished use. Ultimately, adhesive capsulitis can result and may be difficult to treat. Rotator cuff tendon degeneration can lead to tendon tears. The initial degenerative changes cause dysfunction of the tendon, with alterations in mechanics causing further degeneration, and eventually tear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/10\">",
"     10",
"    </a>",
"    ]. The likelihood of these complications increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once an athlete can exhibit full range of motion with appropriate strength and shoulder stability, the athlete can return to activity as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21289/abstract/42\">",
"     42",
"    </a>",
"    ]. A gradual, stepwise increase in activity is preferable. Everyone involved in the athlete's care, including the clinician, athlete, athletic trainer, and coach, should be aware of the progression of activity and monitor the athlete's condition. The nature of this stepwise return to full participation is determined on a sport-specific basis.",
"   </p>",
"   <p>",
"    Return to work is also based upon the return of function, including full range of motion and strength. A graded return to work activity may not be possible. Therefore, the patient should perform work-specific activity without difficulty and without return of symptoms prior to resuming duties.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=see_link\">",
"       \"Patient information: Rotator cuff injury (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"       \"Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rotator cuff tendinopathy is a common cause of shoulder pain. Repetitive overhead activity in sport or work is a major risk factor. Other risk factors include rotator cuff impingement, scapular instability or dyskinesis, and older age. Knowledge of basic shoulder anatomy and biomechanics aids in diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link&amp;anchor=H2#H2\">",
"       \"Evaluation of the patient with shoulder complaints\", section on 'Anatomy and biomechanics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rotator cuff tendinopathy may be a manifestation of shoulder impingement, but must be distinguished from other causes of shoulder and neck pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"       \"Evaluation of the patient with shoulder complaints\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with rotator cuff tendinopathy complain of shoulder pain with overhead activity. Patients may localize the pain to the lateral deltoid and often describe pain at night, especially when lying on the affected shoulder. Overhead athletes often complain of pain while performing their sport, weakness, or a decline in performance. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important elements of the physical examination include neck examination, rotator cuff strength testing, range of motion assessment, the painful arc test, and the Neer and Hawkins-Kennedy tests. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many clinicians consider ultrasound to be the gold standard for the initial evaluation of rotator cuff disease. Plain radiographs are generally not indicated. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Few treatments for rotator cuff tendinopathy are supported by strong scientific evidence. Initial management generally consists of cryotherapy, rest, a short course of NSAIDs, and physical therapy. Our suggested approach to the management of suspected rotator cuff injury is described above. A management algorithm outlining our approach is provided (",
"      <a class=\"graphic graphic_algorithm graphicRef65343 \" href=\"UTD.htm?8/13/8415\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Approach to management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Orthopedic surgical referral is obtained if nonoperative therapy fails to provide relief within six to nine months or a diagnosis of a clinically significant rotator cuff tear is made. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=see_link\">",
"       \"Presentation and diagnosis of rotator cuff tears\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/1\">",
"      Urwin M, Symmons D, Allison T, et al. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. Ann Rheum Dis 1998; 57:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/2\">",
"      Silverstein BA, Viikari-Juntura E, Fan ZJ, et al. Natural course of nontraumatic rotator cuff tendinitis and shoulder symptoms in a working population. Scand J Work Environ Health 2006; 32:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/3\">",
"      van der Windt DA, Koes BW, de Jong BA, Bouter LM. Shoulder disorders in general practice: incidence, patient characteristics, and management. Ann Rheum Dis 1995; 54:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/4\">",
"      Chakravarty K, Webley M. Shoulder joint movement and its relationship to disability in the elderly. J Rheumatol 1993; 20:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/5\">",
"      Dela Rosa, TL, Wang, AW, Zheng, MH. Tendinosis of the rotator cuff: a review. J Musculoskel Res 2001; 5:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/6\">",
"      Iannotti JP, Bernot MP, Kuhlman JR, et al. Postoperative assessment of shoulder function: a prospective study of full-thickness rotator cuff tears. J Shoulder Elbow Surg 1996; 5:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/7\">",
"      Kaergaard A, Andersen JH. Musculoskeletal disorders of the neck and shoulders in female sewing machine operators: prevalence, incidence, and prognosis. Occup Environ Med 2000; 57:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/8\">",
"      Chard MD, Hazleman R, Hazleman BL, et al. Shoulder disorders in the elderly: a community survey. Arthritis Rheum 1991; 34:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/9\">",
"      Chard MD, Hazleman BL. Shoulder disorders in the elderly (a hospital study). Ann Rheum Dis 1987; 46:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/10\">",
"      Mehta S, Gimbel JA, Soslowsky LJ. Etiologic and pathogenetic factors for rotator cuff tendinopathy. Clin Sports Med 2003; 22:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/11\">",
"      Hijioka A, Suzuki K, Nakamura T, Hojo T. Degenerative change and rotator cuff tears. An anatomical study in 160 shoulders of 80 cadavers. Arch Orthop Trauma Surg 1993; 112:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/12\">",
"      Sher JS, Uribe JW, Posada A, et al. Abnormal findings on magnetic resonance images of asymptomatic shoulders. J Bone Joint Surg Am 1995; 77:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/13\">",
"      Wendelboe AM, Hegmann KT, Gren LH, et al. Associations between body-mass index and surgery for rotator cuff tendinitis. J Bone Joint Surg Am 2004; 86-A:743.",
"     </a>",
"    </li>",
"    <li>",
"     Hutton KS, Julin MJ. Shoulder injuries. In: Team Physician's Handbook, 3rd, Mellon MB, Walsh WM, Madsen C, et al.  (Eds), Hanley &amp; Belfus, Inc, Philadelphia 2002. p.397.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/15\">",
"      Rees JD, Wilson AM, Wolman RL. Current concepts in the management of tendon disorders. Rheumatology (Oxford) 2006; 45:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/16\">",
"      Riley G. The pathogenesis of tendinopathy. A molecular perspective. Rheumatology (Oxford) 2004; 43:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/17\">",
"      Maffulli N, Khan KM, Puddu G. Overuse tendon conditions: time to change a confusing terminology. Arthroscopy 1998; 14:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/18\">",
"      Khan KM, Cook JL, Bonar F, et al. Histopathology of common tendinopathies. Update and implications for clinical management. Sports Med 1999; 27:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/19\">",
"      Harryman DT 2nd, Sidles JA, Clark JM, et al. Translation of the humeral head on the glenoid with passive glenohumeral motion. J Bone Joint Surg Am 1990; 72:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/20\">",
"      Vanderhooft, JE, Lippitt, SB, Harris, SL, et al. Glenohumeral stability from concavity-compression: a quantitative analysis. Orthop Trans 1992; 16:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/21\">",
"      Uhthoff HK, Sano H. Pathology of failure of the rotator cuff tendon. Orthop Clin North Am 1997; 28:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/22\">",
"      Naredo E, Aguado P, De Miguel E, et al. Painful shoulder: comparison of physical examination and ultrasonographic findings. Ann Rheum Dis 2002; 61:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/23\">",
"      Broadhurst NA, Simmons N. Musculoskeletal ultrasound - used to best advantage. Aust Fam Physician 2007; 36:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/24\">",
"      Lew HL, Chen CP, Wang TG, Chew KT. Introduction to musculoskeletal diagnostic ultrasound: examination of the upper limb. Am J Phys Med Rehabil 2007; 86:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/25\">",
"      Teefey SA, Hasan SA, Middleton WD, et al. Ultrasonography of the rotator cuff. A comparison of ultrasonographic and arthroscopic findings in one hundred consecutive cases. J Bone Joint Surg Am 2000; 82:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/26\">",
"      Teefey SA, Rubin DA, Middleton WD, et al. Detection and quantification of rotator cuff tears. Comparison of ultrasonographic, magnetic resonance imaging, and arthroscopic findings in seventy-one consecutive cases. J Bone Joint Surg Am 2004; 86-A:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/27\">",
"      Ardic F, Kahraman Y, Kacar M, et al. Shoulder impingement syndrome: relationships between clinical, functional, and radiologic findings. Am J Phys Med Rehabil 2006; 85:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/28\">",
"      Rutten MJ, Jager GJ, Kiemeney LA. Ultrasound detection of rotator cuff tears: observer agreement related to increasing experience. AJR Am J Roentgenol 2010; 195:W440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/29\">",
"      Ottenheijm RP, Jansen MJ, Staal JB, et al. Accuracy of diagnostic ultrasound in patients with suspected subacromial disorders: a systematic review and meta-analysis. Arch Phys Med Rehabil 2010; 91:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/30\">",
"      Papatheodorou A, Ellinas P, Takis F, et al. US of the shoulder: rotator cuff and non-rotator cuff disorders. Radiographics 2006; 26:e23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/31\">",
"      Green S, Buchbinder R, Hetrick S. Physiotherapy interventions for shoulder pain. Cochrane Database Syst Rev 2003; :CD004258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/32\">",
"      Kibler WB. Rehabilitation of rotator cuff tendinopathy. Clin Sports Med 2003; 22:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/33\">",
"      Jonsson P, Wahlstr&ouml;m P, Ohberg L, Alfredson H. Eccentric training in chronic painful impingement syndrome of the shoulder: results of a pilot study. Knee Surg Sports Traumatol Arthrosc 2006; 14:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/34\">",
"      Buchbinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev 2003; :CD004016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/35\">",
"      Koester MC, Dunn WR, Kuhn JE, Spindler KP. The efficacy of subacromial corticosteroid injection in the treatment of rotator cuff disease: A systematic review. J Am Acad Orthop Surg 2007; 15:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/36\">",
"      Arroll B, Goodyear-Smith F. Corticosteroid injections for painful shoulder: a meta-analysis. Br J Gen Pract 2005; 55:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/37\">",
"      Alvarez CM, Litchfield R, Jackowski D, et al. A prospective, double-blind, randomized clinical trial comparing subacromial injection of betamethasone and xylocaine to xylocaine alone in chronic rotator cuff tendinosis. Am J Sports Med 2005; 33:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/38\">",
"      Paoloni JA, Appleyard RC, Nelson J, Murrell GA. Topical glyceryl trinitrate application in the treatment of chronic supraspinatus tendinopathy: a randomized, double-blinded, placebo-controlled clinical trial. Am J Sports Med 2005; 33:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/39\">",
"      Giombini A, Di Cesare A, Safran MR, et al. Short-term effectiveness of hyperthermia for supraspinatus tendinopathy in athletes: a short-term randomized controlled study. Am J Sports Med 2006; 34:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/40\">",
"      Gerdesmeyer L, Wagenpfeil S, Haake M, et al. Extracorporeal shock wave therapy for the treatment of chronic calcifying tendonitis of the rotator cuff: a randomized controlled trial. JAMA 2003; 290:2573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/41\">",
"      Huisstede BM, Gebremariam L, van der Sande R, et al. Evidence for effectiveness of Extracorporal Shock-Wave Therapy (ESWT) to treat calcific and non-calcific rotator cuff tendinosis--a systematic review. Man Ther 2011; 16:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21289/abstract/42\">",
"      Bryan, WJ, Labossiere, D, Coleman, E, Bartz, R. Baseball Shoulder and Elbow Injury Rehabilitation of Varsity, High School, Intercollegiate, and Professional Baseball Players. Sports Med Arthro Rev 2001; 9:154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 239 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21289=[""].join("\n");
var outline_f20_50_21289=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RELEVANT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BASIC BIOMECHANICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOPHYSIOLOGY AND MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION AND EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Musculoskeletal ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INDICATIONS FOR ORTHOPEDIC REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Basic management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Adjunct therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Subacute treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Topical glyceryl trinitrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Experimental treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      APPROACH TO MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/239\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/239|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/13/8415\" title=\"algorithm 1\">",
"      Algorithm for management of rotator cuff tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/239|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/28/15814\" title=\"figure 1A\">",
"      Basic shoulder anatomy anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/60/28613\" title=\"figure 1B\">",
"      Basic shoulder anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/6/27748\" title=\"figure 1C\">",
"      Basic shoulder anatomy posterior view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/239|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/11/177\" title=\"picture 1\">",
"      Painful arc sign for rotator cuff pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/60/1987\" title=\"picture 2\">",
"      Jobes test of supraspinatus strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/13/28882\" title=\"picture 3\">",
"      Test of shoulder external rotation strength",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/9/43155\" title=\"picture 4\">",
"      Gerbers test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/7/44149\" title=\"picture 5\">",
"      Neers test for shoulder impingement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/27/19891\" title=\"picture 6\">",
"      Hawkins Kennedy test for shoulder impingement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/239|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/36/22091\" title=\"table 1\">",
"      Extrinsic causes shoulder pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/20/9549\" title=\"table 2\">",
"      Evaluation shoulder pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/26/10663?source=related_link\">",
"      Acromioclavicular joint injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25991?source=related_link\">",
"      Biceps tendinopathy and tendon rupture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/29/9687?source=related_link\">",
"      Investigational approaches to the pharmacologic therapy of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/53/22358?source=related_link\">",
"      Musculoskeletal complications in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2215?source=related_link\">",
"      Overview of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20089?source=related_link\">",
"      Overview of the management of overuse (chronic) tendinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=related_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=related_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27834?source=related_link\">",
"      Physical examination of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6887?source=related_link\">",
"      Presentation and diagnosis of rotator cuff tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/33/32280?source=related_link\">",
"      Shoulder impingement syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_50_21290="Thiazolidinediones in the treatment of diabetes mellitus";
var content_f20_50_21290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thiazolidinediones in the treatment of diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21290/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21290/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21290/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?20/50/21290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?20/50/21290/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?20/50/21290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classes of oral hypoglycemic drugs improve insulin action as their primary effect: biguanides and thiazolidinediones (",
"    <a class=\"graphic graphic_table graphicRef56876 \" href=\"UTD.htm?3/22/3437\">",
"     table 1",
"    </a>",
"    ). Two thiazolidinediones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    [Avandia] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    [Actos]) are currently available in the United States. Rosiglitazone is only available through a Risk Evaluation and Mitigation Strategy program. A third, troglitazone (Rezulin), was the first drug in this class to be marketed, but was removed from the market in both the United States and United Kingdom because it caused liver dysfunction and, in some patients, liver failure.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     Rosiglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    are used as monotherapy or with a sulfonylurea,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , or insulin. However, there are concerns with combined thiazolidinedione and insulin therapy because of an increased incidence of heart failure (HF). In addition, thiazolidinediones have several other potential side effects, which make them less appealing as initial or second step therapy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cardiovascular Effects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The pharmacology and use of thiazolidinediones will be reviewed here. Biguanides (only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is currently available) and other oral hypoglycemic drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=see_link\">",
"     \"Metformin in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=see_link\">",
"     \"Sulfonylureas and meglitinides in the treatment of diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Insulin sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thiazolidinediones increase insulin sensitivity by acting on adipose, muscle, and liver to increase glucose utilization and decrease glucose production [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The mechanism by which the thiazolidinediones exert their effect is not fully understood. They bind to and activate one or more peroxisome proliferator-activated receptors (PPARs), which regulate gene expression in response to ligand binding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PPAR-gamma is found predominantly in adipose tissue, pancreatic beta-cells, vascular endothelium, macrophages, and the central nervous system. PPAR-alpha is expressed mostly in liver, heart, skeletal muscle, and vascular walls. The various thiazolidinediones have differential effects on PPAR-gamma and PPAR-alpha. Troglitazone and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    are purely PPAR-gamma agonists, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    also exerts some PPAR-alpha effects. This may account for the different effects that pioglitazone and rosiglitazone have on lipids. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Lipids'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The concentration of PPAR-gamma is increased in the skeletal muscle of obese and diabetic patients; the raised concentration correlates well with the serum insulin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/5\">",
"     5",
"    </a>",
"    ]. It appears that the thiazolidinediones improve insulin responsiveness in skeletal muscle by facilitating glucose transport activity, thereby increasing rates of muscle glycogen synthesis and glucose oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In human adipocytes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    treatment has been reported to increase expression of genes involved in promoting lipid storage and decrease expression of genes associated with inflammation, such as IL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, the insulin-sensitizing effect of thiazolidinediones may be related in part to regulation of adipose tissue production of adipokines via PPAR-gamma activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the central nervous system (CNS), PPAR-gamma activation by thiazolidinediones may contribute to improvements in hepatic insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, CNS PPAR-gamma activation mediates weight gain by promoting increased feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. This finding accounts, in part, for the weight gain associated with thiazolidinedione treatment. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Weight gain'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several new thiazolidinediones are being investigated as \"dual PPAR agonists,\" with the hope that they could effectively treat both hyperglycemia and hyperlipidemia. One dual agent, muraglitazar, received initial FDA approval, but data reinterpretation has led to concerns about cardiac safety [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Patients who took muraglitazar had an increased incidence of a composite outcome of death, myocardial infarction (MI), stroke, transient ischemic attack (TIA), or HF [RR 2.62, 95% CI 1.36-5.05]. Further studies monitoring long-term cardiovascular effects are being considered before drug marketing.",
"   </p>",
"   <p>",
"    Another investigational dual PPAR agonist, aleglitazar, performed favorably in a 16-week dose ranging phase II trial (SYNCHRONY) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/14\">",
"     14",
"    </a>",
"    ]. Aleglitazar improved A1C, triglycerides, LDL, and HDL cholesterol compared with placebo. Larger, long-term trials with cardiovascular outcomes are planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Insulin secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones also may improve blood glucose levels by preserving pancreatic beta-cell function. The effect of troglitazone on insulin secretion was demonstrated in a study of obese patients with impaired glucose tolerance who were randomly assigned to receive either 400 mg of troglitazone daily (n = 14) or placebo (n = 7) for 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/15\">",
"     15",
"    </a>",
"    ]. Insulin secretion at each blood glucose concentration increased in the troglitazone group after adjustment of the insulin secretion rates for changes in insulin sensitivity. This finding suggests that troglitazone may improve the early beta-cell dysfunction that occurs in patients with impaired glucose tolerance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of the thiazolidinediones as monotherapy for the treatment of type 2 diabetes was initially demonstrated with troglitazone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/1,16,17\">",
"     1,16,17",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     Pioglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    have similar efficacy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a six-month trial of 408 patients with type 2 diabetes, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"       pioglitazone",
"      </a>",
"      in doses of 15, 30, or 45 mg daily resulted in significant change in hemoglobin A1C (A1C) values (range -1.0 to -1.6 percent compared with placebo change from baseline) and fasting plasma glucose concentrations (-39 to -65",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [-2.2 to -3.6",
"      <span class=\"nowrap\">",
"       mmol/L]",
"      </span>",
"      compared with placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/18\">",
"       18",
"      </a>",
"      ]. Of note, with a maximal dose of pioglitazone (45 mg), A1C decreased from 10.3 at baseline to 9.4 percent.",
"     </li>",
"     <li>",
"      In a randomized, placebo-controlled trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      (4 to 8",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for 26 weeks) in 493 patients with type 2 diabetes, the mean A1C values decreased in the rosiglitazone groups by 1.2 and 1.5 percent, respectively, and serum high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol concentrations increased [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/19\">",
"       19",
"      </a>",
"      ]. Similar improvements in A1C values were noted in a second study in which the patients received similar doses of rosiglitazone [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/20\">",
"       20",
"      </a>",
"      ]. The improvement in A1C was accompanied by a dose-related weight gain of up to 4.2 kg (9.2 pounds) compared with placebo.",
"     </li>",
"     <li>",
"      In a randomized, controlled trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      as initial therapy for type 2 diabetes, rosiglitazone had a lower incidence of monotherapy failure at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/21\">",
"       21",
"      </a>",
"      ]. However, the difference in A1C levels between the rosiglitazone and metformin treated groups was small (about 0.1 percent) and treatment with rosiglitazone was associated with greater weight gain, peripheral edema, and increases in LDL concentrations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, thiazolidinediones are probably similar in efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    as monotherapy. However, we do not generally choose thiazolidinediones over metformin for initial therapy of type 2 diabetes due to concerns about adverse effects and cost. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to use as monotherapy, the thiazolidinediones have been studied in combination with insulin, sulfonylureas, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/22-27\">",
"     22-27",
"    </a>",
"    ], and appear to be more effective when used in combination with other hypoglycemic medications with different mechanisms of action. As an example, the predominant effect of metformin is to inhibit hepatic glucose production, whereas thiazolidinediones act mainly by improving peripheral uptake and utilization of glucose in muscle and fat. The glycemic benefits of thiazolidinediones combined with other medications are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Efficacy of combination therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Thiazolidinediones and insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although thiazolidinediones are effective for combination therapy in patients who have failed monotherapy and are included as an option in the ADA consensus algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef70606 \" href=\"UTD.htm?7/63/8176\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/28\">",
"     28",
"    </a>",
"    ], we typically prefer combination with drugs other than thiazolidinediones because of cost and adverse effects. Thiazolidinediones should not be given to patients who have a history of HF or low bone mass. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Fluid retention/heart failure'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thiazolidinediones have been shown to improve a number of cardiovascular risk factors and surrogate cardiovascular endpoints, including dyslipidemia, markers of inflammation, vascular smooth muscle proliferation, vascular reactivity, endothelial function, carotid intima media thickness, and progression of atherosclerosis on coronary intravascular ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/29-33\">",
"     29-33",
"    </a>",
"    ], data demonstrating their ability to decrease cardiovascular events are unimpressive and concerns about side effects (weight gain, fluid retention, heart failure, myocardial infarction, and fractures) persist. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Fluid retention/heart failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The effect of thiazolidinediones on cardiovascular events may depend upon the specificity of PPAR activation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/34\">",
"     34",
"    </a>",
"    ]. As discussed previously, muraglitazar, a dual PPAR-alpha and gamma agonist, was associated with an excess incidence of adverse cardiovascular events, including MI, and is no longer under development [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanism of action'",
"    </a>",
"    above.) In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    (a pure PPAR-gamma agonist) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    (PPAR-gamma with some alpha agonist activity) have different effects on lipid concentrations, with pioglitazone exerting a less unfavorable effect (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Lipids'",
"    </a>",
"    below). Although both drugs have a similar effect on the incidence of heart failure (both increase risk), they appear to have disparate effects on ischemic outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     Rosiglitazone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    have similar effects on glycemic control, but their effects on serum lipid concentrations are different. Most randomized trials found that pioglitazone produces a more favorable lipid profile [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]. In a review of six randomized trials, LDL cholesterol levels typically remained constant when monotherapy or combination therapy with pioglitazone was used, while increases in LDL cholesterol levels ranging from 8 to 16 percent were noted in studies of rosiglitazone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/3\">",
"     3",
"    </a>",
"    ]. HDL cholesterol levels increased by approximately 10 percent with both drugs. Decreases in triglyceride levels were observed more often with pioglitazone than with rosiglitazone.",
"   </p>",
"   <p>",
"    In the largest randomized trial that directly compared the two drugs, 735 dyslipidemic patients with diabetes were randomly assigned to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/38\">",
"     38",
"    </a>",
"    ]. Similar to the studies reviewed above, triglyceride levels were more significantly decreased by pioglitazone than rosiglitazone (52 versus 13",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.59 versus 0.15",
"    <span class=\"nowrap\">",
"     mmol/liter]).",
"    </span>",
"    The increase in HDL cholesterol was greater (5.2 versus 2.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.13 versus 0.06",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and increase in LDL cholesterol less (12.3 versus 21.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.32 versus 0.55",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    with pioglitazone compared with rosiglitazone. Therefore, the effects of thiazolidinediones on lipid profiles appear to vary with different drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Rosiglitazone",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Meta-analyses and population-based studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    for the treatment of diabetes show adverse [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/35,39-42\">",
"     35,39-42",
"    </a>",
"    ] or no evidence of [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/43,44\">",
"     43,44",
"    </a>",
"    ] effects on myocardial and other (morbidity, mortality, quality of life) adverse outcomes. As an example, a meta-analysis of 42 trials of rosiglitazone demonstrated an increase in MI compared with the comparator group (placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylurea, or insulin) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/35\">",
"     35",
"    </a>",
"    ]. There were 86 MIs in the rosiglitazone group and 72 in the control group (odds ratio 1.43, 95% CI 1.03-1.98). An independent meta-analysis performed by the manufacturers of rosiglitazone showed similar findings (hazard ratio [HR] for all adverse events related to myocardial ischemia 1.31, 95% CI 1.01-1.70) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/42,45\">",
"     42,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence to support the meta-analyses comes from large population-based studies of older (&ge;65 years) patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. In a retrospective cohort study of patients with contraindications or intolerance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sulfonylureas (history of renal disease or cardiovascular disease), treatment with thiazolidinedione monotherapy (predominantly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    ) was associated with an increased risk of myocardial infarction compared with other oral hypoglycemic agent combinations (adjusted RR 1.4, 95% CI 1.0-1.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, monotherapy and combination therapy with thiazolidinediones were associated with an increased risk of HF and death compared with other oral agent combination therapies. Although the associations appeared to be limited to rosiglitazone use, there were a smaller number of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    users, which decreased the power to explore similar associations. However, in retrospective analyses of prescription data obtained from national databases, rosiglitazone was associated with an increase in HF and all-cause mortality compared with pioglitazone [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. The largest study included 227,571 Medicare participants 65 years or older who initiated treatment with rosiglitazone or pioglitazone and who had follow-up for up to three years afterwards [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/49\">",
"     49",
"    </a>",
"    ]. Compared with prescription of pioglitazone, prescription of rosiglitazone to elderly patients with type 2 diabetes was associated with a significantly increased risk of stroke, HF, and all-cause mortality (HRs 1.27, 1.25, and 1.14, respectively). The risk of myocardial infarction was not significantly increased (HR 1.06, 95% CI 0.96-1.18).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     RECORD study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of the above studies were not designed to explore cardiovascular outcomes, which were not uniformly collected or adjudicated; therefore, MI and other cardiovascular events were noted as adverse events. The RECORD study, however, was designed to evaluate the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    on cardiovascular events and mortality in 4447 patients from Europe and Australasia. Subjects who failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or sulfonylurea monotherapy (A1C &gt;7 percent) were randomly assigned to the addition of rosiglitazone, metformin (if initially on sulfonylurea), or sulfonylurea (if initially on metformin) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of an interim analysis of the RECORD data (3.75 years of follow-up) were inconclusive, except for an increased risk of HF (HR 2.24, 95% CI 1.27-3.97) in those assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    combinations compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    plus sulfonylurea [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/51\">",
"     51",
"    </a>",
"    ]. In the final analysis (mean 5.5 years of follow-up), 321 and 323 subjects in the rosiglitazone and control groups, respectively, experienced the primary endpoint (cardiovascular hospitalization or cardiovascular death) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link&amp;anchor=H9#H9\">",
"     \"Heart failure in diabetes mellitus\", section on 'Thiazolidinediones'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The lower than expected event rate and higher dropout rate (18 percent of all subjects) decreased the power of the analysis to assess the primary outcome or individual outcomes, except for heart failure. There was a persistent increased risk of fatal and non-fatal heart failure, occurring in 61 subjects assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    compared with 29 in the control group (HR 2.10, 95% CI 1.35-3.27). The effect of rosiglitazone on myocardial infarction was inconclusive (HR for rosiglitazone compared with the active comparators for fatal and non-fatal MI 1.14, 95% CI 0.80-1.63) due to the small number of events and possibly affected by greater statin use in the rosiglitazone group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     BARI 2D",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI-2D) trial studied whether, in patients with type 2 diabetes and coronary artery disease, initial treatment with angioplasty or bypass surgery is better than initial treatment with a medical program. At the same time, BARI-2D compared two approaches to control blood sugar: providing insulin and insulin stimulating medication or providing medication that sensitizes the body to available insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/53\">",
"     53",
"    </a>",
"    ]. After an average follow-up of 5.3 years, there was no difference in the primary endpoint (death) or the principal secondary endpoint (composite of death, MI, or stroke) between the revascularization group and the medical therapy group or between the insulin stimulating and insulin sensitizing medication groups.",
"   </p>",
"   <p>",
"    The trial had several limitations. Although the majority of patients in the insulin sensitization group were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (75 percent) or thiazolidinediones (62 percent, predominantly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    ), 43 percent of patients in the sensitization group also received insulin or sulfonylureas to achieve glycemic control. In contrast, only 12 percent of subjects in the insulin provision group received metformin or thiazolidinediones in addition to their assigned medications (insulin or sulfonylureas). Throughout the trial, mean A1C values were significantly lower in the sensitization group (mean difference &le;0.5 percentage points). In addition, the trial was limited by lower than expected recruitment and event rates.",
"   </p>",
"   <p>",
"    The revascularization arm of the BARI 2D trial is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H2#H2\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Medical therapy versus revascularization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pioglitazone",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     Pioglitazone",
"    </a>",
"    may not have the same cardiovascular risk profile as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , as illustrated by a meta-analysis of 19 trials of pioglitazone for the treatment of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/36\">",
"     36",
"    </a>",
"    ]. MIs occurred in 131 (1.5 percent) patients in the pioglitazone group and 159 (2.0 percent) in the comparator group (placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylurea, rosiglitazone) [HR 0.81, 95% CI 0.64-1.02]. The primary composite endpoint of death, nonfatal MI, or nonfatal stroke occurred in 4.4 and 5.7 percent of patients in the pioglitazone and control groups, respectively (HR 0.82, 95% CI 0.72-0.94). As in the meta-analyses described above, the majority of trials were not originally intended to assess cardiovascular endpoints, which were collected as adverse events and not uniformly adjudicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     PROactive trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;However, the largest of the trials included in the meta-analysis was the PROactive trial, which was specifically designed to evaluate the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    on cardiovascular events and mortality in 5238 patients at high risk for macrovascular complications (prior MI, stroke, CABG, acute coronary syndrome or symptomatic peripheral artery disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/54\">",
"     54",
"    </a>",
"    ]. The study was stopped prematurely because of a significant decrease in the \"main\" secondary composite end point of all-cause mortality, MI (excluding silent MI), or stroke (defined after the trial was underway, and one of eight secondary outcomes) in the pioglitazone group (HR 0.84, 95% CI 0.72-0.98). However, there was an insignificant impact on the predefined primary outcome of the study: composite of all cause mortality, nonfatal MI and silent MI, stroke, acute coronary syndrome, surgical intervention on coronary or leg arteries, or leg amputation. The incidence of angina pectoris was lower in the pioglitazone group (3 versus 5 percent), but reports of HF were greater (16.0 versus 11.5 percent).",
"   </p>",
"   <p>",
"    In a prespecified subanalysis of 2445 subjects with a previous MI, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    versus placebo did not have a significant impact on the main primary or secondary outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/55\">",
"     55",
"    </a>",
"    ]. However, there was a decrease in the prespecified outcome of subsequent",
"    <span class=\"nowrap\">",
"     fatal/nonfatal",
"    </span>",
"    MI in the pioglitazone group (HR 0.72, 95% CI 0.52-0.99). The reduction in another prespecified endpoint, cardiovascular death or nonfatal MI (excluding silent MI), did not reach statistical significance (HR 0.85, 95% CI 0.66-1.09), perhaps due to the increase in HF in the pioglitazone group (HR 1.43, 95% CI 1.13-1.81).",
"   </p>",
"   <p>",
"    Concern has been expressed over the decision to terminate the study prematurely, prior to achieving the primary outcome, the late definition of a \"main\" secondary endpoint after the trial was underway, the analytic strategy (there were more than eight secondary endpoints), and whether longer-term intervention might have resulted in increasing HF with negative impact on the study results. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Fluid retention/heart failure'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link&amp;anchor=H9#H9\">",
"     \"Heart failure in diabetes mellitus\", section on 'Thiazolidinediones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular benefit-risk ratio of individual thiazolidinediones is not entirely clear [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. The results of the meta-analyses and observational studies described above suggest increased caution with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , in particular. In addition, any potential cardiovascular benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    must be weighed against the increased risk of HF, weight gain, and fractures. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Safety'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 2008 American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) consensus algorithm recommended against the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , owing to concern regarding safety and the availability of alternative therapies, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , that do not have the same concerns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Medications for initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2010, the European Medicines Agency suspended sales of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/58\">",
"     58",
"    </a>",
"    ]. At the same time, the US Food and Drug Administration restricted its use to patients with type 2 diabetes who cannot achieve adequate glycemic control with other medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/59\">",
"     59",
"    </a>",
"    ]. Current users of rosiglitazone may continue to take it. However, current and new users must review and acknowledge the associated cardiovascular risks. For potential new and current users, clinicians must document patient eligibility and enroll them in a Risk Evaluation and Mitigation Strategy program.",
"   </p>",
"   <p>",
"    We support the recommendation to use alternative therapies (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , insulin, sulfonylureas) to achieve glycemic targets. Specifically, patients with type 2 diabetes should not be started on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     Pioglitazone",
"    </a>",
"    may be considered, but it also is associated with fluid retention, HF, and loss of bone mineral density and fracture. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Safety'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21\">",
"     'Fluid retention/heart failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who are currently treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    and not achieving glycemic targets (A1C &lt;7.0 percent) should be changed to an alternative anti-diabetic intervention. For patients who are treated with rosiglitazone, are achieving metabolic goals, and are tolerating their regimen without apparent complications, continuation of rosiglitazone can be considered (keeping in mind that changing from one medication to another always carries some risk). However, we prefer to switch to an alternative medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thiazolidinediones improve blood glucose primarily by increasing insulin sensitivity. Therefore, thiazolidinedione monotherapy is less likely to cause hypoglycemia than sulfonylureas or insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]. However, mild to moderate hypoglycemic events can occur when thiazolidinediones are given in conjunction with sulfonylureas or insulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the thiazolidinediones cause weight gain. It is both dose-dependent and time-dependent and can be substantial (",
"    <a class=\"graphic graphic_figure graphicRef56648 \" href=\"UTD.htm?29/59/30653\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/16-18,22,24,25,60\">",
"     16-18,22,24,25,60",
"    </a>",
"    ]. The weight gain is caused in part by fluid retention. A small study (n = 8) found that 12 weeks of therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    45 mg resulted in 2.4 liters of water accumulation, which accounted for 75 percent of the 3.1 kg weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Fluid retention/heart failure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, weight gain may be due to thiazolidinedione-induced activation of PPAR-gamma in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/11\">",
"     11",
"    </a>",
"    ]. In animal studies, activation of central nervous system PPAR-gamma by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    increased feeding and expanded adipose tissue mass [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In humans, upregulation of genes that facilitate adipocyte lipid storage has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/62\">",
"     62",
"    </a>",
"    ]. Weight gain may also result from the proliferation of new adipocytes. In 20 patients with type 2 diabetes treated with troglitazone, the increase in fat deposition occurred primarily in subcutaneous fat stores, resulting in a decreased visceral-to-subcutaneous fat ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/60\">",
"     60",
"    </a>",
"    ]. There is a suggestion from one cohort of patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    continuously for over 30 months that the average weight gain increases steadily up to 30 months but may plateau (at around 5.3 kg, or 12 pounds) by 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a trial of 39 insulin-resistant, nondiabetic subjects with central obesity randomly assigned to diet and exercise, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 20 weeks, insulin sensitivity improved in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/64\">",
"     64",
"    </a>",
"    ]. Subjects in the diet and exercise group lost a mean of 11.8 kg while the pioglitazone group gained 2.7 kg. Both groups showed a decrease in the waist-to-hip ratio, but in the pioglitazone group, this was due to a preferential increase in lower body fat deposition. Only diet and exercise were associated with a decrease in intraabdominal fat.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fluid retention/heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid retention, which is more prominent with concomitant insulin therapy, can occur with all the thiazolidinediones but does not account for all of the weight gain (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Weight gain'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Peripheral edema occurs in 4 to 6 percent of patients treated with thiazolidinediones (compared with 1 to 2 percent with placebo) and in a higher percentage of patients with a history of HF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/3\">",
"     3",
"    </a>",
"    ]. This fluid retention may lead to the precipitation or worsening of HF.",
"   </p>",
"   <p>",
"    As mentioned above, the thiazolidinediones act by binding to and activating PPAR-gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Along the nephron, PPAR-gamma is most abundant in the collecting tubules, and the fluid retention with thiazolidinediones appears to result from PPAR-gamma stimulation of sodium reabsorption by sodium channels (called the epithelial sodium channel) in the luminal membrane of the collecting tubule cells [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/65\">",
"     65",
"    </a>",
"    ]. This effect is mediated by increased expression of the gamma subunit of the sodium channel gene mRNA.",
"   </p>",
"   <p>",
"    Sodium retention by aldosterone is also mediated by this channel. However, aldosterone excess is not associated with edema, due to the phenomenon of aldosterone escape in which sodium reabsorption is reduced at other sites in the nephron to minimize fluid retention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical features of primary aldosteronism\", section on 'Lack of edema'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the thiazolidinediones act at the same site as aldosterone, the observations with aldosterone excess suggest that edema or heart failure associated with the thiazolidinediones requires additional factors, such as underlying heart disease.",
"   </p>",
"   <p>",
"    Due to the risk of HF, the American Heart Association (AHA) and the American Diabetes Association (ADA) published a consensus statement in 2003 on thiazolidinedione use, fluid retention, and HF [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/66\">",
"     66",
"    </a>",
"    ]. Data related to the risk of HF with thiazolidinedione use and the recommendations included in the",
"    <span class=\"nowrap\">",
"     AHA/ADA",
"    </span>",
"    consensus statement are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link&amp;anchor=H9#H9\">",
"     \"Heart failure in diabetes mellitus\", section on 'Thiazolidinediones'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Skeletal",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increasing body of evidence suggesting that thiazolidinediones decrease bone density and increase fracture risk, particularly in women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/67-73\">",
"     67-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In animal models, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    resulted in bone loss by suppression of osteoblast differentiation and formation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/74\">",
"     74",
"    </a>",
"    ]. The bone loss was associated with an increase in marrow adipocytes. In vivo studies suggest that this finding is mediated by rosiglitazone-induced activation of PPAR-gamma. PPAR-gamma2 isoform is an important regulator of adipocyte differentiation. Activation of PPAR-gamma2 results in diversion of bone marrow stromal cells from the osteoblast lineage into the adipocyte lineage, which subsequently leads to a decrease in bone formation rates and increase in adipogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/75\">",
"     75",
"    </a>",
"    ]. This process, in turn, may be regulated by the IGF system, as rosiglitazone induced activation of PPAR-gamma has been demonstrated to down regulate components of the IGF system both in vivo and in vitro, and IGF-1 is an important regulator of osteoblast proliferation and differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adverse impact of thiazolidinediones on bone is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Health, Aging and Body Composition Study (Health ABC), a four-year observational study, 666 diabetic patients, aged 70 to 79 years at baseline, had bone density assessment every two years [",
"      <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/68\">",
"       68",
"      </a>",
"      ]. Although baseline bone density was similar, the subset of women (not men) taking thiazolidinediones (n = 69) had greater bone loss at the whole body, lumbar spine, and trochanter compared with those not taking thiazolidinediones.",
"     </li>",
"     <li>",
"      A Diabetes Outcome Progression Trial (ADOPT) reported a higher rate of fractures in newly diagnosed women with diabetes randomly assigned to receive four years of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      , compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"       glyburide",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"       \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the RECORD trial described above, the incidence of fractures was higher in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"       rosiglitazone",
"      </a>",
"      group (185 versus 118 in the control group, RR 1.57, 95% CI 1.26-1.97). Fractures occurred mainly in the upper and distal lower limbs and were more common in women than in men. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Rosiglitazone'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This skeletal effect does not appear to be limited to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/71,73,77,78\">",
"     71,73,77,78",
"    </a>",
"    ]. In clinical trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , there were more fractures in women (not men) taking pioglitazone than in the control groups (1.9 fractures versus 1.1 fractures per 100 patient-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. The fractures occurred predominantly in the distal upper or lower extremities (forearm, hand, wrist, foot, ankle, fibula, tibia). In addition, in a large population-based study using the UK-based General Practice Research Database, both pioglitazone (OR 2.59, 95% CI 0.96-7.01) and rosiglitazone (OR 2.38, 95% CI 1.39-4.09) were associated with low-trauma fracture in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absolute increase in fracture risk associated with thiazolidinedione treatment appears to be small. Nevertheless, these drugs should probably not be used in women with low bone density or other risk factors for fracture. The results of observational studies in men are conflicting and suggest that additional studies are required to determine if there is a similar increase in fracture risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12774482\">",
"    <span class=\"h2\">",
"     Bladder cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no data linking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    to bladder cancer, there is concern that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    use increases the risk of bladder cancer. In preclinical studies, pioglitazone was associated with bladder tumors in male rats. In the PROactive trial described above, there were more cases of bladder cancer (14 versus 5) in the pioglitazone than placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/80\">",
"     80",
"    </a>",
"    ]. In an interim analysis of an ongoing, 10-year observational study of pioglitazone use in patients with diabetes, there was not a significant association between pioglitazone exposure and bladder cancer among patients with median duration of therapy of two years (HR for bladder cancer 1.2, 95% CI 0.9-1.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. However, the risk of bladder cancer was significantly increased in those with the longest exposure to pioglitazone and to those exposed to the highest cumulative dose.",
"   </p>",
"   <p>",
"    In subsequent analyses using data from the Adverse Event Reporting System of the US Food and Drug Administration (a voluntary event reporting system) and the French Agency for the Safety of Health Products, the risk of bladder cancer was higher among",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    users (adjusted hazard ratio in the French study 1.22, 95% CI 1.05-1.43) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Meta-analyses of cohort studies found a similar increased risk of bladder cancer with pioglitazone use [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. In the French study, the risk of bladder cancer increased with high cumulative dose and long duration of exposure (&gt;24 months, HR 1.36, 95% CI 1.04-1.79) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/84\">",
"     84",
"    </a>",
"    ]. In June 2011, the French and German Medicines Agencies suspended the use of pioglitazone because of the potential increased risk of bladder cancer and the concern that the overall risks of pioglitazone exceed its benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/87\">",
"     87",
"    </a>",
"    ]. The European Medicines Agency, the US Food and Drug Administration, and Japanese regulators withheld action pending results of ongoing review of the data [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In the interim, pioglitazone should not be used in patients with active bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/89\">",
"     89",
"    </a>",
"    ]. In patients with a history of bladder cancer, the benefits of glycemic control versus the unknown risk for cancer recurrence with pioglitazone should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2872758\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, troglitazone has been removed from the market in the United States and United Kingdom because of reports of severe hepatocellular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/90\">",
"     90",
"    </a>",
"    ], resulting in death or the need for liver transplantation in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     Rosiglitazone",
"    </a>",
"    was not associated with hepatotoxicity in clinical trials involving approximately 5000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/93\">",
"     93",
"    </a>",
"    ]. However, hepatic toxicity has been reported in at least two patients receiving rosiglitazone: one approximately 21 days after starting therapy (although symptoms may have begun earlier) [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/94\">",
"     94",
"    </a>",
"    ], and one approximately eight days after starting therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/95\">",
"     95",
"    </a>",
"    ]. Both patients were taking other drugs or had other illnesses that may have contributed to the hepatic injury, but rosiglitazone appeared to be the most likely cause.",
"   </p>",
"   <p>",
"    Two cases of hepatotoxicity also have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    , one after seven months [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/96\">",
"     96",
"    </a>",
"    ] and one after six months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/97\">",
"     97",
"    </a>",
"    ]. Other potential causes of acute hepatitis were excluded in the second patient, and liver biopsy showed mixed hepatocellular-cholestatic injury compatible with drug toxicity. Serum aminotransferase values normalized after discontinuation of pioglitazone. In data from several double blind trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    and pioglitazone involving over 5000 patients, fewer than 0.3 percent of patients had alanine aminotransferase levels more than three times the upper limit of normal and no patients had values more than 10 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (US FDA) currently recommends that patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    undergo baseline testing followed by periodic monitoring of liver function based upon clinical judgment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Macular edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macular edema has been reported in patients taking thiazolidinediones, though the frequency of occurrence is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/98-101\">",
"     98-101",
"    </a>",
"    ]. Patients at greatest risk seem to be those who are also at risk for peripheral edema (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Fluid retention/heart failure'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Eczema",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     Rosiglitazone",
"    </a>",
"    has been associated with eczema during clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIABETES PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have evaluated the potential for thiazolidinediones to prevent diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/102-104\">",
"     102-104",
"    </a>",
"    ]. Troglitazone (no longer available due to hepatotoxicity) showed some effectiveness in diabetes prevention, while still being given, in the TRIPOD trial [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/102\">",
"     102",
"    </a>",
"    ] and in early data from the DPP [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/103\">",
"     103",
"    </a>",
"    ]. The DREAM trial reported a decrease in diabetes in subjects with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/104\">",
"     104",
"    </a>",
"    ], and the Actos Now for Prevention of Diabetes (ACT-NOW) study reported a reduced risk of developing diabetes in patients with IGT and one or more components of the metabolic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?20/50/21290/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data may reflect the known benefit of thiazolidinediones on glycemic control. Although these drugs delay the onset of diagnosis of diabetes, and therefore reduce the length of exposure of hyperglycemia, the benefit or harm of the intervention, independent of the effect on hyperglycemia, must be considered. Thiazolidinediones are limited by adverse effects (fluid retention, weight gain, heart failure, possibly myocardial infarction for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , and possibly bladder cancer for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    ). Thus, the use of thiazolidinediones for the prevention of diabetes may cause more net harm than benefit. We do not suggest using thiazolidinediones for diabetes prevention.",
"   </p>",
"   <p>",
"    The prevention of diabetes is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thiazolidinediones increase insulin sensitivity by acting on adipose, muscle, and liver to increase glucose utilization and decrease glucose production. When used as monotherapy, they reduce A1C values by approximately 1.5 percentage points.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and thiazolidinediones have similar efficacy as monotherapy, the cost and side effects of thiazolidinediones make them less appealing as initial therapy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cardiovascular Effects'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Safety'",
"    </a>",
"    above.) In a patient who is not a candidate for metformin or who cannot tolerate metformin, we suggest a sulfonylurea (a shorter-duration medication such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/28/40391?source=see_link\">",
"     glipizide",
"    </a>",
"    ) rather than a thiazolidinedione (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A thiazolidinedione may be considered in patients with lower initial A1C values or if there are specific contraindications to sulfonylureas. If a thiazolidinedione is to be used as initial therapy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    is preferred because of the greater concern about atherogenic lipid profiles and a potential increased risk for cardiovascular events with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Cardiovascular Effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Persistent hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to use as monotherapy, the thiazolidinediones have been studied in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylureas, and insulin. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Combination therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Efficacy of combination therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with inadequate glycemic control on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    (A1C &gt;7.0 percent), we suggest adding other agents, such as insulin or sulfonylureas, before thiazolidinediones (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The addition of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/28/43463?source=see_link\">",
"     pioglitazone",
"    </a>",
"    can be considered in individuals without risk factors for heart failure or fracture, who do not reach glycemic goals with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    alone, if there are contraindications to sulfonylureas or patient preference limits the use of sulfonylureas or insulin. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Combination therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Diabetes prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazolidinediones have been evaluated as a therapy to prevent diabetes. In the absence of better trials, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    using thiazolidinediones with a goal of prevention, even in patients felt to be at high risk of developing diabetes (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Diabetes prevention'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/1\">",
"      Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996; 19:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/2\">",
"      Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/3\">",
"      Yki-J&auml;rvinen H. Thiazolidinediones. N Engl J Med 2004; 351:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/4\">",
"      Vidal-Puig AJ, Considine RV, Jimenez-Li&ntilde;an M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/5\">",
"      Park KS, Ciaraldi TP, Abrams-Carter L, et al. PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects. Diabetes 1997; 46:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/6\">",
"      Petersen KF, Krssak M, Inzucchi S, et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 2000; 49:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/7\">",
"      Kolak M, Yki-J&auml;rvinen H, Kannisto K, et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 2007; 92:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/8\">",
"      Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/9\">",
"      Lu M, Sarruf DA, Talukdar S, et al. Brain PPAR-&gamma; promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 2011; 17:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/10\">",
"      Ryan KK, Li B, Grayson BE, et al. A role for central nervous system PPAR-&gamma; in the regulation of energy balance. Nat Med 2011; 17:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/11\">",
"      Myers MG Jr, Burant CF. PPAR-&gamma; action: it's all in your head. Nat Med 2011; 17:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/12\">",
"      Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/13\">",
"      Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006; 29:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/14\">",
"      Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009; 374:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/15\">",
"      Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/16\">",
"      Fonseca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab 1998; 83:3169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/17\">",
"      Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/18\">",
"      Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/19\">",
"      Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/20\">",
"      Phillips LS, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001; 24:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/21\">",
"      Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/22\">",
"      Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/23\">",
"      Horton ES, Whitehouse F, Ghazzi MN, et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 1998; 21:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/24\">",
"      Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/25\">",
"      Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/26\">",
"      Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/27\">",
"      Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/28\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/29\">",
"      Uwaifo GI, Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol 2007; 99:51B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/30\">",
"      Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/31\">",
"      Stocker DJ, Taylor AJ, Langley RW, et al. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007; 153:445.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/32\">",
"      Wajcberg E, Sriwijitkamol A, Musi N, et al. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone. J Clin Endocrinol Metab 2007; 92:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/33\">",
"      Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/34\">",
"      Friedland SN, Leong A, Filion KB, et al. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med 2012; 125:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/35\">",
"      Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/36\">",
"      Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/37\">",
"      Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164:2097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/38\">",
"      Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/39\">",
"      Rosen CJ. The rosiglitazone story--lessons from an FDA Advisory Committee meeting. N Engl J Med 2007; 357:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/40\">",
"      Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/41\">",
"      Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010; 170:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/42\">",
"      Cobitz A, Zambanini A, Sowell M, et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone. Pharmacoepidemiol Drug Saf 2008; 17:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/43\">",
"      Richter B, Bandeira-Echtler E, Bergerhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; :CD006063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/44\">",
"      Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007; 147:578.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=ZM2005%2f00181%2f01&amp;studyId=3C2B35B3-EDAC-42EC-89CF-9A1E3E962266&amp;compound=rosiglitazone&amp;type=Compound&amp;letterrange=Q-U (Accessed on July 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/46\">",
"      Lipscombe LL, Gomes T, L&eacute;vesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/47\">",
"      Winkelmayer WC, Setoguchi S, Levin R, Solomon DH. Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 2008; 168:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/48\">",
"      Juurlink DN, Gomes T, Lipscombe LL, et al. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009; 339:b2942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/49\">",
"      Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/50\">",
"      Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005; 48:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/51\">",
"      Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med 2007; 357:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/52\">",
"      Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/53\">",
"      BARI 2D Study Group, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360:2503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/54\">",
"      Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/55\">",
"      Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/56\">",
"      Bloomgarden ZT. The Avandia debate. Diabetes Care 2007; 30:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/57\">",
"      Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121:1868.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim - September 23, 2010. file://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1&amp;jsenabled=true (Accessed on September 24, 2010).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Q&amp;A: Avandia (rosiglitazone). file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm226976.htm (Accessed on September 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/60\">",
"      Akazawa S, Sun F, Ito M, et al. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/61\">",
"      Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006; 29:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/62\">",
"      Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 2004; 27:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/63\">",
"      King, A, Armstrong, D, Chinnapongse, S. Clinical observations of weight gain associated with pioglitazone: 3 years. Diabetes 2003; 52 (Suppl 1):A123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/64\">",
"      Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003; 26:3148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/65\">",
"      Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/66\">",
"      Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003; 108:2941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/67\">",
"      Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int 2008; 19:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/68\">",
"      Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91:3349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/69\">",
"      Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007; 92:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/70\">",
"      Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/71\">",
"      Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/72\">",
"      Habib ZA, Havstad SL, Wells K, et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/73\">",
"      Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010; 95:4560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/74\">",
"      Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005; 146:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/75\">",
"      Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/76\">",
"      Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007; 148:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/77\">",
"      Dormuth CR, Carney G, Carleton B, et al. Thiazolidinediones and fractures in men and women. Arch Intern Med 2009; 169:1395.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153896.pdf (Accessed on July 23, 2012).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Safety Alerts - Duetact (pioglitazone and glimepiride) file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152118.htm (Accessed on July 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/80\">",
"      Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR, PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32:187.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA drug safety communication: Ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure - September 17, 2010. file://www.fda.gov/Drugs/DrugSafety/ucm226214.htm (Accessed on September 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/82\">",
"      Lewis JD, Ferrara A, Peng T, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/83\">",
"      Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/84\">",
"      Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/85\">",
"      Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184:E675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/86\">",
"      Bosetti C, Rosato V, Buniato D, et al. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013; 18:148.",
"     </a>",
"    </li>",
"    <li>",
"     Endocrine Today. France suspends pioglitazone use due to risk for bladder cancer - June 9, 2011. file://www.endocrinetoday.com/view.aspx?rid=84580 (Accessed on June 10, 2011).",
"    </li>",
"    <li>",
"     European Medicines Agency. Update on ongoing European review of pioglitazone-containing medicines. file://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001275.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1&amp;jsenabled=true (Accessed on June 16, 2011).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. FDA drug safety communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer - June 15, 2011. file://www.fda.gov/Drugs/DrugSafety/ucm259150.htm (Accessed on June 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/90\">",
"      Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/91\">",
"      Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/92\">",
"      Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 1998; 129:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/93\">",
"      Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/94\">",
"      Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 2000; 132:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/95\">",
"      Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med 2000; 132:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/96\">",
"      Maeda K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2001; 135:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/97\">",
"      May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/98\">",
"      Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2005; 123:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/99\">",
"      Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009; 147:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/100\">",
"      Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med 2012; 172:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/101\">",
"      Singh S, Segal JB. Thiazolidinediones and macular edema: comment on \"Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes\". Arch Intern Med 2012; 172:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/102\">",
"      Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51:2796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/103\">",
"      The DPP Research Group. Prevention of type 2 diabetes with troglitazone in the diabetes prevention program. Diabetes 2003; 52 Suppl 1:A58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/104\">",
"      DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?20/50/21290/abstract/105\">",
"      DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011; 364:1104.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1757 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-2A8E9B1E90-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21290=[""].join("\n");
var outline_f20_50_21290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Insulin sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Insulin secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CARDIOVASCULAR EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Rosiglitazone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Meta-analyses and population-based studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - RECORD study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - BARI 2D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pioglitazone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - PROactive trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fluid retention/heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Skeletal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12774482\">",
"      Bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2872758\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Macular edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Eczema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIABETES PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Persistent hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Diabetes prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1757\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1757|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/63/8176\" title=\"algorithm 1\">",
"      Management type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1757|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/59/30653\" title=\"figure 1\">",
"      Weight gain with glitazones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1757|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/22/3437\" title=\"table 1\">",
"      Options for diabetes Tx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/26/38312?source=related_link\">",
"      Metformin in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35559?source=related_link\">",
"      Sulfonylureas and meglitinides in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f20_50_21291="Evaluation AFP";
var content_f20_50_21291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of the patient with acute flaccid paralysis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       History and examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtlist1_start\">",
"       Blood testing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Sedimentation rate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Autoimmune serology for vasculitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Lyme titers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       HIV-1 titers",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       CK level",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cerebrospinal fluid analysis, including viral isolation for polio and nonpolio enteroviruses and for West Nile virus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stool samples for polio and nonpolio enteroviruses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pharyngeal swabs for polio and nonpolio enteroviruses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Electrodiagnostic testing (electromyography and nerve conduction studies), including repetitive stimulation studies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MRI of the spine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MRI of the brain (if bulbar involvement)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nerve and muscle biopsy (if mononeuritis multiplex/vasculitis suspected)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21291=[""].join("\n");
var outline_f20_50_21291=null;
var title_f20_50_21292="Systematic review empyema Rx";
var content_f20_50_21292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the data from a systematic review of primary operative versus nonoperative therapy for pediatric empyema",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibiotics and chest tube (N = 3183)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fibrinolytic therapy* (N = 64)",
"       </td>",
"       <td class=\"subtitle1\">",
"        VATS&bull; (N = 176)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Thoracotomy (N = 175)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mortality rate (range)",
"       </td>",
"       <td>",
"        3.3 percent (0 to 35 percent)",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        0 percent",
"       </td>",
"       <td>",
"        O percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Failure rate&Delta; (range)",
"       </td>",
"       <td>",
"        23.6 percent (0 to 67 percent)",
"       </td>",
"       <td>",
"        9.4 percent (6.7 to 14.2 percent)",
"       </td>",
"       <td>",
"        2.8 percent",
"       </td>",
"       <td>",
"        3.1 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Length of stay",
"       </td>",
"       <td>",
"        20 &plusmn; 8.3 days",
"       </td>",
"       <td>",
"        10.7 &plusmn; 5.1days",
"       </td>",
"       <td>",
"        11.2 days",
"       </td>",
"       <td>",
"        10.6 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of chest tube",
"       </td>",
"       <td>",
"        10.6 &plusmn; 3.4 days",
"       </td>",
"       <td>",
"        4 days",
"       </td>",
"       <td>",
"        4 days",
"       </td>",
"       <td>",
"        6.2 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of antibiotics",
"       </td>",
"       <td>",
"        21.3 &plusmn; 7.9 days",
"       </td>",
"       <td>",
"        Not specified",
"       </td>",
"       <td>",
"        13.2 days",
"       </td>",
"       <td>",
"        Not specified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complication rate&loz; (range)",
"       </td>",
"       <td>",
"        5.6 percent (0 to 45 percent)",
"       </td>",
"       <td>",
"        12.5 percent (0 to 16.6 percent)",
"       </td>",
"       <td>",
"        5.4 percent",
"       </td>",
"       <td>",
"        5.2 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Fibrinolytic therapy: Treatment with fibrinolytics either at the time of or within 24 hours of tube thoracostomy.",
"     <br>",
"      &bull; VATS: Video-assisted thoracoscopy.",
"      <br>",
"       &Delta; Failure: Failure of primary intervention necessitating subsequent operative intervention.",
"       <br>",
"        &loz; Complications typically included pneumothorax, bronchopleural fistula, persistent or recurrent empyema, bleeding, and wound infection.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Avansino, JR, Goldman, B, Sawin, RS, Flum, DR. Primary operative versus nonoperative therapy for pediatric empyema: a meta-analysis. Pediatrics 2005; 115:1652.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21292=[""].join("\n");
var outline_f20_50_21292=null;
var title_f20_50_21293="Chimeric TK in pap thyroid Ca";
var content_f20_50_21293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chimeric tyrosine kinases in papillary thyroid carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 135px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of chimeric tyrosine kinases in papillary thyroid carcinoma. The RET and NTRK1 genes code for tyrosine kinases that are not normally expressed in thyroid epithelial cells. Gene rearrangements that elicit expression of these tyrosine kinases in thyroid epithelial cells cause papillary carcinomas; such rearrangements appear to occur more frequently following external beam radiation or exposure to radiation after a nuclear accident. When the appropriate gene rearrangement occurs, a chimeric gene is formed and the resultant chimeric protein is expressed. The new 5' end of the chimeric gene confers expression in thyroid epithelial cells and codes for the amino terminus of the chimeric protein. Expression of the active tyrosine kinases presumably activates growth pathways by a cascade beginning with tyrosine phosphorylation. The chimeric RET genes are referred to as RET/PTC and the chimeric NTRK1 genes are referred to as TRK.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21293=[""].join("\n");
var outline_f20_50_21293=null;
var title_f20_50_21294="Vascular malformation 9h";
var content_f20_50_21294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pelvic ultrasound after uterine artery embolization no longer demonstrates the abnormal intrauterine vascular structures within the uterus (arrows), which were present before uterine artery embolization. The patient's uterine bleeding was stopped immediately after the embolization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21294=[""].join("\n");
var outline_f20_50_21294=null;
var title_f20_50_21295="Laboratory monitoring of HIV patients";
var content_f20_50_21295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74729%7EPEDS%2F54700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74729%7EPEDS%2F54700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Laboratory monitoring schedule for adolescent and adult patients with HIV prior to and after initiation of antiretroviral therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Entry into care",
"       </td>",
"       <td class=\"subtitle1\">",
"        Follow-up before ART",
"       </td>",
"       <td class=\"subtitle1\">",
"        ART initiation or modification",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        2 to 8 weeks post-ART initiation or modification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Every 3 to 6 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Every 6 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Every 12 months",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment failure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinically indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD4 count",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 3 to 6 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        In clinically stable patients with suppressed viral load, CD4 count can be monitored every 6 to 12 months",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        In clinically stable patients with suppressed viral load, CD4 count can be monitored every 6 to 12 months",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral load",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 3 to 6 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Resistance testing",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLA-B*5701 testing",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if considering ABC",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tropism testing",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if considering a CCR5 antagonist",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if considering a CCR5 antagonist or for failure of CCR5 antagonist-based regimen",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B serology",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"        <br/>",
"        May repeat if HBsAg (-) and HBsAb (-) at baseline",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Basic chemistry",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 6 to 12 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ALT, AST, T. bilirubin",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 6 to 12 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CBC with differential",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        every 3 to 6 months",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic; if on ZDV",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting lipid profile",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        if normal, annually",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &radic;",
"        <br/>",
"        Consider 4 to 8 weeks after starting new ART",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if abnormal at last measurement",
"       </td>",
"       <td>",
"        &radic; if normal at last measurement",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fasting glucose",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        if normal, annually",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if abnormal at last measurement",
"       </td>",
"       <td>",
"        &radic; if normal at last measurement",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinalysis**",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if on TDF",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy test",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic; if starting EFV",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &radic;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     3TC: lamivudine; ABC: abacavir; ALT: alanine aminotransferase; ART: antiretroviral therapy; AST: aspartate aminotranserase; CBC: complete blood count; EFV: efavirenz; FTC: emtricitabine; HBsAb: hepatitis B surface antibody; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus; MDRD: modification of diet in renal disease (equation); TDF: tenofovir; ZDV: zidovudine.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      ARV modification may be done for treatment failure, adverse effects, or simplification.",
"      <br>",
"       &Delta; For the patient on a suppressive regimen whose CD4 cell count has increased well above the threshold for opportunistic infection risk, the CD4 count can be measured less frequently than the viral load. In such patients, CD4 count may be monitored every 6 to 12 months, unless there are changes in the patient's clinical status, such as new HIV-associated clinical symptoms or initiation of treatment with interferon, corticosteroids, or antineoplastic agents.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        If HIV RNA is detectable at 2 to 8 weeks, repeat every 4 to 8 weeks until suppression to &lt;200 copies/mL, then every 3 to 6 months.",
"        <br>",
"         &sect; For adherent patients with suppressed viral load and stable clinical and immunologic status for &gt;2 to 3 years, some experts may extend the interval for HIV RNA monitoring to every 6 months.",
"         <br>",
"          &yen; For ART-na&iuml;ve patients, if resistance testing was performed at entry into care, repeat testing is optional; for patients with viral suppression who are switching therapy for toxicity or convenience, resistance testing will not be possible and therefore is not necessary.",
"          <br>",
"           ������ If HBsAg is positive at baseline or prior to initiation of ART, TDF + (FTC or 3TC) should be used as part of ARV regimen to treat both HBV and HIV infections. If HBsAg and HBsAb are negative at baseline, hepatitis B vaccine series should be administered.",
"           <br>",
"            ������ Serum Na, K, HCO3, Cl, BUN, creatinine, glucose (preferably fasting); some experts suggest monitoring phosphorus while on TDF; determination of renal function should include estimation of creatinine clearance using Cockcroft-Gault equation or estimation of glomerular filtration rate based on MDRD equation.",
"            <br>",
"             ** For patients with renal disease, consult: Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40:1559.",
"             <br>",
"              <span class=\"double_bullet\">",
"               &bull;&bull;",
"              </span>",
"              More frequent monitoring may be indicated for patients with increased risk of renal insufficiency, such as patients with diabetes, hypertension, etc.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Available at",
"     <a href=\"file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf\" target=\"_blank\">",
"      file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"     </a>",
"     (accessed on July 20, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Monitoring for sexually transmitted and opportunistic infections in adolescents with HIV infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended frequency/comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis serologies",
"       </td>",
"       <td>",
"        At initial diagnosis; also may be indicated in patients with initial negative serology if CD4 drops below 100 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RPR or VDRL*",
"       </td>",
"       <td>",
"        At least yearly; in areas highly endemic for syphilis or high risk populations (ie, MSM) every 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonorrhea/chlamydia screening*",
"       </td>",
"       <td>",
"        Every 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PAP smear (females)",
"        <sup>",
"         &bull;",
"        </sup>",
"        /anal cytology (males)",
"       </td>",
"       <td>",
"        Every 6 months initially, if negative x 2, annually",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuberculosis screening",
"       </td>",
"       <td>",
"        Annually: TST or IGRA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis serologies",
"       </td>",
"       <td>",
"        <p>",
"         Annually: anti-HCV to screen for new infection.",
"        </p>",
"        <p>",
"         At initial diagnosis: anti-HAV; if negative, HAV vaccine series should be administered.",
"        </p>",
"        <p>",
"         At initial diagnosis: anti-HBs, HBsAg, anti-HBc; if all are negative, hepatitis B vaccine series should be administered",
"         <sup>",
"          &Delta;",
"         </sup>",
"         .",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph",
"       </td>",
"       <td>",
"        As needed (eg, for symptoms and signs suggesting pulmonary disease or newly detected latent tuberculosis)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIV: human immunodeficiency virus; RPR: rapid plasma reagin; VDRL: venereal disease research laboratory; MSM: men who have sex with men; PAP: Papanicolaou smear; TST: tuberculin skin test; IGRA: interferon-gamma release assay; anti-HCV: hepatitis C antibody; anti-HAV: hepatitis A virus antibody; anti-HBs: hepatitis B surface antibody; HBsAg: hepatitis B surface antigen; anti-HBc: hepatitis B core antibody.",
"     <br>",
"      * Testing should be performed among HIV positive adolescents who are sexually active; it is not necessary among HIV positive adolescents with vertical transmission until they become sexually active.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       In contrast to the recommendations for healthy adolescents, sexually active HIV-infected female adolescents should undergo cervical cancer screening after the onset of sexual activity and not wait until 21 years of age.",
"       <br>",
"        &Delta; If anti-HBs negative after the first vaccination series, the series may be repeated once. Patients with negative anti-HBs who are not hepatitis B infected (anti-HBc negative and HBsAg negative) should be monitored annually or if symptomatic for new infection.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1. Available at:",
"        <a href=\"file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf\" target=\"_blank\">",
"         file://aidsinfo.nih.gov/contentfiles/Adult_OI_041009.pdf",
"        </a>",
"        . (Accessed on August 22, 2011).",
"       </li>",
"       <li>",
"        Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. Available at:",
"        <a href=\"file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf\" target=\"_blank\">",
"         file://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf",
"        </a>",
"        . (Accessed on August 22, 2011).",
"       </li>",
"       <li>",
"        ACOG Practice Bulletin No. 117: Gynecologic care for women with human immunodeficiency virus. Obstet Gynecol 2010; 116:1492.",
"       </li>",
"       <li>",
"        ACOG Committee Opinion No. 463: Cervical cancer in adolescents: screening, evaluation, and management. Obstet Gynecol 2010; 116:469.",
"       </li>",
"       <li>",
"        New York State Department of Health Guidelines. Available at:",
"        <a href=\"file://www.natap.org/2010/HIV/032510_01.htm\" target=\"_blank\">",
"         file://www.natap.org/2010/HIV/032510_01.htm",
"        </a>",
"        . (Accessed on August 22, 2011).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f20_50_21295=[""].join("\n");
var outline_f20_50_21295=null;
